

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT 2017 - 2021

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees



© Kirby Institute, UNSW Sydney

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

Kirby Institute
UNSW Sydney
Sydney NSW 2052
Australia

Telephone: **02 9385 0900** Facsimile: **02 6100 2860** International prefix: **612** Email: info@kirby.unsw.edu.au

AUSTRALIAN NSP SURVEY
Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT
2017 - 2021

Report prepared by

Sue Heard, Jenny Iversen and Lisa Maher

Kirby Institute

UNSW Sydney
Sydney NSW 2052
Australia

July 2022

Any presentation of these data should include acknowledgement of the Australian Needle Syringe Program Survey, Kirby Institute, UNSW Sydney.

Citation: Heard, S; Iversen, J & Maher, L. (2022). Australian Needle Syringe Program Survey National Data Report 2017-2021: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney.

The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health. Kirby Institute, Faculty of Medicine & Health, UNSW Sydney.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist each year in the development and conduct of the Australian Needle Syringe Program Survey (ANSPS), particularly the clients, staff and managers at participating Needle Syringe Program (NSP) services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS from 1995 until 2003.

Special thanks go to Mr Philip Cunningham, Senior Scientist and Operations Manager, Ms Beth Catlett, DBS Coordinator, Mr Mitchell Starr, Senior Hospital Scientist, Ms Thidarat Danwilai, Technical Officer, Mr Michael Palmer, Technical Officer and Mr Andrew Kelly, Technical Officer at the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research. We also appreciate the assistance provided by Ms Louise Geddes and Ms Rachel McCleave from the Kirby Institute.

In 2021, the project received support and input from the following members of the ANSPS National Advisory Group: Ms Jennifer Taleski (ACT); Ms Kate Patten (NSW); Mr David Decolongon (NT); Mr Bruce Surman, Mr Rob Gerrie and Ms Michelle Spudic (SA); Ms Myf Briggs (TAS); Mr Gary Morris and Ms Terrie Spall (VIC); Ms Jude Bevan (WA); Ms Melanie Walker, Ms Lauren Bradley, Mr Sav Gollapally and Mr Adrian Gorringe (Australian Injecting and Illicit Drug Users League); and Ms Sue Heard, Dr Jenny Iversen and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Mr Robert Kemp (QLD) for chairing the National Advisory Group.

Ethical approvals were obtained from institutional ethics committees associated with the investigators and participating NSP sites. The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health.

ABBREVIATIONS

ACT	Australian Capital Territory
ANSPS	Australian Needle Syringe Program Survey
COVID-19	Coronavirus disease 2019
DAA	Direct acting antiviral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
NSW	New South Wales
NT	Northern Territory
OAT	Opioid agonist therapy
PIEDs	Performance and image-enhancing drugs
PWID	People who inject drugs
PBS	Pharmaceutical Benefits Scheme
QLD	Queensland
RNA	Ribonucleic acid
SA	South Australia
SARS-CoV-2	Severe Acute Respiratory Syndrome - Corona Virus 2
TAS	Tasmania
VIC	Victoria
WA	Western Australia

TABLE OF CONTENTS

Summary

Key Findings.....	i
Introduction.....	1
COVID-19	1
Demographic characteristics	3
Injection behaviour	3
Sexual behaviour.....	5
Drug treatment	6
HIV and HCV diagnostic testing	6
HIV antibody prevalence	6
HCV antibody prevalence.....	8
HCV RNA prevalence.....	9
HCV treatment.....	11
References	13

Tables

1. National	14
2. Australian Capital Territory.....	42
3. New South Wales.....	62
4. Northern Territory	90
5. Queensland	110
6. South Australia	138
7. Tasmania.....	166
8. Victoria	186
9. Western Australia	214

Appendix

A. Participating NSP services	242
B. Methodological notes	244
C. List of tables	246

KEY FINDINGS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and injecting and sexual behaviour among people who inject drugs.
- In 2021, 37 Needle Syringe Programs (NSPs) throughout Australia participated in the ANSPS and 1,474 NSP attendees completed the survey. The response rate was 45%.
- The number of participating NSPs and the number of respondents in 2020 and 2021 were lower than in previous years due to the impact of the COVID-19 pandemic and public health measures designed to reduce community transmission during the ANSPS data collection period.

COVID-19

- As a sentinel surveillance system with the capacity to respond to emerging issues, the 2020 and 2021 surveys included a module about COVID-19-related impacts, including vaccination uptake.
- The majority (80%) of respondents in 2021 reported that it was not more difficult to access needles and syringes during the pandemic, while one in two reported no change to their illicit drug use.
- In 2021, one in three respondents reported they had been tested for COVID-19 in the previous 12 months, with the majority (88%) reporting a negative result. Among the remaining respondents, 16 (1%) reported a positive test result, five were unsure of their result, and 33 did not report their test result.
- While all respondents were eligible for COVID-19 vaccination at the time of survey completion in 2021, less than half reported receiving at least one dose of a COVID-19 vaccine.

Demographic characteristics

- Over the period 2017 to 2021, the median age of survey respondents was stable (range 42 to 44 years), with a decline in the proportion of young injectors (aged <25 years) from 5% in 2017 to 2% in 2021.
- The median time since first injection was stable between 2017 and 2021 (range 21 to 23 years), and the proportion of new initiates (those injecting for less than three years) was also stable between 2017 and 2021 (range 4% to 6%).
- The proportion of respondents from an Aboriginal and Torres Strait Islander background increased, from 18% in 2017 to 25% in 2021.
- The proportion of respondents reporting incarceration in the 12 months prior to survey completion was stable over the five-year period 2017 to 2021 (range 11% to 13%).
- While the proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years, condom use at last paid sex declined, from 71% in 2017 to 57% in 2021.

Injection behaviour

- One in two respondents reported injecting daily or more frequently in all survey years between 2017 and 2021.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 41% in 2017 to 51% in 2021. Methamphetamine was the most commonly reported drug last injected nationally in all years 2017 to 2021.

- The proportion of respondents reporting heroin as the last drug injected declined from 30% in 2017 to 20% in 2021, while prevalence of pharmaceutical opioid injection remained stable (range 7% to 9%).
- The proportion of respondents who reported last injecting performance and image enhancing drugs (PIEDs) was low and stable between 2017 and 2021 (range 4% to 6%).
- The proportion of respondents reporting injecting risk behaviours was stable across all three key indicators (receptive sharing of syringes, receptive sharing of drug preparation equipment and re-use of syringes) over the past 5 years 2017 to 2021.
- The prevalence of self-reported drug overdose in the past 12 months declined, from 18% in 2017 to 11% in 2021.

Drug treatment

- Engagement with drug treatment services remained high, with two thirds (64%) of respondents reporting a lifetime history of drug treatment in 2021.
- Although there was a decline in the overall proportion of respondents who reported current engagement in opioid agonist therapy (OAT) between 2017 and 2021, engagement in OAT remained stable among respondents who reported last injecting an opioid (range 44% to 53%).

HIV antibody prevalence

- HIV antibody prevalence remained low and stable nationally, ranging from 1.5% to 2.5% over the five-year period 2017 to 2021.
- In all years 2017 to 2021 HIV antibody prevalence was higher among homosexual men, compared to bisexual or heterosexual men, and compared to women.

HCV antibody prevalence

- Hepatitis C virus (HCV) antibody prevalence declined nationally from 49% in 2017 to 36% in 2021. This is the fifth consecutive year that less than half of respondents had been exposed to HCV, following two decades of HCV antibody prevalence $\geq 50\%$ (all years 1999 to 2016).
- Across all survey years 2017 to 2021, prevalence of HCV antibody was higher among older than among younger respondents and among those with longer injection histories.

HCV RNA prevalence

- The proportion of respondents with detectable HCV RNA (active infection) declined from 26% in 2017 to 16% in 2021. HCV RNA prevalence declined among both males (28% in 2017 to 18% in 2021) and females (21% in 2017 to 13% in 2021).

HCV treatment uptake

- Among respondents assessed as eligible for HCV treatment, the proportion who reported a lifetime history of HCV treatment increased, from 45% in 2017 to 62% in 2021.
- However, among respondents assessed as eligible, the proportion who reported recent (last 12 months) HCV treatment was stable over the 5-year period 2017 to 2021 (range 28% to 44%).
- Whilst the 5-year trend was stable, there was a decline in the proportion of respondents who reported recent HCV treatment in the past 3 years from 2019 (44%) to 2021 (28%). There was also a decline in the proportion of respondents who reported a recent HCV diagnostic test in the past 5 years from 2017 (55%) to 2021 (47%).

INTRODUCTION

The Australian Needle Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence, HCV ribonucleic acid (RNA) prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). Commencing in 2015, HCV RNA testing has also been conducted among respondents with sufficient dried blood spot (DBS) samples. This report presents national and state/territory findings for the period 2017 to 2021.

COVID-19

In Australia, a range of public health measures have been implemented since COVID-19 was declared a global pandemic by the World Health Organisation in March 2020. All Australian states and territories have experienced COVID-19-related travel restrictions, most restricted public and private gatherings, and some introduced full or partial lockdowns during the pandemic. As a sentinel surveillance system with the capacity to respond to emerging issues, the 2020 and 2021 ANSPS included a module about the impacts of COVID-19.

In order to provide flexibility and to accommodate jurisdictional differences in the pandemic response, the 2021 ANSPS was implemented in several phases rather than the usual mid-October time frame nationally. One jurisdiction (QLD) implemented the survey early (in September) and three jurisdictions (NT, TAS and WA) implemented the ANSPS in the usual October timeframe. One jurisdiction (SA) implemented the ANSPS later than usual (in November) and three jurisdictions (ACT, NSW, VIC) implemented the ANSPS in December 2021. Between June and November 2021 both Victoria and NSW experienced outbreaks of community transmission that necessitated the implementation of public health measures to reduce transmission and a limited number of NSP services in these two jurisdictions were in a position to participate in the 2021 ANSPS.

Due to the COVID-19 pandemic, a reduced number of NSP services participated in the 2021 ANSPS compared to previous years (37 sites in 2021, 38 sites in 2020 compared to 54 sites in 2019). Further, as seen in 2020 once again the number of ANSPS respondents was just over half the pre COVID-19 sample size, decreasing from ~2,600 in 2019 to 1,324 in 2020 and 1,474 in 2021. The annual response rate ranged from 35% to 45% (Table 1.1.1). Of the 1,474 ANSPS respondents in 2021, the majority (88%) were recruited from NSP services (n=26) that participated in the ANSPS in each of the past five years (2017 to 2021). Appendix A provides details of participating NSP services over the period 2017 to 2021.

Among the overall 1,474 ANSPS respondents in 2021, 1,301 (88%) completed at least one question in the COVID-19 module. The following discussion and data analysis excludes ANSPS respondents who did not report responses to individual 2021 COVID-19 module questions.

The majority of ANSPS respondents (n=1015, 80%) reported that it was not more difficult to access needles and syringes in the last 12 months, confirming the commitment of NSP services to ensuring access and distribution to sterile injecting equipment during the COVID-19 pandemic. However, around one in eight respondents (n=153, 12%) reported that it was more difficult to access needles and syringes in the last 12 months, and 8% (n=108) reported they had not attempted to access needles and syringes in the past year.

A total of sixty respondents (5%) reported they had commenced depot buprenorphine (Buvidal® or Sublocade®) in the last 12 months, while 121 respondents (10%) reported they had commenced takeaway doses of their OAT and 154 respondents (12%) reported they had injected their own OAT in the last 12 months. Among respondents who reported being prescribed OAT at the time of ANSPS participation, and after excluding those who did not report responses to individual 2021 COVID-19 module questions, 9% had commenced depot buprenorphine, 29% had commenced takeaway doses of their OAT and 30% reported they had injected their own OAT in the past 12 months.

In the last 12 months a total of 247 respondents (19%) who completed the COVID-19 module reported accessing take-home Naloxone (an opioid agonist used to reverse the effects of opioid overdose). Among respondents who reported last injecting an opioid, one in three (n=157, 33%) reported accessing take-home Naloxone in the past 12 months.

Half of respondents (n=650, 52%) who completed the COVID-19 questions reported no change in their illicit drug use in the past 12 months, while one in eight (n=158, 13%) reported that their illicit drug use had increased and one in three (n=435, 35%) reported their illicit drug use had decreased.

One in three respondents (n=450, 38%) reported that they had a COVID-19 test in the last 12 months. Of these, 16 respondents (4%) reported a positive COVID-19 test. The majority of respondents tested for COVID-19 reported a negative result (n=396, 88%), while five respondents (1%) were unsure of their result and 33 respondents (7%) did not report their test result.

The 2021 ANSPS COVID-19 module also included questions on COVID-19 vaccination uptake. A recent publication based on these data assessed COVID-19 vaccine uptake among ANSPS respondents and identified factors associated with sub-optimal uptake¹. For this analysis, 240 respondents who did not answer the COVID-19 vaccine question were excluded, along with a further 68 respondents who did not report their age or whether they had an Aboriginal and/or Torres Strait Island background and for whom their date of vaccine eligibility could not be determined. Among the final sample of 1166 respondents, 49% had been vaccinated. Independent predictors of vaccine uptake were longer duration of vaccine eligibility (AOR 3.42, 95% CI 2.65,4.41); prior SARS-CoV-2 diagnostic testing (AOR 2.90, 95% CI 2.22,3.79); injection of opioids (AOR 1.91, 95% CI 1.20,3.05) and current opioid agonist therapy (AOR 1.70, 95% CI 1.23,2.33). Women (AOR 0.70, 95% CI 0.54,0.92) and those who reported daily or more frequent injection (AOR 0.75, 95% CI 0.57,1.00) were significantly less likely to be vaccinated¹.

Demographic characteristics

Approximately two thirds of ANSPS respondents were male across all years 2017 to 2021. In 2021, the majority (82%) of respondents identified as heterosexual, while 10% identified as bisexual and 4% as homosexual (Table 1.1.1). Women were significantly more likely to identify as bisexual than men in each of the past five years (19% vs 5% respectively in 2021, $p < 0.001$).

Over the period 2017 to 2021 the proportion of respondents from an Aboriginal and Torres Strait Islander background increased significantly, from 18% to 25% (χ^2 trend $p < 0.001$)^{2,3}. In all years 2017 to 2021, the majority of respondents were born in Australia (range 86% to 88%), with the United Kingdom/Ireland (4%) and New Zealand (3%) the predominant countries of birth outside Australia in 2021. Most respondents also reported that their parents spoke English at home (range 93% to 95%) over the period 2017 to 2021.

Over the period 2017 to 2021, the median age at survey completion ranged from 42 to 44 years while the proportion of respondents aged <25 years (2% in 2021) decreased significantly (χ^2 trend $p < 0.001$, Table 1.1.1). The median time since first injection ranged from 21 to 23 years and the proportion of new initiates (those injecting for less than 3 years) was stable, ranging from 6% in 2017 to 4% in 2021 (χ^2 trend $p = 0.438$). The median age at first drug injection was stable across the period 2017 to 2021, (19 years of age in all years). Among new initiates to injection drug use, the median age at first drug injection increased from 29 years in 2017 to 34 years in 2021.

The proportion of respondents reporting incarceration in the 12 months prior to survey completion remained stable, ranging from 11% to 13% over the five-year period 2017 to 2021 (χ^2 trend $p = 0.245$). Among respondents with a history of recent incarceration, approximately one in three reported injecting while in prison and this proportion was stable over the period 2017 to 2021 (χ^2 trend $p = 0.870$, Table 1.1.1).


Injection behaviour

Methamphetamine was the most commonly reported drug last injected nationally in all years 2017 to 2021 (Table 1.1.2). Reports of methamphetamine injection increased significantly over the five-year period, from 41% in 2017 to 51% in 2021 (χ^2 trend $p < 0.001$, Figure 1). Heroin was the second most commonly reported drug last injected nationally in 2021, with a significant decline in prevalence observed between 2017 (30%) and 2021 (20%, χ^2 trend $p < 0.001$).

The third most commonly reported class of drugs last injected nationally was pharmaceutical opioids^{4,5} (7%, including morphine, oxycodone and fentanyl), which was stable over the period 2017 to 2021 (χ^2 trend $p = 0.131$, Figure 2).

Methadone was reported as the last drug injected by less than ten percent of ANSPS respondents in all years 2017 to 2021 (range 6% to 4%) with prevalence stable over this period (χ^2 trend $p = 0.494$). Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents. The prevalence of both buprenorphine-naloxone injection (1% to 2%, χ^2 trend $p = 0.040$), and buprenorphine injection (2% to 4%, χ^2 trend $p = 0.002$) increased over the period 2017 to 2021.


Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine, and all other drugs, 2017–2021



A minority of survey respondents (1% across all survey years) reported cocaine as the last drug injected. The prevalence of performance and image enhancing drugs (PIEDs) as the last drug injected was stable over the period 2017 to 2021 (χ^2 trend $p=0.820$, Figure 2).

In all years 2017 to 2021, methamphetamine was the most commonly reported last drug injected among new initiates (less than 3 years since first injection), with a stable prevalence observed between 2017 and 2021 (range 48% to 63%, χ^2 trend $p=0.165$).


Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone, and performance and image enhancing drugs, 2017–2021



Daily or more frequent injection was reported by approximately half of respondents in each of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion was stable between 2017 and 2021 (range 42% to 47%, χ^2 trend $p=0.472$, Table 1.1.3). In 2021, one in ten respondents reported they had experienced a drug overdose in the previous 12 months ($n=166$, 11%, Table 1.1.2), and reports of overdose declined significantly (χ^2 trend $p<0.001$) over the period 2017 (18%) to 2021 (11%). This may reflect the significant decline in the proportion of respondents reporting heroin as the last drug injected over this period.

As shown in Figure 3, all three key injecting risk behaviour indicators were stable over the five-year period 2017 to 2021. The proportion of respondents who reported reuse of needles and syringes (including one's own) in the month preceding the survey was stable over the past 5 years (range 23% to 26%, χ^2 trend $p=0.720$). Reports of receptive sharing of needles and syringes in the month prior to survey completion were also stable (range 16% to 18%, χ^2 trend $p=0.523$) over the period 2017 to 2021, as were reports of receptive sharing of ancillary equipment (range 25% to 31%, χ^2 trend $p=0.984$). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2021 (Table 1.1.3).

Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2017–2021



Sexual behaviour

In all years 2017 to 2021 approximately half of respondents reported sex with a regular partner in the month prior to survey completion (range 43% to 45%, Table 1.1.6). Of these, the majority (72% to 77%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (13% to 15%) reported sex with other partners in the month preceding survey participation. Condom use was higher among this group, with 23% reporting always using condoms and 22% reporting some condom use with non-regular sex partners in 2021. While the proportion

of respondents reporting sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years (χ^2 trend $p=0.591$), condom use at last paid sex declined significantly, from 71% in 2017 to 57% in 2021 (χ^2 trend $p<0.002$, Table 1.1.6). Of the respondents who reported sex work in the previous month in 2021 ($n=76$), 59% were women, 37% were men, and 4% identified their sex as other.

Drug treatment

Engagement with drug treatment services was high (Table 1.1.4), with two thirds (64%) of respondents in 2021 reporting a lifetime history of drug treatment. Nonetheless, there was a significant decline in the overall proportion of respondents reporting current OAT from 33% in 2017 to 25% in 2021 (χ^2 trend $p<0.001$). This may reflect the significant increase in the proportion of respondents reporting methamphetamine as the last drug injected over this period, with OAT not indicated for methamphetamine dependence. Further, among respondents who reported last injecting opioids, current OAT was stable over the period 2017 to 2021 (range 44% to 53%, χ^2 trend $p=0.174$). In 2021, current methadone treatment was reported by 15% of respondents, with current buprenorphine treatment reported by 8% of respondents and current buprenorphine-naloxone treatment by 7% of respondents.

HIV and HCV diagnostic testing

Prevalence of HIV diagnostic screening among ANSPS respondents over the period 2017 to 2021 was high, with 76% to 81% reporting a lifetime history of HIV diagnostic testing (Table 1.1.5). In 2021, 38% of respondents reported an HIV diagnostic test in the previous 12 months. Among the $n=21$ respondents who tested HIV antibody positive, the majority (76%, $n=16$) were aware of their HIV positive status. A minority (10%, $n=2$) of respondents who tested HIV positive reported that they were HIV negative, and 14% ($n=3$) did not report their HIV status.

Respondents also reported high prevalence of lifetime HCV diagnostic screening over the period 2017 to 2021 (range 78% to 82%). In 2021, 47% of respondents reported an HCV diagnostic test in the previous 12 months, however a significant decline in recent (last 12 months) HCV diagnostic testing was observed over the period 2017 (55%) to 2021 (47%, χ^2 trend $p<0.001$).

HIV antibody prevalence

HIV antibody prevalence was low and stable nationally over the period 2017 to 2021 (range 1.5% to 2.5%, χ^2 trend $p=0.709$, Table 1.2.1). HIV prevalence was low and stable in all jurisdictions (Figure 4). No respondents in the Australian Capital Territory, and no women in South Australia or Tasmania, tested positive to HIV antibodies in any of the five years 2017 to 2021.

Nationally, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male or female respondents in all years, (Table 1.2.2 and Figure 5)⁶. In 2021, the median age of respondents living with HIV was 49 years (range 24 to 65 years) and the median time since first injection was 18.5 years (range 3 to 47 years). In 2021, and comparable to previous years, 75% of respondents living with HIV reported they were on antiretroviral treatment.

Figure 4. HIV antibody prevalence (%) by jurisdiction, 2017–2021





Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2017–2021



Although respondents from an Aboriginal and Torres Strait Islander background were significantly more likely to test HIV antibody positive than respondents who were not from an Aboriginal and Torres Strait Islander background in 2017, 2018 and 2019 ($p < 0.05$), this significant difference was not observed in 2020 or 2021. Further, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents remained stable between 2017 and 2021 (range 1.7% to 3.6%, χ^2 trend $p = 0.106$). Of the six Aboriginal and Torres Strait Islander respondents who tested HIV antibody positive in 2021, half ($n = 3$) identified as homosexual ($n = 2$ heterosexual, $n = 1$ prefer not to answer).

HCV antibody prevalence

HCV antibody prevalence nationally declined significantly, from 49% in 2017 to 36% in 2021 (χ^2 trend $p < 0.001$, Table 1.3.1). Over the five-year period 2017 to 2021, HCV antibody prevalence declined among both men (from 50% in 2017 to 38% in 2021, χ^2 trend $p < 0.001$) and women (from 48% in 2017 to 34% in 2020, χ^2 trend $p < 0.001$).

Figure 6. HCV antibody prevalence (%) by jurisdiction, 2017–2021






Figure 7. HCV antibody prevalence (%) by time since first injection, 2021



At the jurisdictional level (Figure 6), declines in HCV antibody prevalence were observed in most states and territories. Across all five years of the survey, HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.4). Figure 7 illustrates the relationship between exposure to HCV and time since first injection among respondents in 2021.

In all survey years, prevalence of HCV antibody was also higher among respondents reporting heroin or other opioids as the last drug injected, compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents who reported imprisonment in the year preceding survey completion compared to those who did not ($p < 0.010$ in all years 2017 to 2021) and among respondents who reported an Aboriginal and Torres Strait Islander background ($p \leq 0.001$ in all years 2017 to 2021).

Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2017–2021



HCV RNA prevalence

The ANSPS commenced HCV RNA testing in 2015, immediately before HCV direct acting antiviral (DAA) therapies were made available through the Australian Government’s Pharmaceutical Benefits Scheme (PBS) in March 2016. The proportion of the ANSPS sample with sufficient DBS for HCV RNA testing has improved over time, with ~90% of respondents tested for HCV RNA in 2020 and 2021. In order to adjust for potential sample bias in the RNA tested sub-sample in previous years (2017-2019), weights were applied to adjust for gender (given higher rates of spontaneous clearance among women) and HCV antibody status. HCV RNA results with small sample sizes, particularly at the jurisdictional level, should be interpreted with caution.

As previously stated, over the last five years HCV antibody prevalence declined significantly (from 49% in 2017 to 36% in 2021, χ^2 trend $p < 0.001$). Lifetime HCV treatment increased significantly

(from 45% in 2017 to 62% in 2021, χ^2 trend $p < 0.001$) and the proportion of respondents with detectable HCV RNA decreased significantly, from 26% in 2017 to 16% in 2021 (χ^2 trend $p < 0.001$). As shown in Figure 9, HCV RNA prevalence declined significantly among both males (28% in 2017 to 18% in 2021, χ^2 trend $p < 0.001$) and females (21% in 2017 to 13% in 2021, χ^2 trend $p < 0.001$).

Figure 9. Proportion of respondents (%) with detectable HCV RNA* by gender and survey year






Figure 10. HCV viraemic status (%) by survey year



Results of HCV antibody and RNA testing can be combined to provide an estimate of viraemic prevalence among respondents⁷. As shown in Figure 10, the proportion of respondents with cleared infection (HCV antibody positive and HCV RNA negative) remained relatively stable (range 27% in 2019 to 20% in 2021), while the proportion of respondents with no evidence of exposure to HCV (HCV antibody negative) increased from 51% in 2017 to 64% in 2021. Over the five-year period, 2017 to 2021, the proportion of respondents with active HCV infection declined by one third (36%).


Figure 11. HCV viraemic status (%) nationally and by jurisdiction in 2021



HCV treatment


Among respondents who tested HCV antibody positive, and after excluding those who reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV treatment increased significantly from 45% in 2017 to 62% in 2021 (χ^2 trend $p < 0.001$). Notwithstanding this overall increase in lifetime HCV treatment uptake, as shown in Figure 12, the significant increase occurred between 2017 (45%) and 2019 (64%, χ^2 trend $p < 0.001$)⁶, with lifetime treatment uptake stable between 2019 and 2021 (62%, χ^2 trend $p = 0.446$). These trends in lifetime treatment uptake were observed among both men and women. Similarly, among respondents who tested HCV antibody positive, and after excluding those who reported spontaneous or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment increased significantly between 2017 (36%) and 2019 (44%, χ^2 trend $p = 0.003$) but declined significantly between 2019 and 2021 (28%, χ^2 trend $p < 0.001$, Figure 12). These trends in recent treatment uptake were observed among both men and women, except for recent treatment uptake between 2017 and 2019, which was stable among women (χ^2 trend $p = 0.586$).

Figure 12. Proportion of respondents (%) reporting lifetime and recent* HCV treatment among HCV antibody positive respondents who did not report spontaneous clearance by survey year



* The denominator for recent HCV treatment excludes those who reported prior HCV treatment induced clearance.

Figure 13. Lifetime history of HCV treatment (%) nationally and by jurisdiction, 2017-2021



References

1. Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, Heard S, Maher L. Uptake of COVID-19 vaccination among people who inject drugs. *Harm Reduction Journal* 2022;19 (59).
2. Doyle M, Maher L, Graham S, Wand H, Iversen J. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs. *Australia New Zealand Journal of Public Health* 2018;42(1):52-6.
3. Graham S, Maher L, Wand H, Doyle M, Iversen J. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. *International Journal of Drug Policy* 2017;47:69-76.
4. Iversen J, Dertadian G, Geddes L, Maher L. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. *International Journal of Drug Policy* 2017;42:1-6.
5. Geddes L, Iversen J, Memedovic S, Maher L. Intravenous fentanyl use among people who inject drugs in Australia. *Drug and Alcohol Review* 2018;37 Suppl 1:S314-S22.
6. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS* 2014;28(2):275-8.
7. Iversen J, Dore G, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. *Journal of Hepatology* 2019;70(1):33-39.

National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2017	2018	2019	2020*	2021*
Number of sites	52	53	54	38	37
N° surveyed	N=2600	N=2742	N=2609	N=1324	N=1474
Response rate (%)	41%	45%	45%	35%	45%
Gender (%)					
Male	1721 (66)	1828 (67)	1722 (66)	902 (68)	933 (63)
Female	848 (33)	899 (33)	861 (33)	413 (31)	520 (35)
Other	24 (1)	13 (<1)	18 (1)	8 (1)	19 (1)
Not reported	7 (<1)	2 (<1)	8 (<1)	1 (<1)	2 (<1)
Sexual identity (%)					
Heterosexual	2019 (78)	2133 (78)	1969 (75)	1045 (79)	1204 (82)
Bisexual	233 (9)	259 (9)	262 (10)	128 (10)	149 (10)
Gay/Lesbian	132 (5)	122 (4)	119 (5)	50 (4)	65 (4)
Other	-- --	-- --	-- --	35 (3)	45 (3)
Not reported	216 (8)	228 (8)	259 (10)	66 (5)	11 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	2081 (80)	2135 (78)	1994 (76)	982 (74)	1031 (70)
Yes	460 (18)	533 (19)	568 (22)	290 (22)	373 (25)
Not reported	59 (2)	74 (3)	47 (2)	52 (4)	70 (5)
Region/country of birth (%)					
Australia	2257 (87)	2347 (86)	2302 (88)	1142 (86)	1274 (86)
Other Oceania	81 (3)	83 (3)	67 (3)	42 (3)	43 (3)
Asia	31 (1)	31 (1)	26 (1)	18 (1)	12 (1)
UK & Ireland	111 (4)	122 (4)	87 (3)	52 (4)	57 (4)
Other	86 (3)	120 (4)	102 (4)	49 (4)	48 (3)
Not reported	34 (1)	39 (1)	25 (1)	21 (2)	40 (3)
Main language spoken at home by parents (%)					
English	2455 (94)	2538 (93)	2465 (94)	1253 (95)	1406 (95)
Non-English	130 (5)	168 (6)	128 (5)	59 (4)	51 (3)
Not reported	15 (1)	36 (1)	16 (1)	12 (1)	17 (1)
Age and time since first injection (years)					
<i>Median age</i>	42	42	42	43	44
<i>Age range</i>	16-76	14-78	15-73	18-74	16-78
<i>Age group (%)</i>					
<25 years	122 (5)	116 (4)	95 (4)	44 (3)	34 (2)
25+ years	2466 (95)	2617 (95)	2502 (96)	1279 (97)	1431 (97)
Not reported	12 (<1)	9 (<1)	12 (<1)	1 (<1)	9 (1)
<i>Median age first injection</i>					
<i>Age range</i>	10-76	10-64	10-67	10-60	10-85
N° not reported	127	128	135	33	49
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-59	<1-53	<1-59	<1-53	<1-62
<i>Years since first injection</i>					
<3 years	149 (6)	137 (5)	149 (6)	82 (6)	65 (4)
3+ years	2324 (89)	2475 (90)	2321 (89)	1208 (91)	1353 (92)
Not reported	127 (5)	130 (5)	139 (5)	34 (3)	56 (4)
Imprisonment last year (%)					
No	2105 (81)	2208 (81)	2106 (81)	1095 (83)	1230 (83)
Yes	316 (12)	346 (13)	350 (13)	158 (12)	157 (11)
Not reported	179 (7)	188 (7)	153 (6)	71 (5)	87 (6)
N° in prison					
Injected in prison	100 (32)	116 (34)	111 (32)	48 (30)	54 (34)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

National N° surveyed	2017 N=2600	2018 N=2742	2019 N=2609	2020 N=1324	2021 N=1474
Drug last injected (%)					
Cocaine	27 (1)	28 (1)	20 (1)	7 (1)	8 (1)
Methamphetamine	1070 (41)	1314 (48)	1269 (49)	619 (47)	750 (51)
Heroin	778 (30)	714 (26)	707 (27)	286 (22)	299 (20)
Pharm. opioids	227 (9)	204 (7)	153 (6)	109 (8)	110 (7)
Methadone	130 (5)	112 (4)	124 (5)	77 (6)	70 (5)
Buprenorphine	51 (2)	63 (2)	43 (2)	39 (3)	53 (4)
Buprenorphine/naloxone	30 (1)	39 (1)	23 (1)	17 (1)	33 (2)
PIEDs	117 (5)	100 (4)	93 (4)	84 (6)	52 (4)
More than one	120 (5)	137 (5)	119 (5)	64 (5)	77 (5)
Other	25 (1)	18 (1)	37 (1)	5 (<1)	11 (1)
Not reported	25 (1)	13 (<1)	21 (1)	17 (1)	11 (1)
Ever injected opioids					
No	573 (22)	627 (23)	603 (23)	377 (28)	434 (29)
Yes	2013 (77)	2078 (76)	1989 (76)	946 (71)	1030 (70)
Not reported	14 (1)	37 (1)	17 (1)	1 (<1)	10 (1)
Frequency of injection last month (%)					
Not last month	249 (10)	228 (8)	235 (9)	138 (10)	186 (13)
Less than weekly	387 (15)	387 (14)	371 (14)	228 (17)	293 (20)
Weekly not daily	593 (23)	669 (24)	586 (22)	300 (23)	312 (21)
Daily or more	1334 (51)	1396 (51)	1376 (53)	645 (49)	654 (44)
Not reported	37 (1)	62 (2)	41 (2)	13 (1)	29 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	2048 (79)	2157 (79)	2056 (79)	1088 (82)	1207 (82)
Yes	452 (17)	475 (17)	448 (17)	206 (16)	234 (16)
Not reported	100 (4)	110 (4)	105 (4)	30 (2)	33 (2)
Overdosed in last 12 months					
No	2029 (78)	2106 (77)	2060 (79)	1120 (85)	1265 (86)
Yes	463 (18)	520 (19)	438 (17)	171 (13)	166 (11)
Not reported	108 (4)	116 (4)	111 (4)	33 (2)	43 (3)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

National	2017	2018	2019	2020	2021
N° injected last month	N=2314	N=2452	N=2333	N=1173	N=1259
Places injected last month (%)					
All private	1275 (55)	1307 (53)	1214 (52)	673 (57)	694 (55)
Any public	1022 (44)	1129 (46)	1105 (47)	496 (42)	559 (44)
Not reported	17 (1)	16 (1)	14 (1)	4 (<1)	6 (<1)
Use of new and sterile needles and syringes last month (%)					
All injections	1734 (75)	1795 (73)	1746 (75)	891 (76)	941 (75)
Most of the time	457 (20)	502 (20)	449 (19)	220 (19)	244 (19)
Half of the time	46 (2)	60 (2)	53 (2)	23 (2)	27 (2)
Some of the time	30 (1)	44 (2)	39 (2)	19 (2)	28 (2)
Not last month	12 (1)	20 (1)	13 (1)	4 (<1)	10 (1)
Not reported	35 (2)	31 (1)	33 (1)	16 (1)	9 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1890 (82)	1977 (81)	1924 (82)	980 (84)	1030 (82)
Once	126 (5)	164 (7)	126 (5)	66 (6)	61 (5)
Twice	115 (5)	92 (4)	113 (5)	40 (3)	61 (5)
3-5 times	87 (4)	104 (4)	82 (4)	51 (4)	44 (3)
>5 times	61 (3)	89 (4)	57 (2)	28 (2)	54 (4)
Not reported	35 (2)	26 (1)	31 (1)	8 (1)	9 (1)
Number of people needle & syringe was re-used after last month (%)					
None	1890 (82)	1977 (81)	1924 (82)	980 (84)	1029 (82)
One	158 (7)	194 (8)	168 (7)	73 (6)	94 (7)
Two	39 (2)	36 (1)	38 (2)	20 (2)	30 (2)
Three to five	24 (1)	34 (1)	27 (1)	14 (1)	14 (1)
More than five	17 (1)	31 (1)	17 (1)	10 (1)	14 (1)
Don't know	101 (4)	85 (3)	79 (3)	46 (4)	50 (4)
Not reported	85 (4)	95 (4)	80 (3)	30 (3)	28 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	131 (6)	172 (7)	147 (6)	73 (6)	77 (6)
Casual sex partner	21 (1)	21 (1)	18 (1)	14 (1)	12 (1)
Close friend	115 (5)	131 (5)	82 (4)	48 (4)	67 (5)
Acquaintance	54 (2)	55 (2)	58 (2)	30 (3)	42 (3)
Other	40 (2)	38 (2)	47 (2)	19 (2)	17 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	506 (22)	513 (21)	482 (21)	182 (16)	252 (20)
Water	435 (19)	484 (20)	451 (19)	191 (16)	284 (23)
Filter	251 (11)	243 (10)	221 (9)	71 (6)	123 (10)
Drug mix	210 (9)	251 (10)	234 (10)	89 (8)	127 (10)
None	1541 (67)	1644 (67)	1555 (67)	836 (71)	834 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	1905 (82)	1980 (81)	1939 (83)	1005 (86)	1030 (82)
Yes	377 (16)	431 (18)	369 (16)	159 (14)	219 (17)
Not reported	32 (1)	41 (2)	25 (1)	9 (1)	10 (1)
Source of needle acquisition					
Needle Syringe Program	2019 (87)	2140 (87)	2032 (87)	1001 (85)	1071 (85)
Chemist/Pharmacy	539 (23)	588 (24)	572 (25)	319 (27)	327 (26)
Personal sources	272 (12)	306 (12)	325 (14)	130 (11)	143 (11)
Dispensing/Vending Machine	351 (15)	400 (16)	441 (19)	172 (15)	134 (11)
Other sources	71 (3)	100 (4)	69 (3)	37 (3)	27 (2)

Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year

National	2017	2018	2019	2020	2021
N° surveyed	N=2600	N=2742	N=2609	N=1324	N=1474
Ever any treatment/therapy for drug use (%)					
No	745 (29)	810 (30)	809 (31)	460 (35)	536 (36)
Yes	1837 (71)	1901 (69)	1789 (69)	862 (65)	937 (64)
Not reported	18 (1)	31 (1)	11 (<1)	2 (<1)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	617 (24)	583 (21)	634 (24)	235 (18)	219 (15)
Previously	575 (22)	645 (24)	522 (20)	236 (18)	281 (19)
Never	1343 (52)	1411 (51)	1395 (53)	809 (61)	921 (62)
Not reported	65 (3)	103 (4)	58 (2)	44 (3)	53 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	184 (7)	196 (7)	169 (6)	105 (8)	119 (8)
Previously	638 (25)	703 (26)	640 (25)	278 (21)	310 (21)
Never	1715 (66)	1759 (64)	1759 (67)	903 (68)	1001 (68)
Not reported	63 (2)	84 (3)	41 (2)	38 (3)	44 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	196 (8)	212 (8)	173 (7)	70 (5)	105 (7)
Previously	568 (22)	645 (24)	596 (23)	258 (19)	298 (20)
Never	1775 (68)	1799 (66)	1795 (69)	987 (75)	1053 (71)
Not reported	61 (2)	86 (3)	45 (2)	9 (1)	18 (1)

Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

National	2017	2018	2019	2020	2021
N° surveyed	N=2600	N=2742	N=2609	N=1324	N=1474
Previous HIV test (%)					
Yes, ever	2097 (81)	2211 (81)	2105 (81)	1042 (79)	1116 (76)
Yes, last year	1273 (49)	1363 (50)	1271 (49)	601 (45)	557 (38)
>1 year ago	824 (32)	848 (31)	834 (32)	441 (33)	559 (38)
Never tested	369 (14)	390 (14)	381 (15)	232 (18)	296 (20)
Not reported	134 (5)	141 (5)	123 (5)	50 (4)	62 (4)
Previous HCV test (%)					
Yes, ever	2099 (81)	2201 (80)	2101 (81)	1087 (82)	1147 (78)
Yes, last year	1420 (55)	1455 (53)	1409 (54)	631 (48)	686 (47)
>1 year ago	679 (26)	746 (27)	692 (27)	456 (34)	462 (31)
Never tested	253 (10)	251 (9)	257 (10)	128 (10)	194 (13)
Not reported	248 (10)	290 (11)	251 (10)	109 (8)	132 (9)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=697	N=738	N=667	N=289	N=309
Antiviral treatment	314 (45)	409 (55)	428 (64)	180 (62)	191 (62)
No antiviral treatment	376 (54)	322 (44)	237 (36)	107 (37)	116 (38)
Not reported	7 (1)	7 (1)	2 (<1)	2 (1)	2 (1)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=639	N=603	N=502	N=196	N=200
Antiviral treatment	227 (36)	236 (39)	222 (44)	62 (32)	56 (28)
No antiviral treatment	405 (63)	360 (60)	278 (55)	132 (67)	142 (71)
Not reported	7 (1)	7 (1)	2 (<1)	2 (1)	2 (1)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

National	2017	2018	2019	2020	2021
N° surveyed	N=2600	N=2742	N=2609	N=1324	N=1474
Sex with a regular partner last month (%)					
No	1329 (51)	1374 (50)	1345 (52)	684 (52)	758 (51)
Yes	1129 (43)	1228 (45)	1124 (43)	584 (44)	631 (43)
Not reported	142 (5)	140 (5)	140 (5)	56 (4)	85 (6)
Condom used with regular partner last month (%)					
N° surveyed	N=1129	N=1228	N=1124	N=584	N=631
Never	822 (73)	924 (75)	808 (72)	450 (77)	479 (76)
Sometimes	136 (12)	137 (11)	150 (13)	55 (9)	68 (11)
Every time	126 (11)	95 (8)	110 (10)	51 (9)	52 (8)
Not reported	45 (4)	72 (6)	56 (5)	28 (5)	32 (5)
Sex with other partner(s) last month (%)					
No	2074 (80)	2137 (78)	2040 (78)	1063 (80)	1154 (78)
Yes	349 (13)	420 (15)	399 (15)	190 (14)	213 (14)
Not reported	177 (7)	185 (7)	170 (7)	71 (5)	107 (7)
Condom used with other partner(s) last month (%)					
N° surveyed	N=349	N=420	N=399	N=190	N=213
Never	126 (36)	179 (43)	184 (46)	90 (47)	104 (49)
Sometimes	123 (35)	117 (28)	100 (25)	54 (28)	47 (22)
Every time	84 (24)	105 (25)	89 (22)	41 (22)	48 (23)
Not reported	16 (5)	19 (5)	26 (7)	5 (3)	14 (7)
Sex work last month (%)					
No	2274 (87)	2394 (87)	2276 (87)	1190 (90)	1292 (88)
Yes	133 (5)	154 (6)	134 (5)	61 (5)	76 (5)
Not reported	193 (7)	194 (7)	199 (8)	73 (6)	106 (7)
Condom used at last sex work (%)					
Yes	94 (71)	100 (65)	78 (58)	27 (44)	43 (57)

Table 1.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

National	2020	2021
N° surveyed	N=1324	N=1474
More difficult to access sterile needles and syringes		
Yes	144 (11)	153 (10)
No	960 (73)	1015 (69)
Not applicable	113 (9)	108 (7)
Not reported	107 (8)	198 (13)
Start depot buprenorphine		
Yes	50 (4)	60 (4)
No	803 (61)	731 (50)
Not applicable	339 (26)	450 (31)
Not reported	132 (10)	233 (16)
Access take home naloxone		
Yes	202 (15)	247 (17)
No	667 (50)	606 (41)
Not applicable	315 (24)	395 (27)
Not reported	140 (11)	226 (15)
Change illicit drug use		
Yes, increased	125 (9)	158 (11)
Yes, decreased	416 (31)	435 (30)
No change	643 (49)	650 (44)
Not reported	140 (11)	231 (16)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	116 (9)	121 (8)
No	688 (52)	652 (44)
Not applicable	382 (29)	471 (32)
Not reported	138 (10)	230 (16)
Inject own methadone/bupe/suboxone		
Yes	145 (11)	154 (10)
No	688 (52)	662 (45)
Not applicable	364 (27)	433 (29)
Not reported	127 (10)	225 (15)
COVID-19 vaccine uptake		
≥1 dose	-- --	599 (41)
COVID-19 vaccine doses		
One dose	-- --	232 (16)
Two doses	-- --	367 (25)
No doses	-- --	635 (43)
Not reported	-- --	240 (16)
Vaccine type		
Astra Zeneca	-- --	139 (9)
Pfizer	-- --	310 (21)
Don't know	-- --	104 (7)
Not reported	-- --	921 (62)
COVID-19 test		
Yes	337 (25)	450 (31)
No	802 (61)	680 (46)
Don't know	60 (5)	63 (4)
Not reported	125 (9)	281 (19)
Self-reported positive COVID-19 test result		
Yes	4 (<1)	16 (1)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017	1641	45 (2.7)	820	7 (0.9)	2492	53 (2.1)
2018	1784	37 (2.1)	888	8 (0.9)	2686	46 (1.7)
2019	1675	51 (3.0)	841	6 (0.7)	2542	59 (2.3)
2020	877	27 (3.1)	406	3 (0.7)	1292	32 (2.5)
2021	902	16 (1.8)	514	3 (0.6)	1435	21 (1.5)
X ² p trend		0.687		0.520		0.709

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heterosexual	1352	12 (0.9)	577	3 (0.5)	1934	16 (0.8)
Bisexual	82	6 (7.3)	135	3 (2.2)	227	9 (4.0)
Homosexual	68	24 (35.3)	44	0 (0.0)	122	24 (19.7)
p value		<0.001		0.165		<0.001
2018						
Heterosexual	1473	12 (0.8)	611	6 (1.0)	2086	18 (0.9)
Bisexual	90	6 (6.7)	162	2 (1.2)	255	8 (3.1)
Homosexual	80	16 (20.0)	35	0 (0.0)	120	17 (14.2)
p value		<0.001		0.773		<0.001
2019						
Heterosexual	1355	13 (1.0)	560	5 (0.9)	1919	18 (0.9)
Bisexual	92	13 (14.1)	148	0 (0.0)	253	14 (5.5)
Homosexual	79	25 (31.7)	36	0 (0.0)	117	26 (22.2)
p value		<0.001		0.680		<0.001
2020						
Heterosexual	746	5 (0.7)	276	3 (1.1)	1023	8 (0.8)
Bisexual	43	4 (9.3)	72	0 (0.0)	120	5 (4.2)
Homosexual	38	17 (44.7)	10	0 (0.0)	49	18 (36.7)
p value		<0.001		1.000		<0.001
2021						
Heterosexual	793	4 (0.5)	375	2 (0.5)	1172	7 (0.6)
Bisexual	49	0 (0.0)	96	0 (0.0)	148	0 (0.0)
Homosexual	40	11 (27.5)	16	1 (6.3)	61	13 (21.3)
p value		<0.001		0.201		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<25 years	76	1 (1.3)	40	0 (0.0)	118	1 (0.9)
25-34 years	275	7 (2.6)	166	0 (0.0)	454	8 (1.8)
35-44 years	587	14 (2.4)	302	2 (0.7)	894	16 (1.8)
45+ years	695	23 (3.3)	308	5 (1.6)	1014	28 (2.8)
p value		0.716		0.329		0.390
2018						
<25 years	60	1 (1.7)	49	0 (0.0)	111	1 (0.9)
25-34 years	284	12 (4.2)	194	2 (1.0)	480	14 (2.9)
35-44 years	643	6 (0.9)	338	1 (0.3)	987	7 (0.7)
45+ years	791	18 (2.3)	304	5 (1.6)	1099	24 (2.2)
p value		0.013		0.313		0.005
2019						
<25 years	51	0 (0.0)	39	0 (0.0)	91	0 (0.0)
25-34 years	254	8 (3.2)	175	0 (0.0)	436	9 (2.1)
35-44 years	605	11 (1.8)	332	2 (0.6)	943	13 (1.4)
45+ years	757	31 (4.1)	294	4 (1.4)	1062	36 (3.4)
p value		0.062		0.457		0.011
2020						
<25 years	23	0 (0.0)	18	1 (5.6)	42	1 (2.4)
25-34 years	145	4 (2.8)	78	1 (1.3)	225	5 (2.2)
35-44 years	288	6 (2.1)	160	0 (0.0)	449	6 (1.3)
45+ years	420	17 (4.1)	150	1 (0.7)	575	20 (3.5)
p value		0.487		0.054		0.151
2021						
<25 years	21	1 (4.8)	12	0 (0.0)	34	1 (2.9)
25-34 years	122	1 (0.8)	83	0 (0.0)	209	2 (1.0)
35-44 years	306	3 (1.0)	194	2 (1.0)	509	6 (1.2)
45+ years	449	11 (2.5)	221	1 (0.5)	675	12 (1.8)
p value		0.202		0.785		0.483

Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heroin	468	7 (1.5)	274	3 (1.1)	751	10 (1.3)
Methamphetamine	651	31 (4.8)	356	3 (0.8)	1016	35 (3.4)
Other opioids	292	3 (1.0)	131	0 (0.0)	428	3 (0.7)
PIEDs	99	0 (0.0)	3	0 (0.0)	105	0 (0.0)
Other drugs	131	4 (3.1)	56	1 (1.8)	192	5 (2.6)
p value		0.001		0.479		0.001
2018						
Heroin	460	8 (1.7)	238	2 (0.8)	701	10 (1.4)
Methamphetamine	828	25 (3.0)	452	6 (1.3)	1287	32 (2.5)
Other opioids	274	1 (0.4)	137	0 (0.0)	412	1 (0.2)
PIEDs	90	0 (0.0)	5	0 (0.0)	96	0 (0.0)
Other drugs	126	3 (2.4)	53	0 (0.0)	181	3 (1.7)
p value		0.035		0.671		0.012
2019						
Heroin	429	9 (2.1)	249	2 (0.8)	689	12 (1.7)
Methamphetamine	794	37 (4.7)	427	3 (0.7)	1231	41 (3.3)
Other opioids	241	4 (1.7)	96	0 (0.0)	339	4 (1.2)
PIEDs	88	0 (0.0)	5	0 (0.0)	93	0 (0.0)
Other drugs	114	1 (0.9)	55	1 (1.8)	170	2 (1.2)
p value		0.008		0.565		0.030
2020						
Heroin	191	2 (1.1)	88	1 (1.1)	280	3 (1.1)
Methamphetamine	391	21 (5.4)	207	2 (1.0)	603	24 (4.0)
Other opioids	161	2 (1.2)	78	0 (0.0)	241	2 (0.8)
PIEDs	77	0 (0.0)	3	0 (0.0)	80	0 (0.0)
Other drugs	50	1 (2.0)	27	0 (0.0)	78	2 (2.6)
p value		0.008		1.000		0.013
2021						
Heroin	180	2 (1.1)	106	1 (0.9)	292	4 (1.4)
Methamphetamine	419	11 (2.6)	299	2 (0.7)	725	14 (1.9)
Other opioids	187	2 (1.1)	72	0 (0.0)	263	2 (0.8)
PIEDs	51	0 (0.0)	0	0 (0.0)	51	0 (0.0)
Other drugs	59	0 (0.0)	33	0 (0.0)	93	0 (0.0)
p value		0.515		1.000		0.564

Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<3 years	97	1 (1.0)	44	0 (0.0)	143	1 (0.7)
3 to 10 years	212	10 (4.7)	122	0 (0.0)	339	11 (3.2)
11+ years	1332	34 (2.6)	654	7 (1.1)	2010	41 (2.0)
p value		0.129		0.731		0.215
2018						
<3 years	83	3 (3.6)	46	0 (0.0)	129	3 (2.3)
3 to 10 years	235	9 (3.8)	148	0 (0.0)	384	9 (2.3)
11+ years	1466	25 (1.7)	694	8 (1.2)	2173	34 (1.6)
p value		0.046		0.584		0.420
2019						
<3 years	97	3 (3.1)	49	0 (0.0)	146	3 (2.1)
3 to 10 years	210	12 (5.7)	145	1 (0.7)	361	14 (3.9)
11+ years	1278	35 (2.7)	608	5 (0.8)	1091	41 (2.2)
p value		0.076		1.000		0.165
2020						
<3 years	56	1 (1.8)	26	0 (0.0)	82	1 (1.2)
3 to 10 years	134	8 (6.0)	61	2 (3.3)	197	10 (5.1)
11+ years	665	18 (2.7)	309	1 (0.3)	981	21 (2.1)
p value		0.131		0.123		0.055
2021						
<3 years	43	0 (0.0)	19	0 (0.0)	64	0 (0.0)
3 to 10 years	108	6 (5.6)	76	0 (0.0)	185	7 (3.8)
11+ years	719	9 (1.3)	397	3 (0.8)	1131	13 (1.2)
p value		0.015		1.000		0.035

Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No receptive sharing	1190	31 (2.6)	603	5 (0.8)	1817	36 (2.0)
Receptive sharing	250	7 (2.8)	119	2 (1.7)	372	10 (2.7)
p value		0.861		0.325		0.386
2018						
No receptive sharing	1309	29 (2.2)	637	6 (0.9)	1951	35 (1.8)
Receptive sharing	293	5 (1.7)	148	0 (0.0)	444	5 (1.1)
p value		0.390		0.601		0.414
2019						
No receptive sharing	1235	41 (3.3)	625	3 (0.5)	1877	46 (2.5)
Receptive sharing	247	6 (2.4)	115	2 (1.7)	366	8 (2.2)
p value		0.466		0.174		0.762
2020						
No receptive sharing	663	20 (3.0)	284	3 (1.1)	955	25 (2.6)
Receptive sharing	107	2 (1.9)	75	0 (0.0)	182	2 (1.1)
p value		0.756		0.494		0.293
2021						
No receptive sharing	638	14 (2.2)	355	2 (0.6)	1003	18 (1.8)
Receptive sharing	135	1 (0.7)	75	1 (1.3)	215	2 (0.9)
p value		0.490		0.438		0.555

Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Less than daily	643	22 (3.4)	292	3 (1.0)	944	25 (2.7)
Daily or more	817	17 (2.1)	440	4 (0.9)	1276	22 (1.7)
Not last month	153	5 (3.3)	81	0 (0.0)	236	5 (2.1)
p value		0.240		1.000		0.310
2018						
Less than daily	717	13 (1.8)	324	4 (1.2)	1044	17 (1.6)
Daily or more	899	21 (2.3)	472	3 (0.6)	1376	24 (1.7)
Not last month	137	3 (2.2)	82	1 (1.2)	223	5 (2.2)
p value		0.760		0.466		0.817
2019						
Less than daily	643	26 (4.0)	291	2 (0.7)	941	28 (3.0)
Daily or more	856	21 (2.5)	461	4 (0.9)	1331	27 (2.0)
Not last month	149	3 (2.0)	78	0 (0.0)	230	3 (1.3)
p value		0.172		1.000		0.204
2020						
Less than daily	350	11 (3.1)	159	2 (1.3)	514	13 (2.5)
Daily or more	425	11 (2.6)	202	1 (0.5)	630	14 (2.2)
Not last month	93	5 (5.4)	42	0 (0.0)	136	5 (3.7)
p value		0.373		0.702		0.615
2021						
Less than daily	373	10 (2.7)	209	0 (0.0)	588	10 (1.7)
Daily or more	402	5 (1.2)	228	3 (1.3)	639	10 (1.6)
Not last month	111	0 (0.0)	67	0 (0.0)	180	0 (0.0)
p value		0.118		0.361		0.199

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No imprisonment	1300	40 (3.1)	698	5 (0.7)	2023	46 (2.3)
Imprisonment	229	2 (0.9)	67	1 (1.5)	299	3 (1.0)
p value		0.076		0.424		0.196
2018						
No imprisonment	1421	30 (2.1)	748	7 (0.9)	2179	38 (1.7)
Imprisonment	249	7 (2.8)	92	0 (0.0)	343	7 (2.0)
p value		0.489		1.000		0.699
2019						
No imprisonment	1322	43 (3.3)	708	5 (0.7)	2049	50 (2.4)
Imprisonment	250	3 (1.2)	89	1 (1.1)	344	4 (1.2)
p value		0.099		0.510		0.170
2020						
No imprisonment	711	23 (3.2)	349	3 (0.9)	1069	28 (2.6)
Imprisonment	118	4 (3.4)	38	0 (0.0)	156	4 (2.6)
p value		1		1.000		0.614
2021						
No imprisonment	733	13 (1.8)	447	3 (0.7)	1196	18 (1.5)
Imprisonment	114	1 (0.9)	39	0 (0.0)	154	1 (0.7)
p value		0.707		1.000		0.714

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

National Condom use at last sex	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No condom use	462	17 (3.7)	319	2 (0.6)	786	19 (2.4)
Condom use	170	7 (4.1)	81	1 (1.2)	254	8 (3.2)
p value		0.798		0.494		0.523
2018						
No condom use	545	11 (2.0)	369	1 (0.3)	917	12 (1.3)
Condom use	154	7 (4.6)	67	0 (0.0)	226	7 (3.1)
p value		0.080		1.000		0.060
2019						
No condom use	469	18 (3.8)	317	0 (0.0)	790	18 (2.3)
Condom use	159	1 (0.6)	89	3 (3.4)	253	4 (1.6)
p value		0.056		0.010		0.621
2020						
No condom use	278	13 (4.7)	159	1 (0.6)	439	15 (3.4)
Condom use	75	3 (4.0)	29	0 (0.0)	104	3 (2.9)
p value		1.000		1.000		1.000
2021						
No condom use	267	4 (1.5)	200	0 (0.0)	473	4 (0.9)
Condom use	65	0 (0.0)	48	0 (0.0)	116	1 (0.9)
p value		1.000		--		1.000

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year

National Sex work last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No sex work	1464	39 (2.7)	696	6 (0.9)	2182	45 (2.1)
Sex work	57	4 (7.0)	61	0 (0.0)	126	5 (4.0)
p value		0.074		1.000		0.192
2018						
No sex work	1614	31 (1.9)	740	6 (0.8)	2363	38 (1.6)
Sex work	65	2 (3.1)	81	0 (0.0)	150	2 (1.3)
p value		0.368		1.000		1.000
2019						
No sex work	1490	44 (3.0)	717	5 (0.7)	2226	51 (2.3)
Sex work	60	4 (6.7)	64	1 (1.6)	129	5 (3.9)
p value		0.111		0.402		0.251
2020						
No sex work	807	23 (2.9)	352	2 (0.6)	1166	26 (2.2)
Sex work	26	4 (15.4)	30	1 (3.3)	58	6 (10.3)
p value		0.008		0.218		<0.001
2021						
No sex work	820	13 (1.6)	425	3 (0.7)	1259	16 (1.3)
Sex work	27	1 (3.7)	44	0 (0.0)	74	3 (4.1)
p value		0.367		1.000		0.084

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Non Indigenous	1341	33 (2.5)	627	3 (0.5)	1991	37 (1.9)
Indigenous	266	12 (4.5)	172	4 (2.3)	446	16 (3.6)
p value		0.064		0.042		0.024
2018						
Non Indigenous	1439	20 (1.4)	662	3 (0.5)	2111	23 (1.1)
Indigenous	311	15 (4.8)	209	3 (1.4)	523	19 (3.6)
p value		<0.001		0.153		<0.001
2019						
Non Indigenous	1314	37 (2.8)	615	1 (0.2)	1947	39 (2.0)
Indigenous	331	14 (4.2)	215	5 (2.3)	552	20 (3.6)
p value		0.185		0.005		0.027
2020						
Non Indigenous	675	20 (3.0)	278	2 (0.7)	958	23 (2.4)
Indigenous	168	6 (3.6)	115	1 (0.9)	285	8 (2.8)
p value		0.683		1.000		0.699
2021						
Non Indigenous	650	13 (2.0)	347	1 (0.3)	1008	15 (1.5)
Indigenous	207	3 (1.5)	145	2 (1.4)	359	6 (1.7)
p value		0.773		0.209		0.804

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
English speaking	1534	43 (2.8)	790	7 (0.9)	2352	51 (2.2)
Non-English speaking	96	2 (2.1)	27	0 (0.0)	126	2 (1.6)
p value		1.000		1.000		1.000
2018						
English speaking	1653	36 (2.2)	846	4 (0.5)	2508	41 (1.6)
Non-English speaking	120	1 (0.8)	39	2 (5.1)	164	3 (1.8)
p value		0.511		0.025		0.750
2019						
English speaking	1566	48 (3.1)	817	5 (0.6)	2405	55 (2.3)
Non-English speaking	100	3 (3.0)	22	1 (4.6)	125	4 (3.2)
p value		1.000		0.148		0.534
2020						
English speaking	824	26 (3.2)	392	3 (0.8)	1225	31 (2.5)
Non-English speaking	48	1 (2.1)	10	0 (0.0)	58	1 (1.7)
p value		1.000		1.000		1.000
2021						
English speaking	856	15 (1.8)	495	3 (0.6)	1368	20 (1.5)
Non-English speaking	35	1 (2.9)	14	0 (0.0)	51	1 (2.0)
p value		0.476		1.000		0.539

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Australia	1415	39 (2.8)	729	6 (0.8)	2167	46 (2.1)
Other Oceania	43	1 (2.3)	31	0 (0.0)	77	1 (1.3)
Asia	18	1 (5.6)	9	0 (0.0)	27	1 (3.7)
UK & Ireland	73	1 (1.4)	33	0 (0.0)	107	1 (0.9)
Other	68	1 (1.5)	10	0 (0.0)	82	1 (1.2)
p value		0.740		1.000		0.820
2018						
Australia	1518	33 (2.2)	793	6 (0.8)	2320	39 (1.7)
Other Oceania	57	1 (1.8)	23	0 (0.0)	82	2 (2.4)
Asia	26	0 (0.0)	4	0 (0.0)	30	0 (0.0)
UK & Ireland	83	2 (2.4)	38	0 (0.0)	121	2 (1.7)
Other	90	1 (1.1)	24	0 (0.0)	117	1 (0.9)
p value		0.964		1.000		0.936
2019						
Australia	1467	45 (3.1)	763	6 (0.8)	2248	53 (2.4)
Other Oceania	38	1 (2.6)	23	0 (0.0)	66	1 (1.5)
Asia	22	3 (13.6)	3	0 (0.0)	25	3 (12.0)
UK & Ireland	55	0 (0.0)	28	0 (0.0)	83	0 (0.0)
Other	77	2 (2.6)	22	0 (0.0)	100	2 (2.0)
p value		0.085		1.000		0.055
2020						
Australia	740	22 (3.0)	365	3 (0.8)	1113	26 (2.3)
Other Oceania	33	1 (3.0)	9	0 (0.0)	42	1 (2.4)
Asia	16	1 (6.3)	2	0 (0.0)	18	1 (5.6)
UK & Ireland	34	1 (2.9)	17	0 (0.0)	51	1 (2.0)
Other	39	1 (2.6)	10	0 (0.0)	49	1 (2.0)
p value		0.722		1.000		0.652
2021						
Australia	776	12 (1.6)	449	3 (0.7)	1241	16 (1.3)
Other Oceania	22	0 (0.0)	18	0 (0.0)	43	1 (2.3)
Asia	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
UK & Ireland	39	0 (0.0)	15	0 (0.0)	54	0 (0.0)
Other	32	3 (9.4)	15	0 (0.0)	47	3 (6.4)
p value		0.080		1.000		0.087

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	1577	786 (50)	799	381 (48)	2404	1178 (49)
2018	1770	817 (46)	884	376 (43)	2668	1200 (45)
2019	1670	781 (47)	835	360 (43)	2531	1151 (45)
2020	877	342 (39)	405	163 (40)	1291	507 (39)
2021	902	343 (38)	514	173 (34)	1435	522 (36)
X ² p trend		<0.001		<0.001		<0.001

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	1292	657 (51)	560	265 (47)	1856	923 (50)
Bisexual	80	40 (50)	132	66 (50)	221	109 (49)
Homosexual	70	15 (21)	45	16 (36)	125	36 (29)
p value		<0.001		0.239		<0.001
2018						
Heterosexual	1462	690 (47)	610	264 (43)	2074	955 (46)
Bisexual	89	34 (38)	161	64 (40)	253	101 (40)
Homosexual	80	28 (35)	35	15 (43)	120	44 (37)
p value		0.032		0.723		0.031
2019						
Heterosexual	1351	645 (48)	554	239 (43)	1909	887 (46)
Bisexual	91	38 (42)	149	61 (41)	253	104 (41)
Homosexual	79	15 (19)	36	15 (42)	117	30 (26)
p value		<0.001		0.894		<0.001
2020						
Heterosexual	746	297 (40)	275	106 (39)	1022	404 (40)
Bisexual	43	16 (37)	72	40 (56)	120	56 (47)
Homosexual	38	6 (16)	10	3 (30)	49	9 (18)
p value		0.024		0.027		0.004
2021						
Heterosexual	791	316 (40)	375	118 (31)	1170	436 (37)
Bisexual	49	16 (33)	96	38 (40)	148	54 (36)
Homosexual	42	6 (14)	16	7 (44)	63	13 (21)
p value		0.004		0.216		0.156

Table 1.3.3 HCV antibody prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	73	6 (8)	40	9 (23)	115	15 (13)
25-34 years	264	104 (39)	163	72 (44)	438	180 (41)
35-44 years	558	278 (50)	296	143 (48)	859	422 (49)
45+ years	674	394 (58)	296	155 (52)	980	555 (57)
p value		<0.001		0.003		<0.001
2018						
<25 years	58	10 (17)	49	10 (20)	109	21 (19)
25-34 years	283	96 (34)	192	75 (39)	477	172 (36)
35-44 years	638	296 (46)	337	150 (45)	981	449 (46)
45+ years	785	411 (52)	303	140 (46)	1092	553 (51)
p value		<0.001		0.005		<0.001
2019						
<25 years	51	13 (25)	40	8 (20)	92	21 (23)
25-34 years	254	66 (26)	175	74 (42)	436	141 (32)
35-44 years	601	275 (46)	331	137 (41)	938	416 (44)
45+ years	756	424 (56)	288	141 (49)	1055	569 (54)
p value		<0.001		0.004		<0.001
2020						
<25 years	23	3 (13)	18	7 (39)	42	10 (24)
25-34 years	145	30 (21)	78	26 (33)	225	56 (25)
35-44 years	289	118 (41)	159	70 (44)	449	188 (42)
45+ years	419	190 (45)	150	60 (40)	574	252 (44)
p value		<0.001		0.473		<0.001
2021						
<25 years	21	4 (19)	12	3 (25)	34	7 (21)
25-34 years	122	30 (25)	83	25 (30)	209	56 (27)
35-44 years	307	126 (41)	194	60 (31)	510	189 (37)
45+ years	448	183 (41)	221	83 (38)	674	268 (40)
p value		0.001		0.410		0.002

Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<3 years	96	4 (4)	44	5 (11)	142	9 (6)
3 to 10 years	207	55 (27)	122	37 (30)	333	93 (28)
11+ years	1199	684 (57)	594	323 (54)	1813	1016 (56)
p value		<0.001		<0.001		<0.001
2018						
<3 years	83	9 (11)	46	2 (4)	129	11 (9)
3 to 10 years	233	51 (22)	146	47 (32)	380	99 (26)
11+ years	1373	713 (52)	659	312 (47)	2043	1031 (50)
p value		<0.001		<0.001		<0.001
2019						
<3 years	96	8 (8)	50	0 (0)	146	8 (5)
3 to 10 years	210	46 (22)	145	48 (33)	361	96 (27)
11+ years	1273	683 (54)	601	294 (49)	1889	982 (52)
p value		<0.001		<0.001		<0.001
2020						
<3 years	56	5 (9)	26	0 (0)	82	5 (6)
3 to 10 years	135	21 (16)	61	22 (36)	198	43 (22)
11+ years	663	305 (46)	308	136 (44)	978	443 (45)
p value		<0.001		<0.001		<0.001
2021						
<3 years	43	2 (5)	19	3 (16)	64	5 (8)
3 to 10 years	108	19 (18)	76	16 (21)	185	35 (19)
11+ years	719	308 (43)	397	147 (37)	1131	460 (41)
p value		<0.001		0.005		<0.001

Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No receptive sharing	106	6 (6)	1580	801 (51)	1747	841 (48)
Receptive sharing	18	2 (11)	317	188 (59)	359	204 (57)
p value		0.328		0.005		0.003
2018						
No receptive sharing	86	6 (7)	1787	813 (46)	1935	849 (44)
Receptive sharing	23	4 (17)	391	219 (56)	442	244 (55)
p value		0.214		<0.001		<0.001
2019						
No receptive sharing	113	5 (4)	1683	803 (48)	1870	853 (46)
Receptive sharing	15	1 (7)	318	170 (53)	362	185 (51)
p value		0.534		0.060		0.055
2020						
No receptive sharing	65	4 (6)	872	352 (40)	953	364 (38)
Receptive sharing	5	0 (0)	171	88 (51)	182	93 (51)
p value		1.000		0.007		0.001
2021						
No receptive sharing	44	3 (7)	924	343 (37)	1003	358 (36)
Receptive sharing	5	2 (40)	202	100 (50)	214	106 (50)
p value		0.075		0.001		<0.001

Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

National Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	16	4 (25)	653	442 (68)	703	473 (67)
Methamphetamine	70	4 (6)	883	343 (39)	987	363 (37)
Other opioids	8	1 (13)	380	229 (60)	412	240 (58)
PIEDs	36	0 (0)	64	2 (3)	103	2 (2)
Other drugs	12	0 (0)	144	80 (56)	166	84 (51)
p value		0.010		<0.001		<0.001
2018						
Heroin	12	2 (17)	650	381 (59)	685	399 (58)
Methamphetamine	82	7 (9)	1127	433 (38)	1260	463 (37)
Other opioids	3	1 (33)	385	212 (55)	404	223 (55)
PIEDs	20	0 (0)	68	1 (1)	95	1 (1)
Other drugs	11	1 (9)	149	81 (55)	172	88 (51)
p value		0.266		<0.001		<0.001
2019						
Heroin	14	2 (14)	632	415 (66)	677	441 (65)
Methamphetamine	90	4 (4)	1058	385 (36)	1210	415 (34)
Other opioids	7	1 (14)	319	171 (54)	334	178 (53)
PIEDs	27	0 (0)	59	1 (2)	91	1 (1)
Other drugs	5	1 (20)	148	89 (60)	168	97 (58)
p value		0.147		<0.001		<0.001
2020						
Heroin	6	1 (17)	267	160 (60)	278	164 (59)
Methamphetamine	42	4 (10)	546	162 (30)	599	173 (29)
Other opioids	5	0 (0)	230	116 (50)	238	119 (50)
PIEDs	23	0 (0)	49	2 (4)	79	2 (3)
Other drugs	4	0 (0)	69	40 (58)	76	42 (55)
p value		0.404		<0.001		<0.001
2021						
Heroin	4	1 (25)	277	134 (48)	289	139 (48)
Methamphetamine	39	1 (3)	649	184 (28)	710	193 (27)
Other opioids	8	2 (25)	239	119 (50)	257	125 (49)
PIEDs	8	0 (0)	41	4 (10)	51	4 (8)
Other drugs	2	0 (0)	81	42 (52)	91	45 (49)
p value		0.079		<0.000		<0.001

Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

National Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Less than daily	66	4 (6)	815	398 (49)	913	416 (46)
Daily or more	59	4 (7)	1107	607 (55)	1223	647 (53)
Not last month	17	1 (6)	202	91 (45)	235	99 (42)
p value		1.000		0.005		<0.001
2018						
Less than daily	60	6 (10)	948	432 (46)	1040	453 (44)
Daily or more	50	4 (8)	1253	611 (49)	1362	652 (48)
Not last month	18	1 (6)	185	68 (37)	223	74 (33)
p value		0.914		0.007		<0.001
2019						
Less than daily	65	4 (6)	835	365 (44)	935	389 (41)
Daily or more	66	3 (5)	1190	617 (52)	1326	660 (50)
Not last month	15	1 (7)	195	82 (42)	231	86 (37)
p value		0.772		<0.001		<0.001
2020						
Less than daily	38	2 (5)	469	170 (36)	516	176 (34)
Daily or more	32	2 (6)	581	273 (47)	626	284 (45)
Not last month	12	1 (8)	116	38 (33)	137	41 (30)
p value		1.000		<0.001		<0.001
2021						
Less than daily	32	1 (3)	541	160 (30)	589	167 (28)
Daily or more	18	4 (22)	592	286 (48)	637	301 (47)
Not last month	13	0 (0)	160	38 (24)	181	41 (23)
p value		0.041		<0.001		<0.001

Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

National Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No imprisonment	126	8 (6)	1742	860 (49)	1955	908 (46)
Imprisonment	8	0 (0)	258	166 (64)	285	182 (64)
p value		1.000		<0.001		<0.001
2018						
No imprisonment	109	8 (7)	1979	889 (45)	2166	932 (43)
Imprisonment	16	1 (6)	300	172 (57)	338	186 (55)
p value		1.000		<0.001		<0.001
2019						
No imprisonment	129	7 (5)	1815	827 (46)	2041	878 (43)
Imprisonment	12	0 (0)	301	178 (59)	342	194 (57)
p value		1.000		<0.001		<0.001
2020						
No imprisonment	75	4 (5)	969	381 (39)	1068	395 (37)
Imprisonment	7	1 (14)	141	68 (48)	156	75 (48)
p value		0.367		0.044		0.008
2021						
No imprisonment	55	4 (7)	1100	395 (36)	1196	413 (35)
Imprisonment	4	0 (0)	142	66 (46)	154	70 (45)
p value		1.000		0.014		0.008

Table 1.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	1290	603 (47)	611	288 (47)	1922	899 (47)
Indigenous	254	163 (64)	167	83 (50)	428	249 (58)
p value		<0.001		0.556		<0.001
2018						
Non Indigenous	1431	625 (44)	660	270 (41)	2101	899 (43)
Indigenous	305	175 (57)	208	99 (48)	516	276 (53)
p value		<0.001		0.089		<0.001
2019						
Non Indigenous	1309	584 (45)	610	253 (41)	1937	844 (44)
Indigenous	331	180 (54)	214	102 (48)	551	284 (52)
p value		0.001		0.116		0.001
2020						
Non Indigenous	676	234 (35)	277	101 (36)	958	337 (35)
Indigenous	167	91 (54)	115	54 (47)	284	145 (51)
p value		<0.001		0.053		<0.001
2021						
Non Indigenous	650	214 (33)	347	108 (31)	1008	324 (32)
Indigenous	207	108 (52)	145	58 (40)	359	169 (47)
p value		<0.001		0.058		<0.001

Table 1.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	1476	729 (49)	769	366 (48)	2270	1106 (49)
Non-English speaking	91	51 (56)	27	14 (52)	121	65 (54)
p value		0.218		0.663		0.284
2018						
English speaking	1640	752 (46)	843	360 (43)	2492	1116 (45)
Non-English speaking	118	61 (52)	39	16 (41)	162	80 (49)
p value		0.219		0.836		0.254
2019						
English speaking	1561	726 (47)	811	347 (43)	2394	1081 (45)
Non-English speaking	100	53 (53)	22	12 (55)	125	67 (54)
p value		0.207		0.272		0.065
2020						
English speaking	824	319 (39)	391	157 (40)	1224	478 (39)
Non-English speaking	48	22 (46)	10	6 (60)	58	28 (48)
p value		0.326		0.328		0.160
2021						
English speaking	856	326 (38)	495	163 (33)	1368	494 (36)
Non-English speaking	35	14 (40)	14	7 (50)	51	22 (43)
p value		0.819		0.182		0.306

Table 1.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Australia	1357	665 (49)	709	344 (49)	2086	1017 (49)
Other Oceania	41	21 (51)	30	11 (37)	74	34 (46)
Asia	17	9 (53)	9	6 (67)	26	15 (58)
UK & Ireland	71	40 (56)	33	13 (39)	105	54 (51)
Other	67	35 (52)	10	3 (30)	81	38 (47)
p value		0.775		0.287		0.832
2018						
Australia	1504	689 (46)	790	342 (43)	2303	1035 (45)
Other Oceania	57	23 (40)	23	6 (26)	82	29 (35)
Asia	26	17 (65)	4	4 (100)	30	21 (70)
UK & Ireland	82	39 (48)	38	14 (37)	120	53 (44)
Other	90	44 (49)	24	8 (33)	117	55 (47)
p value		0.282		0.052		0.028
2019						
Australia	1463	684 (47)	757	325 (43)	2238	1015 (45)
Other Oceania	38	19 (50)	23	11 (48)	66	32 (48)
Asia	23	7 (30)	3	1 (33)	26	8 (31)
UK & Ireland	55	31 (56)	28	14 (50)	83	45 (54)
Other	75	33 (44)	22	7 (32)	98	40 (41)
p value		0.299		0.741		0.204
2020						
Australia	740	292 (39)	365	149 (41)	1113	443 (40)
Other Oceania	33	10 (30)	9	2 (22)	42	12 (29)
Asia	16	5 (31)	2	1 (50)	18	6 (33)
UK & Ireland	34	10 (29)	16	5 (31)	50	15 (30)
Other	39	22 (56)	10	5 (50)	49	27 (55)
p value		0.102		0.679		0.054
2021						
Australia	775	292 (38)	449	147 (33)	1240	445 (36)
Other Oceania	22	12 (55)	18	8 (44)	43	20 (47)
Asia	7	1 (14)	5	3 (60)	12	4 (33)
UK & Ireland	39	12 (31)	15	3 (20)	54	15 (28)
Other	33	14 (42)	15	7 (47)	48	21 (44)
p value		0.270		0.264		0.293

HCV RNA prevalence

Table 1.4.1 HCV RNA prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*	1073	305 (28)	529	110 (21)	1621	416 (26)
2018*	932	195 (21)	458	89 (19)	1397	284 (20)
2019*	1412	264 (19)	706	111 (16)	2140	378 (18)
2020	808	136 (17)	361	57 (16)	1175	193 (16)
2021	835	148 (18)	474	62 (13)	1328	214 (16)
X ² p trend		<0.001		<0.001		<0.001

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
Heterosexual	903	256 (28)	369	75 (20)	1275	331 (26)
Bisexual	58	22 (38)	84	18 (21)	147	40 (27)
Homosexual	31	3 (10)	31	7 (23)	68	11 (16)
p value		0.039		0.891		0.169
2018*						
Heterosexual	764	166 (22)	309	65 (21)	1074	231 (22)
Bisexual	44	7 (16)	85	13 (15)	131	21 (16)
Homosexual	44	5 (11)	21	3 (14)	68	8 (12)
p value		0.155		0.439		0.062
2019*						
Heterosexual	1148	215 (19)	460	69 (15)	1611	285 (18)
Bisexual	77	14 (18)	132	20 (15)	220	36 (16)
Homosexual	70	3 (4)	34	6 (18)	106	9 (8)
p value		0.008		0.921		0.043
2020						
Heterosexual	684	117 (17)	244	43 (18)	929	160 (17)
Bisexual	41	7 (17)	65	10 (15)	109	17 (16)
Homosexual	36	2 (6)	10	0 (0)	46	2 (4)
p value		0.191		0.326		0.069
2021						
Heterosexual	736	136 (18)	345	41 (12)	1085	179 (16)
Bisexual	43	8 (19)	90	11 (12)	136	19 (14)
Homosexual	37	1 (3)	16	4 (25)	58	5 (9)
p value		0.049		0.298		0.226

Table 1.4.3 HCV RNA prevalence by age group, gender and survey year

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	52	5 (10)	27	5 (19)	81	10 (12)
25-34 years	191	57 (30)	105	23 (22)	304	80 (26)
35-44 years	398	118 (30)	189	42 (22)	590	160 (27)
45+ years	428	124 (29)	206	40 (19)	641	166 (26)
p value		0.060		0.908		0.092
2018*						
<25 years	33	6 (18)	25	6 (24)	59	12 (20)
25-34 years	138	22 (16)	102	23 (23)	241	45 (19)
35-44 years	345	81 (23)	172	34 (20)	521	116 (22)
45+ years	410	84 (20)	157	26 (17)	570	110 (19)
p value		0.571		0.633		0.686
2019*						
<25 years	44	5 (11)	39	7 (18)	84	12 (14)
25-34 years	220	27 (12)	146	24 (16)	372	52 (14)
35-44 years	503	102 (20)	277	46 (17)	785	148 (19)
45+ years	639	129 (20)	244	34 (14)	891	165 (19)
p value		0.028		0.773		0.143
2020						
<25 years	20	1 (5)	19	4 (21)	40	5 (13)
25-34 years	129	12 (9)	71	12 (17)	201	24 (12)
35-44 years	271	63 (23)	139	27 (19)	411	90 (22)
45+ years	387	60 (16)	132	14 (11)	522	74 (14)
p value		0.001		0.211		0.003
2021						
<25 years	21	2 (10)	12	2 (17)	34	4 (12)
25-34 years	113	21 (19)	78	10 (13)	195	33 (17)
35-44 years	281	55 (20)	174	18 (10)	464	74 (16)
45+ years	416	70 (17)	206	31 (15)	627	102 (16)
p value		0.593		0.573		0.899

Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	66	2 (3)	27	1 (4)	94	3 (3)
3 to 10 years	138	28 (20)	76	18 (24)	216	46 (21)
11+ years	824	258 (31)	402	84 (21)	1243	344 (28)
p value		<0.001		0.081		<0.001
2018*						
<3 years	37	3 (8)	23	3 (13)	60	6 (10)
3 to 10 years	118	20 (17)	66	15 (23)	184	35 (19)
11+ years	733	159 (22)	351	67 (19)	1090	227 (21)
p value		0.163		0.537		0.164
2019*						
<3 years	87	7 (8)	43	1 (2)	130	8 (6)
3 to 10 years	174	22 (13)	126	28 (22)	305	51 (17)
11+ years	1073	220 (21)	509	76 (15)	1594	297 (19)
p value		0.001		0.007		0.001
2020						
<3 years	51	2 (4)	22	0 (0)	73	2 (3)
3 to 10 years	125	12 (10)	57	12 (21)	183	24 (13)
11+ years	610	117 (19)	273	44 (16)	888	161 (18)
p value		0.001		0.071		0.001
2021						
<3 years	42	1 (2)	17	1 (6)	61	2 (3)
3 to 10 years	103	21 (20)	67	9 (13)	171	31 (18)
11+ years	660	122 (18)	368	48 (13)	1043	172 (16)
p value		0.024		0.680		0.018

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	792	218 (28)	400	89 (22)	1207	307 (25)
Receptive sharing	167	62 (37)	68	10 (15)	235	72 (31)
p value		0.020		0.209		0.109
2018*						
No receptive sharing	685	133 (19)	325	60 (18)	1012	193 (19)
Receptive sharing	143	48 (34)	69	18 (26)	214	66 (31)
p value		<0.001		0.164		<0.001
2019*						
No receptive sharing	1055	205 (19)	527	81 (15)	1597	288 (18)
Receptive sharing	196	43 (22)	99	21 (21)	300	65 (22)
p value		0.456		0.169		0.152
2020						
No receptive sharing	610	97 (16)	246	39 (16)	861	136 (16)
Receptive sharing	94	33 (35)	72	14 (19)	166	47 (28)
p value		<0.001		0.472		<0.001
2021						
No receptive sharing	588	101 (17)	325	39 (12)	923	142 (15)
Receptive sharing	124	36 (29)	72	15 (21)	201	52 (26)
p value		0.002		0.048		<0.001

Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year

National Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	288	99 (34)	184	53 (29)	482	154 (32)
Methamphetamine	421	110 (26)	216	37 (17)	641	147 (23)
Other opioids	209	59 (28)	91	17 (19)	302	76 (25)
PIEDs	66	2 (3)	2	0 (0)	70	2 (3)
Other drugs	79	31 (39)	32	3 (9)	112	34 (30)
p value		<0.001		0.012		<0.001
2018*						
Heroin	294	59 (20)	139	26 (19)	435	85 (20)
Methamphetamine	363	87 (24)	205	35 (17)	572	122 (21)
Other opioids	142	28 (20)	71	17 (24)	214	45 (21)
PIEDs	50	1 (2)	1	0 (0)	51	1 (2)
Other drugs	64	16 (25)	33	9 (27)	98	25 (26)
p value		0.038		0.531		0.026
2019*						
Heroin	364	81 (22)	205	41 (20)	578	122 (21)
Methamphetamine	659	122 (19)	351	46 (13)	1019	171 (17)
Other opioids	202	39 (19)	87	9 (10)	291	49 (17)
PIEDs	73	1 (1)	5	0 (0)	78	1 (1)
Other drugs	90	18 (20)	48	13 (27)	139	30 (22)
p value		0.001		0.019		<0.001
2020						
Heroin	177	34 (19)	85	14 (16)	263	48 (18)
Methamphetamine	354	56 (16)	171	24 (14)	529	80 (15)
Other opioids	145	31 (21)	74	8 (11)	220	39 (18)
PIEDs	71	0 (0)	3	0 (0)	74	0 (0)
Other drugs	46	12 (26)	25	11 (44)	71	23 (32)
p value		<0.001		0.002		<0.001
2021						
Heroin	164	29 (18)	95	14 (15)	265	45 (17)
Methamphetamine	382	72 (19)	267	28 (10)	656	100 (15)
Other opioids	173	32 (18)	67	11 (16)	244	44 (18)
PIEDs	48	3 (6)	0	0 (0)	48	3 (6)
Other drugs	50	7 (14)	32	7 (22)	82	14 (17)
p value		0.264		0.198		0.320

Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

National Frequency of injection last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Less than daily	423	104 (25)	197	39 (20)	625	143 (23)
Daily or more	547	182 (33)	277	63 (23)	837	245 (29)
Not last month	93	16 (17)	51	8 (16)	145	26 (18)
p value		0.001		0.541		0.003
2018*						
Less than daily	368	71 (19)	173	35 (20)	542	106 (20)
Daily or more	468	110 (24)	227	44 (19)	696	154 (22)
Not last month	81	12 (15)	52	8 (15)	134	20 (15)
p value		0.144		0.733		0.141
2019*						
Less than daily	559	93 (17)	246	40 (16)	810	133 (16)
Daily or more	706	157 (22)	390	63 (16)	1108	223 (20)
Not last month	131	12 (9)	64	7 (11)	197	19 (10)
p value		<0.001		0.518		<0.001
2020						
Less than daily	326	49 (15)	141	22 (16)	471	71 (15)
Daily or more	383	81 (21)	179	31 (17)	563	112 (20)
Not last month	90	4 (4)	38	4 (11)	129	8 (6)
p value		<0.001		0.578		<0.001
2021						
Less than daily	352	56 (16)	196	20 (10)	554	76 (14)
Daily or more	362	81 (22)	206	35 (17)	577	119 (21)
Not last month	106	6 (6)	62	5 (8)	170	11 (6)
p value		<0.001		0.060		<0.001

Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

National Imprisonment last year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No imprisonment	857	228 (27)	458	91 (20)	1329	320 (24)
Imprisonment	148	60 (41)	38	10 (26)	189	70 (37)
p value		0.002		0.283		<0.001
2018*						
No imprisonment	732	147 (20)	388	76 (20)	1125	223 (20)
Imprisonment	134	32 (24)	41	9 (22)	176	41 (23)
p value		0.326		0.674		0.287
2019*						
No imprisonment	1107	186 (17)	594	88 (15)	1718	276 (16)
Imprisonment	215	57 (27)	76	17 (22)	295	75 (25)
p value		<0.001		0.101		<0.001
2020						
No imprisonment	658	102 (16)	309	48 (16)	973	150 (15)
Imprisonment	107	26 (24)	35	7 (20)	142	33 (23)
p value		0.024		0.494		0.019
2021						
No imprisonment	680	110 (16)	412	50 (12)	1108	163 (15)
Imprisonment	107	23 (21)	36	6 (17)	144	29 (20)
p value		0.172		0.431		0.089

Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Non Indigenous	878	238 (27)	401	76 (19)	1293	315 (24)
Indigenous	171	57 (33)	116	32 (28)	292	90 (31)
p value		0.107		0.043		0.033
2018*						
Non Indigenous	750	144 (19)	339	66 (19)	1094	210 (19)
Indigenous	163	47 (29)	107	20 (19)	272	67 (25)
p value		0.020		0.880		0.073
2019*						
Non Indigenous	1117	185 (17)	514	71 (14)	1646	258 (16)
Indigenous	273	74 (27)	182	39 (21)	461	114 (25)
p value		<0.001		0.020		<0.001
2020						
Non Indigenous	617	90 (15)	241	35 (15)	862	125 (15)
Indigenous	158	38 (24)	108	20 (19)	267	58 (22)
p value		0.004		0.344		0.005
2021						
Non Indigenous	596	81 (14)	315	40 (13)	922	123 (13)
Indigenous	197	55 (28)	140	21 (15)	344	78 (23)
p value		<0.001		0.506		<0.001

Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
English speaking	1003	283 (28)	510	105 (21)	1530	389 (25)
Non-English speaking	62	19 (31)	18	5 (28)	82	24 (29)
p value		0.716		0.368		0.436
2018*						
English speaking	859	178 (21)	432	85 (20)	1296	263 (20)
Non-English speaking	66	17 (26)	23	4 (17)	90	21 (23)
p value		0.364		0.956		0.484
2019*						
English speaking	1322	248 (19)	685	105 (15)	2026	355 (18)
Non-English speaking	85	17 (20)	19	6 (32)	107	23 (21)
p value		0.858		0.056		0.242
2020						
English speaking	758	127 (17)	351	54 (15)	1115	181 (16)
Non-English speaking	46	9 (20)	9	3 (33)	55	12 (22)
p value		0.622		0.145		0.276
2021						
English speaking	794	140 (18)	459	56 (12)	1270	199 (16)
Non-English speaking	32	7 (22)	13	4 (31)	47	12 (26)
p value		0.538		0.047		0.070

Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Australia	931	259 (28)	471	97 (21)	1416	357 (25)
Other Oceania	27	8 (30)	22	5 (23)	51	14 (27)
Asia	10	5 (50)	4	1 (25)	14	6 (43)
UK & Ireland	49	15 (31)	21	3 (14)	70	18 (26)
Other	42	11 (26)	8	2 (25)	52	14 (27)
p value		0.800		0.930		0.765
2018*						
Australia	806	166 (21)	400	80 (20)	1211	247 (20)
Other Oceania	26	3 (12)	12	2 (17)	39	5 (13)
Asia	9	5 (56)	1	0 (0)	10	5 (50)
UK & Ireland	35	5 (14)	20	5 (25)	55	10 (18)
Other	49	14 (29)	18	2 (11)	69	16 (23)
p value		0.014		0.650		0.060
2019*						
Australia	1244	238 (19)	636	101 (16)	1895	340 (18)
Other Oceania	32	4 (13)	19	4 (21)	55	10 (18)
Asia	16	3 (19)	3	0 (0)	19	3 (16)
UK & Ireland	44	8 (18)	26	4 (15)	70	13 (19)
Other	63	10 (16)	21	1 (5)	85	11 (13)
p value		0.813		0.575		0.782
2020						
Australia	681	109 (16)	328	53 (16)	1015	162 (16)
Other Oceania	31	5 (16)	8	1 (13)	39	6 (15)
Asia	16	0 (0)	2	0 (0)	18	0 (0)
UK & Ireland	29	7 (24)	13	2 (15)	42	9 (21)
Other	37	13 (35)	9	1 (11)	46	14 (30)
p value		0.018		0.976		0.048
2021						
Australia	718	126 (18)	416	52 (13)	1150	181 (16)
Other Oceania	20	7 (35)	15	4 (27)	38	12 (32)
Asia	6	1 (17)	5	2 (40)	11	3 (27)
UK & Ireland	36	6 (17)	14	1 (7)	50	7 (14)
Other	30	5 (17)	14	2 (14)	44	7 (16)
p value		0.391		0.187		0.093

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Australian Capital Territory	2017	2018	2019	2020*	2021*
Number of sites	1	1	1	1	1
N° surveyed	N=119	N=127	N=128	N=104	N=100
Response rate (%)	89%	93%	71%	67%	68%
Gender (%)					
Male	80 (67)	90 (71)	86 (67)	70 (67)	68 (68)
Female	38 (32)	35 (28)	42 (33)	33 (32)	32 (32)
Other	1 (1)	2 (2)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	92 (77)	100 (79)	93 (73)	84 (81)	87 (87)
Bisexual	15 (13)	13 (10)	13 (10)	11 (11)	7 (7)
Gay/Lesbian	1 (1)	3 (2)	4 (3)	2 (2)	4 (4)
Other	-- --	-- --	-- --	3 (3)	1 (1)
Not reported	11 (9)	11 (9)	18 (14)	4 (4)	1 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	90 (76)	98 (77)	106 (83)	82 (79)	68 (68)
Yes	28 (24)	27 (21)	21 (16)	19 (18)	29 (29)
Not reported	1 (1)	2 (2)	1 (1)	3 (3)	3 (3)
Region/country of birth (%)					
Australia	105 (88)	110 (87)	113 (88)	93 (89)	91 (91)
Other Oceania	3 (3)	1 (1)	6 (5)	3 (3)	2 (2)
Asia	2 (2)	1 (1)	0 (0)	1 (1)	0 (0)
UK & Ireland	2 (2)	6 (5)	4 (3)	3 (3)	3 (3)
Other	5 (4)	7 (6)	5 (4)	2 (2)	4 (4)
Not reported	2 (2)	2 (2)	0 (0)	2 (2)	0 (0)
Main language spoken at home by parents (%)					
English	114 (96)	114 (90)	119 (93)	99 (95)	95 (95)
Non-English	3 (3)	11 (9)	9 (7)	5 (5)	5 (5)
Not reported	2 (2)	2 (2)	0 (0)	0 (0)	0 (0)
Age and time since first injection (years)					
<i>Median age</i>	41.5	41	42	44	42.5
<i>Age range</i>	18-64	20-67	18-66	23-63	21-65
Age group (%)					
<25 years	3 (3)	4 (3)	5 (4)	1 (1)	2 (2)
25+ years	115 (97)	123 (97)	123 (96)	103 (99)	98 (98)
Not reported	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Median age first injection					
<i>Median age first injection</i>	18	18	18	18	19
<i>Age range</i>	10-49	10-50	11-43	11-53	12-65
N° not reported	6	5	3	3	4
Median yrs since first injection					
<i>Median yrs since first injection</i>	20	21	24	24	23
<i>Range</i>	<1-46	<1-46	<1-46	<1-47	<1-43
Years since first injection					
<3 years	3 (3)	3 (2)	8 (6)	4 (4)	10 (10)
3+ years	110 (92)	119 (94)	117 (91)	97 (93)	86 (86)
Not reported	6 (5)	5 (4)	3 (2)	3 (3)	4 (4)
Imprisonment last year (%)					
No	95 (80)	99 (78)	104 (81)	84 (81)	81 (81)
Yes	18 (15)	11 (9)	19 (15)	15 (14)	12 (12)
Not reported	6 (5)	17 (13)	5 (4)	5 (5)	7 (7)
N° in prison					
N° in prison	N=18	N=11	N=19	N=15	N=12
Injected in prison	6 (33)	5 (45)	5 (26)	3 (20)	8 (67)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Australian Capital Territory	2017	2018	2019	2020	2021
N° surveyed	N=119	N=127	N=128	N=104	N=100
Drug last injected (%)					
Cocaine	3 (3)	1 (1)	0 (0)	2 (2)	1 (1)
Methamphetamine	48 (40)	60 (47)	58 (45)	39 (38)	40 (40)
Heroin	58 (49)	51 (40)	59 (46)	50 (48)	44 (44)
Pharm. opioids	1 (1)	4 (3)	2 (2)	3 (3)	0 (0)
Methadone	3 (3)	3 (2)	5 (4)	4 (4)	6 (6)
Buprenorphine	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Buprenorphine/naloxone	2 (2)	1 (1)	0 (0)	0 (0)	0 (0)
PIEDs	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
More than one	3 (3)	5 (4)	4 (3)	3 (3)	7 (7)
Other	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)
Ever injected opioids					
No	7 (6)	15 (12)	8 (6)	11 (11)	15 (15)
Yes	110 (92)	110 (87)	120 (94)	93 (89)	84 (84)
Not reported	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)
Frequency of injection last month (%)					
Not last month	16 (13)	11 (9)	10 (8)	7 (7)	7 (7)
Less than weekly	16 (13)	17 (13)	18 (14)	14 (13)	16 (16)
Weekly not daily	27 (23)	30 (24)	32 (25)	24 (23)	17 (17)
Daily or more	57 (48)	66 (52)	66 (52)	59 (57)	58 (58)
Not reported	3 (3)	3 (2)	2 (2)	0 (0)	2 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	100 (84)	103 (81)	111 (87)	89 (86)	83 (83)
Yes	15 (13)	20 (16)	15 (12)	11 (11)	16 (16)
Not reported	4 (3)	4 (3)	2 (2)	4 (4)	1 (1)
Overdosed in last 12 months					
No	90 (76)	93 (73)	101 (79)	77 (74)	79 (79)
Yes	24 (20)	30 (24)	26 (20)	23 (22)	19 (19)
Not reported	5 (4)	4 (3)	1 (1)	4 (4)	2 (2)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Australian Capital Territory	2017	2018	2019	2020	2021
N° injected last month	N=100	N=113	N=116	N=97	N=91
Places injected last month (%)					
All private	47 (47)	50 (44)	53 (46)	39 (40)	56 (62)
Any public	52 (52)	63 (56)	61 (53)	58 (60)	35 (38)
Not reported	1 (1)	0 (0)	2 (2)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	64 (64)	76 (67)	86 (74)	73 (75)	70 (77)
Most of the time	31 (31)	30 (27)	25 (22)	18 (19)	20 (22)
Half of the time	2 (2)	4 (4)	2 (2)	3 (3)	0 (0)
Some of the time	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)
Not last month	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Not reported	1 (1)	1 (1)	2 (2)	2 (2)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	71 (71)	83 (73)	99 (85)	79 (81)	71 (78)
Once	12 (12)	8 (7)	7 (6)	8 (8)	4 (4)
Twice	8 (8)	9 (8)	3 (3)	1 (1)	6 (7)
3-5 times	7 (7)	6 (5)	4 (3)	7 (7)	1 (1)
>5 times	2 (2)	6 (5)	2 (2)	1 (1)	8 (9)
Not reported	0 (0)	1 (1)	1 (1)	1 (1)	1 (1)
Number of people needle & syringe was re-used after last month (%)					
None	71 (71)	83 (73)	99 (85)	79 (81)	71 (78)
One	10 (10)	11 (10)	4 (3)	8 (8)	7 (8)
Two	2 (2)	1 (1)	3 (3)	1 (1)	3 (3)
Three to five	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)
More than five	1 (1)	2 (2)	0 (0)	0 (0)	2 (2)
Don't know	13 (13)	10 (9)	5 (4)	8 (8)	6 (7)
Not reported	3 (3)	4 (4)	4 (3)	1 (1)	2 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	10 (10)	10 (9)	5 (4)	3 (3)	8 (9)
Casual sex partner	2 (2)	0 (0)	1 (1)	1 (1)	1 (1)
Close friend	7 (7)	5 (4)	4 (3)	9 (9)	4 (4)
Acquaintance	6 (6)	5 (4)	2 (2)	4 (4)	2 (2)
Other	2 (2)	1 (1)	3 (3)	0 (0)	1 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	31 (31)	33 (29)	27 (23)	24 (25)	29 (32)
Water	21 (21)	21 (19)	14 (12)	12 (12)	21 (23)
Filter	16 (16)	11 (10)	7 (6)	9 (9)	12 (13)
Drug mix	10 (10)	14 (12)	9 (8)	8 (8)	11 (12)
None	65 (65)	74 (65)	79 (68)	65 (67)	58 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	85 (85)	90 (80)	102 (88)	86 (89)	74 (81)
Yes	15 (15)	23 (20)	13 (11)	11 (11)	16 (18)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Source of needle acquisition					
Needle Syringe Program	90 (90)	101 (89)	108 (93)	86 (89)	75 (82)
Chemist/Pharmacy	36 (36)	37 (33)	33 (28)	26 (27)	25 (27)
Personal sources	22 (22)	24 (21)	17 (15)	17 (18)	14 (15)
Dispensing/Vending Machine	28 (28)	29 (26)	32 (28)	17 (18)	9 (10)
Other sources	0 (0)	5 (4)	3 (3)	3 (3)	3 (3)

Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Australian Capital Territory	2017	2018	2019	2020	2021
N° surveyed	N=119	N=127	N=128	N=104	N=100
Ever any treatment/therapy for drug use (%)					
No	22 (18)	33 (26)	26 (20)	21 (20)	21 (21)
Yes	96 (81)	93 (73)	101 (80)	83 (80)	79 (79)
Not reported	1 (<1)	1 (<1)	1 (<1)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	44 (37)	33 (26)	49 (38)	33 (32)	39 (39)
Previously	20 (17)	29 (23)	32 (25)	23 (22)	26 (26)
Never	51 (43)	58 (46)	43 (34)	45 (43)	33 (33)
Not reported	4 (3)	7 (6)	4 (3)	3 (3)	2 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	12 (10)	7 (6)	5 (4)	7 (7)	5 (5)
Previously	32 (27)	31 (24)	29 (23)	35 (34)	38 (38)
Never	74 (62)	86 (68)	91 (71)	60 (58)	56 (56)
Not reported	1 (1)	3 (2)	3 (2)	2 (2)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	11 (9)	8 (6)	9 (7)	3 (3)	5 (5)
Previously	29 (24)	33 (26)	28 (22)	29 (28)	34 (34)
Never	75 (63)	83 (65)	88 (69)	72 (69)	60 (60)
Not reported	4 (3)	3 (2)	3 (2)	0 (0)	1 (1)

Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Australian Capital Territory	2017	2018	2019	2020	2021
N° surveyed	N=119	N=127	N=128	N=104	N=100
Previous HIV test (%)					
Yes, ever	97 (82)	102 (80)	113 (88)	85 (82)	82 (82)
Yes, last year	59 (50)	62 (49)	70 (55)	49 (47)	44 (44)
>1 year ago	38 (32)	40 (32)	43 (34)	36 (35)	38 (38)
Never tested	19 (16)	15 (12)	12 (9)	14 (13)	16 (16)
Not reported	3 (3)	10 (8)	3 (2)	5 (5)	2 (2)
Previous HCV test (%)					
Yes, ever	92 (77)	104 (82)	116 (91)	87 (84)	80 (80)
Yes, last year	63 (53)	68 (54)	80 (63)	48 (46)	46 (46)
>1 year ago	29 (24)	36 (28)	36 (28)	39 (38)	34 (34)
Never tested	11 (9)	11 (9)	4 (3)	8 (8)	7 (7)
Not reported	16 (13)	12 (9)	8 (6)	9 (9)	13 (13)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=35	N=46	N=50	N=29	N=24
Antiviral treatment	16 (46)	21 (46)	33 (66)	16 (55)	11 (46)
No antiviral treatment	19 (54)	25 (54)	17 (34)	12 (41)	13 (54)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=28	N=40	N=37	N=18	N=18
Antiviral treatment	9 (32)	14 (35)	17 (46)	2 (11)	4 (22)
No antiviral treatment	19 (68)	26 (65)	20 (54)	15 (83)	14 (78)
Not reported	0 (0)	0 (0)	0 (0)	1 (6)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Australian Capital Territory	2017	2018	2019	2020	2021
N° surveyed	N=119	N=127	N=128	N=104	N=100
Sex with a regular partner last month (%)					
No	75 (63)	75 (59)	78 (61)	69 (66)	62 (62)
Yes	39 (33)	43 (34)	46 (36)	31 (30)	35 (35)
Not reported	5 (4)	9 (7)	4 (3)	4 (4)	3 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=39	N=43	N=46	N=31	N=35
Never	29 (74)	34 (79)	38 (83)	25 (81)	23 (66)
Sometimes	4 (10)	4 (9)	3 (7)	4 (13)	1 (3)
Every time	5 (13)	2 (5)	3 (7)	1 (3)	6 (17)
Not reported	1 (3)	3 (7)	2 (4)	1 (3)	5 (14)
Sex with other partner(s) last month (%)					
No	107 (90)	103 (81)	115 (90)	95 (91)	86 (86)
Yes	7 (6)	12 (9)	11 (9)	5 (5)	10 (10)
Not reported	5 (4)	12 (9)	2 (2)	4 (4)	4 (4)
Condom used with other partner(s) last month (%)					
N° surveyed	N=7	N=12	N=11	N=5	N=10
Never	3 (43)	7 (58)	7 (64)	2 (40)	5 (50)
Sometimes	1 (14)	0 (0)	1 (9)	3 (60)	2 (20)
Every time	1 (14)	4 (33)	2 (18)	0 (0)	3 (30)
Not reported	2 (29)	1 (8)	1 (9)	0 (0)	0 (0)
Sex work last month (%)					
No	111 (93)	108 (85)	117 (91)	97 (93)	93 (93)
Yes	3 (3)	8 (6)	5 (4)	4 (4)	5 (5)
Not reported	5 (4)	11 (9)	6 (5)	3 (3)	2 (2)
Condom used at last sex work (%)					
Yes	1 (33)	7 (88)	4 (80)	1 (25)	1 (20)

Table 2.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

Australian Capital Territory	2020	2021
N° surveyed	N=104	N=100
More difficult to access sterile needles and syringes		
Yes	15 (14)	15 (15)
No	81 (78)	69 (69)
Not applicable	7 (7)	9 (9)
Not reported	1 (1)	7 (7)
Start depot buprenorphine		
Yes	9 (9)	10 (10)
No	70 (67)	62 (62)
Not applicable	24 (23)	21 (21)
Not reported	1 (1)	7 (7)
Access take home naloxone		
Yes	27 (26)	21 (21)
No	58 (56)	46 (46)
Not applicable	15 (14)	23 (23)
Not reported	4 (4)	10 (10)
Change illicit drug use		
Yes, increased	22 (21)	22 (22)
Yes, decreased	29 (28)	24 (24)
No change	51 (49)	47 (47)
Not reported	2 (2)	7 (7)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	4 (4)	19 (19)
No	74 (71)	52 (52)
Not applicable	24 (23)	23 (23)
Not reported	2 (2)	6 (6)
Inject own methadone/bupe/suboxone		
Yes	11 (11)	13 (13)
No	74 (71)	57 (57)
Not applicable	17 (16)	22 (22)
Not reported	2 (2)	8 (8)
COVID-19 vaccine uptake		
≥1 dose	-- --	82 (82)
COVID-19 vaccine doses		
One dose	-- --	11 (11)
Two doses	-- --	71 (71)
No doses	-- --	12 (12)
Not reported	-- --	6 (6)
Vaccine type		
Astra Zeneca	-- --	17 (17)
Pfizer	-- --	46 (46)
Don't know	-- --	4 (4)
Not reported	-- --	33 (33)
COVID-19 test		
Yes	27 (26)	56 (56)
No	71 (68)	23 (23)
Don't know	5 (5)	5 (5)
Not reported	1 (1)	16 (16)
Self-reported positive COVID-19 test result		
Yes	0 (0)	10 (10)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017	80	0 (0.0)	38	0 (0.0)	119	0 (0.0)
2018	90	0 (0.0)	35	0 (0.0)	127	0 (0.0)
2019	84	0 (0.0)	42	0 (0.0)	126	0 (0.0)
2020	69	0 (0.0)	33	0 (0.0)	103	0 (0.0)
2021	67	0 (0.0)	32	0 (0.0)	99	0 (0.0)
X ² p trend		--		--		--

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and survey year

Aust. Capital Territory	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017	77	46 (60)	38	23 (61)	116	70 (60)
2018	90	51 (57)	35	22 (63)	127	73 (57)
2019	84	38 (45)	42	23 (55)	126	61 (48)
2020	69	32 (46)	33	19 (58)	103	51 (50)
2021	67	27 (40)	32	9 (28)	99	36 (36)
X ² p trend		0.007		0.007		<0.001

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Heterosexual	66	42 (64)	23	15 (65)	89	57 (64)
Bisexual	5	1 (20)	9	3 (33)	15	5 (33)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.075		0.126		0.031
2018						
Heterosexual	77	43 (56)	22	14 (64)	100	57 (57)
Bisexual	6	2 (33)	7	4 (57)	13	6 (46)
Homosexual	2	1 (50)	0	0 (0)	3	1 (33)
p value		0.701		1.000		0.594
2019						
Heterosexual	64	28 (44)	27	15 (56)	91	43 (47)
Bisexual	5	3 (60)	8	5 (63)	13	8 (62)
Homosexual	3	3 (100)	1	0 (0)	4	3 (75)
p value		0.158		0.495		0.401
2020						
Heterosexual	63	28 (44)	21	12 (57)	84	40 (48)
Bisexual	5	3 (60)	5	3 (60)	10	6 (60)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.653		0.580		0.381
2021						
Heterosexual	62	25 (40)	24	7 (29)	86	32 (37)
Bisexual	3	2 (67)	4	2 (50)	7	4 (57)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.490		0.717		0.260

Table 2.3.3 HCV antibody prevalence by age group, gender and survey year

Aust. Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	0	0 (0)	3	1 (33)	3	1 (33)
25-34 years	15	7 (47)	10	5 (50)	26	13 (50)
35-44 years	27	19 (70)	12	7 (58)	39	26 (67)
45+ years	34	19 (56)	13	10 (77)	47	29 (62)
p value		0.287		0.393		0.417
2018						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	13	7 (54)	9	6 (67)	22	13 (59)
35-44 years	40	28 (70)	14	8 (57)	56	36 (64)
45+ years	35	16 (46)	10	7 (70)	45	23 (51)
p value		0.056		0.952		0.321
2019						
<25 years	1	0 (0)	4	2 (50)	5	2 (40)
25-34 years	9	1 (11)	10	6 (60)	19	7 (37)
35-44 years	33	16 (48)	14	6 (43)	47	22 (47)
45+ years	41	21 (51)	14	9 (64)	55	30 (55)
p value		0.097		0.777		0.602
2020						
<25 years	0	0 (0)	1	1 (100)	1	1 (100)
25-34 years	9	2 (22)	5	4 (80)	15	6 (40)
35-44 years	23	8 (35)	15	8 (53)	38	16 (42)
45+ years	37	22 (59)	12	6 (50)	49	28 (57)
p value		0.059		0.668		0.298
2021						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	15	5 (33)	5	1 (20)	20	6 (30)
35-44 years	23	11 (48)	11	4 (36)	34	15 (44)
45+ years	29	11 (38)	14	3 (21)	43	14 (33)
p value		0.634		0.764		0.579

Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Aust. Capital Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<3 years	1	0 (0)	2	1 (50)	3	1 (33)
3 to 10 years	10	5 (50)	6	2 (33)	16	7 (44)
11+ years	63	39 (62)	28	18 (64)	92	58 (63)
p value		0.383		0.391		0.213
2018						
<3 years	3	2 (67)	0	0 (0)	3	2 (67)
3 to 10 years	9	2 (22)	7	4 (57)	16	6 (38)
11+ years	74	43 (58)	27	17 (63)	103	60 (58)
p value		0.106		1.000		0.286
2019						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	6	1 (17)	6	5 (83)	12	6 (50)
11+ years	73	36 (49)	30	17 (57)	103	53 (51)
p value		0.108		0.016		0.014
2020						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3 to 10 years	6	1 (17)	2	2 (100)	8	3 (38)
11+ years	59	31 (53)	28	15 (54)	88	46 (52)
p value		0.069		0.337		0.122
2021						
<3 years	5	1 (20)	5	2 (40)	10	3 (30)
3 to 10 years	4	1 (25)	4	1 (25)	8	2 (25)
11+ years	57	24 (42)	20	6 (30)	77	30 (39)
p value		0.649		1.000		0.785

Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No receptive sharing	3	1 (33)	65	37 (57)	71	41 (58)
Receptive sharing	0	0 (0)	26	16 (62)	27	17 (63)
p value		--		0.687		0.639
2018						
No receptive sharing	2	1 (50)	79	46 (58)	83	49 (59)
Receptive sharing	1	1 (100)	27	15 (56)	29	17 (59)
p value		1.000		0.808		0.969
2019						
No receptive sharing	8	0 (0)	87	45 (52)	97	46 (47)
Receptive sharing	0	0 (0)	15	8 (53)	16	9 (56)
p value		--		0.908		0.513
2020						
No receptive sharing	4	0 (0)	73	36 (49)	78	36 (46)
Receptive sharing	0	0 (0)	15	9 (60)	17	11 (65)
p value		--		0.451		0.166
2021						
No receptive sharing	7	2 (29)	60	24 (40)	70	27 (39)
Receptive sharing	2	1 (50)	17	8 (47)	19	9 (47)
p value		1.000		0.602		0.488

Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Aust. Capital Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	1	1 (100)	49	33 (67)	52	36 (69)
Methamphetamine	2	0 (0)	45	22 (49)	48	23 (48)
Other opioids	0	0 (0)	6	3 (50)	7	4 (57)
Other drugs	0	0 (0)	6	5 (83)	6	5 (83)
p value		0.083		0.172		0.104
2018						
Heroin	0	0 (0)	49	28 (57)	51	30 (59)
Methamphetamine	2	1 (50)	54	28 (52)	58	31 (53)
Other opioids	0	0 (0)	7	5 (71)	7	5 (71)
Other drugs	1	1 (100)	6	5 (83)	7	6 (86)
p value		0.386		0.411		0.358
2019						
Heroin	2	0 (0)	53	32 (60)	57	33 (58)
Methamphetamine	5	0 (0)	50	19 (38)	56	20 (36)
Other opioids	1	0 (0)	6	3 (50)	7	3 (43)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.104		0.076
2020						
Heroin	1	0 (0)	46	28 (61)	50	30 (60)
Methamphetamine	3	0 (0)	35	16 (46)	38	16 (42)
Other opioids	0	0 (0)	8	3 (38)	8	3 (38)
Other drugs	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.243		0.193
2021						
Heroin	2	0 (0)	39	14 (36)	43	15 (35)
Methamphetamine	5	0 (0)	32	12 (38)	39	12 (31)
Other opioids	2	2 (100)	3	1 (33)	5	3 (60)
Other drugs	0	0 (0)	9	5 (56)	9	5 (56)
p value		0.011		0.738		0.361

Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Less than daily	0	0 (0)	39	19 (49)	43	23 (53)
Daily or more	3	1 (33)	52	34 (65)	55	35 (64)
Not last month	0	0 (0)	15	10 (67)	15	10 (67)
p value		--		0.244		0.511
2018						
Less than daily	3	2 (67)	41	22 (54)	47	27 (57)
Daily or more	0	0 (0)	66	40 (61)	66	40 (61)
Not last month	0	0 (0)	9	4 (44)	11	6 (55)
p value		--		0.541		0.902
2019						
Less than daily	6	0 (0)	42	22 (52)	50	24 (48)
Daily or more	2	0 (0)	61	31 (51)	64	31 (48)
Not last month	0	0 (0)	10	4 (40)	10	4 (40)
p value		--		0.850		0.926
2020						
Less than daily	1	0 (0)	36	11 (31)	37	11 (30)
Daily or more	3	0 (0)	53	35 (66)	59	37 (63)
Not last month	0	0 (0)	7	3 (43)	7	3 (43)
p value		--		0.003		0.005
2021						
Less than daily	4	1 (25)	27	5 (19)	32	6 (19)
Daily or more	5	2 (40)	51	27 (53)	58	30 (52)
Not last month	1	0 (0)	5	0 (0)	7	0 (0)
p value		1.000		0.001		0.001

Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No imprisonment	3	1 (33)	85	48 (56)	92	52 (57)
Imprisonment	0	0 (0)	17	11 (65)	18	12 (67)
p value		--		0.530		0.425
2018						
No imprisonment	2	1 (50)	95	50 (53)	99	53 (54)
Imprisonment	0	0 (0)	10	6 (60)	11	7 (64)
p value		--		0.748		0.751
2019						
No imprisonment	6	0 (0)	95	50 (53)	102	51 (50)
Imprisonment	2	0 (0)	15	6 (40)	19	7 (37)
p value		--		0.363		0.292
2020						
No imprisonment	3	0 (0)	80	38 (48)	83	38 (46)
Imprisonment	1	0 (0)	12	7 (58)	15	9 (60)
p value		--		0.310		0.310
2021						
No imprisonment	8	3 (38)	68	25 (37)	80	29 (36)
Imprisonment	1	0 (0)	11	3 (27)	12	3 (25)
p value		1.000		0.738		0.532

Table 2.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Aust. Capital Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	62	38 (61)	25	15 (60)	88	54 (61)
Indigenous	14	7 (50)	13	8 (62)	27	15 (56)
p value		0.438		1.000		0.590
2018						
Non Indigenous	74	41 (55)	22	12 (55)	98	53 (54)
Indigenous	15	9 (60)	12	9 (75)	27	18 (67)
p value		0.744		0.292		0.242
2019						
Non Indigenous	73	34 (47)	31	16 (52)	104	50 (48)
Indigenous	10	4 (40)	11	7 (64)	21	11 (52)
p value		0.748		0.726		0.719
2020						
Non Indigenous	57	22 (39)	23	11 (48)	81	33 (41)
Indigenous	10	8 (80)	9	7 (78)	19	15 (79)
p value		0.034		0.235		0.004
2021						
Non Indigenous	49	18 (37)	19	5 (26)	68	23 (34)
Indigenous	16	9 (56)	12	3 (25)	28	12 (43)
p value		0.169		1.000		0.403

Table 2.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Aust. Capital Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	73	43 (59)	37	22 (59)	111	66 (59)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
p value		1.000		--		1.000
2018						
English speaking	81	47 (58)	31	20 (65)	114	67 (59)
Non-English speaking	7	3 (43)	4	2 (50)	11	5 (45)
p value		0.459		0.618		0.393
2019						
English speaking	78	38 (49)	39	20 (51)	117	58 (50)
Non-English speaking	6	0 (0)	3	3 (100)	9	3 (33)
p value		0.030		0.102		0.494
2020						
English speaking	64	29 (45)	33	19 (58)	98	48 (49)
Non-English speaking	5	3 (60)	0	0 (0)	5	3 (60)
p value		0.657		--		0.678
2021						
English speaking	65	26 (40)	29	7 (24)	94	33 (35)
Non-English speaking	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.184		0.350

Table 2.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Aust. Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Australia	64	38 (59)	37	22 (59)	102	61 (60)
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	1	1 (100)	5	4 (80)
p value		0.180		1.000		0.134
2018						
Australia	76	45 (59)	32	21 (66)	110	66 (60)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	2 (40)	1	0 (0)	6	2 (33)
Other	6	3 (50)	1	0 (0)	7	3 (43)
p value		0.472		0.139		0.212
2019						
Australia	72	33 (46)	39	21 (54)	111	54 (49)
Other Oceania	3	2 (67)	3	2 (67)	6	4 (67)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	4	2 (50)	0	0 (0)	4	2 (50)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.618		1.000		0.520
2020						
Australia	60	27 (45)	31	18 (58)	92	45 (49)
Other Oceania	3	1 (33)	0	0 (0)	3	1 (33)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	1	1 (100)	2	1 (50)	3	2 (67)
Other	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.315		1.000		0.636
2021						
Australia	62	23 (37)	28	7 (25)	90	30 (33)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	0 (0)	3	1 (33)
Other	1	1 (100)	3	2 (67)	4	3 (75)
p value		0.128		0.421		0.070

HCV RNA prevalence

Table 2.4.1 HCV RNA prevalence by gender and survey year

Australian Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*	56	18 (32)	27	8 (30)	84	26 (31)
2018*	67	17 (25)	26	9 (35)	95	26 (27)
2019*	77	16 (21)	38	10 (26)	115	25 (22)
2020	60	13 (22)	30	5 (17)	91	18 (20)
2021	62	14 (23)	32	6 (19)	94	20 (21)
X ² p trend		0.208		0.119		0.062

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 2.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Australian Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heterosexual	45	13 (29)	14	4 (29)	59	17 (29)
Bisexual	5	2 (40)	7	1 (14)	13	3 (23)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.860		0.243		0.270
2018*						
Heterosexual	62	14 (23)	17	5 (29)	80	20 (25)
Bisexual	2	1 (50)	6	3 (50)	8	4 (50)
Homosexual	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.608		0.598		0.315
2019*						
Heterosexual	61	12 (20)	25	6 (24)	85	17 (20)
Bisexual	4	1 (25)	8	2 (25)	12	3 (25)
Homosexual	3	1 (33)	1	0 (0)	4	1 (25)
p value		0.823		0.856		0.924
2020						
Heterosexual	55	12 (22)	19	2 (11)	74	14 (19)
Bisexual	4	1 (25)	4	2 (50)	8	3 (38)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.882		0.120		0.356
2021						
Heterosexual	57	13 (23)	24	4 (17)	81	17 (21)
Bisexual	3	1 (33)	4	2 (50)	7	3 (43)
Homosexual	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.676		0.233		0.226

Table 2.4.3 HCV RNA prevalence by age group, gender and survey year

Australian Capital Territory	Male		Female		Total	
Age group	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	12	4 (33)	6	1 (17)	18	5 (28)
35-44 years	24	7 (29)	7	2 (29)	31	9 (29)
45+ years	20	7 (35)	12	4 (33)	32	11 (34)
p value		0.830		0.882		0.845
2018*						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	9	3 (33)	6	4 (67)	16	8 (50)
35-44 years	29	7 (24)	12	3 (25)	42	10 (24)
45+ years	26	6 (23)	7	1 (14)	34	7 (21)
p value		0.803		0.045		0.212
2019*						
<25 years	1	0 (0)	4	1 (25)	5	1 (20)
25-34 years	8	1 (13)	9	5 (56)	17	6 (35)
35-44 years	32	7 (22)	12	2 (17)	44	9 (20)
45+ years	35	8 (23)	13	2 (15)	49	10 (20)
p value		0.858		0.128		0.650
2020						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	9	0 (0)	5	2 (40)	15	2 (13)
35-44 years	19	3 (16)	12	3 (25)	31	6 (19)
45+ years	32	10 (31)	12	0 (0)	44	10 (23)
p value		0.100		0.160		0.829
2021						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	14	5 (36)	5	1 (20)	19	6 (32)
35-44 years	21	5 (24)	11	2 (18)	32	7 (22)
45+ years	27	4 (15)	14	2 (14)	41	6 (15)
p value		0.312		0.689		0.351

Table 2.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Australian Capital Territory	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	8	3 (38)	5	3 (60)	13	6 (46)
11+ years	45	14 (31)	19	3 (16)	65	18 (28)
p value		0.482		0.110		0.384
2018*						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	8	2 (25)	4	3 (75)	12	5 (42)
11+ years	56	13 (23)	22	6 (27)	79	20 (25)
p value		0.233		0.091		0.161
2019*						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	4 (67)	12	4 (33)
11+ years	65	15 (23)	28	6 (21)	93	20 (22)
p value		0.278		0.027		0.222
2020						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3 to 10 years	6	0 (0)	2	1 (50)	8	1 (13)
11+ years	50	13 (26)	25	4 (16)	76	17 (22)
p value		0.223		0.431		0.470
2021						
<3 years	5	0 (0)	5	1 (20)	10	1 (10)
3 to 10 years	4	1 (25)	4	1 (25)	8	2 (25)
11+ years	52	12 (23)	20	4 (20)	72	16 (22)
p value		0.476		0.974		0.648

Table 2.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Australian Capital Territory	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	34	12 (35)	16	4 (25)	51	16 (31)
Receptive sharing	16	6 (38)	5	3 (60)	21	9 (43)
p value		0.862		0.169		0.392
2018*						
No receptive sharing	40	10 (25)	20	8 (40)	61	19 (31)
Receptive sharing	19	5 (26)	4	1 (25)	23	6 (26)
p value		0.917		0.554		0.680
2019*						
No receptive sharing	55	12 (22)	33	9 (27)	88	20 (23)
Receptive sharing	14	3 (21)	1	0 (0)	15	3 (20)
p value		0.951		0.557		0.732
2020						
No receptive sharing	45	11 (24)	22	3 (14)	68	14 (21)
Receptive sharing	10	1 (10)	6	2 (33)	16	3 (19)
p value		0.317		0.264		0.869
2021						
No receptive sharing	44	9 (20)	22	3 (14)	66	12 (18)
Receptive sharing	12	5 (42)	6	3 (50)	18	8 (44)
p value		0.133		0.054		0.020

Table 2.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Australian Capital Territory	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	18	7 (39)	15	3 (20)	33	11 (33)
Methamphetamine	31	7 (23)	10	4 (40)	41	11 (27)
Other opioids	3	1 (33)	1	0 (0)	4	1 (25)
Other drugs	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.203		0.648		0.439
2018*						
Heroin	29	7 (24)	10	4 (40)	41	12 (29)
Methamphetamine	32	9 (28)	11	2 (18)	43	11 (26)
Other opioids	4	0 (0)	2	1 (50)	6	1 (17)
Other drugs	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.441		0.333		0.419
2019*						
Heroin	30	6 (20)	23	7 (30)	53	12 (23)
Methamphetamine	37	8 (22)	12	2 (17)	50	10 (20)
Other opioids	5	0 (0)	2	0 (0)	7	0 (0)
Other drugs	3	1 (33)	1	1 (100)	4	2 (50)
p value		0.655		0.215		0.266
2020						
Heroin	31	6 (19)	12	2 (17)	43	8 (19)
Methamphetamine	21	5 (24)	12	2 (17)	34	7 (21)
Other opioids	2	0 (0)	5	1 (20)	7	1 (14)
Other drugs	6	2 (33)	1	0 (0)	7	2 (29)
p value		0.756		0.971		0.913
2021						
Heroin	28	5 (18)	14	2 (14)	42	7 (17)
Methamphetamine	25	7 (28)	11	2 (18)	36	9 (25)
Other opioids	4	0 (0)	1	1 (100)	5	1 (20)
Other drugs	4	2 (50)	4	1 (25)	8	3 (38)
p value		0.306		0.224		0.569

Table 2.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Australian Capital Territory	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Less than daily	24	8 (33)	9	3 (33)	33	11 (33)
Daily or more	27	9 (33)	11	4 (36)	39	14 (36)
Not last month	5	0 (0)	5	1 (20)	11	1 (9)
p value		0.308		0.829		0.288
2018*						
Less than daily	25	5 (20)	10	4 (40)	35	9 (26)
Daily or more	35	10 (29)	13	5 (38)	50	16 (32)
Not last month	5	1 (20)	3	0 (0)	8	1 (13)
p value		0.701		0.406		0.504
2019*						
Less than daily	29	10 (34)	17	3 (18)	47	13 (28)
Daily or more	40	5 (13)	17	6 (35)	57	11 (19)
Not last month	5	0 (0)	4	1 (25)	9	1 (11)
p value		0.049		0.524		0.391
2020						
Less than daily	21	2 (10)	8	0 (0)	30	2 (7)
Daily or more	35	10 (29)	20	5 (25)	55	15 (27)
Not last month	4	1 (25)	2	0 (0)	6	1 (17)
p value		0.242		0.223		0.073
2021						
Less than daily	19	3 (16)	12	0 (0)	31	3 (10)
Daily or more	37	11 (30)	17	6 (35)	54	17 (31)
Not last month	5	0 (0)	2	0 (0)	7	0 (0)
p value		0.223		0.047		0.022

Table 2.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Australian Capital Territory	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No imprisonment	48	15 (31)	24	7 (29)	72	22 (31)
Imprisonment	5	2 (40)	3	1 (33)	8	3 (38)
p value		0.901		0.890		0.980
2018*						
No imprisonment	50	12 (24)	20	7 (35)	71	20 (28)
Imprisonment	6	1 (17)	2	1 (50)	8	2 (25)
p value		0.636		0.706		0.812
2019*						
No imprisonment	56	13 (23)	35	7 (20)	91	20 (22)
Imprisonment	17	2 (12)	2	2 (100)	19	4 (21)
p value		0.305		0.011		0.928
2020						
No imprisonment	49	9 (18)	24	2 (8)	74	11 (15)
Imprisonment	8	3 (38)	5	2 (40)	13	5 (38)
p value		0.218		0.062		0.043
2021						
No imprisonment	48	9 (19)	28	6 (21)	76	15 (20)
Imprisonment	8	1 (13)	3	0 (0)	11	1 (9)
p value		0.669		0.372		0.394

Table 2.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Australian Capital Territory	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Non Indigenous	48	18 (38)	17	4 (24)	66	22 (33)
Indigenous	8	0 (0)	10	4 (40)	18	4 (22)
p value		0.042		0.401		0.322
2018*						
Non Indigenous	55	11 (20)	17	5 (24)	73	16 (22)
Indigenous	12	5 (42)	8	5 (63)	20	10 (50)
p value		0.099		0.156		0.017
2019*						
Non Indigenous	67	14 (21)	29	5 (17)	96	18 (19)
Indigenous	9	2 (22)	10	5 (50)	19	7 (37)
p value		0.961		0.044		0.113
2020						
Non Indigenous	49	10 (20)	20	1 (5)	70	11 (16)
Indigenous	9	2 (22)	9	4 (44)	18	6 (33)
p value		0.902		0.009		0.091
2021						
Non Indigenous	45	7 (16)	19	4 (21)	64	11 (17)
Indigenous	15	7 (47)	12	2 (17)	27	9 (33)
p value		0.017		0.763		0.089

Table 2.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Australian Capital Territory	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
English speaking	53	17 (32)	27	8 (30)	80	25 (31)
Non-English speaking	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.790		--		0.750
2018*						
English speaking	61	16 (26)	22	8 (36)	85	24 (28)
Non-English speaking	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.964		0.678		0.856
2019*						
English speaking	70	16 (23)	35	9 (26)	106	24 (23)
Non-English speaking	6	0 (0)	3	1 (33)	9	1 (11)
p value		0.186		0.730		0.368
2020						
English speaking	55	11 (20)	30	5 (17)	86	16 (19)
Non-English speaking	5	2 (40)	0	0 (0)	5	2 (40)
p value		0.299		--		0.243
2021						
English speaking	60	13 (22)	29	5 (17)	89	18 (20)
Non-English speaking	2	1 (50)	3	1 (33)	5	2 (40)
p value		0.346		0.497		0.293

Table 2.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Australian Capital Territory	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Australia	49	15 (31)	26	7 (27)	75	22 (29)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	4	2 (50)	1	1 (100)	5	3 (60)
p value		0.326		0.121		0.207
2018*						
Australia	58	16 (28)	24	9 (38)	83	25 (30)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	6	1 (17)	1	0 (0)	7	1 (14)
p value		0.799		0.551		0.588
2019*						
Australia	66	15 (23)	35	9 (26)	102	23 (23)
Other Oceania	3	0 (0)	3	1 (33)	6	1 (17)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.352		0.733		0.465
2020						
Australia	51	11 (22)	29	5 (17)	81	16 (20)
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	1	0 (0)	2	1 (50)
Other	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.285		0.649		0.581
2021						
Australia	57	14 (25)	28	5 (18)	85	19 (22)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	0 (0)	1	0 (0)	3	0 (0)
Other	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.663		0.717		0.695

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2017	2018	2019	2020*	2021*
Number of sites	18	19	18	12	3
N° surveyed	N=575	N=574	N=553	N=338	N=46
Response rate (%)	31%	37%	41%	25%	40%
Gender (%)					
Male	402 (70)	420 (73)	397 (72)	242 (72)	29 (63)
Female	159 (28)	147 (26)	146 (26)	91 (27)	16 (35)
Other	11 (2)	5 (1)	9 (2)	5 (1)	1 (2)
Not reported	3 (1)	2 (<1)	1 (<1)	0 (0)	
Sexual identity (%)					
Heterosexual	443 (77)	417 (73)	397 (72)	257 (76)	32 (70)
Bisexual	45 (8)	65 (11)	69 (12)	36 (11)	5 (11)
Gay/Lesbian	43 (7)	36 (6)	38 (7)	21 (6)	7 (15)
Other	-- --	-- --	-- --	9 (3)	2 (4)
Not reported	44 (8)	56 (10)	49 (9)	15 (4)	
Aboriginal and Torres Strait Islander origin (%)					
No	466 (81)	446 (78)	424 (77)	252 (75)	31 (67)
Yes	97 (17)	94 (16)	118 (21)	67 (20)	11 (24)
Not reported	12 (2)	34 (6)	11 (2)	19 (6)	4 (9)
Region/country of birth (%)					
Australia	492 (86)	470 (82)	471 (85)	276 (82)	36 (78)
Other Oceania	23 (4)	22 (4)	22 (4)	9 (3)	3 (7)
Asia	11 (2)	6 (1)	9 (2)	12 (4)	1 (2)
UK & Ireland	18 (3)	16 (3)	12 (2)	9 (3)	2 (4)
Other	21 (4)	38 (7)	29 (5)	25 (7)	2 (4)
Not reported	10 (2)	22 (4)	10 (2)	7 (2)	2 (4)
Main language spoken at home by parents (%)					
English	546 (95)	512 (89)	510 (92)	303 (90)	43 (93)
Non-English	26 (5)	43 (7)	37 (7)	28 (8)	2 (4)
Not reported	3 (1)	19 (3)	6 (1)	7 (2)	1 (2)
Age and time since first injection (years)					
<i>Median age</i>	43	44	44	42.5	49
<i>Age range</i>	17-76	18-69	18-73	18-67	27-66
<i>Age group (%)</i>					
<25 years	28 (5)	24 (4)	23 (4)	10 (3)	0 (0)
25+ years	545 (95)	550 (96)	530 (96)	328 (97)	46 (100)
Not reported	2 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	19	19	19	20	20
<i>Age range</i>	10-76	10-54	10-63	10-60	13-45
<i>N° not reported</i>	36	40	22	15	1
<i>Median yrs since first injection</i>	22	23	23	22	26
<i>Range</i>	<1-50	<1-53	<1-59	<1-52	4-49
<i>Years since first injection</i>					
<3 years	46 (8)	28 (5)	40 (7)	27 (8)	0 (0)
3+ years	493 (86)	505 (88)	491 (89)	296 (88)	45 (98)
Not reported	36 (6)	41 (7)	22 (4)	15 (4)	1 (2)
Imprisonment last year (%)					
No	455 (79)	459 (80)	454 (82)	265 (78)	41 (89)
Yes	69 (12)	68 (12)	67 (12)	41 (12)	4 (9)
Not reported	51 (9)	47 (8)	32 (6)	32 (9)	1 (2)
N° in prison	N=69	N=68	N=67	N=41	N=4
Injected in prison	26 (38)	26 (38)	26 (39)	15 (37)	1 (25)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

New South Wales	2017	2018	2019	2020	2021
N° surveyed	N=575	N=574	N=553	N=338	N=46
Drug last injected (%)					
Cocaine	13 (2)	11 (2)	11 (2)	2 (1)	1 (2)
Methamphetamine	205 (36)	203 (35)	213 (39)	118 (35)	25 (54)
Heroin	190 (33)	175 (30)	172 (31)	94 (28)	16 (35)
Pharm. opioids	20 (3)	26 (5)	15 (3)	8 (2)	1 (2)
Methadone	39 (7)	41 (7)	30 (5)	32 (9)	2 (4)
Buprenorphine	5 (1)	5 (1)	8 (1)	2 (1)	0 (0)
Buprenorphine/naloxone	2 (<1)	3 (1)	3 (1)	4 (1)	0 (0)
PIEDs	57 (10)	64 (11)	56 (10)	47 (14)	1 (2)
More than one	29 (5)	37 (6)	24 (4)	22 (7)	0 (0)
Other	9 (2)	4 (1)	13 (2)	2 (1)	0 (0)
Not reported	6 (1)	5 (1)	8 (1)	7 (2)	0 (0)
Ever injected opioids					
No	144 (25)	135 (24)	133 (24)	109 (32)	12 (26)
Yes	429 (75)	419 (73)	418 (76)	229 (68)	34 (74)
Not reported	2 (<1)	20 (3)	2 (<1)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	73 (13)	94 (16)	80 (14)	42 (12)	11 (24)
Less than weekly	99 (17)	90 (16)	85 (15)	51 (15)	9 (20)
Weekly not daily	131 (23)	136 (24)	123 (22)	84 (25)	12 (26)
Daily or more	263 (46)	232 (40)	254 (46)	155 (46)	14 (30)
Not reported	9 (2)	22 (4)	11 (2)	6 (2)	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
No	463 (81)	464 (81)	432 (78)	276 (82)	40 (87)
Yes	82 (14)	77 (13)	96 (17)	47 (14)	6 (13)
Not reported	30 (5)	33 (6)	25 (5)	15 (4)	0 (0)
Overdosed in last 12 months					
No	453 (79)	436 (76)	432 (78)	287 (85)	39 (85)
Yes	88 (15)	103 (18)	92 (17)	35 (10)	7 (15)
Not reported	34 (6)	35 (6)	29 (5)	16 (5)	0 (0)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

New South Wales	2017	2018	2019	2020	2021
N° injected last month	N=493	N=458	N=462	N=290	N=35
Places injected last month (%)					
All private	321 (65)	298 (65)	261 (56)	184 (63)	25 (71)
Any public	169 (34)	158 (35)	200 (43)	104 (36)	10 (29)
Not reported	3 (1)	2 (<1)	1 (<1)	2 (1)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	406 (82)	363 (79)	355 (77)	230 (79)	29 (83)
Most of the time	67 (14)	71 (16)	83 (18)	44 (15)	4 (11)
Half of the time	6 (1)	7 (2)	8 (2)	3 (1)	1 (3)
Some of the time	4 (1)	6 (1)	9 (2)	3 (1)	1 (3)
Not last month	3 (1)	6 (1)	3 (1)	1 (<1)	0 (0)
Not reported	7 (1)	5 (1)	4 (1)	9 (3)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	428 (87)	384 (84)	388 (84)	257 (89)	31 (89)
Once	19 (4)	25 (5)	24 (5)	11 (4)	2 (6)
Twice	21 (4)	13 (3)	17 (4)	6 (2)	1 (3)
3-5 times	9 (2)	20 (4)	16 (3)	3 (1)	1 (3)
>5 times	8 (2)	7 (2)	10 (2)	8 (3)	0 (0)
Not reported	8 (2)	9 (2)	7 (2)	5 (2)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	428 (87)	384 (84)	388 (84)	257 (89)	31 (89)
One	19 (4)	31 (7)	26 (6)	8 (3)	2 (6)
Two	5 (1)	5 (1)	7 (2)	3 (1)	0 (0)
Three to five	3 (1)	5 (1)	5 (1)	5 (2)	0 (0)
More than five	5 (1)	3 (1)	2 (<1)	3 (1)	0 (0)
Don't know	14 (3)	12 (3)	15 (3)	6 (2)	1 (3)
Not reported	19 (4)	18 (4)	19 (4)	8 (3)	1 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	23 (5)	25 (5)	19 (4)	13 (4)	0 (0)
Casual sex partner	1 (<1)	0 (0)	2 (<1)	3 (1)	0 (0)
Close friend	16 (3)	15 (3)	16 (3)	6 (2)	0 (0)
Acquaintance	5 (1)	8 (2)	12 (3)	6 (2)	2 (6)
Other	3 (1)	8 (2)	8 (2)	4 (1)	1 (3)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	95 (19)	87 (19)	100 (22)	55 (19)	4 (11)
Water	59 (12)	72 (16)	78 (17)	39 (13)	3 (9)
Filter	30 (6)	35 (8)	37 (8)	21 (7)	1 (3)
Drug mix	31 (6)	33 (7)	51 (11)	23 (8)	2 (6)
None	367 (74)	330 (72)	317 (69)	209 (72)	32 (91)
Injected by someone after that person injected themselves or others last month (%)					
No	432 (88)	394 (86)	396 (86)	238 (82)	30 (86)
Yes	57 (12)	56 (12)	64 (14)	45 (16)	5 (14)
Not reported	4 (1)	8 (2)	2 (<1)	7 (2)	0 (0)
Source of needle acquisition					
Needle Syringe Program	428 (87)	393 (86)	398 (86)	240 (83)	32 (91)
Chemist/Pharmacy	80 (16)	83 (18)	79 (17)	55 (19)	3 (9)
Personal sources	39 (8)	56 (12)	76 (16)	35 (12)	3 (9)
Dispensing/Vending Machine	111 (23)	124 (27)	159 (34)	92 (32)	12 (34)
Other sources	16 (3)	26 (6)	14 (3)	14 (5)	2 (6)

Table 3.1.4 Number (percentage) of respondents by treatment for drug use and survey year

New South Wales	2017	2018	2019	2020	2021
N° surveyed	N=575	N=574	N=553	N=338	N=46
Ever any treatment/therapy for drug use (%)					
No	161 (28)	153 (27)	168 (30)	103 (30)	11 (24)
Yes	408 (71)	402 (70)	381 (69)	234 (69)	35 (76)
Not reported	6 (1)	19 (3)	4 (1)	1 (<1)	0 (0)
History of methadone maintenance treatment (%)					
Currently	192 (33)	183 (32)	187 (34)	90 (27)	13 (28)
Previously	104 (18)	132 (23)	103 (19)	67 (20)	6 (13)
Never	262 (46)	225 (39)	252 (46)	158 (47)	24 (52)
Not reported	17 (3)	34 (6)	11 (2)	23 (7)	3 (7)
History of buprenorphine (Subutex®) treatment (%)					
Currently	39 (7)	47 (8)	33 (6)	24 (7)	2 (4)
Previously	122 (21)	147 (26)	148 (27)	74 (22)	10 (22)
Never	396 (69)	348 (61)	363 (66)	218 (65)	30 (65)
Not reported	18 (3)	32 (6)	9 (2)	22 (7)	4 (9)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	41 (7)	35 (6)	26 (5)	17 (5)	0 (0)
Previously	98 (17)	130 (23)	126 (23)	67 (20)	10 (22)
Never	420 (73)	374 (65)	389 (70)	251 (74)	33 (72)
Not reported	16 (3)	35 (6)	12 (2)	3 (1)	3 (7)

Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales	2017	2018	2019	2020	2021
N° surveyed	N=575	N=574	N=553	N=338	N=46
Previous HIV test (%)					
Yes, ever	461 (80)	463 (81)	463 (84)	255 (75)	38 (83)
Yes, last year	283 (49)	307 (53)	274 (50)	156 (46)	22 (48)
>1 year ago	178 (31)	156 (27)	189 (34)	99 (29)	16 (35)
Never tested	69 (12)	70 (12)	63 (11)	60 (18)	4 (9)
Not reported	45 (8)	41 (7)	27 (5)	23 (7)	4 (9)
Previous HCV test (%)					
Yes, ever	456 (79)	452 (79)	455 (82)	271 (80)	38 (83)
Yes, last year	316 (55)	315 (55)	309 (56)	167 (49)	29 (63)
>1 year ago	140 (24)	137 (24)	146 (26)	104 (31)	9 (20)
Never tested	56 (10)	53 (9)	54 (10)	31 (9)	2 (4)
Not reported	63 (11)	69 (12)	44 (8)	36 (11)	6 (13)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=157	N=163	N=147	N=64	N=9
Antiviral treatment	77 (49)	97 (60)	93 (63)	46 (72)	5 (56)
No antiviral treatment	78 (50)	65 (40)	53 (36)	18 (28)	4 (44)
Not reported	2 (1)	1 (1)	1 (1)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=142	N=131	N=114	N=47	N=8
Antiviral treatment	57 (40)	57 (44)	53 (46)	22 (47)	4 (50)
No antiviral treatment	83 (58)	73 (56)	60 (53)	25 (53)	4 (50)
Not reported	2 (1)	1 (1)	1 (1)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

^{**} excludes people who reported treatment induced clearance more than 12 months previously

Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

New South Wales	2017	2018	2019	2020	2021
N° surveyed	N=575	N=574	N=553	N=338	N=46
Sex with a regular partner last month (%)					
No	286 (50)	279 (49)	279 (50)	143 (42)	30 (65)
Yes	247 (43)	255 (44)	245 (44)	174 (51)	11 (24)
Not reported	42 (7)	40 (7)	29 (5)	21 (6)	5 (11)
Condom used with regular partner last month (%)					
N° surveyed	N=247	N=255	N=245	N=174	N=11
Never	187 (76)	182 (71)	171 (70)	127 (73)	9 (82)
Sometimes	24 (10)	26 (10)	35 (14)	21 (12)	2 (18)
Every time	27 (11)	32 (13)	26 (11)	20 (11)	0 (0)
Not reported	9 (4)	15 (6)	13 (5)	6 (3)	0 (0)
Sex with other partner(s) last month (%)					
No	441 (77)	437 (76)	421 (76)	252 (75)	37 (80)
Yes	78 (14)	82 (14)	91 (16)	61 (18)	5 (11)
Not reported	56 (10)	55 (10)	41 (7)	25 (7)	4 (9)
Condom used with other partner(s) last month (%)					
N° surveyed	N=78	N=82	N=91	N=61	N=5
Never	31 (40)	33 (40)	35 (38)	25 (41)	2 (40)
Sometimes	23 (29)	21 (26)	20 (22)	19 (31)	2 (40)
Every time	22 (28)	25 (30)	28 (31)	15 (25)	1 (20)
Not reported	2 (3)	3 (4)	8 (9)	2 (3)	0 (0)
Sex work last month (%)					
No	482 (84)	487 (85)	474 (86)	293 (87)	40 (87)
Yes	35 (6)	30 (5)	28 (5)	20 (6)	1 (2)
Not reported	58 (10)	57 (10)	51 (9)	25 (7)	5 (11)
Condom used at last sex work (%)					
Yes	24 (69)	19 (63)	19 (68)	10 (50)	1 (100)

Table 3.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

New South Wales	2020	2021
N° surveyed	N=338	N=46
More difficult to access sterile needles and syringes		
Yes	45 (13)	3 (7)
No	226 (67)	32 (70)
Not applicable	39 (12)	3 (7)
Not reported	28 (8)	8 (17)
Start depot buprenorphine		
Yes	20 (6)	2 (4)
No	189 (56)	21 (46)
Not applicable	92 (27)	15 (33)
Not reported	37 (11)	8 (17)
Access take home naloxone		
Yes	56 (17)	13 (28)
No	155 (46)	13 (28)
Not applicable	85 (25)	12 (26)
Not reported	42 (12)	8 (17)
Change illicit drug use		
Yes, increased	35 (10)	2 (4)
Yes, decreased	89 (26)	15 (33)
No change	172 (51)	21 (46)
Not reported	42 (12)	8 (17)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	48 (14)	4 (9)
No	151 (45)	18 (39)
Not applicable	95 (28)	14 (30)
Not reported	44 (13)	10 (22)
Inject own methadone/bupe/suboxone		
Yes	43 (13)	0 (0)
No	168 (50)	22 (48)
Not applicable	92 (27)	16 (35)
Not reported	35 (10)	8 (17)
COVID-19 vaccine uptake		
≥1 dose	-- --	38 (83)
COVID-19 vaccine doses		
One dose	-- --	8 (17)
Two doses	-- --	30 (65)
No doses	-- --	0 (0)
Not reported	-- --	8 (17)
Vaccine type		
Astra Zeneca	-- --	12 (26)
Pfizer	-- --	21 (46)
Don't know	-- --	1 (2)
Not reported	-- --	12 (26)
COVID-19 test		
Yes	138 (41)	25 (54)
No	155 (46)	8 (17)
Don't know	9 (3)	0 (0)
Not reported	36 (11)	13 (28)
Self-reported positive COVID-19 test result		
Yes	2 (1)	0 (0)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017	369	17 (4.6)	150	3 (2.0)	533	21 (3.9)
2018	395	15 (3.8)	144	1 (0.7)	546	17 (3.1)
2019	387	22 (5.7)	143	1 (0.7)	540	24 (4.4)
2020	232	11 (4.7)	88	0 (0.0)	325	13 (4.0)
2021	27	2 (7.4)	16	1 (6.3)	44	3 (6.8)
X ² p trend		0.477		0.612		0.464

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heterosexual	293	3 (1.0)	119	1 (0.8)	415	5 (1.2)
Bisexual	24	2 (4.2)	15	2 (13.3)	41	3 (7.3)
Homosexual	25	12 (48.0)	5	0 (0.0)	36	12 (33.3)
p value		<0.001		0.054		<0.001
2018						
Heterosexual	301	0 (0.0)	90	1 (1.1)	392	1 (0.3)
Bisexual	26	2 (7.7)	36	0 (0.0)	64	2 (3.1)
Homosexual	26	10 (38.5)	7	0 (0.0)	34	11 (32.4)
p value		<0.001		1.000		<0.001
2019						
Heterosexual	299	1 (0.3)	88	1 (1.1)	388	2 (0.5)
Bisexual	26	4 (15.3)	36	0 (0.0)	67	5 (7.5)
Homosexual	31	17 (54.8)	6	0 (0.0)	38	17 (44.7)
p value		<0.001		1.000		<0.001
2020						
Heterosexual	194	2 (1.0)	53	0 (0.0)	248	2 (0.8)
Bisexual	8	0 (0.0)	24	0 (0.0)	34	1 (2.9)
Homosexual	18	9 (50.0)	1	0 (0.0)	20	10 (50.0)
p value		<0.001		--		<0.001
2021						
Heterosexual	21	0 (0.0)	10	1 (10.0)	31	1 (3.2)
Bisexual	1	0 (0.0)	3	0 (0.0)	5	0 (0.0)
Homosexual	5	2 (40.0)	1	0 (0.0)	6	2 (33.3)
p value		0.043		1.000		0.204

Table 3.2.3 HIV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<25 years	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
25-34 years	55	0 (0.0)	21	0 (0.0)	80	1 (1.3)
35-44 years	114	6 (5.3)	61	2 (3.3)	177	8 (4.5)
45+ years	180	11 (6.1)	62	1 (1.6)	250	12 (4.8)
p value		0.230		0.786		0.462
2018						
<25 years	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)
25-34 years	54	5 (9.3)	24	0 (0.0)	79	5 (6.3)
35-44 years	127	3 (2.4)	55	1 (1.8)	184	4 (2.2)
45+ years	200	6 (3.0)	58	0 (0.0)	261	7 (2.7)
p value		0.094		0.597		0.229
2019						
<25 years	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
25-34 years	66	3 (4.6)	25	0 (0.0)	93	3 (3.2)
35-44 years	118	3 (2.5)	51	0 (0.0)	171	3 (1.8)
45+ years	188	16 (8.5)	61	1 (1.6)	255	18 (7.1)
p value		0.150		1.000		0.051
2020						
<25 years	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)
25-34 years	49	1 (2.0)	16	0 (0.0)	65	1 (1.5)
35-44 years	70	1 (1.4)	37	0 (0.0)	107	1 (0.9)
45+ years	105	9 (8.6)	34	0 (0.0)	143	11 (7.7)
p value		0.154		--		0.039
2021						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
35-44 years	7	2 (28.6)	3	1 (33.3)	10	3 (30.0)
45+ years	17	0 (0.0)	10	0 (0.0)	28	0 (0.0)
p value		0.128		0.375		0.011

Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heroin	110	3 (2.7)	61	1 (1.6)	177	4 (2.3)
Methamphetamine	134	11 (8.2)	51	2 (3.9)	188	14 (7.5)
Other opioids	43	1 (2.3)	21	0 (0.0)	65	1 (1.5)
PIEDs	43	0 (0.0)	3	0 (0.0)	47	0 (0.0)
Other drugs	39	2 (5.1)	14	0 (0.0)	56	2 (3.6)
p value		0.134		0.831		0.051
2018						
Heroin	107	3 (2.8)	56	0 (0.0)	165	3 (1.8)
Methamphetamine	140	9 (6.4)	47	1 (2.1)	191	11 (5.8)
Other opioids	47	1 (2.1)	27	0 (0.0)	74	1 (1.4)
PIEDs	56	0 (0.0)	3	0 (0.0)	60	0 (0.0)
Other drugs	42	2 (4.8)	10	0 (0.0)	52	2 (3.9)
p value		0.247		0.608		0.106
2019						
Heroin	110	1 (0.9)	51	0 (0.0)	168	2 (1.2)
Methamphetamine	153	19 (12.4)	51	1 (2.0)	207	20 (9.7)
Other opioids	36	2 (5.6)	19	0 (0.0)	55	2 (3.6)
PIEDs	54	0 (0.0)	2	0 (0.0)	56	0 (0.0)
Other drugs	29	0 (0.0)	17	0 (0.0)	46	0 (0.0)
p value		<0.001		1.000		<0.001
2020						
Heroin	62	1 (1.6)	28	0 (0.0)	91	1 (1.1)
Methamphetamine	80	9 (11.3)	30	0 (0.0)	113	10 (8.9)
Other opioids	27	0 (0.0)	19	0 (0.0)	46	0 (0.0)
PIEDs	43	0 (0.0)	2	0 (0.0)	45	0 (0.0)
Other drugs	16	0 (0.0)	7	0 (0.0)	24	1 (4.2)
p value		0.019		--		0.012
2021						
Heroin	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
Methamphetamine	14	2 (14.3)	8	1 (12.5)	23	3 (13.0)
Other opioids	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
PIEDs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
Other drugs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
p value		0.641		1.000		0.486

Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
<3 years	34	0 (0.0)	8	0 (0.0)	42	0 (0.0)
3 to 10 years	50	4 (8.0)	11	0 (0.0)	63	5 (7.9)
11+ years	285	13 (4.6)	131	3 (2.3)	428	16 (3.7)
p value		0.236		1.000		0.114
2018						
<3 years	19	1 (5.3)	5	0 (0.0)	24	1 (4.2)
3 to 10 years	60	5 (8.3)	13	0 (0.0)	73	5 (6.9)
11+ years	316	9 (2.9)	126	1 (0.8)	449	11 (2.5)
p value		0.090		1.000		0.098
2019						
<3 years	31	1 (3.2)	8	0 (0.0)	39	1 (2.6)
3 to 10 years	63	7 (11.1)	11	0 (0.0)	75	7 (9.3)
11+ years	275	14 (5.1)	122	1 (0.8)	405	16 (4.0)
p value		0.144		1.000		0.121
2020						
<3 years	19	1 (5.3)	8	0 (0.0)	27	1 (3.7)
3 to 10 years	42	3 (7.1)	7	0 (0.0)	50	3 (6.0)
11+ years	161	7 (4.4)	70	0 (0.0)	235	9 (3.8)
p value		0.582		--		0.698
2021						
<3 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
3 to 10 years	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
11+ years	24	2 (8.3)	13	1 (7.7)	38	3 (7.9)
p value		1.000		1.000		1.000

Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
No receptive sharing	277	13 (4.7)	112	2 (1.8)	398	15 (3.8)
Receptive sharing	38	1 (2.6)	15	1 (6.7)	54	3 (5.6)
p value		1.000		0.316		0.463
2018						
No receptive sharing	284	12 (4.2)	87	0 (0.0)	374	12 (3.2)
Receptive sharing	48	2 (4.2)	17	0 (0.0)	65	2 (3.1)
p value		1.000		--		1.000
2019						
No receptive sharing	277	18 (6.5)	98	0 (0.0)	381	19 (5.0)
Receptive sharing	47	3 (6.4)	17	1 (5.9)	65	4 (6.2)
p value		1.000		0.148		0.760
2020						
No receptive sharing	174	7 (4.0)	69	0 (0.0)	247	9 (3.6)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		1.000		--		0.606
2021						
No receptive sharing	18	1 (5.6)	11	1 (9.1)	30	2 (6.7)
Receptive sharing	2	1 (50.0)	2	0 (0.0)	4	1 (25.0)
p value		0.195		1.000		0.322

Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

New South Wales		Male		Female		Total	
Frequency of injection	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2017							
Less than daily	169	7 (4.1)	45	2 (4.4)	215	9 (4.2)	
Daily or more	150	7 (4.7)	85	1 (1.2)	245	9 (3.7)	
Not last month	44	2 (4.6)	19	0 (0.0)	65	2 (3.1)	
p value		1.000		0.520		0.949	
2018							
Less than daily	166	6 (3.6)	52	0 (0.0)	220	6 (2.7)	
Daily or more	169	8 (4.7)	57	0 (0.0)	227	8 (3.5)	
Not last month	56	1 (1.8)	33	1 (3.0)	92	3 (3.3)	
p value		0.725		0.232		0.898	
2019							
Less than daily	155	13 (8.4)	49	0 (0.0)	205	13 (6.3)	
Daily or more	171	8 (4.7)	69	1 (1.5)	246	10 (4.1)	
Not last month	51	1 (2.0)	24	0 (0.0)	78	1 (1.3)	
p value		0.209		1.000		0.195	
2020							
Less than daily	95	3 (3.2)	33	0 (0.0)	129	3 (2.3)	
Daily or more	98	4 (4.1)	48	0 (0.0)	149	6 (4.0)	
Not last month	34	4 (11.8)	7	0 (0.0)	42	4 (9.5)	
p value		0.137		--		0.119	
2021							
Less than daily	13	1 (7.7)	7	0 (0.0)	20	1 (5.0)	
Daily or more	7	1 (14.3)	6	1 (16.7)	0	0 (0.0)	
Not last month	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
p value		1.000		0.562		0.444	

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

New South Wales		Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	
2017							
No imprisonment	283	16 (5.7)	128	1 (0.8)	421	18 (4.3)	
Imprisonment	51	0 (0.0)	10	1 (10.0)	63	1 (1.6)	
p value		0.145		0.140		0.491	
2018							
No imprisonment	320	14 (4.4)	123	1 (0.8)	448	16 (3.6)	
Imprisonment	52	1 (1.9)	15	0 (0.0)	68	1 (1.5)	
p value		0.705		1.000		0.712	
2019							
No imprisonment	315	21 (6.7)	123	1 (0.8)	445	23 (5.2)	
Imprisonment	48	0 (0.0)	14	0 (0.0)	64	0 (0.0)	
p value		0.091		1.000		0.098	
2020							
No imprisonment	180	11 (6.1)	72	0 (0.0)	257	13 (5.1)	
Imprisonment	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)	
p value		0.367		--		0.228	
2021							
No imprisonment	24	1 (4.2)	14	1 (7.1)	39	2 (5.1)	
Imprisonment	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
p value		1.000		1.000		1.000	

Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

New South Wales		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No condom use	107	11 (10.3)	63	1 (1.6)	171	12 (7.0)	
Condom use	37	0 (0.0)	11	0 (0.0)	49	0 (0.0)	
p value		0.066		1.000		0.073	
2018							
No condom use	128	3 (2.3)	49	0 (0.0)	178	3 (1.7)	
Condom use	37	5 (13.5)	16	0 (0.0)	56	5 (8.9)	
p value		0.015		--		0.021	
2019							
No condom use	120	8 (6.7)	49	0 (0.0)	169	8 (4.7)	
Condom use	44	1 (2.3)	13	1 (7.7)	59	2 (3.4)	
p value		0.447		0.210		1.000	
2020							
No condom use	83	6 (7.2)	37	0 (0.0)	122	7 (5.7)	
Condom use	28	1 (3.6)	13	0 (0.0)	41	1 (2.4)	
p value		0.677		--		0.681	
2021							
No condom use	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)	
Condom use	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
p value		--		--		--	

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year

New South Wales		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No sex work	316	14 (4.4)	124	2 (1.6)	447	16 (3.6)	
Sex work	15	2 (13.3)	12	0 (0.0)	33	3 (9.1)	
p value		0.159		1.000		0.135	
2018							
No sex work	354	10 (2.8)	117	1 (0.9)	476	12 (2.5)	
Sex work	13	2 (15.4)	15	0 (0.0)	30	2 (6.7)	
p value		0.063		1.000		0.199	
2019							
No sex work	338	18 (5.3)	121	1 (0.8)	465	20 (4.3)	
Sex work	12	2 (16.7)	12	0 (0.0)	27	2 (7.4)	
p value		0.145		1.000		0.343	
2020							
No sex work	210	10 (4.8)	72	0 (0.0)	285	11 (3.9)	
Sex work	7	1 (14.3)	10	0 (0.0)	19	2 (10.5)	
p value		0.309		--		0.191	
2021							
No sex work	23	1 (4.4)	14	1 (7.1)	38	2 (5.3)	
Sex work	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)	
p value		--		1.000		1.000	

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Non Indigenous	306	14 (4.6)	110	1 (0.9)	428	16 (3.7)
Indigenous	56	3 (5.4)	37	2 (5.4)	95	5 (5.3)
p value		0.734		0.156		0.561
2018						
Non Indigenous	321	9 (2.8)	110	0 (0.0)	437	9 (2.1)
Indigenous	62	5 (8.1)	30	0 (0.0)	93	6 (6.5)
p value		0.043		--		0.020
2019						
Non Indigenous	315	17 (5.4)	94	0 (0.0)	417	17 (4.1)
Indigenous	65	5 (7.7)	47	1 (2.1)	113	7 (6.2)
p value		0.557		0.333		0.337
2020						
Non Indigenous	184	10 (5.4)	56	0 (0.0)	243	11 (4.5)
Indigenous	35	1 (2.9)	29	0 (0.0)	66	2 (3.0)
p value		1		--		0.742
2021						
Non Indigenous	19	2 (10.5)	9	0 (0.0)	29	2 (6.9)
Indigenous	7	0 (0.0)	4	1 (25.0)	11	1 (9.1)
p value		1.000		0.308		1.000

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
English speaking	350	17 (4.9)	143	3 (2.1)	507	21 (4.1)
Non-English speaking	17	0 (0.0)	7	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		0.616
2018						
English speaking	361	15 (4.2)	135	0 (0.0)	501	16 (3.2)
Non-English speaking	33	0 (0.0)	8	0 (0.0)	43	0 (0.0)
p value		0.625		--		0.628
2019						
English speaking	354	21 (5.9)	136	0 (0.0)	498	22 (4.4)
Non-English speaking	29	1 (3.5)	7	1 (14.3)	37	2 (5.4)
p value		1.000		0.049		0.678
2020						
English speaking	206	10 (4.9)	81	0 (0.0)	292	12 (4.1)
Non-English speaking	24	1 (4.2)	4	0 (0.0)	28	1 (3.6)
p value		1.000		--		1.000
2021						
English speaking	25	2 (8.0)	15	1 (6.7)	41	3 (7.3)
Non-English speaking	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
p value		1.000		--		1.000

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
Australia	317	14 (4.4)	131	2 (1.5)	459	17 (3.7)	
Other Oceania	14	1 (7.1)	6	0 (0.0)	21	1 (4.8)	
Asia	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
UK & Ireland	11	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
Other	14	1 (7.1)	4	0 (0.0)	19	1 (5.3)	
p value		0.651		1.000		0.743	
2018							
Australia	330	12 (3.6)	125	0 (0.0)	460	12 (2.6)	
Other Oceania	14	1 (7.1)	7	0 (0.0)	22	2 (9.1)	
Asia	5	0 (0.0)	0	0 (0.0)	5	0 (0.0)	
UK & Ireland	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)	
Other	31	1 (3.2)	6	0 (0.0)	38	1 (2.6)	
p value		0.478		--		0.240	
2019							
Australia	329	18 (5.5)	127	1 (0.8)	461	20 (4.3)	
Other Oceania	14	1 (7.1)	5	0 (0.0)	22	1 (4.6)	
Asia	9	3 (33.3)	0	0 (0.0)	9	3 (33.3)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	20	0 (0.0)	7	0 (0.0)	28	0 (0.0)	
p value		0.044		1.000		0.024	
2020							
Australia	189	7 (3.7)	72	0 (0.0)	265	8 (3.0)	
Other Oceania	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)	
Asia	10	1 (10.0)	2	0 (0.0)	12	1 (8.3)	
UK & Ireland	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)	
Other	18	1 (5.6)	7	0 (0.0)	25	1 (4.0)	
p value		0.277		--		0.296	
2021							
Australia	21	1 (4.8)	14	1 (7.1)	35	2 (5.7)	
Other Oceania	1	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
UK & Ireland	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
Other	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		1.000		1.000		1.000	

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	357	172 (48)	146	73 (50)	515	252 (49)
2018	395	183 (46)	144	60 (42)	546	247 (45)
2019	384	154 (40)	141	72 (51)	535	231 (43)
2020	233	79 (34)	88	34 (39)	326	115 (35)
2021	28	7 (25)	16	6 (38)	45	13 (29)
X ² p trend		<0.001		0.244		<0.001

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	281	149 (53)	115	62 (54)	398	212 (53)
Bisexual	24	8 (33)	15	6 (40)	40	15 (38)
Homosexual	25	3 (12)	5	3 (60)	36	10 (28)
p value		<0.001		0.628		0.004
2018						
Heterosexual	301	143 (48)	90	34 (38)	392	178 (45)
Bisexual	26	12 (46)	36	17 (47)	64	31 (48)
Homosexual	26	8 (31)	7	3 (43)	34	11 (32)
p value		0.259		0.616		0.282
2019						
Heterosexual	297	126 (42)	85	46 (54)	383	173 (45)
Bisexual	25	8 (32)	37	18 (49)	67	29 (43)
Homosexual	31	4 (13)	6	2 (33)	38	6 (16)
p value		0.003		0.575		0.002
2020						
Heterosexual	194	69 (36)	53	18 (34)	248	88 (35)
Bisexual	8	3 (38)	24	15 (63)	34	18 (53)
Homosexual	19	2 (11)	1	0 (0)	21	2 (10)
p value		0.107		0.030		0.007
2021						
Heterosexual	21	6 (29)	10	5 (50)	31	11 (35)
Bisexual	1	0 (0)	3	1 (33)	5	1 (20)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
p value		1.000		1.000		0.787

Table 3.3.3 HCV antibody prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	17	0 (0)	5	1 (20)	22	1 (5)
25-34 years	52	17 (33)	20	9 (45)	75	27 (36)
35-44 years	110	48 (44)	60	33 (55)	172	82 (48)
45+ years	177	107 (60)	60	30 (50)	244	142 (58)
p value		<0.001		0.489		<0.001
2018						
<25 years	14	2 (14)	7	0 (0)	22	2 (9)
25-34 years	54	12 (22)	24	11 (46)	79	24 (30)
35-44 years	126	66 (52)	55	24 (44)	183	91 (50)
45+ years	201	103 (51)	58	25 (43)	262	130 (50)
p value		<0.001		0.151		<0.001
2019						
<25 years	15	3 (20)	7	1 (14)	22	4 (18)
25-34 years	66	13 (20)	25	16 (64)	93	29 (31)
35-44 years	116	52 (45)	51	26 (51)	169	80 (47)
45+ years	187	86 (46)	58	29 (50)	251	118 (47)
p value		<0.001		0.144		0.003
2020						
<25 years	8	0 (0)	1	0 (0)	10	0 (0)
25-34 years	49	10 (20)	16	3 (19)	65	13 (20)
35-44 years	70	22 (31)	37	15 (41)	107	37 (35)
45+ years	106	47 (44)	34	16 (47)	144	65 (45)
p value		0.003		0.202		<0.001
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	3	0 (0)	6	0 (0)
35-44 years	8	2 (25)	3	1 (33)	11	3 (27)
45+ years	17	5 (29)	10	5 (50)	28	10 (36)
p value		0.831		0.494		0.253

Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
<3 years	34	2 (6)	8	0 (0)	42	2 (5)
3 to 10 years	48	17 (35)	11	4 (36)	60	21 (35)
11+ years	252	142 (56)	118	67 (57)	380	216 (57)
p value		<0.001		0.002		<0.001
2018						
<3 years	19	1 (5)	5	0 (0)	24	1 (4)
3 to 10 years	60	6 (10)	13	3 (23)	73	9 (12)
11+ years	288	164 (57)	119	55 (46)	413	223 (54)
p value		<0.001		0.040		<0.001
2019						
<3 years	30	2 (7)	9	0 (0)	39	2 (5)
3 to 10 years	63	11 (17)	11	3 (27)	75	15 (20)
11+ years	273	134 (49)	119	69 (58)	400	206 (52)
p value		<0.001		<0.001		<0.001
2020						
<3 years	19	2 (11)	8	0 (0)	27	2 (7)
3 to 10 years	42	7 (17)	7	3 (43)	50	10 (20)
11+ years	161	68 (42)	70	31 (44)	235	101 (43)
p value		<0.001		0.042		<0.001
2021						
<3 years	0	0 (0)	0	0	0	0 (0)
3 to 10 years	3	1 (33)	2	0	5	1 (20)
11+ years	25	6 (24)	13	6	39	12 (31)
p value		1.000		0.486		1.000

Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No receptive sharing	28	2 (7)	337	178 (53)	383	188 (49)
Receptive sharing	3	0 (0)	43	25 (58)	52	27 (52)
p value		1.000		0.510		0.701
2018						
No receptive sharing	16	0 (0)	338	160 (47)	374	168 (45)
Receptive sharing	0	0 (0)	59	36 (61)	65	40 (62)
p value		--		0.052		0.013
2019						
No receptive sharing	28	1 (4)	340	156 (46)	378	163 (43)
Receptive sharing	4	1 (25)	56	34 (61)	63	37 (59)
p value		0.238		0.040		0.021
2020						
No receptive sharing	22	2 (9)	220	83 (38)	248	87 (35)
Receptive sharing	1	0 (0)	25	13 (52)	27	13 (48)
p value		1.000		0.166		0.180
2021						
No receptive sharing	--	-- --	29	9 (31)	30	9 (30)
Receptive sharing	--	-- --	4	2 (50)	4	2 (50)
p value		--		0.586		0.580

Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

New South Wales Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	4	0 (0)	152	100 (66)	170	110 (65)
Methamphetamine	15	2 (13)	156	67 (43)	179	70 (39)
Other opioids	0	0 (0)	59	39 (66)	62	40 (65)
PIEDs	20	0 (0)	24	0 (0)	46	0 (0)
Other drugs	3	0 (0)	45	28 (62)	50	28 (56)
p value		0.286		<0.001		<0.001
2018						
Heroin	2	0 (0)	156	94 (60)	162	96 (59)
Methamphetamine	10	1 (10)	167	71 (43)	190	77 (41)
Other opioids	1	0 (0)	65	40 (62)	73	44 (60)
PIEDs	11	0 (0)	43	1 (2)	60	1 (2)
Other drugs	0	0 (0)	46	21 (46)	50	23 (46)
p value		0.691		<0.001		<0.001
2019						
Heroin	6	0 (0)	150	91 (61)	163	95 (58)
Methamphetamine	15	2 (13)	185	75 (41)	204	79 (39)
Other opioids	1	0 (0)	52	25 (48)	53	25 (47)
PIEDs	13	0 (0)	37	0 (0)	54	0 (0)
Other drugs	1	0 (0)	41	27 (66)	44	29 (66)
p value		0.564		<0.001		<0.001
2020						
Heroin	4	1 (25)	85	42 (49)	90	43 (48)
Methamphetamine	7	1 (14)	105	35 (33)	114	37 (32)
Other opioids	2	0 (0)	42	21 (50)	45	22 (49)
PIEDs	12	0 (0)	26	0 (0)	44	0 (0)
Other drugs	1	0 (0)	21	12 (57)	23	12 (52)
p value		0.499		<0.001		<0.001
2021						
Heroin	--	-- --	16	5 (31)	16	5 (31)
Methamphetamine	--	-- --	23	6 (26)	24	6 (26)
Other opioids	--	-- --	3	2 (67)	3	2 (67)
PIEDs	--	-- --	1	0 (0)	1	0 (0)
Other drugs	--	-- --	1	0 (0)	1	0 (0)
p value		--		0.561		0.538

Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Less than daily	20	2 (10)	182	89 (49)	209	91 (44)
Daily or more	11	0 (0)	205	119 (58)	234	129 (55)
Not last month	11	0 (0)	49	26 (53)	64	28 (44)
p value		0.489		0.197		0.035
2018						
Less than daily	10	0 (0)	202	93 (46)	221	95 (43)
Daily or more	6	0 (0)	203	105 (52)	226	115 (51)
Not last month	8	1 (13)	75	30 (40)	92	33 (36)
p value		0.583		0.190		0.037
2019						
Less than daily	15	1 (7)	181	70 (39)	201	75 (37)
Daily or more	17	1 (6)	220	123 (56)	245	128 (52)
Not last month	7	0 (0)	66	26 (39)	78	26 (33)
p value		1.000		0.001		0.001
2020						
Less than daily	11	2 (18)	116	38 (33)	130	40 (31)
Daily or more	12	0 (0)	133	60 (45)	149	62 (42)
Not last month	4	0 (0)	32	12 (38)	42	12 (29)
p value		0.436		0.135		0.101
2021						
Less than daily	--	-- --	19	6 (32)	20	6 (30)
Daily or more	--	-- --	14	5 (36)	14	5 (36)
Not last month	--	-- --	11	2 (18)	11	2 (18)
p value		--		0.645		0.644

Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No imprisonment	40	2 (5)	343	174 (51)	406	183 (45)
Imprisonment	0	0 (0)	52	43 (83)	61	49 (80)
p value		--		<0.001		<0.001
2018						
No imprisonment	18	0 (0)	401	185 (46)	448	194 (43)
Imprisonment	6	1 (17)	57	32 (56)	68	36 (53)
p value		0.250		0.157		0.136
2019						
No imprisonment	36	2 (6)	389	175 (45)	440	181 (41)
Imprisonment	2	0 (0)	58	29 (50)	64	31 (48)
p value		1.000		0.475		0.269
2020						
No imprisonment	24	2 (8)	223	80 (36)	258	83 (32)
Imprisonment	3	0 (0)	34	17 (50)	40	18 (45)
p value		1.000		0.113		0.111
2021						
No imprisonment	0	0 (0)	39	12 (31)	40	12 (30)
Imprisonment	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.563		0.562

Table 3.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	297	128 (43)	107	50 (47)	414	184 (44)
Indigenous	53	38 (72)	36	21 (58)	91	60 (66)
p value		<0.001		0.228		<0.001
2018						
Non Indigenous	321	144 (45)	110	41 (37)	437	189 (43)
Indigenous	62	34 (55)	30	16 (53)	93	50 (54)
p value		0.149		0.112		0.064
2019						
Non Indigenous	311	116 (37)	92	44 (48)	411	165 (40)
Indigenous	66	34 (52)	47	26 (55)	114	60 (53)
p value		0.032		0.403		0.017
2020						
Non Indigenous	185	60 (32)	56	20 (36)	244	82 (34)
Indigenous	35	15 (43)	29	12 (41)	66	27 (41)
p value		0.233		0.609		0.27
2021						
Non Indigenous	20	5 (25)	9	3 (33)	30	8 (27)
Indigenous	7	2 (29)	4	2 (50)	11	4 (36)
p value		1.000		1.000		0.701

Table 3.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	340	166 (49)	139	69 (50)	491	242 (49)
Non-English speaking	15	5 (33)	7	4 (57)	22	9 (41)
p value		0.296		1.000		0.442
2018						
English speaking	361	169 (47)	135	58 (43)	501	230 (46)
Non-English speaking	33	14 (42)	8	2 (25)	43	17 (40)
p value		0.628		0.468		0.421
2019						
English speaking	352	140 (40)	134	69 (51)	494	213 (43)
Non-English speaking	28	13 (46)	7	3 (43)	36	17 (47)
p value		0.489		0.715		0.631
2020						
English speaking	207	69 (33)	81	32 (40)	293	103 (35)
Non-English speaking	24	10 (42)	4	2 (50)	28	12 (43)
p value		0.415		1.000		0.417
2021						
English speaking	26	6 (23)	15	5 (33)	42	11 (26)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.444		--		0.476

Table 3.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017							
Australia	306	144 (47)	127	64 (50)	442	213 (48)	
Other Oceania	13	9 (69)	6	3 (50)	20	13 (65)	
Asia	5	2 (40)	3	1 (33)	8	3 (38)	
UK & Ireland	11	6 (55)	5	3 (60)	17	10 (59)	
Other	14	6 (43)	4	2 (50)	19	8 (42)	
p value		0.576		1.000		0.466	
2018							
Australia	330	154 (47)	125	52 (42)	460	209 (45)	
Other Oceania	14	7 (50)	7	3 (43)	22	10 (45)	
Asia	5	4 (80)	0	0 (0)	5	4 (80)	
UK & Ireland	13	6 (46)	3	2 (67)	16	8 (50)	
Other	31	11 (35)	6	2 (33)	38	14 (37)	
p value		0.445		0.860		0.474	
2019							
Australia	327	132 (40)	125	64 (51)	457	199 (44)	
Other Oceania	14	7 (50)	5	3 (60)	22	11 (50)	
Asia	9	3 (33)	0	0 (0)	9	3 (33)	
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)	
Other	19	6 (32)	7	2 (29)	27	8 (30)	
p value		0.857		0.517		0.493	
2020							
Australia	190	65 (34)	72	26 (36)	266	93 (35)	
Other Oceania	8	1 (13)	1	0 (0)	9	1 (11)	
Asia	10	3 (30)	2	1 (50)	12	4 (33)	
UK & Ireland	4	0 (0)	4	2 (50)	8	2 (25)	
Other	18	10 (56)	7	4 (57)	25	14 (56)	
p value		0.136		0.709		0.13	
2021							
Australia	21	5 (24)	14	6 (43)	35	11 (31)	
Other Oceania	1	0 (0)	1	0 (0)	3	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.764		1.000		0.720	

HCV RNA prevalence

Table 3.4.1 HCV RNA prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*	186	52 (28)	74	13 (18)	265	65 (25)
2018*	270	50 (19)	98	20 (20)	373	71 (19)
2019*	320	46 (14)	118	26 (22)	446	72 (16)
2020	221	20 (9)	76	9 (12)	300	29 (10)
2021	26	2 (8)	14	2 (14)	41	4 (10)
X ² p trend		<0.001		0.417		<0.001

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 3.4.2 HCV RNA prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heterosexual	165	49 (30)	63	11 (17)	229	60 (26)
Bisexual	8	1 (13)	5	1 (20)	13	2 (15)
Homosexual	6	0 (0)	2	1 (50)	11	1 (9)
p value		0.186		0.487		0.350
2018*						
Heterosexual	202	37 (18)	59	12 (20)	262	49 (19)
Bisexual	17	5 (29)	22	4 (18)	41	9 (22)
Homosexual	20	3 (15)	6	3 (50)	27	6 (22)
p value		0.501		0.266		0.842
2019*						
Heterosexual	254	36 (14)	69	14 (20)	323	50 (15)
Bisexual	20	2 (10)	32	8 (25)	57	10 (18)
Homosexual	26	0 (0)	6	0 (0)	33	0 (0)
p value		0.112		0.416		0.036
2020						
Heterosexual	184	19 (10)	46	6 (13)	231	25 (11)
Bisexual	8	0 (0)	20	3 (15)	29	3 (10)
Homosexual	17	0 (0)	1	0 (0)	18	0 (0)
p value		0.242		0.903		0.339
2021						
Heterosexual	21	2 (10)	9	2 (22)	30	4 (13)
Bisexual	1	0 (0)	2	0 (0)	4	0 (0)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.773		0.67		0.512

Table 3.4.3 HCV RNA prevalence by age group, gender and survey year

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	8	0 (0)	3	0 (0)	11	0 (0)
25-34 years	31	11 (35)	8	1 (13)	40	12 (30)
35-44 years	47	7 (15)	26	8 (31)	75	15 (20)
45+ years	99	33 (33)	35	4 (11)	137	38 (28)
p value		0.082		0.227		0.249
2018*						
<25 years	12	1 (8)	5	0 (0)	18	1 (6)
25-34 years	31	5 (16)	13	2 (15)	44	7 (16)
35-44 years	81	21 (26)	35	7 (20)	117	30 (26)
45+ years	146	23 (16)	45	10 (22)	193	33 (17)
p value		0.132		0.588		0.109
2019*						
<25 years	12	2 (17)	6	1 (17)	18	3 (17)
25-34 years	56	5 (9)	22	5 (23)	80	10 (13)
35-44 years	96	22 (23)	41	10 (24)	138	32 (23)
45+ years	156	17 (11)	49	10 (20)	210	27 (13)
p value		0.035		0.899		0.049
2020						
<25 years	7	0 (0)	1	0 (0)	9	0 (0)
25-34 years	46	4 (9)	16	1 (6)	62	5 (8)
35-44 years	69	8 (12)	30	5 (17)	99	13 (13)
45+ years	99	8 (8)	29	3 (10)	130	11 (8)
p value		0.715		0.719		0.436
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35-44 years	6	1 (17)	3	0 (0)	9	1 (11)
45+ years	17	1 (6)	9	2 (22)	27	3 (11)
p value		0.604		0.523		0.735

Table 3.4.4 HCV RNA prevalence by years since first injection, gender and survey year

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	19	0 (0)	4	0 (0)	24	0 (0)
3 to 10 years	19	6 (32)	5	1 (20)	24	7 (29)
11+ years	136	43 (32)	60	12 (20)	202	56 (28)
p value		0.024		0.588		0.018
2018*						
<3 years	15	1 (7)	5	0 (0)	20	1 (5)
3 to 10 years	37	2 (5)	5	2 (40)	42	4 (10)
11+ years	197	44 (22)	83	16 (19)	284	60 (21)
p value		0.030		0.304		0.045
2019*						
<3 years	25	2 (8)	7	0 (0)	32	2 (6)
3 to 10 years	49	3 (6)	11	2 (18)	60	6 (10)
11+ years	232	37 (16)	98	23 (23)	337	59 (18)
p value		0.139		0.331		0.085
2020						
<3 years	18	2 (11)	7	0 (0)	25	2 (8)
3 to 10 years	40	3 (8)	6	1 (17)	47	4 (9)
11+ years	152	14 (9)	61	8 (13)	215	22 (10)
p value		0.898		0.567		0.893
2021						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	1 (33)	1	0 (0)	4	1 (25)
11+ years	23	1 (4)	12	2 (17)	36	3 (8)
p value		0.076		0.657		0.292

Table 3.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	142	38 (27)	50	11 (22)	196	49 (25)
Receptive sharing	16	6 (38)	5	0 (0)	21	6 (29)
p value		0.395		0.207		0.762
2018*						
No receptive sharing	193	32 (17)	57	10 (18)	252	42 (17)
Receptive sharing	34	14 (41)	13	3 (23)	47	17 (36)
p value		0.002		0.767		0.004
2019*						
No receptive sharing	232	32 (14)	81	20 (25)	318	53 (17)
Receptive sharing	36	10 (28)	12	4 (33)	50	14 (28)
p value		0.037		0.643		0.056
2020						
No receptive sharing	166	16 (10)	60	9 (15)	228	25 (11)
Receptive sharing	15	4 (27)	10	0 (0)	25	4 (16)
p value		0.044		0.190		0.453
2021						
No receptive sharing	17	0 (0)	10	2 (20)	28	2 (7)
Receptive sharing	1	1 (100)	2	0 (0)	3	1 (33)
p value		<0.001		0.488		0.145

Table 3.4.6 HCV RNA prevalence by last drug injected, gender and survey year

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	50	16 (32)	29	8 (28)	83	25 (30)
Methamphetamine	75	16 (21)	19	2 (11)	95	18 (19)
Other opioids	23	11 (48)	16	2 (13)	39	13 (33)
PIEDs	24	0 (0)	2	0 (0)	26	0 (0)
Other drugs	14	8 (57)	7	1 (14)	22	9 (41)
p value		0.001		0.494		0.013
2018*						
Heroin	79	16 (20)	38	8 (21)	119	24 (20)
Methamphetamine	91	22 (24)	31	5 (16)	125	27 (22)
Other opioids	27	6 (22)	18	4 (22)	45	10 (22)
PIEDs	34	1 (3)	0	0 (0)	36	1 (3)
Other drugs	31	4 (13)	2	2 (100)	40	6 (15)
p value		0.080		0.972		0.095
2019*						
Heroin	95	20 (21)	37	9 (24)	138	28 (20)
Methamphetamine	123	16 (13)	44	9 (20)	169	25 (15)
Other opioids	30	5 (17)	17	3 (18)	47	8 (17)
PIEDs	43	0 (0)	2	0 (0)	45	0 (0)
Other drugs	22	4 (18)	13	6 (46)	36	10 (28)
p value		0.024		0.350		0.007
2020						
Heroin	58	8 (14)	27	1 (3)	86	9 (11)
Methamphetamine	76	7 (9)	22	4 (18)	100	11 (11)
Other opioids	25	3 (12)	19	2 (11)	44	5 (11)
PIEDs	39	0 (0)	2	0 (0)	41	0 (0)
Other drugs	15	2 (13)	6	2 (33)	21	4 (19)
p value		0.211		0.238		0.151
2021						
Heroin	9	1 (11)	5	1 (20)	14	2 (14)
Methamphetamine	13	1 (8)	8	1 (13)	22	2 (9)
Other opioids	2	0 (0)	1	0 (0)	3	0 (0)
PIEDs	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.975		0.852		0.928

Table 3.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

New South Wales Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
Less than daily	96	19 (20)	22	3 (14)	118	22 (19)
Daily or more	64	26 (41)	37	9 (24)	106	35 (33)
Not last month	25	6 (24)	15	1 (7)	41	8 (20)
p value		0.043		0.287		0.070
2018*						
Less than daily	119	20 (17)	33	7 (21)	154	27 (18)
Daily or more	111	27 (24)	39	5 (13)	151	32 (21)
Not last month	36	3 (8)	25	6 (24)	62	9 (15)
p value		0.086		0.419		0.508
2019*						
Less than daily	133	15 (11)	40	10 (25)	174	24 (14)
Daily or more	136	27 (20)	55	14 (25)	197	42 (21)
Not last month	46	3 (7)	21	2 (10)	69	5 (7)
p value		0.036		0.263		0.013
2020						
Less than daily	92	9 (10)	29	5 (17)	122	14 (11)
Daily or more	92	11 (12)	42	4 (10)	135	15 (11)
Not last month	32	0 (0)	5	0 (0)	38	0 (0)
p value		0.129		0.428		0.092
2021						
Less than daily	12	0 (0)	7	1 (14)	19	1 (5)
Daily or more	6	1 (17)	5	1 (20)	12	2 (17)
Not last month	8	1 (13)	2	0 (0)	10	1 (10)
p value		0.379		0.792		0.581

Table 3.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

New South Wales Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
No imprisonment	138	32 (23)	63	10 (16)	203	43 (21)
Imprisonment	34	17 (50)	5	2 (40)	40	19 (48)
p value		0.087		0.170		0.011
2018*						
No imprisonment	213	37 (17)	84	19 (23)	301	56 (19)
Imprisonment	40	9 (23)	10	1 (10)	51	10 (20)
p value		0.465		0.300		0.943
2019*						
No imprisonment	264	33 (13)	104	21 (20)	374	55 (15)
Imprisonment	37	9 (24)	10	4 (40)	49	13 (27)
p value		0.061		0.151		0.039
2020						
No imprisonment	172	15 (9)	62	9 (15)	237	24 (10)
Imprisonment	26	3 (12)	11	0 (0)	37	3 (8)
p value		0.641		0.177		0.702
2021						
No imprisonment	24	2 (8)	12	2 (17)	37	4 (11)
Imprisonment	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.671		0.533		0.489

Table 3.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

New South Wales		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2017*							
Non Indigenous	156	37 (24)	52	8 (15)	213	45 (21)	
Indigenous	28	12 (43)	21	5 (24)	50	17 (34)	
p value		0.095		0.412		0.126	
2018*							
Non Indigenous	222	38 (17)	72	15 (21)	299	53 (18)	
Indigenous	39	12 (31)	23	3 (13)	63	15 (24)	
p value		0.048		0.317		0.318	
2019*							
Non Indigenous	263	31 (12)	78	13 (17)	348	45 (13)	
Indigenous	53	13 (25)	37	11 (30)	91	24 (26)	
p value		0.014		0.090		0.001	
2020							
Non Indigenous	174	14 (8)	47	6 (13)	223	20 (9)	
Indigenous	34	3 (9)	27	3 (11)	62	6 (10)	
p value		0.880		0.843		0.864	
2021							
Non Indigenous	18	0 (0)	7	2 (29)	26	2 (8)	
Indigenous	7	2 (29)	4	0 (0)	11	2 (18)	
p value		0.018		0.237		0.348	

Table 3.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

New South Wales		Male		Female		Total	
Main language spoken at home by parents	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2017*							
English speaking	179	51 (28)	68	12 (18)	253	63 (25)	
Non-English speaking	7	1 (14)	5	1 (20)	12	2 (17)	
p value		0.257		0.973		0.344	
2018*							
English speaking	252	48 (19)	92	19 (21)	347	68 (20)	
Non-English speaking	18	2 (11)	6	1 (17)	26	3 (12)	
p value		0.364		0.695		0.273	
2019*							
English speaking	298	42 (14)	112	25 (22)	417	67 (16)	
Non-English speaking	21	4 (19)	6	1 (17)	28	5 (18)	
p value		0.558		0.750		0.835	
2020							
English speaking	196	17 (9)	71	8 (11)	270	25 (9)	
Non-English speaking	23	3 (13)	4	1 (25)	27	4 (15)	
p value		0.491		0.411		0.354	
2021							
English speaking	24	2 (8)	13	1 (8)	38	3 (8)	
Non-English speaking	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.671		--		0.679	

Table 3.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
Australia	165	48 (29)	62	11 (18)	232	59 (25)	
Other Oceania	10	1 (10)	3	1 (33)	13	3 (23)	
Asia	1	0 (0)	2	0 (0)	3	0 (0)	
UK & Ireland	6	2 (33)	3	0 (0)	9	2 (22)	
Other	3	0 (0)	4	1 (25)	8	1 (13)	
p value		0.536		0.765		0.836	
2018*							
Australia	225	43 (19)	84	18 (21)	312	62 (20)	
Other Oceania	9	1 (11)	5	1 (20)	15	2 (13)	
Asia	4	2 (50)	0	0 (0)	4	2 (50)	
UK & Ireland	11	2 (18)	2	1 (50)	13	3 (23)	
Other	20	2 (10)	6	0 (0)	26	2 (8)	
p value		0.440		0.430		0.268	
2019*							
Australia	277	41 (15)	104	25 (24)	386	65 (17)	
Other Oceania	11	0 (0)	4	1 (25)	17	2 (12)	
Asia	6	2 (33)	0	0 (0)	6	2 (33)	
UK & Ireland	3	0 (0)	4	0 (0)	7	0 (0)	
Other	17	2 (12)	6	0 (0)	24	2 (8)	
p value		0.385		0.380		0.367	
2020							
Australia	181	16 (9)	62	7 (11)	246	23 (9)	
Other Oceania	8	0 (0)	0	0 (0)	8	0 (0)	
Asia	10	0 (0)	2	0 (0)	12	0 (0)	
UK & Ireland	3	0 (0)	4	1 (25)	7	1 (14)	
Other	16	4 (25)	7	1 (14)	23	5 (22)	
p value		0.196		0.890		0.252	
2021							
Australia	20	2 (10)	12	2 (17)	32	4 (13)	
Other Oceania	1	0 (0)	1	0 (0)	3	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.969		0.823		0.893	

Northern Territory

Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Northern Territory	2017	2018	2019	2020*	2021*
Number of sites	3	3	3	3	3
N° surveyed	N=66	N=67	N=85	N=37	N=40
Response rate (%)	39%	37%	42%	23%	18%
Gender (%)					
Male	34 (52)	41 (61)	53 (62)	25 (68)	25 (63)
Female	30 (45)	26 (39)	31 (36)	12 (32)	15 (38)
Other	2 (3)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	46 (70)	60 (90)	68 (80)	30 (81)	29 (73)
Bisexual	8 (12)	3 (4)	8 (9)	4 (11)	7 (18)
Gay/Lesbian	2 (3)	4 (6)	2 (2)	0 (0)	2 (5)
Other	-- --	-- --	-- --	1 (3)	2 (5)
Not reported	10 (15)	0 (0)	7 (8)	2 (5)	0 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	42 (64)	41 (61)	55 (65)	25 (68)	20 (50)
Yes	18 (27)	25 (37)	30 (35)	10 (27)	20 (50)
Not reported	6 (9)	1 (1)	0 (0)	2 (5)	0 (0)
Region/country of birth (%)					
Australia	59 (89)	62 (93)	79 (93)	35 (95)	39 (98)
Other Oceania	2 (3)	2 (3)	1 (1)	1 (3)	0 (0)
Asia	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
UK & Ireland	1 (2)	0 (0)	1 (1)	0 (0)	0 (0)
Other	1 (2)	1 (1)	3 (4)	0 (0)	0 (0)
Not reported	3 (5)	1 (1)	1 (1)	1 (3)	1 (3)
Main language spoken at home by parents (%)					
English	63 (95)	64 (96)	80 (94)	33 (89)	39 (98)
Non-English	0 (0)	1 (1)	4 (5)	2 (5)	1 (3)
Not reported	3 (5)	2 (3)	1 (1)	2 (5)	0 (0)
Age and time since first injection (years)					
<i>Median age</i>	43	43	43.5	45	50
<i>Age range</i>	19-62	24-61	30-70	21-64	31-65
<i>Age group (%)</i>					
<25 years	5 (8)	1 (1)	0 (0)	1 (3)	0 (0)
25+ years	61 (92)	65 (97)	84 (99)	36 (97)	40 (100)
Not reported	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
<i>Median age first injection</i>	20	17.5	18	19	17
<i>Age range</i>	14-40	10-43	11-65	10-42	10-42
<i>N° not reported</i>	4	5	3	0	1
<i>Median yrs since first injection</i>	20.5	23.5	22.5	24	29
<i>Range</i>	0-44	1-47	2-50	4-51	1-50
<i>Years since first injection</i>					
<3 years	3 (5)	2 (3)	1 (1)	0 (0)	1 (3)
3+ years	59 (89)	60 (90)	81 (95)	37 (100)	38 (95)
Not reported	4 (6)	5 (7)	3 (4)	0 (0)	1 (3)
Imprisonment last year (%)					
No	57 (86)	59 (88)	68 (80)	32 (86)	36 (90)
Yes	3 (5)	4 (6)	10 (12)	3 (8)	4 (10)
Not reported	6 (9)	4 (6)	7 (8)	2 (5)	0 (0)
N° in prison					
Injected in prison	0 (0)	1 (25)	1 (10)	0 (0)	0 (0)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Northern Territory	2017	2018	2019	2020	2021
N° surveyed	N=66	N=67	N=85	N=37	N=40
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	2 (2)	0 (0)	1 (3)
Methamphetamine	31 (47)	27 (40)	46 (54)	25 (68)	27 (68)
Heroin	3 (5)	1 (1)	0 (0)	0 (0)	1 (3)
Pharm. opioids	22 (33)	24 (36)	23 (27)	7 (19)	4 (10)
Methadone	3 (5)	1 (1)	6 (7)	0 (0)	3 (8)
Buprenorphine	3 (5)	5 (7)	4 (5)	3 (8)	1 (3)
Buprenorphine/naloxone	0 (0)	2 (3)	0 (0)	1 (3)	0 (0)
PIEDs	1 (2)	2 (3)	0 (0)	0 (0)	0 (0)
More than one	1 (2)	5 (7)	2 (2)	1 (3)	1 (3)
Other	1 (2)	0 (0)	1 (1)	0 (0)	1 (3)
Not reported	1 (2)	0 (0)	1 (1)	0 (0)	1 (3)
Ever injected opioids					
No	10 (15)	12 (18)	19 (22)	10 (27)	11 (28)
Yes	56 (85)	53 (79)	65 (76)	27 (73)	29 (73)
Not reported	0 (0)	2 (3)	1 (1)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	8 (12)	1 (1)	6 (7)	5 (14)	5 (13)
Less than weekly	5 (8)	6 (9)	8 (9)	8 (22)	10 (25)
Weekly not daily	11 (17)	14 (21)	12 (14)	7 (19)	7 (18)
Daily or more	42 (64)	44 (66)	59 (69)	17 (46)	16 (40)
Not reported	0 (0)	2 (3)	0 (0)	0 (0)	2 (5)
Present when someone injected for the first time in the last 12 months (%)					
No	54 (82)	54 (81)	63 (74)	33 (89)	31 (78)
Yes	8 (12)	8 (12)	17 (20)	2 (5)	9 (23)
Not reported	4 (6)	5 (7)	5 (6)	2 (5)	0 (0)
Overdosed in last 12 months					
No	56 (85)	56 (84)	72 (85)	33 (89)	35 (88)
Yes	6 (9)	6 (9)	8 (9)	1 (3)	4 (10)
Not reported	4 (6)	5 (7)	5 (6)	3 (8)	1 (3)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Northern Territory	2017	2018	2019	2020	2021
N° injected last month	N=58	N=64	N=79	N=32	N=33
Places injected last month (%)					
All private	31 (53)	40 (63)	51 (65)	19 (59)	15 (45)
Any public	27 (47)	24 (38)	28 (35)	12 (38)	18 (55)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	50 (86)	53 (83)	67 (85)	26 (81)	27 (82)
Most of the time	3 (5)	11 (17)	8 (10)	2 (6)	4 (12)
Half of the time	1 (2)	0 (0)	2 (3)	2 (6)	1 (3)
Some of the time	0 (0)	0 (0)	1 (1)	1 (3)	1 (3)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	4 (7)	0 (0)	1 (1)	1 (3)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	52 (90)	55 (86)	70 (89)	27 (84)	28 (85)
Once	2 (3)	6 (9)	3 (4)	1 (3)	0 (0)
Twice	0 (0)	1 (2)	0 (0)	1 (3)	2 (6)
3-5 times	3 (5)	1 (2)	4 (5)	1 (3)	1 (3)
>5 times	1 (2)	1 (2)	1 (1)	1 (3)	2 (6)
Not reported	0 (0)	0 (0)	1 (1)	1 (3)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	52 (90)	55 (86)	70 (89)	27 (84)	28 (85)
One	0 (0)	5 (8)	2 (3)	0 (0)	1 (3)
Two	2 (3)	0 (0)	1 (1)	1 (3)	2 (6)
Three to five	1 (2)	1 (2)	1 (1)	0 (0)	0 (0)
More than five	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)
Don't know	1 (2)	1 (2)	2 (3)	2 (6)	2 (6)
Not reported	2 (3)	1 (2)	3 (4)	1 (3)	0 (0)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	2 (3)	6 (9)	3 (4)	2 (6)	0 (0)
Casual sex partner	1 (2)	1 (2)	1 (1)	0 (0)	0 (0)
Close friend	2 (3)	2 (3)	0 (0)	2 (6)	4 (12)
Acquaintance	1 (2)	0 (0)	3 (4)	0 (0)	1 (3)
Other	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	9 (16)	8 (13)	15 (19)	3 (9)	2 (6)
Water	13 (22)	10 (16)	10 (13)	5 (16)	6 (18)
Filter	5 (9)	8 (13)	7 (9)	3 (9)	3 (9)
Drug mix	5 (9)	8 (13)	4 (5)	0 (0)	1 (3)
None	40 (69)	50 (78)	55 (70)	25 (78)	22 (67)
Injected by someone after that person injected themselves or others last month (%)					
No	46 (79)	54 (84)	63 (80)	26 (81)	28 (85)
Yes	9 (16)	10 (16)	16 (20)	5 (16)	5 (15)
Not reported	3 (5)	0 (0)	0 (0)	1 (3)	0 (0)
Source of needle acquisition					
Needle Syringe Program	46 (79)	58 (91)	67 (85)	28 (88)	30 (91)
Chemist/Pharmacy	10 (17)	11 (17)	9 (11)	0 (0)	2 (6)
Personal sources	10 (17)	5 (8)	7 (9)	1 (3)	4 (12)
Dispensing/Vending Machine	12 (21)	15 (23)	17 (22)	5 (16)	3 (9)
Other sources	0 (0)	0 (0)	1 (1)	1 (3)	1 (3)

Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Northern Territory	2017	2018	2019	2020	2021
N° surveyed	N=66	N=67	N=85	N=37	N=40
Ever any treatment/therapy for drug use (%)					
No	28 (42)	31 (46)	39 (46)	16 (43)	20 (50)
Yes	35 (53)	35 (52)	46 (54)	21 (57)	20 (50)
Not reported	3 (5)	1 (1)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	1 (2)	1 (1)	10 (12)	1 (3)	6 (15)
Previously	10 (15)	11 (16)	17 (20)	7 (19)	4 (10)
Never	51 (77)	50 (75)	57 (67)	28 (76)	29 (73)
Not reported	4 (6)	5 (7)	1 (1)	1 (3)	1 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	2 (3)	6 (9)	5 (6)	6 (16)	3 (8)
Previously	13 (20)	15 (22)	17 (20)	4 (11)	2 (5)
Never	48 (73)	44 (66)	62 (73)	26 (70)	35 (88)
Not reported	3 (5)	2 (3)	1 (1)	1 (3)	0 (0)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	7 (11)	2 (3)	3 (4)	4 (11)	1 (3)
Previously	10 (15)	16 (24)	18 (21)	6 (16)	4 (10)
Never	46 (70)	46 (69)	64 (75)	27 (73)	35 (88)
Not reported	3 (5)	3 (4)	0 (0)	0 (0)	0 (0)

Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Northern Territory	2017	2018	2019	2020	2021
N° surveyed	N=66	N=67	N=85	N=37	N=40
Previous HIV test (%)					
Yes, ever	50 (76)	54 (81)	69 (81)	26 (70)	34 (85)
Yes, last year	34 (52)	34 (51)	43 (51)	14 (38)	18 (45)
>1 year ago	16 (24)	20 (30)	26 (31)	12 (32)	16 (40)
Never tested	10 (15)	10 (15)	11 (13)	9 (24)	6 (15)
Not reported	6 (9)	3 (4)	5 (6)	2 (5)	0 (0)
Previous HCV test (%)					
Yes, ever	49 (74)	51 (76)	66 (78)	27 (73)	34 (85)
Yes, last year	32 (48)	34 (51)	44 (52)	10 (27)	20 (50)
>1 year ago	17 (26)	17 (25)	22 (26)	17 (46)	14 (35)
Never tested	8 (12)	6 (9)	8 (9)	3 (8)	4 (10)
Not reported	9 (14)	10 (15)	11 (13)	7 (19)	2 (5)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=15	N=19	N=23	N=2	N=6
Antiviral treatment	3 (20)	3 (16)	16 (70)	2 (100)	3 (50)
No antiviral treatment	9 (60)	16 (84)	7 (30)	0 (0)	3 (50)
Not reported	3 (20)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=14	N=19	N=16	N=1	N=4
Antiviral treatment	1 (7)	3 (16)	8 (50)	1 (100)	0 (0)
No antiviral treatment	10 (71)	16 (84)	8 (50)	0 (0)	4 (100)
Not reported	3 (21)	0 (0)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Northern Territory	2017	2018	2019	2020	2021
N° surveyed	N=66	N=67	N=85	N=37	N=40
Sex with a regular partner last month (%)					
No	36 (55)	29 (43)	43 (51)	22 (59)	25 (63)
Yes	25 (38)	33 (49)	36 (42)	13 (35)	14 (35)
Not reported	5 (8)	5 (7)	6 (7)	2 (5)	1 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=25	N=33	N=36	N=13	N=14
Never	16 (64)	22 (67)	28 (78)	11 (85)	8 (57)
Sometimes	5 (20)	4 (12)	5 (14)	1 (8)	1 (7)
Every time	2 (8)	4 (12)	3 (8)	1 (8)	5 (36)
Not reported	2 (8)	3 (9)	0 (0)	0 (0)	0 (0)
Sex with other partner(s) last month (%)					
No	49 (74)	44 (66)	58 (68)	31 (84)	29 (73)
Yes	12 (18)	17 (25)	20 (24)	4 (11)	10 (25)
Not reported	5 (8)	6 (9)	7 (8)	2 (5)	1 (3)
Condom used with other partner(s) last month (%)					
N° surveyed	N=12	N=17	N=20	N=4	N=10
Never	2 (17)	7 (41)	7 (35)	0 (0)	3 (30)
Sometimes	4 (33)	1 (6)	6 (30)	0 (0)	0 (0)
Every time	6 (50)	7 (41)	6 (30)	4 (100)	6 (60)
Not reported	0 (0)	2 (12)	1 (5)	0 (0)	1 (10)
Sex work last month (%)					
No	52 (79)	53 (79)	67 (79)	31 (84)	32 (80)
Yes	7 (11)	6 (9)	11 (13)	3 (8)	8 (20)
Not reported	7 (11)	8 (12)	7 (8)	3 (8)	0 (0)
Condom used at last sex work (%)					
Yes	6 (86)	3 (50)	7 (64)	3 (100)	7 (88)

Table 4.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

Northern Territory	2020	2021
N° surveyed	N=37	N=40
More difficult to access sterile needles and syringes		
Yes	1 (3)	4 (10)
No	29 (78)	29 (73)
Not applicable	5 (14)	4 (10)
Not reported	2 (5)	3 (8)
Start depot buprenorphine		
Yes	0 (0)	2 (5)
No	27 (73)	20 (50)
Not applicable	8 (22)	14 (35)
Not reported	2 (5)	4 (10)
Access take home naloxone		
Yes	5 (14)	0 (0)
No	20 (54)	24 (60)
Not applicable	10 (27)	12 (30)
Not reported	2 (5)	4 (10)
Change illicit drug use		
Yes, increased	2 (5)	4 (10)
Yes, decreased	10 (27)	9 (23)
No change	23 (62)	23 (58)
Not reported	2 (5)	4 (10)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	2 (5)	2 (5)
No	24 (65)	20 (50)
Not applicable	9 (24)	13 (33)
Not reported	2 (5)	5 (13)
Inject own methadone/bupe/suboxone		
Yes	1 (3)	4 (10)
No	24 (65)	19 (48)
Not applicable	10 (27)	12 (30)
Not reported	2 (5)	5 (13)
COVID-19 vaccine uptake		
≥1 dose	-- --	23 (58)
COVID-19 vaccine doses		
One dose	-- --	5 (13)
Two doses	-- --	18 (45)
No doses	-- --	13 (33)
Not reported	-- --	4 (10)
Vaccine type		
Astra Zeneca	-- --	7 (18)
Pfizer	-- --	11 (28)
Don't know	-- --	1 (3)
Not reported	-- --	21 (53)
COVID-19 test		
Yes	8 (22)	9 (23)
No	25 (68)	21 (53)
Don't know	1 (3)	1 (3)
Not reported	3 (8)	9 (23)
Self-reported positive COVID-19 test result		
Yes	0 (0)	0 (0)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017	34	0 (0.0)	29	0 (0.0)	65	0 (0.0)
2018	41	0 (0.0)	25	0 (0.0)	66	0 (0.0)
2019	52	1 (1.9)	29	1 (3.5)	82	2 (2.4)
2020	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
2021	25	1 (4.0)	14	1 (7.1)	39	2 (5.1)
X ² p trend		0.178		0.126		0.044

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017	32	15 (47)	29	8 (28)	63	23 (37)
2018	41	15 (37)	25	11 (44)	66	26 (39)
2019	51	23 (45)	29	7 (24)	81	30 (37)
2020	20	5 (25)	10	0 (0)	30	5 (17)
2021	24	7 (29)	14	2 (14)	38	9 (24)
X ² p trend		0.149		0.063		0.049

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Heterosexual	28	12 (43)	15	2 (13)	43	14 (33)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.051		0.079
2018						
Heterosexual	40	15 (38)	20	9 (45)	60	24 (40)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	3	2 (67)	4	2 (50)
p value		1.000		0.480		0.656
2019						
Heterosexual	43	20 (47)	21	4 (19)	65	24 (37)
Bisexual	4	2 (50)	3	1 (33)	7	3 (43)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		0.234		1.000
2020						
Heterosexual	19	5 (26)	5	0 (0)	24	5 (21)
Bisexual	1	0 (0)	2	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2021						
Heterosexual	18	6 (33)	9	1 (11)	27	7 (26)
Bisexual	4	1 (25)	3	0 (0)	7	1 (14)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		0.308		0.790

Table 4.3.3 HCV antibody prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	2	1 (50)	3	0 (0)	5	1 (20)
25-34 years	5	0 (0)	2	1 (50)	8	1 (13)
35-44 years	13	4 (31)	10	3 (30)	23	7 (30)
45+ years	12	10 (83)	14	4 (29)	27	14 (52)
p value		0.003		0.729		0.152
2018						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	5	1 (20)	4	1 (25)	9	2 (22)
35-44 years	18	5 (28)	7	4 (57)	25	9 (36)
45+ years	16	8 (50)	14	6 (43)	30	14 (47)
p value		0.417		0.654		0.501
2019						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	9	3 (33)	5	0 (0)	14	3 (21)
35-44 years	14	7 (50)	15	5 (33)	29	12 (41)
45+ years	27	13 (48)	9	2 (22)	37	15 (41)
p value		0.799		0.376		0.459
2020						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	0 (0)	0	0 (0)	3	0 (0)
35-44 years	4	1 (25)	3	0 (0)	7	1 (14)
45+ years	12	4 (33)	7	0 (0)	19	4 (21)
p value		0.830		--		1.000
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	7	2 (29)	4	1 (4)	11	3 (27)
45+ years	15	5 (33)	10	1 (10)	25	6 (24)
p value		1.000		0.505		1.000

Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	4	2 (50)	5	0 (0)	9	2 (22)
11+ years	25	11 (44)	20	8 (40)	47	19 (40)
p value		1.000		0.197		0.282
2018						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 10 years	6	3 (50)	2	1 (50)	8	4 (50)
11+ years	31	10 (32)	21	8 (38)	52	18 (35)
p value		0.555		1.000		0.419
2019						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	5	2 (40)	5	0 (0)	10	2 (20)
11+ years	43	20 (47)	23	7 (30)	67	27 (40)
p value		1.000		0.461		0.370
2020						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	0 (0)	0	0 (0)	3	0 (0)
11+ years	17	5 (29)	10	0 (0)	27	5 (19)
p value		0.539		--		1.000
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	22	7 (32)	14	2 (14)	36	9 (25)
p value		1.000		--		1.000

Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No receptive sharing	3	3 (100)	42	17 (40)	49	19 (39)
Receptive sharing	0	0 (0)	6	1 (17)	6	1 (17)
p value		--		0.388		0.399
2018						
No receptive sharing	2	2 (100)	49	20 (41)	55	24 (44)
Receptive sharing	0	0 (0)	9	2 (22)	9	2 (22)
p value		--		0.459		0.291
2019						
No receptive sharing	1	0 (0)	62	22 (35)	66	23 (35)
Receptive sharing	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.458		0.452
2020						
No receptive sharing	0	0 (0)	22	3 (14)	22	3 (14)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		1.000		1.000
2021						
No receptive sharing	0	0 (0)	26	5 (19)	26	5 (19)
Receptive sharing	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.562		0.562

Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Methamphetamine	1	1 (100)	28	7 (25)	30	7 (23)
Pharm. Opioids	0	0 (0)	19	10 (53)	22	12 (55)
OAT*	1	1 (100)	4	2 (50)	5	2 (40)
Other drugs	1	1 (100)	5	2 (40)	6	2 (33)
p value		--		0.261		0.146
2018						
Methamphetamine	1	1 (100)	24	11 (46)	26	12 (46)
Pharm. Opioids	0	0 (0)	21	6 (29)	23	8 (35)
OAT*	0	0 (0)	7	4 (57)	8	5 (63)
Other drugs	1	1 (100)	7	1 (14)	8	1 (13)
p value		--		0.241		0.181
2019						
Methamphetamine	1	0 (0)	39	12 (31)	42	13 (31)
Pharm. Opioids	0	0 (0)	23	11 (48)	23	11 (48)
OAT*	0	0 (0)	10	3 (30)	10	3 (30)
Other drugs	0	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.511		0.563
2020						
Methamphetamine	0	0 (0)	19	2 (11)	19	2 (11)
Pharm. Opioids	0	0 (0)	6	2 (33)	6	2 (33)
OAT*	0	0 (0)	4	0 (0)	4	0 (0)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.057		0.057
2021						
Methamphetamine	1	0 (0)	23	3 (13)	24	3 (13)
Pharm. Opioids	0	0 (0)	4	1 (25)	4	1 (25)
OAT*	0	0 (0)	4	2 (50)	4	2 (50)
Other drugs	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.203		0.179

*OAT = methadone, buprenorphine or buprenorphine/naloxone

Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Less than daily	2	2 (100)	12	5 (42)	15	5 (33)
Daily or more	1	1 (100)	36	13 (36)	40	15 (38)
Not last month	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.922		1.000
2018						
Less than daily	1	1 (100)	18	9 (50)	20	10 (50)
Daily or more	1	1 (100)	40	13 (33)	44	16 (36)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.363		0.481
2019						
Less than daily	0	0 (0)	19	9 (47)	20	9 (45)
Daily or more	1	0 (0)	52	17 (33)	55	18 (33)
Not last month	0	0 (0)	6	3 (50)	6	3 (50)
p value		--		0.378		0.483
2020						
Less than daily	0	0 (0)	12	2 (17)	12	2 (17)
Daily or more	0	0 (0)	14	1 (7)	14	1 (7)
Not last month	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.134		0.134
2021						
Less than daily	0	0 (0)	17	2 (12)	17	2 (12)
Daily or more	0	0 (0)	14	5 (36)	14	5 (36)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		--		0.220		0.345

Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No imprisonment	3	3 (100)	50	19 (38)	56	21 (38)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.527		0.530
2018						
No imprisonment	2	2 (100)	54	20 (37)	59	23 (39)
Imprisonment	0	0 (0)	3	2 (67)	4	3 (75)
p value		--		0.553		0.297
2019						
No imprisonment	1	0 (0)	65	27 (42)	66	27 (41)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.694		0.469
2020						
No imprisonment	0	0 (0)	25	5 (20)	25	5 (20)
Imprisonment	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		1.000		1.000
2021						
No imprisonment	1	0 (0)	32	9 (28)	34	9 (26)
Imprisonment	0	0 (0)	4	0 (0)	4	0 (0)
p value		--		0.553		0.554

Table 4.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	24	12 (50)	15	5 (33)	40	17 (43)
Indigenous	5	1 (20)	11	2 (18)	17	3 (18)
p value		0.343		0.658		0.128
2018						
Non Indigenous	27	9 (33)	14	7 (50)	41	16 (39)
Indigenous	14	6 (43)	11	4 (36)	25	10 (40)
p value		0.548		0.689		0.937
2019						
Non Indigenous	39	16 (41)	13	1 (8)	53	17 (32)
Indigenous	12	7 (58)	16	6 (38)	28	13 (46)
p value		0.292		0.093		0.203
2020						
Non Indigenous	12	3 (25)	9	0 (0)	21	3 (14)
Indigenous	6	1 (17)	1	0 (0)	7	1 (14)
p value		1.000		--		1.000
2021						
Non Indigenous	13	4 (31)	6	0 (0)	19	4 (21)
Indigenous	11	3 (27)	8	2 (25)	19	5 (26)
p value		0.605		0.473		1.000

Table 4.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	30	14 (47)	28	8 (29)	60	22 (37)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018						
English speaking	39	14 (36)	25	11 (44)	64	25 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2019						
English speaking	48	22 (46)	28	7 (25)	77	29 (38)
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)
p value		1.000		1.000		1.000
2020						
English speaking	18	4 (22)	9	0 (0)	27	4 (15)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		1.000
2021						
English speaking	23	6 (26)	14	2 (14)	37	8 (22)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.292		--		0.237

Table 4.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Northern Territory Region/Country of birth	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Australia	26	11 (42)	28	8 (29)	56	19 (34)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.143		--		0.075
2018						
Australia	38	14 (37)	24	11 (46)	62	25 (40)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	1	0 (0)	1	0 (0)
p value		1.000		1.000		1.000
2019						
Australia	47	21 (45)	28	7 (25)	76	28 (37)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.849		1.000		0.824
2020						
Australia	18	5 (28)	10	0 (0)	28	5 (18)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000
2021						
Australia	23	7 (30)	14	2 (14)	37	9 (24)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

HCV RNA prevalence

Table 4.4.1 HCV RNA prevalence by gender and survey year

Northern Territory Survey year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*	26	5 (19)	22	4 (18)	50	9 (18)
2018*	27	6 (22)	16	4 (25)	43	10 (23)
2019*	36	4 (11)	18	2 (11)	56	6 (11)
2019	13	0 (0)	5	0 (0)	18	0 (0)
2021	22	3 (14)	11	0 (0)	33	3 (9)
X ² p trend		0.201		0.068		0.041

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 4.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Northern Territory Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
Heterosexual	23	4 (17)	10	2 (20)	34	6 (18)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.141		0.109
2018*						
Heterosexual	27	6 (22)	12	3 (25)	39	9 (23)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.566		0.549
2019*						
Heterosexual	28	4 (14)	15	1 (7)	43	5 (12)
Bisexual	3	0 (0)	1	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.731		0.935		0.698
2020						
Heterosexual	13	0 (0)	3	0 (0)	16	0 (0)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
Heterosexual	17	2 (12)	8	0 (0)	25	2 (8)
Bisexual	3	1 (33)	2	0 (0)	5	1 (20)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.564		--		0.629

Table 4.4.3 HCV RNA prevalence by age group, gender and survey year

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	2	0 (0)	4	0 (0)	6	0 (0)
25-34 years	5	0 (0)	1	0 (0)	7	0 (0)
35-44 years	11	3 (27)	6	3 (50)	17	6 (35)
45+ years	8	2 (25)	11	1 (9)	20	3 (15)
p value		0.477		0.227		0.126
2018*						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	2	0 (0)	3	1 (33)	5	1 (20)
35-44 years	11	2 (18)	4	2 (50)	16	4 (25)
45+ years	11	4 (36)	9	1 (11)	20	5 (25)
p value		0.575		0.200		0.889
2019*						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	3	0 (0)	7	0 (0)
35-44 years	7	0 (0)	12	2 (17)	19	2 (11)
45+ years	24	4 (17)	6	0 (0)	30	4 (13)
p value		0.405		0.464		0.617
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	1	0 (0)	2	0 (0)	3	0 (0)
45+ years	10	0 (0)	3	0 (0)	13	0 (0)
p value		--		--		--
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	6	1 (17)	4	0 (0)	10	1 (10)
45+ years	14	2 (14)	7	0 (0)	21	2 (10)
p value		0.832		--		0.898

Table 4.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	4	1 (25)	4	0 (0)	8	1 (13)
11+ years	21	4 (19)	15	4 (27)	38	8 (21)
p value		0.836		0.548		0.727
2018*						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	1 (50)	1	0 (0)	3	1 (33)
11+ years	22	4 (18)	13	4 (31)	35	8 (23)
p value		0.539		0.562		0.790
2019*						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	0 (0)	6	0 (0)
11+ years	32	4 (13)	16	2 (13)	47	6 (13)
p value		0.566		0.720		0.606
2020						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	12	0 (0)	5	0 (0)	17	0 (0)
p value		--		--		--
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	20	3 (15)	11	0 (0)	31	3 (10)
p value		0.676		--		0.744

Table 4.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Northern Territory Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	22	5 (23)	17	4 (24)	41	9 (22)
Receptive sharing	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.454		0.493		0.311
2018*						
No receptive sharing	20	5 (25)	12	3 (25)	33	8 (24)
Receptive sharing	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.808		0.956		0.869
2019*						
No receptive sharing	29	4 (14)	17	1 (6)	46	5 (11)
Receptive sharing	4	0 (0)	3	1 (33)	7	1 (14)
p value		0.496		0.153		0.805
2020						
No receptive sharing	9	0 (0)	5	0 (0)	14	0 (0)
Receptive sharing	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--
2021						
No receptive sharing	14	1 (7)	10	0 (0)	24	1 (4)
Receptive sharing	4	1 (25)	1	0 (0)	5	1 (20)
p value		0.316		--		0.204

Table 4.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Northern Territory Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Methamphetamine	10	2 (20)	10	1 (10)	21	3 (14)
Pharm. Opioids	9	2 (22)	8	1 (13)	17	3 (18)
OAT	3	1 (33)	2	1 (50)	6	2 (33)
Other drugs	4	0 (0)	2	1 (50)	6	1 (17)
p value		0.659		0.469		0.696
2018*						
Methamphetamine	13	4 (31)	5	1 (20)	18	5 (28)
Pharm. Opioids	8	2 (25)	7	2 (29)	16	4 (25)
OAT	4	0 (0)	2	1 (50)	6	1 (17)
Other drugs	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.467		0.651		0.755
2019*						
Methamphetamine	15	2 (13)	11	1 (9)	26	3 (12)
Pharm. Opioids	12	2 (17)	6	0 (0)	18	2 (11)
OAT	6	0 (0)	1	0 (0)	7	0 (0)
Other drugs	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.746		0.849		0.707
2020						
Methamphetamine	5	0 (0)	4	0 (0)	9	0 (0)
Pharm. Opioids	4	0 (0)	1	0 (0)	5	0 (0)
OAT	3	0 (0)	0	0 (0)	3	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--
2021						
Methamphetamine	11	1 (9)	10	0 (0)	21	1 (5)
Pharm. Opioids	3	0 (0)	0	0 (0)	3	0 (0)
OAT	4	1 (25)	0	0 (0)	4	1 (25)
Other drugs	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.667		--		0.425

OAT: methadone, buprenorphine or buprenorphine/naloxone

Table 4.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Northern Territory Frequency of injection last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
Less than daily	7	1 (14)	7	1 (14)	15	2 (13)
Daily or more	17	4 (24)	12	3 (25)	30	7 (23)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		0.645		0.630		0.386
2018*						
Less than daily	8	3 (38)	6	1 (17)	14	4 (29)
Daily or more	18	3 (17)	9	3 (33)	27	6 (22)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.289		0.533		0.816
2019*						
Less than daily	11	2 (18)	5	1 (20)	15	3 (20)
Daily or more	23	2 (9)	15	1 (7)	37	3 (8)
Not last month	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.820		0.630		0.607
2020						
Less than daily	5	0 (0)	2	0 (0)	7	0 (0)
Daily or more	6	0 (0)	3	0 (0)	9	0 (0)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--
2021						
Less than daily	9	1 (11)	7	0 (0)	16	1 (6)
Daily or more	9	1 (11)	4	0 (0)	13	1 (8)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.884		--		0.918

Table 4.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Northern Territory Imprisonment last year	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
No imprisonment	23	5 (22)	16	4 (25)	43	9 (21)
Imprisonment	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.463		--		0.492
2018*						
No imprisonment	24	4 (17)	14	3 (21)	38	8 (21)
Imprisonment	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.395		0.134		0.129
2019*						
No imprisonment	31	4 (13)	18	1 (6)	48	5 (10)
Imprisonment	2	0 (0)	2	1 (50)	4	1 (25)
p value		0.561		0.059		0.452
2020						
No imprisonment	11	0 (0)	4	0 (0)	15	0 (0)
Imprisonment	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--
2021						
No imprisonment	19	3 (16)	10	0 (0)	29	3 (10)
Imprisonment	3	0 (0)	1	0 (0)	4	0 (0)
p value		0.459		--		0.500

Table 4.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Non Indigenous	19	4 (21)	10	2 (20)	29	6 (21)
Indigenous	4	0 (0)	10	2 (20)	16	2 (13)
p value		0.261		0.941		0.432
2018*						
Non Indigenous	20	4 (20)	7	2 (29)	27	6 (22)
Indigenous	7	2 (29)	9	2 (22)	16	4 (25)
p value		0.681		0.733		0.525
2019*						
Non Indigenous	32	2 (6)	9	0 (0)	41	2 (5)
Indigenous	4	2 (50)	11	2 (18)	15	4 (27)
p value		0.108		0.183		0.102
2020						
Non Indigenous	9	0 (0)	5	0 (0)	14	0 (0)
Indigenous	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		--
2021						
Non Indigenous	11	2 (18)	4	0 (0)	15	2 (13)
Indigenous	11	1 (9)	7	0 (0)	18	1 (6)
p value		0.534		--		0.439

Table 4.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
English speaking	24	4 (17)	22	4 (18)	48	8 (17)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018*						
English speaking	26	6 (23)	16	4 (25)	42	10 (24)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2019*						
English speaking	34	4 (12)	19	2 (11)	53	6 (11)
Non-English speaking	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.644		0.746		0.569
2020						
English speaking	12	0 (0)	5	0 (0)	17	0 (0)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	21	3 (14)	11	0 (0)	32	3 (9)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.684		--		0.748

Table 4.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
Australia	21	2 (10)	22	4 (18)	45	6 (13)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.016		--		0.010	
2018*							
Australia	26	6 (23)	15	4 (27)	41	10 (24)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	1	0 (0)	1	0 (0)	
p value		0.597		0.533		0.719	
2019*							
Australia	32	4 (13)	19	2 (11)	51	6 (12)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)	
Other	2	0 (0)	1	0 (0)	3	0 (0)	
p value		0.859		0.746		0.823	
2020							
Australia	12	0 (0)	5	0 (0)	17	0 (0)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2021							
Australia	21	3 (14)	11	0 (0)	32	3 (9)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Queensland	2017	2018	2019	2020*	2021*
Number of sites	9	9	10	7	11
N° surveyed	N=619	N=633	N=574	N=391	N=458
Response rate (%)	33%	41%	34%	33%	31%
Gender (%)					
Male	447 (72)	441 (70)	407 (71)	285 (73)	307 (67)
Female	171 (28)	191 (30)	160 (28)	104 (27)	145 (32)
Other	1 (<1)	1 (<1)	3 (1)	1 (<1)	6 (1)
Not reported	0 (0)	0 (0)	4 (1)	1 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	483 (78)	506 (80)	427 (74)	315 (81)	382 (83)
Bisexual	55 (9)	62 (10)	63 (11)	38 (10)	42 (9)
Gay/Lesbian	33 (5)	25 (4)	27 (5)	12 (3)	24 (5)
Other	-- --	-- --	-- --	8 (2)	9 (2)
Not reported	48 (8)	40 (6)	57 (10)	18 (5)	1 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	501 (81)	511 (81)	452 (79)	317 (81)	365 (80)
Yes	100 (16)	115 (18)	116 (20)	64 (16)	79 (17)
Not reported	18 (3)	7 (1)	6 (1)	10 (3)	14 (3)
Region/country of birth (%)					
Australia	548 (89)	570 (90)	525 (91)	352 (90)	407 (89)
Other Oceania	32 (5)	20 (3)	12 (2)	15 (4)	11 (2)
Asia	2 (<1)	0 (0)	4 (1)	1 (<1)	3 (1)
UK & Ireland	19 (3)	24 (4)	11 (2)	11 (3)	11 (2)
Other	11 (2)	15 (2)	17 (3)	8 (2)	14 (3)
Not reported	7 (1)	4 (1)	5 (1)	4 (1)	12 (3)
Main language spoken at home by parents (%)					
English	594 (96)	612 (97)	550 (96)	382 (98)	441 (96)
Non-English	22 (4)	18 (3)	22 (4)	9 (2)	11 (2)
Not reported	3 (<1)	3 (<1)	2 (<1)	0 (0)	6 (1)
Age and time since first injection (years)					
<i>Median age</i>	41	41	42	42	42
<i>Age range</i>	16-75	14-78	16-70	19-69	16-72
<i>Age group (%)</i>					
<25 years	37 (6)	37 (6)	30 (5)	19 (5)	20 (4)
25+ years	581 (94)	595 (94)	543 (95)	372 (95)	438 (96)
Not reported	1 (<1)	1 (<1)	1 (<1)	0 (0)	0 (0)
<i>Median age first injection</i>					
<i>Age range</i>	10-65	10-64	10-60	11-59	12-52
N° not reported	16	22	26	4	14
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-59	<1-52	<1-51	<1-53	<1-58
<i>Years since first injection</i>					
<3 years	47 (8)	42 (7)	51 (9)	32 (8)	27 (6)
3+ years	556 (90)	569 (90)	497 (87)	354 (91)	415 (91)
Not reported	16 (3)	22 (3)	26 (5)	5 (1)	16 (3)
Imprisonment last year (%)					
No	528 (85)	535 (85)	480 (84)	336 (86)	385 (84)
Yes	69 (11)	72 (11)	66 (12)	39 (10)	46 (10)
Not reported	22 (4)	26 (4)	28 (5)	16 (4)	27 (6)
N° in prison					
Injected in prison	27 (39)	29 (40)	30 (45)	18 (46)	27 (59)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 5.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Queensland N° surveyed	2017 N=619	2018 N=633	2019 N=574	2020 N=391	2021 N=458
Drug last injected (%)					
Cocaine	5 (1)	10 (2)	3 (1)	2 (1)	2 (<1)
Methamphetamine	265 (43)	304 (48)	281 (49)	156 (40)	194 (42)
Heroin	89 (14)	84 (13)	93 (16)	63 (16)	72 (16)
Pharm. opioids	117 (19)	104 (16)	75 (13)	69 (18)	73 (16)
Methadone	27 (4)	28 (4)	29 (5)	22 (6)	20 (4)
Buprenorphine	23 (4)	33 (5)	22 (4)	23 (6)	25 (5)
Buprenorphine/naloxone	11 (2)	17 (3)	9 (2)	4 (1)	12 (3)
PIEDs	49 (8)	28 (4)	27 (5)	31 (8)	34 (7)
More than one	22 (4)	21 (3)	26 (5)	16 (4)	15 (3)
Other	6 (1)	3 (<1)	8 (1)	2 (1)	4 (1)
Not reported	5 (1)	1 (<1)	1 (<1)	3 (1)	7 (2)
Ever injected opioids					
No	173 (28)	151 (24)	143 (25)	101 (26)	120 (26)
Yes	446 (72)	480 (76)	428 (75)	290 (74)	333 (73)
Not reported	0 (0)	2 (<1)	3 (1)	0 (0)	5 (1)
Frequency of injection last month (%)					
Not last month	54 (9)	41 (6)	47 (8)	46 (12)	73 (16)
Less than weekly	94 (15)	90 (14)	86 (15)	59 (15)	75 (16)
Weekly not daily	150 (24)	160 (25)	133 (23)	78 (20)	89 (19)
Daily or more	316 (51)	332 (52)	305 (53)	204 (52)	215 (47)
Not reported	5 (1)	10 (2)	3 (1)	4 (1)	6 (1)
Present when someone injected for the first time in the last 12 months (%)					
No	496 (80)	499 (79)	457 (80)	320 (82)	377 (82)
Yes	106 (17)	117 (18)	96 (17)	67 (17)	73 (16)
Not reported	17 (3)	17 (3)	21 (4)	4 (1)	8 (2)
Overdosed in last 12 months					
No	512 (83)	521 (82)	478 (83)	329 (84)	400 (87)
Yes	93 (15)	96 (15)	78 (14)	58 (15)	49 (11)
Not reported	14 (2)	16 (3)	18 (3)	4 (1)	9 (2)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Queensland	2017	2018	2019	2020	2021
N° injected last month	N=560	N=582	N=524	N=341	N=379
Places injected last month (%)					
All private	375 (67)	378 (65)	327 (62)	225 (66)	249 (66)
Any public	182 (33)	198 (34)	194 (37)	116 (34)	128 (34)
Not reported	3 (1)	6 (1)	3 (1)	0 (0)	2 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	434 (78)	445 (76)	416 (79)	274 (80)	306 (81)
Most of the time	98 (18)	107 (18)	87 (17)	55 (16)	57 (15)
Half of the time	8 (1)	8 (1)	8 (2)	6 (2)	9 (2)
Some of the time	12 (2)	14 (2)	8 (2)	5 (1)	5 (1)
Not last month	4 (1)	2 (<1)	2 (<1)	0 (0)	2 (1)
Not reported	4 (1)	6 (1)	3 (1)	1 (<1)	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	471 (84)	490 (84)	464 (89)	292 (86)	327 (86)
Once	27 (5)	29 (5)	13 (2)	16 (5)	12 (3)
Twice	22 (4)	17 (3)	17 (3)	10 (3)	13 (3)
3-5 times	19 (3)	23 (4)	15 (3)	13 (4)	14 (4)
>5 times	16 (3)	18 (3)	12 (2)	9 (3)	12 (3)
Not reported	5 (1)	5 (1)	3 (1)	1 (<1)	1 (0)
Number of people needle & syringe was re-used after last month (%)					
None	471 (84)	490 (84)	464 (89)	292 (86)	327 (86)
One	32 (6)	37 (6)	19 (4)	18 (5)	22 (6)
Two	7 (1)	7 (1)	4 (1)	7 (2)	4 (1)
Three to five	5 (1)	5 (1)	6 (1)	3 (1)	2 (1)
More than five	3 (1)	10 (2)	4 (1)	2 (1)	4 (1)
Don't know	27 (5)	20 (3)	14 (3)	9 (3)	13 (3)
Not reported	15 (3)	13 (2)	13 (2)	10 (3)	7 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	24 (4)	29 (5)	19 (4)	16 (5)	15 (4)
Casual sex partner	4 (1)	5 (1)	3 (1)	4 (1)	3 (1)
Close friend	25 (4)	33 (6)	19 (4)	15 (4)	14 (4)
Acquaintance	12 (2)	17 (3)	9 (2)	5 (1)	10 (3)
Other	9 (2)	7 (1)	6 (1)	4 (1)	7 (2)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	102 (18)	116 (20)	102 (19)	43 (13)	74 (20)
Water	106 (19)	105 (18)	102 (19)	47 (14)	65 (17)
Filter	69 (12)	63 (11)	59 (11)	17 (5)	36 (10)
Drug mix	52 (9)	51 (9)	63 (12)	21 (6)	38 (10)
None	381 (68)	413 (71)	368 (70)	263 (77)	274 (72)
Injected by someone after that person injected themselves or others last month (%)					
No	474 (85)	475 (82)	442 (84)	305 (89)	325 (86)
Yes	81 (14)	97 (17)	78 (15)	35 (10)	53 (14)
Not reported	5 (1)	10 (2)	4 (1)	1 (<1)	1 (0)
Source of needle acquisition					
Needle Syringe Program	502 (90)	533 (92)	473 (90)	309 (91)	339 (89)
Chemist/Pharmacy	138 (25)	143 (25)	161 (31)	89 (26)	96 (25)
Personal sources	53 (9)	44 (8)	55 (11)	24 (7)	37 (10)
Dispensing/Vending Machine	76 (14)	66 (11)	87 (17)	45 (13)	47 (12)
Other sources	16 (3)	21 (4)	12 (2)	9 (3)	9 (2)

Table 5.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Queensland	2017	2018	2019	2020	2021
N° surveyed	N=619	N=633	N=574	N=391	N=458
Ever any treatment/therapy for drug use (%)					
No	204 (33)	187 (30)	179 (31)	126 (32)	152 (33)
Yes	412 (67)	443 (70)	394 (69)	264 (68)	305 (67)
Not reported	3 (<1)	3 (<1)	1 (<1)	1 (<1)	1 (0)
History of methadone maintenance treatment (%)					
Currently	89 (14)	87 (14)	81 (14)	58 (15)	42 (9)
Previously	125 (20)	141 (22)	113 (20)	77 (20)	101 (22)
Never	394 (64)	391 (62)	369 (64)	247 (63)	297 (65)
Not reported	11 (2)	14 (2)	11 (2)	9 (2)	18 (4)
History of buprenorphine (Subutex®) treatment (%)					
Currently	41 (7)	56 (9)	52 (9)	45 (12)	52 (11)
Previously	138 (22)	147 (23)	131 (23)	99 (25)	93 (20)
Never	429 (69)	415 (66)	381 (66)	240 (61)	299 (65)
Not reported	11 (2)	15 (2)	10 (2)	7 (2)	14 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	37 (6)	54 (9)	44 (8)	26 (7)	36 (8)
Previously	128 (21)	139 (22)	125 (22)	90 (23)	100 (22)
Never	442 (71)	428 (68)	395 (69)	273 (70)	317 (69)
Not reported	12 (2)	12 (2)	10 (2)	2 (1)	5 (1)

Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland	2017	2018	2019	2020	2021
N° surveyed	N=619	N=619	N=574	N=391	N=458
Previous HIV test (%)					
Yes, ever	510 (82)	534 (84)	489 (85)	328 (84)	350 (76)
Yes, last year	302 (49)	312 (49)	287 (50)	180 (46)	146 (32)
>1 year ago	208 (34)	222 (35)	202 (35)	148 (38)	204 (45)
Never tested	90 (15)	78 (12)	69 (12)	56 (14)	95 (21)
Not reported	19 (3)	21 (3)	16 (3)	7 (2)	13 (3)
Previous HCV test (%)					
Yes, ever	516 (83)	540 (85)	482 (84)	341 (87)	367 (80)
Yes, last year	343 (55)	342 (54)	322 (56)	192 (49)	198 (43)
>1 year ago	173 (28)	198 (31)	160 (28)	149 (38)	169 (37)
Never tested	63 (10)	37 (6)	46 (8)	29 (7)	59 (13)
Not reported	40 (6)	56 (9)	46 (8)	21 (5)	32 (7)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=156	N=172	N=146	N=100	N=107
Antiviral treatment	69 (44)	101 (59)	92 (63)	65 (65)	80 (75)
No antiviral treatment	87 (56)	69 (40)	54 (37)	35 (35)	25 (23)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	2 (2)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=143	N=129	N=113	N=62	N=54
Antiviral treatment	52 (36)	50 (39)	48 (42)	23 (37)	20 (37)
No antiviral treatment	91 (64)	77 (60)	65 (58)	39 (63)	32 (59)
Not reported	0 (0)	2 (2)	0 (0)	0 (0)	2 (4)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Queensland	2017	2018	2019	2020	2021
N° surveyed	N=619	N=633	N=574	N=391	N=458
Sex with a regular partner last month (%)					
No	316 (51)	319 (50)	301 (52)	217 (56)	234 (51)
Yes	279 (45)	297 (47)	256 (45)	168 (43)	210 (46)
Not reported	24 (4)	17 (3)	17 (3)	6 (2)	14 (3)
Condom used with regular partner last month (%)					
N° surveyed	N=279	N=297	N=256	N=168	N=210
Never	198 (71)	230 (77)	197 (77)	133 (79)	161 (77)
Sometimes	37 (13)	32 (11)	26 (10)	12 (7)	28 (13)
Every time	33 (12)	16 (5)	22 (9)	15 (9)	14 (7)
Not reported	11 (4)	19 (6)	11 (4)	8 (5)	7 (3)
Sex with other partner(s) last month (%)					
No	497 (80)	500 (79)	457 (80)	317 (81)	366 (80)
Yes	92 (15)	108 (17)	96 (17)	58 (15)	70 (15)
Not reported	30 (5)	25 (4)	21 (4)	16 (4)	22 (5)
Condom used with other partner(s) last month (%)					
N° surveyed	N=92	N=108	N=96	N=58	N=70
Never	31 (34)	49 (45)	43 (45)	28 (48)	31 (44)
Sometimes	33 (36)	36 (33)	25 (26)	15 (26)	22 (31)
Every time	23 (25)	17 (16)	21 (22)	14 (24)	12 (17)
Not reported	5 (5)	6 (6)	7 (7)	1 (2)	5 (7)
Sex work last month (%)					
No	568 (92)	581 (92)	528 (92)	363 (93)	422 (92)
Yes	22 (4)	30 (5)	21 (4)	14 (4)	14 (3)
Not reported	29 (5)	22 (3)	25 (4)	14 (4)	22 (5)
Condom used at last sex work (%)					
Yes	17 (77)	16 (53)	13 (62)	8 (57)	8 (57)

Table 5.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

Queensland	2020	2021
N° surveyed	N=391	N=458
More difficult to access sterile needles and syringes		
Yes	29 (7)	34 (7)
No	287 (73)	298 (65)
Not applicable	29 (7)	29 (6)
Not reported	46 (12)	97 (21)
Start depot buprenorphine		
Yes	9 (2)	19 (4)
No	248 (63)	169 (37)
Not applicable	82 (21)	161 (35)
Not reported	52 (13)	109 (24)
Access take home naloxone		
Yes	41 (10)	66 (14)
No	212 (54)	142 (31)
Not applicable	86 (22)	137 (30)
Not reported	52 (13)	113 (25)
Change illicit drug use		
Yes, increased	39 (10)	41 (9)
Yes, decreased	94 (24)	105 (23)
No change	203 (52)	210 (46)
Not reported	55 (14)	102 (22)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	37 (9)	33 (7)
No	205 (52)	148 (32)
Not applicable	99 (25)	169 (37)
Not reported	50 (13)	108 (24)
Inject own methadone/bupe/suboxone		
Yes	47 (12)	49 (11)
No	203 (52)	142 (31)
Not applicable	91 (23)	159 (35)
Not reported	50 (13)	108 (24)
COVID-19 vaccine uptake		
≥1 dose	-- --	103 (22)
COVID-19 vaccine doses		
One dose	-- --	53 (12)
Two doses	-- --	50 (11)
No doses	-- --	239 (52)
Not reported	-- --	116 (25)
Vaccine type		
Astra Zeneca	-- --	48 (10)
Pfizer	-- --	37 (8)
Don't know	-- --	26 (6)
Not reported	-- --	347 (76)
COVID-19 test		
Yes	78 (20)	122 (27)
No	246 (63)	205 (45)
Don't know	16 (4)	12 (3)
Not reported	51 (13)	119 (26)
Self-reported positive COVID-19 test result		
Yes	0 (0)	0 (0)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017	441	14 (3.2)	167	1 (0.6)	609	15 (2.5)
2018	437	6 (1.4)	189	2 (1.1)	627	8 (1.3)
2019	401	11 (2.7)	157	0 (0.0)	565	12 (2.1)
2020	284	13 (4.6)	102	1 (1.0)	388	14 (3.6)
2021	304	7 (2.3)	145	0 (0.0)	455	8 (1.8)
X ² p trend		0.634		0.412		0.716

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heterosexual	358	3 (0.8)	118	0 (0.0)	476	3 (0.6)
Bisexual	27	3 (11.1)	28	1 (3.6)	55	4 (7.3)
Homosexual	22	7 (31.8)	7	0 (0.0)	30	7 (23.3)
p value		<0.001		0.229		<0.001
2018						
Heterosexual	365	1 (0.3)	136	2 (1.5)	501	3 (0.6)
Bisexual	25	2 (8.0)	36	0 (0.0)	61	2 (3.3)
Homosexual	21	3 (14.3)	3	0 (0.0)	25	3 (12.0)
p value		<0.001		1.000		0.001
2019						
Heterosexual	322	1 (0.3)	95	0 (0.0)	419	1 (0.2)
Bisexual	24	4 (16.7)	36	0 (0.0)	62	4 (6.5)
Homosexual	21	6 (28.6)	5	0 (0.0)	27	7 (25.9)
p value		<0.001		--		<0.001
2020						
Heterosexual	245	2 (0.8)	69	1 (1.5)	314	3 (1.0)
Bisexual	13	3 (23.1)	21	0 (0.0)	36	3 (8.3)
Homosexual	9	7 (77.8)	3	0 (0.0)	12	7 (58.3)
p value		<0.001		1.000		<0.001
2021						
Heterosexual	267	1 (0.4)	110	0 (0.0)	379	1 (0.3)
Bisexual	18	0 (0.0)	24	0 (0.0)	42	0 (0.0)
Homosexual	15	5 (33.3)	6	0 (0.0)	24	6 (25.0)
p value		<0.001		--		<0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<25 years	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
25-34 years	86	3 (3.5)	41	0 (0.0)	127	3 (2.4)
35-44 years	157	5 (3.2)	53	0 (0.0)	210	5 (2.4)
45+ years	172	6 (3.5)	62	1 (1.6)	234	7 (3.0)
p value		1.000		1.000		0.935
2018						
<25 years	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)
25-34 years	75	1 (1.3)	46	2 (4.4)	122	3 (2.5)
35-44 years	158	2 (1.3)	67	0 (0.0)	225	2 (0.9)
45+ years	182	3 (1.7)	61	0 (0.0)	243	3 (1.2)
p value		1.000		0.211		0.671
2019						
<25 years	18	0 (0.0)	12	0 (0.0)	30	0 (0.0)
25-34 years	62	1 (1.6)	34	0 (0.0)	99	2 (2.0)
35-44 years	147	2 (1.4)	67	0 (0.0)	217	2 (0.9)
45+ years	173	8 (4.6)	44	0 (0.0)	218	8 (3.7)
p value		0.330		--		0.244
2020						
<25 years	11	0 (0.0)	7	1 (14.3)	18	1 (5.6)
25-34 years	42	3 (7.1)	20	0 (0.0)	62	3 (4.8)
35-44 years	103	4 (3.9)	40	0 (0.0)	144	4 (2.8)
45+ years	128	6 (4.7)	35	0 (0.0)	164	6 (3.7)
p value		0.814		0.069		0.621
2021						
<25 years	14	0 (0.0)	5	0 (0.0)	20	0 (0.0)
25-34 years	49	0 (0.0)	30	0 (0.0)	80	0 (0.0)
35-44 years	108	0 (0.0)	49	0 (0.0)	161	1 (0.6)
45+ years	133	7 (5.3)	61	0 (0.0)	194	7 (3.6)
p value		0.496		--		0.120

Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heroin	57	0 (0.0)	31	1 (3.2)	88	1 (1.1)
Methamphetamine	176	11 (6.3)	84	0 (0.0)	261	11 (4.2)
Other opioids	132	1 (0.8)	45	0 (0.0)	177	1 (0.6)
PIEDs	48	0 (0.0)	0	0 (0.0)	48	0 (0.0)
Other drugs	28	2 (7.1)	7	0 (0.0)	35	2 (5.7)
p value		0.011		0.228		0.045
2018						
Heroin	56	0 (0.0)	27	0 (0.0)	83	0 (0.0)
Methamphetamine	200	6 (3.0)	100	2 (2.0)	301	8 (2.7)
Other opioids	130	0 (0.0)	50	0 (0.0)	180	0 (0.0)
PIEDs	27	0 (0.0)	1	0 (0.0)	28	0 (0.0)
Other drugs	23	0 (0.0)	11	0 (0.0)	34	0 (0.0)
p value		0.218		0.719		0.119
2019						
Heroin	58	2 (3.5)	31	0 (0.0)	90	2 (2.2)
Methamphetamine	189	9 (4.8)	85	0 (0.0)	277	10 (3.6)
Other opioids	101	0 (0.0)	31	0 (0.0)	134	0 (0.0)
PIEDs	24	0 (0.0)	3	0 (0.0)	27	0 (0.0)
Other drugs	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
p value		0.131		--		0.138
2020						
Heroin	45	0 (0.0)	17	0 (0.0)	62	0 (0.0)
Methamphetamine	110	11 (10.0)	44	1 (2.3)	155	12 (7.7)
Other opioids	85	2 (2.4)	32	0 (0.0)	118	2 (1.7)
PIEDs	29	0 (0.0)	1	0 (0.0)	30	0 (0.0)
Other drugs	14	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		0.030		1.000		0.025
2021						
Heroin	48	0 (0.0)	22	0 (0.0)	71	0 (0.0)
Methamphetamine	108	5 (4.6)	82	0 (0.0)	193	6 (3.1)
Other opioids	94	2 (2.1)	33	0 (0.0)	129	2 (1.6)
PIEDs	34	0 (0.0)	0	0 (0.0)	34	0 (0.0)
Other drugs	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
p value		0.496		--		0.585

Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
<3 years	31	0 (0.0)	15	0 (0.0)	46	0 (0.0)
3 to 10 years	63	4 (6.4)	35	0 (0.0)	98	4 (4.1)
11+ years	347	10 (2.9)	117	1 (0.9)	465	11 (2.4)
p value		0.280		1.000		0.302
2018						
<3 years	28	1 (3.6)	13	0 (0.0)	41	1 (2.4)
3 to 10 years	61	2 (3.3)	34	0 (0.0)	95	2 (2.1)
11+ years	348	3 (0.9)	142	2 (1.4)	491	5 (1.0)
p value		0.126		1.000		0.268
2019						
<3 years	36	2 (5.6)	14	0 (0.0)	50	2 (4.0)
3 to 10 years	59	2 (3.4)	29	0 (0.0)	90	3 (3.3)
11+ years	285	7 (2.5)	110	0 (0.0)	399	7 (1.8)
p value		0.369		--		0.302
2020						
<3 years	24	0 (0.0)	8	0 (0.0)	32	0 (0.0)
3 to 10 years	42	5 (11.9)	18	1 (5.6)	60	6 (10.0)
11+ years	213	8 (3.8)	76	0 (0.0)	291	8 (2.8)
p value		0.053		0.255		0.025
2021						
<3 years	20	0 (0.0)	6	0 (0.0)	27	0 (0.0)
3 to 10 years	47	2 (4.3)	20	0 (0.0)	67	2 (3.0)
11+ years	228	5 (2.2)	112	0 (0.0)	345	6 (1.7)
p value		0.600		--		0.773

Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
No receptive sharing	337	11 (3.3)	129	1 (0.8)	467	12 (2.6)
Receptive sharing	55	1 (1.8)	28	0 (0.0)	83	1 (1.2)
p value		1.000		1.000		0.703
2018						
No receptive sharing	337	4 (1.2)	147	2 (1.4)	485	6 (1.2)
Receptive sharing	62	2 (3.2)	25	0 (0.0)	87	2 (2.3)
p value		0.236		1.000		0.350
2019						
No receptive sharing	321	9 (2.8)	130	0 (0.0)	456	10 (2.2)
Receptive sharing	40	1 (2.5)	15	0 (0.0)	56	1 (1.8)
p value		1.000		--		1.000
2020						
No receptive sharing	217	11 (5.1)	71	1 (1.4)	290	12 (4.1)
Receptive sharing	32	1 (3.1)	15	0 (0.0)	47	1 (2.1)
p value		1.000		1.000		1.000
2021						
No receptive sharing	225	7 (3.1)	95	0 (0.0)	324	8 (2.5)
Receptive sharing	32	0 (0.0)	19	0 (0.0)	51	0 (0.0)
p value		0.602		--		0.605

Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Less than daily	179	11 (6.2)	60	0 (0.0)	240	11 (4.6)
Daily or more	217	1 (0.5)	97	1 (1.0)	314	2 (0.6)
Not last month	40	2 (5.0)	10	0 (0.0)	50	2 (4.0)
p value		0.002		1.000		0.004
2018						
Less than daily	176	2 (1.1)	72	2 (2.8)	248	4 (1.6)
Daily or more	226	4 (1.8)	102	0 (0.0)	329	4 (1.2)
Not last month	27	0 (0.0)	13	0 (0.0)	40	0 (0.0)
p value		0.797		0.282		0.843
2019						
Less than daily	163	7 (4.3)	53	0 (0.0)	218	7 (3.2)
Daily or more	200	3 (1.5)	93	0 (0.0)	297	4 (1.4)
Not last month	37	1 (2.7)	10	0 (0.0)	47	1 (2.1)
p value		0.221		--		0.267
2020						
Less than daily	93	7 (7.5)	41	1 (2.4)	136	8 (5.9)
Daily or more	156	5 (3.2)	46	0 (0.0)	202	5 (2.5)
Not last month	32	1 (3.1)	14	0 (0.0)	46	1 (2.2)
p value		0.238		0.545		0.235
2021						
Less than daily	121	4 (3.3)	40	0 (0.0)	162	4 (2.5)
Daily or more	136	3 (2.2)	75	0 (0.0)	214	4 (1.9)
Not last month	42	0 (0.0)	29	0 (0.0)	73	0 (0.0)
p value		0.670		--		0.498

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No imprisonment	367	13 (3.5)	152	1 (0.7)	520	14 (2.7)
Imprisonment	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.704		1.000		1.000
2018						
No imprisonment	365	5 (1.4)	165	2 (1.2)	531	7 (1.3)
Imprisonment	55	1 (1.8)	16	0 (0.0)	71	1 (1.4)
p value		0.572		1.000		1.000
2019						
No imprisonment	334	11 (3.3)	133	0 (0.0)	472	12 (2.5)
Imprisonment	48	0 (0.0)	15	0 (0.0)	65	0 (0.0)
p value		0.372		--		0.377
2020						
No imprisonment	240	10 (4.2)	91	1 (1.1)	333	11 (3.3)
Imprisonment	33	3 (9.1)	6	0 (0.0)	39	3 (7.7)
p value		0.198		1.000		0.172
2021						
No imprisonment	252	7 (2.8)	126	0 (0.0)	383	8 (2.1)
Imprisonment	36	0 (0.0)	9	0 (0.0)	45	0 (0.0)
p value		0.602		--		1.000

Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Queensland	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No condom use	134	3 (2.2)	63	1 (1.6)	197	4 (2.0)
Condom use	49	4 (8.2)	18	0 (0.0)	68	4 (5.9)
p value		0.840		1.000		0.210
2018						
No condom use	145	3 (2.1)	84	0 (0.0)	229	3 (1.3)
Condom use	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		0.582		--		0.528
2019						
No condom use	128	6 (4.7)	65	0 (0.0)	196	6 (3.1)
Condom use	32	0 (0.0)	14	0 (0.0)	47	0 (0.0)
p value		0.601		--		0.600
2020						
No condom use	88	6 (6.8)	43	0 (0.0)	131	6 (4.6)
Condom use	21	1 (4.8)	5	0 (0.0)	26	1 (3.9)
p value		1.000		--		1.000
2021						
No condom use	106	1 (0.9)	54	0 (0.0)	160	1 (0.6)
Condom use	26	0 (0.0)	15	0 (0.0)	42	1 (2.4)
p value		1.000		--		0.373

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Queensland	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No sex work	413	13 (3.2)	146	1 (0.7)	559	14 (2.5)
Sex work	10	1 (10.0)	11	0 (0.0)	22	1 (4.6)
p value		0.288		1.000		0.444
2018						
No sex work	409	6 (1.5)	168	2 (1.2)	577	8 (1.4)
Sex work	14	0 (0.0)	14	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
2019						
No sex work	373	9 (2.4)	140	0 (0.0)	519	10 (1.9)
Sex work	13	2 (15.4)	7	0 (0.0)	21	2 (9.5)
p value		0.049		--		0.075
2020						
No sex work	268	10 (3.7)	91	1 (1.1)	361	11 (3.1)
Sex work	9	3 (33.3)	4	0 (0.0)	13	3 (23.1)
p value		0.006		1.000		0.010
2021						
No sex work	285	7 (2.5)	131	0 (0.0)	420	7 (1.7)
Sex work	8	0 (0.0)	5	0 (0.0)	14	1 (7.1)
p value		1.000		--		0.232

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Non Indigenous	358	11 (3.1)	135	1 (0.7)	493	12 (2.4)
Indigenous	69	3 (4.4)	30	0 (0.0)	100	3 (3.0)
p value		0.482		1.000		0.727
2018						
Non Indigenous	362	3 (0.8)	143	2 (1.4)	506	5 (1.0)
Indigenous	71	3 (4.2)	44	0 (0.0)	115	3 (2.6)
p value		0.058		1.000		0.170
2019						
Non Indigenous	314	8 (2.6)	129	0 (0.0)	448	9 (2.0)
Indigenous	83	3 (3.6)	27	0 (0.0)	112	3 (2.7)
p value		0.705		--		0.714
2020						
Non Indigenous	231	9 (3.9)	82	1 (1.2)	314	10 (3.2)
Indigenous	45	3 (6.7)	19	0 (0.0)	64	3 (4.7)
p value		0.421		1.000		0.468
2021						
Non Indigenous	247	6 (2.4)	114	0 (0.0)	364	6 (1.7)
Indigenous	49	1 (2.0)	26	0 (0.0)	78	2 (2.6)
p value		1.000		--		0.635

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
English speaking	425	14 (3.3)	159	1 (0.6)	584	15 (2.6)
Non-English speaking	13	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000
2018						
English speaking	425	6 (1.4)	183	0 (0.0)	608	6 (1.0)
Non-English speaking	11	0 (0.0)	6	2 (33.3)	18	2 (11.1)
p value		1.000		0.001		0.020
2019						
English speaking	383	11 (2.9)	153	0 (0.0)	542	12 (2.2)
Non-English speaking	17	0 (0.0)	4	0 (0.0)	22	0 (0.0)
p value		1.000		--		1.000
2020						
English speaking	276	13 (4.7)	101	1 (1.0)	379	14 (3.7)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		1.000		1.000
2021						
English speaking	292	7 (2.4)	143	0 (0.0)	439	8 (1.8)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	11	0 (0.0)
p value		1.000		--		1.000

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Australia	398	14 (3.5)	141	1 (0.7)	539	15 (2.8)
Other Oceania	13	0 (0.0)	17	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
Other	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
2018						
Australia	391	5 (1.3)	175	2 (1.1)	566	7 (1.2)
Other Oceania	16	0 (0.0)	3	0 (0.0)	20	0 (0.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	17	1 (5.9)	7	0 (0.0)	24	1 (4.2)
Other	11	0 (0.0)	4	0 (0.0)	15	0 (15.0)
p value		0.475		1.000		0.550
2019						
Australia	366	11 (3.0)	145	0 (0.0)	517	12 (2.3)
Other Oceania	9	0 (0.0)	2	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		1.000		--		1.000
2020						
Australia	252	12 (4.8)	95	1 (1.1)	349	13 (3.7)
Other Oceania	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
Other	7	0 (0.0)	1	0 (0.0)	8	0 (0.0)
p value		0.607		1.000		0.584
2021						
Australia	273	6 (2.2)	127	0 (0.0)	405	7 (1.7)
Other Oceania	7	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Other	10	1 (10.0)	4	0 (0.0)	14	1 (7.1)
p value		0.487		--		0.524

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	425	179 (42)	161	66 (41)	587	245 (42)
2018	436	182 (42)	188	84 (45)	625	266 (43)
2019	401	175 (44)	156	57 (37)	564	234 (41)
2020	283	104 (37)	102	42 (41)	387	146 (38)
2021	304	120 (39)	145	51 (35)	455	172 (38)
X ² p trend		0.251		0.188		0.076

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	343	142 (41)	113	46 (41)	456	188 (41)
Bisexual	26	17 (65)	27	12 (44)	53	29 (55)
Homosexual	24	7 (29)	8	2 (25)	33	9 (27)
p value		0.024		0.642		0.038
2018						
Heterosexual	364	160 (44)	136	61 (45)	500	221 (44)
Bisexual	25	8 (32)	36	17 (47)	61	25 (41)
Homosexual	21	7 (33)	3	1 (33)	25	8 (32)
p value		0.340		0.939		0.450
2019						
Heterosexual	322	142 (44)	94	34 (36)	418	178 (43)
Bisexual	24	11 (46)	36	14 (39)	62	25 (40)
Homosexual	21	6 (29)	5	3 (60)	27	9 (33)
p value		0.414		0.531		0.620
2020						
Heterosexual	244	92 (38)	69	30 (43)	313	122 (39)
Bisexual	13	2 (15)	21	10 (48)	36	12 (33)
Homosexual	9	1 (11)	3	0 (0)	12	1 (8)
p value		0.027		0.559		0.064
2021						
Heterosexual	267	111 (42)	110	39 (35)	379	151 (40)
Bisexual	18	5 (28)	24	7 (29)	42	12 (29)
Homosexual	15	3 (20)	6	4 (67)	24	7 (29)
p value		0.238		0.466		0.333

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	24	2 (8)	11	2 (18)	36	4 (11)
25-34 years	84	30 (36)	42	22 (52)	126	52 (41)
35-44 years	148	65 (44)	53	17 (32)	201	82 (41)
45+ years	168	82 (49)	55	25 (45)	223	107 (48)
p value		0.001		0.081		<0.001
2018						
<25 years	20	2 (10)	15	3 (20)	35	5 (14)
25-34 years	76	23 (30)	45	18 (40)	122	41 (34)
35-44 years	158	59 (37)	67	34 (51)	225	93 (41)
45+ years	181	97 (54)	61	29 (48)	242	126 (52)
p value		<0.001		0.153		<0.001
2019						
<25 years	18	5 (28)	12	2 (17)	30	7 (23)
25-34 years	62	16 (26)	34	11 (32)	99	28 (28)
35-44 years	147	66 (45)	67	26 (39)	217	93 (43)
45+ years	173	88 (51)	43	18 (42)	217	106 (49)
p value		0.003		0.412		0.001
2020						
<25 years	11	3 (27)	7	2 (29)	18	5 (28)
25-34 years	42	3 (7)	20	9 (45)	62	12 (19)
35-44 years	103	42 (41)	40	17 (43)	144	59 (41)
45+ years	127	56 (44)	35	14 (40)	163	70 (43)
p value		<0.001		0.921		0.005
2021						
<25 years	14	2 (14)	5	1 (20)	20	3 (15)
25-34 years	49	14 (29)	30	12 (40)	80	26 (33)
35-44 years	108	47 (44)	49	17 (35)	161	65 (40)
45+ years	133	57 (43)	61	21 (34)	194	78 (40)
p value		0.055		0.865		0.092

Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
<3 years	31	1 (3)	15	2 (13)	46	3 (7)
3 to 10 years	62	10 (16)	35	7 (20)	97	17 (18)
11+ years	318	161 (51)	111	57 (51)	430	218 (51)
p value		<0.001		<0.001		<0.001
2018						
<3 years	28	1 (4)	13	1 (8)	41	2 (5)
3 to 10 years	60	11 (18)	33	8 (24)	93	19 (20)
11+ years	333	164 (49)	137	73 (53)	470	237 (50)
p value		<0.001		<0.001		<0.001
2019						
<3 years	36	3 (8)	14	0 (0)	50	3 (6)
3 to 10 years	59	12 (20)	29	7 (24)	90	19 (21)
11+ years	285	151 (53)	109	50 (46)	398	203 (51)
p value		<0.001		<0.001		<0.001
2020						
<3 years	24	3 (13)	8	0 (0)	32	3 (9)
3 to 10 years	42	2 (5)	18	5 (28)	60	7 (12)
11+ years	212	96 (45)	76	37 (49)	290	133 (46)
p value		<0.001		0.008		<0.001
2021						
<3 years	20	0 (0)	6	0 (0)	27	0 (0)
3 to 10 years	47	4 (9)	20	4 (20)	67	8 (12)
11+ years	228	111 (49)	112	45 (40)	345	157 (46)
p value		<0.001		0.043		<0.001

Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No receptive sharing	34	1 (3)	407	182 (45)	449	186 (41)
Receptive sharing	8	2 (25)	68	36 (53)	80	41 (51)
p value		0.088		0.208		0.102
2018						
No receptive sharing	30	1 (3)	441	189 (43)	483	194 (40)
Receptive sharing	7	1 (14)	75	45 (60)	87	50 (57)
p value		0.347		0.006		0.003
2019						
No receptive sharing	41	2 (5)	401	175 (44)	455	183 (40)
Receptive sharing	3	0 (0)	48	31 (65)	56	33 (59)
p value		1.000		0.006		0.007
2020						
No receptive sharing	22	2 (9)	265	104 (39)	289	107 (37)
Receptive sharing	3	0 (0)	43	23 (53)	47	24 (51)
p value		0.77		0.078		0.067
2021						
No receptive sharing	19	0 (0)	295	113 (38)	324	118 (36)
Receptive sharing	1	0 (0)	49	26 (53)	51	26 (51)
p value		--		0.051		0.047

Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Queensland Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	4	1 (25)	77	44 (57)	82	46 (56)
Methamphetamine	20	1 (5)	230	87 (38)	255	91 (36)
Other opioids	6	1 (17)	160	93 (58)	170	96 (56)
PIEDs	12	0 (0)	34	2 (6)	47	2 (4)
Other drugs	4	0 (0)	23	7 (30)	30	8 (27)
p value		0.349		<0.001		<0.001
2018						
Heroin	3	1 (33)	74	36 (49)	80	40 (50)
Methamphetamine	25	1 (4)	262	99 (38)	297	102 (34)
Other opioids	1	0 (0)	172	99 (58)	177	101 (57)
PIEDs	7	0 (0)	19	0 (0)	27	0 (0)
Other drugs	4	0 (0)	27	16 (59)	33	17 (52)
p value		0.218		<0.001		<0.001
2019						
Heroin	1	0 (0)	87	55 (63)	90	57 (63)
Methamphetamine	31	1 (3)	230	71 (31)	275	75 (27)
Other opioids	4	1 (25)	125	78 (62)	133	82 (62)
PIEDs	11	0 (0)	15	0 (0)	27	0 (0)
Other drugs	3	1 (33)	29	16 (55)	36	18 (50)
p value		0.102		<0.001		<0.001
2020						
Heroin	0	0 (0)	61	37 (61)	61	37 (61)
Methamphetamine	14	3 (21)	138	29 (21)	155	34 (22)
Other opioids	3	0 (0)	112	57 (51)	116	58 (50)
PIEDs	11	0 (0)	18	1 (6)	30	1 (3)
Other drugs	3	0 (0)	17	13 (76)	20	13 (65)
p value		0.258		<0.001		<0.001
2021						
Heroin	0	0 (0)	71	41 (58)	71	41 (58)
Methamphetamine	17	0 (0)	168	46 (27)	190	49 (26)
Other opioids	2	0 (0)	120	64 (53)	127	65 (51)
PIEDs	6	0 (0)	27	3 (11)	34	3 (9)
Other drugs	1	0 (0)	15	7 (47)	20	9 (45)
p value		--		<0.001		<0.001

Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Less than daily	23	1 (4)	201	81 (40)	229	84 (37)
Daily or more	19	2 (11)	278	138 (50)	304	144 (47)
Not last month	4	0 (0)	45	14 (31)	51	15 (29)
p value		0.683		0.022		0.008
2018						
Less than daily	22	2 (9)	217	91 (42)	246	96 (39)
Daily or more	15	0 (0)	304	146 (48)	329	151 (46)
Not last month	3	0 (0)	34	13 (38)	40	13 (33)
p value		0.577		0.276		0.111
2019						
Less than daily	25	1 (4)	185	74 (40)	217	77 (35)
Daily or more	19	1 (5)	267	133 (50)	297	140 (47)
Not last month	6	1 (17)	34	13 (38)	47	15 (32)
p value		0.491		0.083		0.012
2020						
Less than daily	16	0 (0)	119	41 (34)	136	41 (30)
Daily or more	9	2 (22)	190	86 (45)	201	90 (45)
Not last month	7	1 (14)	37	10 (27)	46	12 (26)
p value		0.113		0.043		0.006
2021						
Less than daily	15	0 (0)	143	38 (27)	162	40 (25)
Daily or more	5	0 (0)	202	102 (51)	214	105 (49)
Not last month	7	0 (0)	61	22 (36)	73	24 (33)
p value		--		<0.001		<0.001

Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No imprisonment	40	2 (5)	450	190 (42)	501	196 (39)
Imprisonment	3	0 (0)	58	34 (59)	64	37 (58)
p value		1.000		0.018		0.004
2018						
No imprisonment	39	2 (5)	472	210 (44)	529	218 (41)
Imprisonment	2	0 (0)	65	35 (54)	70	37 (53)
p value		1.000		0.156		0.064
2019						
No imprisonment	46	3 (7)	402	170 (42)	471	181 (38)
Imprisonment	3	0 (0)	60	41 (68)	65	41 (63)
p value		1.000		<0.001		<0.001
2020						
No imprisonment	31	2 (6)	297	112 (38)	333	117 (35)
Imprisonment	1	1 (100)	37	17 (46)	38	18 (47)
p value		0.094		0.372		0.138
2021						
No imprisonment	25	0 (0)	345	124 (36)	383	129 (34)
Imprisonment	0	0 (0)	44	31 (70)	45	32 (71)
p value		--		<0.001		<0.001

Table 5.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	346	134 (39)	130	51 (39)	476	185 (39)
Indigenous	66	41 (62)	29	15 (52)	96	56 (58)
p value		<0.001		0.217		<0.001
2018						
Non Indigenous	362	145 (40)	142	63 (44)	505	208 (41)
Indigenous	69	35 (51)	44	21 (48)	113	56 (50)
p value		0.100		0.695		0.104
2019						
Non Indigenous	314	128 (41)	128	42 (33)	447	170 (38)
Indigenous	83	45 (54)	27	15 (56)	112	62 (55)
p value		0.028		0.026		0.001
2020						
Non Indigenous	231	76 (33)	82	33 (40)	314	109 (35)
Indigenous	44	26 (59)	19	9 (47)	63	35 (56)
p value		0.001		0.57		0.002
2021						
Non Indigenous	247	84 (34)	114	37 (32)	364	122 (34)
Indigenous	49	33 (67)	26	12 (46)	78	45 (58)
p value		<0.001		0.186		<0.001

Table 5.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	410	175 (43)	153	61 (40)	563	236 (42)
Non-English speaking	13	3 (23)	8	5 (63)	22	8 (36)
p value		0.253		0.274		0.604
2018						
English speaking	423	176 (42)	182	82 (45)	605	258 (43)
Non-English speaking	11	5 (45)	6	2 (33)	18	7 (39)
p value		0.798		0.693		0.751
2019						
English speaking	383	166 (43)	152	55 (36)	541	223 (41)
Non-English speaking	17	8 (47)	4	2 (50)	22	10 (45)
p value		0.762		0.623		0.693
2020						
English speaking	275	99 (36)	101	41 (41)	378	140 (37)
Non-English speaking	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.148		0.412		0.087
2021						
English speaking	292	118 (40)	143	49 (34)	439	167 (38)
Non-English speaking	8	2 (25)	1	1 (100)	11	4 (36)
p value		0.483		0.347		1.000

Table 5.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Australia	383	162 (42)	136	61 (45)	519	223 (43)
Other Oceania	13	6 (46)	16	3 (19)	30	9 (30)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	14	8 (57)	5	1 (20)	19	9 (47)
Other	9	1 (11)	2	0 (0)	11	1 (9)
p value		0.194		0.069		0.087
2018						
Australia	389	164 (42)	174	80 (46)	563	244 (43)
Other Oceania	16	6 (38)	3	1 (33)	20	7 (35)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	17	9 (53)	7	2 (29)	24	11 (46)
Other	11	2 (18)	4	1 (25)	15	3 (20)
p value		0.319		0.694		0.285
2019						
Australia	366	163 (45)	144	52 (36)	516	217 (42)
Other Oceania	9	5 (56)	2	1 (50)	12	6 (50)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	8	3 (38)	3	2 (67)	11	5 (45)
Other	12	2 (17)	5	2 (40)	17	4 (24)
p value		0.213		0.728		0.246
2020						
Australia	251	94 (37)	95	41 (43)	348	135 (39)
Other Oceania	11	4 (36)	4	1 (25)	15	5 (33)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	9	1 (11)	2	0 (0)	11	1 (9)
Other	7	4 (57)	1	0 (0)	8	4 (50)
p value		0.347		0.586		0.23
2021						
Australia	273	108 (40)	127	41 (32)	405	150 (37)
Other Oceania	7	3 (43)	3	3 (100)	11	6 (55)
Asia	2	0 (0)	1	1 (100)	3	1 (33)
UK & Ireland	8	3 (38)	3	1 (33)	11	4 (36)
Other	10	5 (50)	4	2 (50)	14	7 (50)
p value		0.857		0.049		0.637

HCV RNA prevalence

Table 5.4.1 HCV RNA prevalence by gender and survey year

Queensland	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*	368	83 (23)	141	20 (14)	509	103 (20)
2018*	196	43 (22)	84	16 (19)	280	59 (21)
2019*	371	62 (17)	144	16 (11)	522	79 (15)
2020	267	41 (15)	101	10 (10)	370	51 (14)
2021	291	32 (11)	143	15 (10)	440	48 (11)
X ² p trend		<0.001		0.128		<0.001

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 5.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Queensland	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
Heterosexual	303	68 (22)	101	10 (10)	404	78 (19)
Bisexual	24	9 (38)	20	5 (25)	44	14 (32)
Homosexual	14	1 (7)	7	2 (29)	21	3 (14)
p value		0.135		0.085		0.150
2018*						
Heterosexual	172	39 (23)	62	12 (19)	234	51 (22)
Bisexual	8	1 (13)	14	3 (21)	22	4 (18)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.332		0.680		0.228
2019*						
Heterosexual	300	50 (17)	86	9 (10)	388	61 (16)
Bisexual	23	6 (26)	34	4 (12)	58	10 (17)
Homosexual	19	1 (5)	5	1 (20)	25	2 (8)
p value		0.203		0.801		0.554
2020						
Heterosexual	230	34 (15)	67	6 (9)	297	40 (13)
Bisexual	13	1 (8)	22	4 (18)	37	5 (14)
Homosexual	9	0 (0)	3	0 (0)	12	0 (0)
p value		0.364		0.400		0.395
2021						
Heterosexual	256	30 (12)	108	11 (10)	366	42 (11)
Bisexual	17	2 (12)	24	1 (4)	41	3 (7)
Homosexual	15	0 (0)	6	2 (33)	24	2 (8)
p value		0.372		0.106		0.661

Table 5.4.3 HCV RNA prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	22	1 (5)	10	2 (20)	33	3 (9)
25-34 years	71	22 (31)	35	8 (23)	106	30 (28)
35-44 years	138	33 (24)	45	3 (7)	183	36 (20)
45+ years	135	27 (20)	50	7 (14)	185	34 (18)
p value		0.098		0.232		0.101
2018*						
<25 years	10	2 (20)	6	1 (17)	16	3 (19)
25-34 years	43	5 (12)	23	3 (13)	66	8 (12)
35-44 years	74	18 (24)	26	5 (19)	100	23 (23)
45+ years	69	18 (26)	28	7 (25)	97	25 (26)
p value		0.407		0.612		0.222
2019*						
<25 years	17	2 (12)	11	3 (27)	28	5 (18)
25-34 years	55	5 (9)	29	2 (7)	87	8 (9)
35-44 years	136	28 (21)	65	11 (17)	204	38 (19)
45+ years	162	28 (17)	39	0 (0)	202	28 (14)
p value		0.288		0.019		0.178
2020						
<25 years	10	1 (10)	8	1 (13)	18	2 (11)
25-34 years	36	1 (3)	20	5 (25)	56	6 (11)
35-44 years	100	24 (24)	39	4 (10)	140	28 (20)
45+ years	121	15 (12)	34	0 (0)	156	15 (10)
p value		0.011		0.030		0.061
2021						
<25 years	14	0 (0)	5	0 (0)	20	0 (0)
25-34 years	47	9 (19)	29	3 (10)	77	12 (16)
35-44 years	102	16 (16)	49	6 (12)	155	23 (15)
45+ years	128	7 (5)	60	6 (10)	188	13 (7)
p value		0.011		0.858		0.021

Table 5.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Queensland Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
<3 years	28	1 (4)	12	1 (8)	40	2 (5)
3 to 10 years	51	6 (12)	31	4 (13)	82	10 (12)
11+ years	278	72 (26)	98	15 (15)	376	87 (23)
p value		0.003		0.773		0.003
2018*						
<3 years	11	0 (0)	7	0 (0)	18	0 (0)
3 to 10 years	33	7 (21)	15	1 (7)	48	8 (17)
11+ years	149	36 (24)	59	14 (24)	208	50 (24)
p value		0.225		0.086		0.052
2019*						
<3 years	33	2 (6)	13	1 (8)	46	3 (7)
3 to 10 years	55	6 (11)	25	4 (16)	82	10 (12)
11+ years	264	52 (20)	102	11 (11)	370	64 (17)
p value		0.055		0.631		0.113
2020						
<3 years	22	0 (0)	8	0 (0)	30	0 (0)
3 to 10 years	40	1 (3)	19	4 (21)	59	5 (8)
11+ years	200	39 (20)	74	6 (8)	276	45 (16)
p value		0.003		0.150		0.021
2021						
<3 years	20	0 (0)	6	0 (0)	27	0 (0)
3 to 10 years	47	5 (11)	19	0 (0)	66	5 (8)
11+ years	215	27 (13)	111	15 (14)	331	43 (13)
p value		0.235		0.150		0.071

Table 5.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Queensland Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
No receptive sharing	281	64 (23)	109	17 (16)	390	81 (21)
Receptive sharing	47	12 (26)	23	3 (13)	70	15 (21)
p value		0.708		0.741		0.915
2018*						
No receptive sharing	150	29 (19)	60	12 (20)	210	42 (20)
Receptive sharing	29	11 (38)	15	3 (20)	45	14 (31)
p value		0.039		0.750		0.122
2019*						
No receptive sharing	296	50 (17)	118	13 (11)	418	64 (15)
Receptive sharing	37	8 (22)	14	2 (14)	52	10 (19)
p value		0.501		0.649		0.457
2020						
No receptive sharing	203	27 (13)	69	6 (9)	274	33 (12)
Receptive sharing	29	12 (41)	16	3 (19)	45	15 (33)
p value		<0.001		0.239		<0.001
2021						
No receptive sharing	214	24 (11)	94	10 (11)	312	35 (11)
Receptive sharing	30	6 (20)	19	1 (5)	49	7 (14)
p value		0.170		0.471		0.534

Table 5.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	39	13 (33)	25	7 (28)	65	20 (31)
Methamphetamine	147	37 (25)	71	10 (14)	219	47 (21)
Other opioids	114	24 (21)	38	3 (8)	152	27 (18)
PIEDs	41	2 (5)	0	0 (0)	41	2 (5)
Other drugs	23	6 (26)	7	0 (0)	30	6 (20)
p value		0.045		0.112		0.033
2018*						
Heroin	22	6 (27)	9	2 (22)	31	8 (26)
Methamphetamine	87	21 (24)	47	9 (19)	134	30 (22)
Other opioids	58	10 (17)	21	4 (19)	79	15 (19)
PIEDs	13	0 (0)	0	0 (0)	13	0 (0)
Other drugs	13	4 (31)	5	0 (0)	18	4 (22)
p value		0.271		0.677		0.420
2019*						
Heroin	55	10 (18)	28	2 (7)	83	12 (14)
Methamphetamine	175	28 (16)	76	7 (9)	254	35 (14)
Other opioids	92	19 (21)	30	3 (10)	124	23 (19)
PIEDs	21	0 (0)	3	0 (0)	24	0 (0)
Other drugs	27	6 (22)	7	2 (29)	34	8 (24)
p value		0.208		0.525		0.105
2020						
Heroin	44	7 (16)	18	1 (6)	62	8 (13)
Methamphetamine	103	15 (15)	43	3 (7)	147	18 (12)
Other opioids	78	15 (19)	30	1 (3)	109	16 (15)
PIEDs	27	0 (0)	1	0 (0)	28	0 (0)
Other drugs	11	3 (27)	8	5 (63)	19	8 (42)
p value		0.130		<0.001		0.001
2021						
Heroin	46	4 (9)	22	2 (9)	69	7 (10)
Methamphetamine	103	10 (10)	80	6 (8)	186	16 (9)
Other opioids	86	13 (15)	33	7 (21)	121	20 (17)
PIEDs	34	2 (6)	0	0 (0)	34	2 (6)
Other drugs	15	2 (13)	5	0 (0)	20	2 (10)
p value		0.571		0.149		0.208

Table 5.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Queensland	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Less than daily	149	34 (23)	52	8 (15)	201	42 (21)
Daily or more	183	44 (24)	80	12 (15)	263	56 (21)
Not last month	33	4 (12)	9	0 (0)	42	4 (10)
p value		0.441		0.420		0.281
2018*						
Less than daily	84	19 (23)	30	8 (27)	114	27 (24)
Daily or more	95	21 (22)	45	7 (16)	140	29 (21)
Not last month	14	2 (14)	6	0 (0)	20	2 (10)
p value		0.753		0.181		0.354
2019*						
Less than daily	152	21 (14)	46	4 (9)	200	26 (13)
Daily or more	182	38 (21)	88	11 (13)	273	48 (18)
Not last month	36	4 (11)	10	0 (0)	46	4 (9)
p value		0.142		0.469		0.162
2020						
Less than daily	88	12 (14)	40	2 (5)	130	14 (11)
Daily or more	144	27 (19)	46	7 (15)	190	34 (18)
Not last month	32	1 (3)	14	1 (7)	46	2 (4)
p value		0.074		0.269		0.027
2021						
Less than daily	115	9 (8)	40	2 (5)	156	11 (7)
Daily or more	129	21 (16)	73	9 (12)	205	31 (15)
Not last month	42	1 (2)	29	4 (14)	73	5 (7)
p value		0.017		0.392		0.025

Table 5.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Queensland	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No imprisonment	305	65 (21)	128	16 (13)	434	81 (19)
Imprisonment	47	14 (30)	7	3 (43)	54	17 (31)
p value		0.163		0.044		0.026
2018*						
No imprisonment	162	35 (22)	74	14 (19)	236	50 (21)
Imprisonment	27	7 (26)	7	1 (14)	35	8 (23)
p value		0.759		0.621		0.911
2019*						
No imprisonment	310	43 (14)	121	11 (9)	435	55 (13)
Imprisonment	45	14 (31)	14	3 (21)	61	18 (30)
p value		0.004		0.164		<0.001
2020						
No imprisonment	228	30 (13)	90	9 (10)	320	39 (12)
Imprisonment	30	9 (30)	6	1 (17)	36	10 (28)
p value		0.015		0.605		0.010
2021						
No imprisonment	243	21 (9)	124	13 (10)	372	34 (9)
Imprisonment	34	10 (29)	9	2 (22)	43	12 (28)
p value		<0.001		0.282		<0.001

Table 5.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Non Indigenous	298	61 (20)	113	13 (12)	411	74 (18)
Indigenous	59	22 (37)	26	7 (27)	85	29 (34)
p value		0.009		0.046		0.002
2018*						
Non Indigenous	159	34 (21)	65	11 (17)	224	45 (20)
Indigenous	33	9 (27)	18	4 (22)	52	14 (27)
p value		0.497		0.496		0.367
2019*						
Non Indigenous	290	39 (13)	118	9 (8)	412	48 (12)
Indigenous	78	23 (29)	26	6 (23)	105	30 (29)
p value		<0.001		0.018		<0.001
2020						
Non Indigenous	215	28 (13)	81	8 (10)	297	36 (12)
Indigenous	44	13 (30)	19	2 (11)	63	15 (24)
p value		0.006		0.932		0.016
2021						
Non Indigenous	236	18 (8)	112	12 (11)	351	31 (9)
Indigenous	47	14 (30)	26	3 (12)	76	17 (22)
p value		<0.001		0.903		0.001

Table 5.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
English speaking	354	82 (23)	134	17 (13)	488	99 (20)
Non-English speaking	12	1 (8)	7	3 (43)	19	4 (21)
p value		0.283		0.021		0.922
2018*						
English speaking	188	42 (22)	80	16 (20)	268	58 (22)
Non-English speaking	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.661		0.999		0.349
2019*						
English speaking	354	59 (17)	141	15 (11)	501	75 (15)
Non-English speaking	16	3 (19)	3	1 (33)	20	4 (20)
p value		0.843		0.190		0.521
2020						
English speaking	259	39 (15)	100	10 (10)	361	49 (14)
Non-English speaking	8	2 (25)	1	0 (0)	9	2 (22)
p value		0.442		0.739		0.457
2021						
English speaking	279	31 (11)	142	15 (11)	425	46 (11)
Non-English speaking	8	1 (13)	1	0 (0)	11	2 (18)
p value		0.902		0.731		0.441

Table 5.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Australia	326	74 (23)	120	17 (14)	447	91 (20)
Other Oceania	12	3 (25)	14	2 (14)	27	5 (19)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	13	4 (31)	4	1 (25)	17	5 (29)
Other	8	0 (0)	2	0 (0)	10	0 (0)
p value		0.454		0.849		0.370
2018*						
Australia	180	40 (22)	75	15 (20)	255	55 (22)
Other Oceania	6	1 (17)	1	0 (0)	7	1 (14)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	5	1 (20)	4	1 (25)	9	2 (22)
Other	3	1 (33)	4	0 (0)	7	1 (14)
p value		0.952		0.727		0.908
2019*						
Australia	338	61 (18)	132	15 (11)	476	77 (16)
Other Oceania	9	1 (11)	2	0 (0)	12	1 (8)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	8	0 (0)	3	0 (0)	11	0 (0)
Other	10	0 (0)	5	1 (20)	15	1 (7)
p value		0.323		0.853		0.377
2020						
Australia	237	35 (15)	94	10 (11)	333	45 (14)
Other Oceania	10	3 (30)	4	0 (0)	14	3 (21)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	8	0 (0)	2	0 (0)	10	0 (0)
Other	7	3 (43)	1	0 (0)	8	3 (38)
p value		0.148		0.843		0.229
2021						
Australia	261	27 (10)	126	13 (10)	392	41 (10)
Other Oceania	6	1 (17)	3	1 (33)	10	2 (20)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	8	1 (13)	3	0 (0)	11	1 (9)
Other	10	3 (30)	4	1 (25)	14	4 (29)
p value		0.379		0.576		0.224

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year

South Australia	2017	2018	2019	2020*	2021*
Number of sites	7	7	8	7	8
N° surveyed	N=270	N=321	N=326	N=20	N=210
Response rate (%)	54%	53%	57%	--	50%
Gender (%)					
Male	138 (51)	197 (61)	191 (59)	13 (65)	133 (63)
Female	127 (47)	123 (38)	134 (41)	7 (35)	70 (33)
Other	5 (2)	1 (<1)	1 (<1)	0 (0)	7 (3)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	190 (70)	248 (77)	257 (79)	16 (80)	166 (79)
Bisexual	37 (14)	30 (9)	27 (8)	1 (5)	23 (11)
Gay/Lesbian	25 (9)	20 (6)	19 (6)	0 (0)	10 (5)
Other	-- --	-- --	-- --	1 (5)	9 (4)
Not reported	18 (7)	23 (7)	23 (7)	2 (10)	2 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	210 (78)	264 (82)	251 (77)	17 (85)	138 (66)
Yes	49 (18)	51 (16)	67 (21)	3 (15)	55 (26)
Not reported	11 (4)	6 (2)	8 (2)	0 (0)	17 (8)
Region/country of birth (%)					
Australia	238 (88)	277 (86)	285 (87)	17 (85)	181 (86)
Other Oceania	3 (1)	4 (1)	5 (2)	0 (0)	3 (1)
Asia	2 (1)	6 (2)	6 (2)	0 (0)	3 (1)
UK & Ireland	12 (4)	21 (7)	20 (6)	3 (15)	12 (6)
Other	12 (4)	11 (3)	7 (2)	0 (0)	5 (2)
Not reported	3 (1)	2 (1)	3 (1)	0 (0)	6 (3)
Main language spoken at home by parents (%)					
English	255 (94)	293 (91)	312 (96)	20 (100)	200 (95)
Non-English	14 (5)	25 (8)	12 (4)	0 (0)	7 (3)
Not reported	1 (<1)	3 (1)	2 (1)	0 (0)	3 (1)
Age and time since first injection (years)					
<i>Median age</i>	43	43	44	48	45
<i>Age range</i>	18-69	18-71	19-72	32-62	19-78
<i>Age group (%)</i>					
<25 years	21 (8)	10 (3)	8 (2)	0 (0)	3 (1)
25+ years	249 (92)	310 (97)	315 (97)	20 (100)	206 (98)
Not reported	0 (0)	1 (<1)	3 (1)	0 (0)	1 (0)
<i>Median age first injection</i>					
<i>Age range</i>	18	18	18	21	19
<i>N° not reported</i>	17	11	23	0	10
<i>Median yrs since first injection</i>					
<i>Age range</i>	10-60	10-64	12-67	12-42	12-46
<i>Range</i>	22	23	24	27	25
<i>Years since first injection</i>					
<3 years	1-47	1-49	<1-52	<1-45	<1-62
3+ years	10 (4)	8 (2)	8 (2)	2 (10)	3 (1)
Not reported	243 (90)	302 (94)	295 (90)	18 (90)	196 (93)
Not reported	17 (6)	11 (3)	23 (7)	0 (0)	11 (5)
Imprisonment last year (%)					
No	224 (83)	261 (81)	267 (82)	19 (95)	176 (84)
Yes	32 (12)	33 (10)	32 (10)	1 (5)	20 (10)
Not reported	14 (5)	27 (8)	27 (8)	0 (0)	14 (7)
N° in prison					
Injected in prison	N=32	N=33	N=32	N=1	N=20
Injected in prison	6 (19)	9 (27)	6 (19)	0 (0)	2 (10)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

South Australia	2017	2018	2019	2020	2021
N° surveyed	N=270	N=321	N=326	N=20	N=210
Drug last injected (%)					
Cocaine	4 (1)	2 (1)	0 (0)	0 (0)	2 (1)
Methamphetamine	133 (49)	183 (57)	175 (54)	12 (60)	115 (55)
Heroin	89 (33)	98 (31)	79 (24)	5 (25)	57 (27)
Pharm. opioids	17 (6)	5 (2)	10 (3)	1 (5)	5 (2)
Methadone	11 (4)	16 (5)	33 (10)	1 (5)	9 (4)
Buprenorphine	2 (1)	2 (1)	1 (<1)	0 (0)	1 (0)
Buprenorphine/naloxone	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
PIEDs	2 (1)	0 (0)	2 (1)	0 (0)	5 (2)
More than one	8 (3)	13 (4)	17 (5)	1 (5)	16 (8)
Other	2 (1)	0 (0)	2 (1)	0 (0)	0 (0)
Not reported	1 (<1)	2 (1)	7 (2)	0 (0)	0 (0)
Ever injected opioids					
No	68 (25)	84 (26)	85 (26)	7 (35)	84 (40)
Yes	199 (74)	234 (73)	237 (73)	13 (65)	126 (60)
Not reported	3 (1)	3 (1)	4 (1)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	28 (10)	15 (5)	40 (12)	1 (5)	38 (18)
Less than weekly	37 (14)	56 (17)	49 (15)	5 (25)	43 (20)
Weekly not daily	69 (26)	94 (29)	83 (25)	4 (20)	40 (19)
Daily or more	130 (48)	151 (47)	143 (44)	10 (50)	83 (40)
Not reported	6 (2)	5 (2)	11 (3)	0 (0)	6 (3)
Present when someone injected for the first time in the last 12 months (%)					
No	208 (77)	252 (79)	255 (78)	19 (95)	175 (83)
Yes	59 (22)	57 (18)	53 (16)	1 (5)	26 (12)
Not reported	3 (1)	12 (4)	18 (6)	0 (0)	9 (4)
Overdosed in last 12 months					
No	220 (81)	258 (80)	282 (87)	18 (90)	185 (88)
Yes	44 (16)	49 (15)	26 (8)	2 (10)	15 (7)
Not reported	6 (2)	14 (4)	18 (6)	0 (0)	10 (5)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

South Australia	2017	2018	2019	2020	2021
N° injected last month	N=236	N=301	N=275	N=19	N=166
Places injected last month (%)					
All private	130 (55)	161 (53)	156 (57)	13 (68)	86 (52)
Any public	104 (44)	136 (45)	114 (41)	6 (32)	80 (48)
Not reported	2 (1)	4 (1)	5 (2)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	188 (80)	232 (77)	218 (79)	18 (95)	135 (81)
Most of the time	40 (17)	59 (20)	41 (15)	1 (5)	23 (14)
Half of the time	4 (2)	3 (1)	5 (2)	0 (0)	2 (1)
Some of the time	1 (<1)	1 (<1)	2 (1)	0 (0)	3 (2)
Not last month	1 (<1)	0 (0)	2 (1)	0 (0)	1 (1)
Not reported	2 (1)	6 (2)	7 (3)	0 (0)	2 (1)
Re-used someone else's used needle & syringe last month (%)					
None	194 (82)	258 (86)	224 (81)	19 (100)	141 (85)
Once	14 (6)	18 (6)	19 (7)	0 (0)	7 (4)
Twice	17 (7)	10 (3)	15 (5)	0 (0)	6 (4)
3-5 times	5 (2)	5 (2)	5 (2)	0 (0)	5 (3)
>5 times	2 (1)	6 (2)	5 (2)	0 (0)	4 (2)
Not reported	4 (2)	4 (1)	7 (3)	0 (0)	3 (2)
Number of people needle & syringe was re-used after last month (%)					
None	194 (82)	258 (86)	224 (81)	19 (100)	141 (85)
One	22 (9)	21 (7)	18 (7)	0 (0)	10 (6)
Two	2 (1)	3 (1)	5 (2)	0 (0)	3 (2)
Three to five	4 (2)	0 (0)	4 (1)	0 (0)	1 (1)
More than five	3 (1)	0 (0)	3 (1)	0 (0)	1 (1)
Don't know	5 (2)	7 (2)	8 (3)	0 (0)	5 (3)
Not reported	6 (3)	12 (4)	13 (5)	0 (0)	5 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	18 (8)	17 (6)	24 (9)	0 (0)	9 (5)
Casual sex partner	3 (1)	1 (<1)	1 (<1)	0 (0)	2 (1)
Close friend	11 (5)	9 (3)	8 (3)	0 (0)	9 (5)
Acquaintance	4 (2)	4 (1)	6 (2)	0 (0)	1 (1)
Other	3 (1)	1 (<1)	4 (1)	0 (0)	1 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	50 (21)	41 (14)	45 (16)	1 (5)	29 (17)
Water	48 (20)	62 (21)	56 (20)	1 (5)	36 (22)
Filter	23 (10)	23 (8)	24 (9)	0 (0)	11 (7)
Drug mix	22 (9)	32 (11)	22 (8)	1 (5)	11 (7)
None	155 (66)	208 (69)	184 (67)	16 (84)	107 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	183 (78)	250 (83)	231 (84)	18 (95)	138 (83)
Yes	50 (21)	44 (15)	38 (14)	1 (5)	25 (15)
Not reported	3 (1)	7 (2)	6 (2)	0 (0)	3 (2)
Source of needle acquisition					
Needle Syringe Program	210 (89)	266 (88)	238 (87)	16 (84)	142 (86)
Chemist/Pharmacy	45 (19)	60 (20)	44 (16)	3 (16)	25 (15)
Personal sources	32 (14)	53 (18)	43 (16)	4 (21)	18 (11)
Dispensing/Vending Machine	43 (18)	56 (19)	55 (20)	3 (16)	36 (22)
Other sources	4 (2)	4 (1)	3 (1)	0 (0)	3 (2)

Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year

South Australia	2017	2018	2019	2020	2021
N° surveyed	N=270	N=321	N=326	N=20	N=210
Ever any treatment/therapy for drug use (%)					
No	81 (30)	104 (32)	109 (33)	6 (30)	87 (41)
Yes	188 (70)	216 (67)	214 (66)	14 (70)	123 (59)
Not reported	1 (<1)	1 (<1)	3 (1)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	73 (27)	68 (21)	86 (26)	4 (20)	34 (16)
Previously	48 (18)	81 (25)	49 (15)	2 (10)	44 (21)
Never	142 (53)	160 (50)	181 (56)	13 (65)	120 (57)
Not reported	7 (3)	12 (4)	10 (3)	1 (5)	12 (6)
History of buprenorphine (Subutex®) treatment (%)					
Currently	17 (6)	13 (4)	10 (3)	2 (10)	8 (4)
Previously	78 (29)	86 (27)	70 (21)	6 (30)	56 (27)
Never	164 (61)	214 (67)	240 (74)	12 (60)	138 (66)
Not reported	11 (4)	8 (2)	6 (2)	0 (0)	8 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	23 (9)	22 (7)	21 (6)	2 (10)	24 (11)
Previously	71 (26)	69 (22)	57 (17)	5 (25)	44 (21)
Never	171 (63)	222 (69)	240 (74)	13 (65)	142 (68)
Not reported	5 (2)	8 (2)	8 (2)	0 (0)	0 (0)

Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

South Australia	2017	2018	2019	2020	2021
N° surveyed	N=270	N=321	N=326	N=20	N=210
Previous HIV test (%)					
Yes, ever	210 (78)	256 (80)	241 (74)	16 (80)	136 (65)
Yes, last year	122 (45)	149 (46)	124 (38)	8 (40)	59 (28)
>1 year ago	88 (33)	107 (33)	117 (36)	8 (40)	77 (37)
Never tested	55 (20)	52 (16)	60 (18)	4 (20)	63 (30)
Not reported	5 (2)	13 (4)	25 (8)	0 (0)	11 (5)
Previous HCV test (%)					
Yes, ever	220 (81)	241 (75)	241 (74)	17 (85)	139 (66)
Yes, last year	149 (55)	145 (45)	150 (46)	8 (40)	66 (31)
>1 year ago	71 (26)	96 (30)	91 (28)	9 (45)	73 (35)
Never tested	37 (14)	45 (14)	48 (15)	2 (10)	51 (24)
Not reported	13 (5)	35 (11)	37 (11)	1 (5)	20 (10)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=68	N=68	N=56	N=3	N=23
Antiviral treatment	34 (50)	44 (65)	41 (73)	3 (100)	18 (78)
No antiviral treatment	34 (50)	23 (34)	15 (27)	0 (0)	5 (22)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=64	N=53	N=38	N=1	N=11
Antiviral treatment	25 (39)	22 (42)	21 (55)	1 (100)	3 (27)
No antiviral treatment	39 (61)	30 (57)	17 (45)	0 (0)	8 (73)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

South Australia	2017	2018	2019	2020	2021
N° surveyed	N=270	N=321	N=326	N=20	N=210
Sex with a regular partner last month (%)					
No	130 (48)	152 (47)	165 (51)	14 (70)	116 (55)
Yes	131 (49)	145 (45)	134 (41)	6 (30)	83 (40)
Not reported	9 (3)	24 (7)	27 (8)	0 (0)	11 (5)
Condom used with regular partner last month (%)					
N° surveyed	N=131	N=145	N=134	N=6	N=83
Never	95 (73)	114 (79)	89 (66)	4 (67)	58 (70)
Sometimes	14 (11)	7 (5)	18 (13)	0 (0)	17 (20)
Every time	16 (12)	16 (11)	19 (14)	0 (0)	5 (6)
Not reported	6 (5)	8 (6)	8 (6)	2 (33)	3 (4)
Sex with other partner(s) last month (%)					
No	232 (86)	257 (80)	254 (78)	18 (90)	165 (79)
Yes	29 (11)	38 (12)	43 (13)	2 (10)	33 (16)
Not reported	9 (3)	26 (8)	29 (9)	0 (0)	12 (6)
Condom used with other partner(s) last month (%)					
N° surveyed	N=29	N=38	N=43	N=2	N=33
Never	7 (24)	7 (18)	21 (49)	1 (50)	17 (52)
Sometimes	11 (38)	14 (37)	10 (23)	1 (50)	5 (15)
Every time	9 (31)	17 (45)	12 (28)	0 (0)	9 (27)
Not reported	2 (7)	0 (0)	0 (0)	0 (0)	2 (6)
Sex work last month (%)					
No	232 (86)	286 (89)	279 (86)	20 (100)	186 (89)
Yes	22 (8)	15 (5)	12 (4)	0 (0)	11 (5)
Not reported	16 (6)	20 (6)	35 (11)	0 (0)	13 (6)
Condom used at last sex work (%)					
Yes	16 (73)	10 (67)	7 (58)	0 (0)	8 (73)

Table 6.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

South Australia	2020	2021
N° surveyed	N=20	N=210
More difficult to access sterile needles and syringes		
Yes	1 (5)	23 (11)
No	16 (80)	150 (71)
Not applicable	3 (15)	18 (9)
Not reported	0 (0)	19 (9)
Start depot buprenorphine		
Yes	0 (0)	5 (2)
No	14 (70)	131 (62)
Not applicable	5 (25)	50 (24)
Not reported	1 (5)	24 (11)
Access take home naloxone		
Yes	4 (20)	39 (19)
No	8 (40)	101 (48)
Not applicable	7 (35)	50 (24)
Not reported	1 (5)	20 (10)
Change illicit drug use		
Yes, increased	2 (10)	27 (13)
Yes, decreased	4 (20)	50 (24)
No change	14 (70)	110 (52)
Not reported	0 (0)	23 (11)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	3 (15)	25 (12)
No	8 (40)	112 (53)
Not applicable	8 (40)	49 (23)
Not reported	1 (5)	24 (11)
Inject own methadone/bupe/suboxone		
Yes	0 (0)	19 (9)
No	10 (50)	125 (60)
Not applicable	8 (40)	44 (21)
Not reported	2 (10)	22 (10)
COVID-19 vaccine uptake		
≥1 dose	-- --	93 (44)
COVID-19 vaccine doses		
One dose	-- --	44 (21)
Two doses	-- --	49 (23)
No doses	-- --	94 (45)
Not reported	-- --	23 (11)
Vaccine type		
Astra Zeneca	-- --	11 (5)
Pfizer	-- --	48 (23)
Don't know	-- --	20 (10)
Not reported	-- --	131 (62)
COVID-19 test		
Yes	4 (20)	70 (33)
No	15 (75)	93 (44)
Don't know	1 (5)	15 (7)
Not reported	0 (0)	32 (15)
Self-reported positive COVID-19 test result		
Yes	0 (0)	1 (<1)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and survey year

South Australia Survey year	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017	132	5 (3.8)	125	0 (0.0)	262	5 (1.9)
2018	193	2 (1.0)	122	0 (0.0)	315	2 (0.6)
2019	177	4 (2.3)	126	0 (0.0)	304	4 (1.3)
2020	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
2021	116	0 (0.0)	67	0 (0.0)	188	0 (0.0)
X ² p trend		0.059		--		0.089

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year

South Australia Sexual identity	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
Heterosexual	103	1 (1.0)	79	0 (0.0)	183	1 (0.6)
Bisexual	7	1 (14.3)	26	0 (0.0)	37	1 (2.7)
Homosexual	9	3 (33.3)	16	0 (0.0)	25	3 (12.0)
p value		0.001		--		0.005
2018						
Heterosexual	167	2 (1.2)	76	0 (0.0)	243	2 (0.8)
Bisexual	4	0 (0.0)	26	0 (0.0)	30	0 (0.0)
Homosexual	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
p value		1.000		--		1.000
2019						
Heterosexual	149	2 (1.3)	92	0 (0.0)	241	2 (0.8)
Bisexual	6	1 (16.7)	17	0 (0.0)	24	1 (4.2)
Homosexual	8	1 (12.5)	10	0 (0.0)	18	1 (5.6)
p value		0.037		--		0.106
2020						
Heterosexual	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Bisexual	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
Homosexual	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
p value		--		--		--
2021						
Heterosexual	100	0 (0.0)	49	0 (0.0)	149	0 (0.0)
Bisexual	7	0 (0.0)	14	0 (0.0)	22	0 (0.0)
Homosexual	7	0 (0.0)	0	0 (0.0)	8	0 (0.0)
p value		--		--		--

Table 6.2.3 HIV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<25 years	11	1 (9.1)	9	0 (0.0)	21	1 (4.8)
25-34 years	17	0 (0.0)	26	0 (0.0)	45	0 (0.0)
35-44 years	41	1 (2.4)	43	0 (0.0)	86	1 (1.2)
45+ years	63	3 (4.8)	47	0 (0.0)	110	3 (2.7)
p value		0.571		--		0.386
2018						
<25 years	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
25-34 years	34	1 (2.9)	20	0 (0.0)	54	1 (1.9)
35-44 years	65	0 (0.0)	48	0 (0.0)	113	0 (0.0)
45+ years	90	1 (1.1)	47	0 (0.0)	137	1 (0.7)
p value		0.468		--		0.495
2019						
<25 years	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
25-34 years	21	0 (0.0)	23	0 (0.0)	44	0 (0.0)
35-44 years	58	1 (1.7)	45	0 (0.0)	103	1 (1.0)
45+ years	92	3 (3.3)	55	0 (0.0)	148	3 (2.0)
p value		1.000		--		0.832
2020						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
35-44 years	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
45+ years	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)
p value		--		--		--
2021						
<25 years	3	0 (0.0)	0	0 (0.0)	3	0 (0.0)
25-34 years	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
35-44 years	37	0 (0.0)	28	0 (0.0)	67	0 (0.0)
45+ years	61	0 (0.0)	30	0 (0.0)	94	0 (0.0)
p value		--		--		--

Table 6.2.4 HIV antibody prevalence by last drug injected, gender and survey year

South Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heroin	40	1 (2.5)	46	0 (0.0)	86	1 (1.2)
Methamphetamine	61	4 (6.6)	65	0 (0.0)	128	4 (3.1)
Other opioids	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other drugs	10	0 (0.0)	4	0 (0.0)	17	0 (0.0)
p value		0.715		--		0.781
2018						
Heroin	66	0 (0.0)	32	0 (0.0)	98	0 (0.0)
Methamphetamine	102	2 (2.0)	79	0 (0.0)	181	2 (1.1)
Other opioids	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)
Other drugs	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		0.633		--		0.639
2019						
Heroin	41	0 (0.0)	32	0 (0.0)	74	0 (0.0)
Methamphetamine	94	3 (3.2)	67	0 (0.0)	161	3 (1.9)
Other opioids	29	1 (3.5)	14	0 (0.0)	43	1 (2.3)
Other drugs	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)
p value		0.723		--		0.608
2020						
Heroin	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
Methamphetamine	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
Other opioids	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
Other drugs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
p value		--		--		--
2021						
Heroin	32	0 (0.0)	18	0 (0.0)	52	0 (0.0)
Methamphetamine	59	0 (0.0)	41	0 (0.0)	102	0 (0.0)
Other opioids	10	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Other drugs	15	0 (0.0)	4	0 (0.0)	19	0 (0.0)
p value		--		--		--

Table 6.2.5 HIV antibody prevalence by years of injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
<3 years	6	1 (16.7)	4	0 (0.0)	10	1 (10.0)
3 to 10 years	21	1 (4.8)	23	0 (0.0)	47	1 (2.1)
11+ years	105	3 (2.9)	98	0 (0.0)	205	3 (1.5)
p value		0.143		--		0.144
2018						
<3 years	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
3 to 10 years	24	0 (0.0)	19	0 (0.0)	43	0 (0.0)
11+ years	166	2 (1.2)	98	0 (0.0)	264	2 (0.8)
p value		1.000		--		1.000
2019						
<3 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
3 to 10 years	16	0 (0.0)	20	0 (0.0)	36	0 (0.0)
11+ years	147	4 (2.7)	92	0 (0.0)	240	4 (1.7)
p value		1.000		--		1.000
2020						
<3 years	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
3 to 10 years	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
11+ years	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)
p value		--		--		--
2021						
<3 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
3 to 10 years	10	0 (0.0)	9	0 (0.0)	19	0 (0.0)
11+ years	98	0 (0.0)	54	0 (0.0)	157	0 (0.0)
p value		--		--		--

Table 6.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
No receptive sharing	94	2 (2.1)	91	0 (0.0)	188	2 (1.1)
Receptive sharing	19	2 (10.5)	16	0 (0.0)	37	2 (5.4)
p value		0.131		--		0.127
2018						
No receptive sharing	159	2 (1.3)	96	0 (0.0)	255	2 (0.8)
Receptive sharing	18	0 (0.0)	19	0 (0.0)	37	0 (0.0)
p value		1.000		--		1.000
2019						
No receptive sharing	125	3 (2.4)	84	0 (0.0)	210	3 (1.4)
Receptive sharing	24	0 (0.0)	15	0 (0.0)	39	0 (0.0)
p value		1.000		--		1.000
2020						
No receptive sharing	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
Receptive sharing	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
p value		--		--		--
2021						
No receptive sharing	82	0 (0.0)	42	0 (0.0)	127	0 (0.0)
Receptive sharing	12	0 (0.0)	5	0 (0.0)	19	0 (0.0)
p value		--		--		--

Table 6.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

South Australia		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
Less than daily	47	1 (2.1)	55	0 (0.0)	105	1 (1.0)	
Daily or more	68	3 (4.4)	53	0 (0.0)	123	3 (2.4)	
Not last month	13	1 (7.7)	15	0 (0.0)	28	1 (3.6)	
p value		0.390		--		0.414	
2018							
Less than daily	91	0 (0.0)	58	0 (0.0)	149	0 (0.0)	
Daily or more	89	2 (2.3)	58	0 (0.0)	147	2 (1.4)	
Not last month	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)	
p value		0.321		--		0.312	
2019							
Less than daily	67	1 (1.5)	57	0 (0.0)	125	1 (0.8)	
Daily or more	87	2 (2.3)	87	0 (0.0)	131	2 (1.5)	
Not last month	18	0 (0.0)	18	0 (0.0)	38	0 (0.0)	
p value		1.000		--		1.000	
2020							
Less than daily	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Daily or more	6	0 (0.0)	4	0 (0.0)	10	0 (0.0)	
Not last month	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		--		--		--	
2021							
Less than daily	42	0 (0.0)	30	0 (0.0)	75	0 (0.0)	
Daily or more	52	0 (0.0)	20	0 (0.0)	74	0 (0.0)	
Not last month	21	0 (0.0)	13	0 (0.0)	34	0 (0.0)	
p value		--		--		--	

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

South Australia		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No imprisonment	105	4 (3.8)	109	0 (0.0)	219	4 (1.8)	
Imprisonment	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)	
p value		0.571		--		0.466	
2018							
No imprisonment	150	1 (0.7)	106	0 (0.0)	256	1 (0.4)	
Imprisonment	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)	
p value		0.266		--		0.210	
2019							
No imprisonment	138	3 (2.2)	109	0 (0.0)	248	3 (1.2)	
Imprisonment	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)	
p value		1.000		--		1.000	
2020							
No imprisonment	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)	
Imprisonment	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		--		--		--	
2021							
No imprisonment	95	0 (0.0)	56	0 (0.0)	156	0 (0.0)	
Imprisonment	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)	
p value		--		--		--	

Table 6.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

South Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No condom use	36	2 (5.6)	54	0 (0.0)	91	2 (2.2)	
Condom use	18	2 (11.1)	12	0 (0.0)	30	2 (6.7)	
p value		0.594		--		0.256	
2018							
No condom use	56	1 (1.8)	57	0 (0.0)	113	1 (0.9)	
Condom use	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)	
p value		1.000		--		1.000	
2019							
No condom use	38	1 (2.6)	43	0 (0.0)	81	1 (1.2)	
Condom use	20	0 (0.0)	16	0 (0.0)	36	0 (0.0)	
p value		1.000		--		1.000	
2020							
No condom use	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)	
Condom use	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--		--	
2021							
No condom use	26	0 (0.0)	25	0 (0.0)	54	0 (0.0)	
Condom use	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)	
p value		--		--		--	

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year

South Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No sex work	114	4 (3.5)	107	0 (0.0)	225	4 (1.8)	
Sex work	10	1 (10.0)	10	0 (0.0)	21	1 (4.8)	
p value		0.348		--		0.362	
2018							
No sex work	180	2 (1.1)	101	0 (0.0)	281	2 (0.7)	
Sex work	3	0 (0.0)	11	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	
2019							
No sex work	154	3 (2.0)	107	0 (0.0)	262	3 (1.2)	
Sex work	4	0 (0.0)	7	0 (0.0)	11	0 (0.0)	
p value		1.000		--		1.000	
2020							
No sex work	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)	
Sex work	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--		--	
2021							
No sex work	109	0 (0.0)	53	0 (0.0)	166	0 (0.0)	
Sex work	2	0 (0.0)	8	0 (0.0)	11	0 (0.0)	
p value		--		--		--	

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Non Indigenous	105	4 (3.8)	96	0 (0.0)	205	4 (2.0)
Indigenous	23	1 (4.4)	22	0 (0.0)	46	1 (2.2)
p value		1.000		--		1.000
2018						
Non Indigenous	158	1 (0.6)	102	0 (0.0)	260	1 (0.4)
Indigenous	32	1 (3.1)	17	0 (0.0)	49	1 (2.0)
p value		0.309		--		0.292
2019						
Non Indigenous	135	4 (3.0)	98	0 (0.0)	233	4 (1.7)
Indigenous	39	0 (0.0)	24	0 (0.0)	64	0 (0.0)
p value		0.576		--		0.581
2020						
Non Indigenous	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)
Indigenous	3	0 (0.0)	0	0 (0.0)	3	0 (0.0)
p value		--		--		--
2021						
Non Indigenous	78	0 (0.0)	43	0 (0.0)	124	0 (0.0)
Indigenous	28	0 (0.0)	18	0 (0.0)	48	0 (0.0)
p value		--		--		--

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
English speaking	122	4 (3.3)	122	0 (0.0)	247	4 (1.6)
Non-English speaking	9	1 (11.1)	3	0 (0.0)	14	1 (7.1)
p value		0.303		--		0.243
2018						
English speaking	171	1 (0.6)	119	0 (0.0)	290	1 (0.3)
Non-English speaking	19	1 (5.3)	3	0 (0.0)	22	1 (4.6)
p value		0.190		--		0.136
2019						
English speaking	167	3 (1.8)	124	0 (0.0)	292	3 (1.0)
Non-English speaking	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.191		--		0.138
2020						
English speaking	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
Non-English speaking	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
p value		--		--		--
2021						
English speaking	110	0 (0.0)	63	0 (0.0)	178	0 (0.0)
Non-English speaking	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
p value		--		--		--

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
Australia	116	3 (2.6)	112	0 (0.0)	231	3 (1.3)	
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	3	1 (33.3)	8	0 (0.0)	11	1 (9.1)	
Other	9	0 (0.0)	1	0 (0.0)	12	0 (0.0)	
p value		0.169		--		0.236	
2018							
Australia	164	2 (1.2)	110	0 (0.0)	274	2 (0.7)	
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
Asia	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)	
UK & Ireland	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
p value		1.000		--		1.000	
2019							
Australia	153	4 (2.6)	113	0 (0.0)	267	4 (1.5)	
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
Asia	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)	
UK & Ireland	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)	
Other	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)	
p value		1.000		--		1.000	
2020							
Australia	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
Other Oceania	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
UK & Ireland	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Other	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--		--	
2021							
Australia	99	0 (0.0)	58	0 (0.0)	162	0 (0.0)	
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)	
UK & Ireland	7	0 (0.0)	3	0 (0.0)	10	0 (0.0)	
Other	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)	
p value		--		--		--	

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	128	60 (47)	125	54 (43)	258	115 (45)
2018	187	89 (48)	122	34 (28)	309	123 (40)
2019	175	82 (47)	126	43 (34)	302	125 (41)
2020	13	2 (15)	7	2 (29)	20	4 (20)
2021	116	36 (31)	67	20 (30)	188	57 (30)
X ² p trend		0.003		0.114		0.002

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	101	47 (47)	79	36 (46)	181	83 (46)
Bisexual	6	2 (33)	26	14 (54)	36	17 (47)
Homosexual	9	4 (44)	16	2 (13)	25	6 (24)
p value		0.915		0.019		0.107
2018						
Heterosexual	161	81 (50)	76	22 (29)	237	103 (43)
Bisexual	4	0 (0)	26	7 (27)	30	7 (23)
Homosexual	9	2 (22)	11	2 (18)	20	4 (20)
p value		0.045		0.847		0.019
2019						
Heterosexual	147	73 (50)	92	33 (36)	239	106 (44)
Bisexual	6	2 (33)	17	5 (29)	24	7 (29)
Homosexual	8	0 (0)	10	1 (10)	18	1 (6)
p value		0.009		0.256		0.001
2020						
Heterosexual	11	2 (18)	5	1 (20)	16	3 (19)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.333		0.405
2021						
Heterosexual	100	31 (31)	49	13 (27)	149	44 (30)
Bisexual	7	4 (57)	14	4 (29)	22	8 (36)
Homosexual	7	1 (14)	0	0 (0)	8	1 (13)
p value		0.361		0.749		0.828

Table 6.3.3 HCV antibody prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	11	0 (0)	9	2 (22)	21	2 (10)
25-34 years	17	4 (24)	26	8 (31)	45	13 (29)
35-44 years	38	20 (53)	43	22 (51)	83	42 (51)
45+ years	62	36 (58)	47	22 (47)	109	58 (53)
p value		<0.001		0.220		<0.001
2018						
<25 years	4	0 (0)	6	0 (0)	10	0 (0)
25-34 years	33	9 (27)	20	4 (20)	53	13 (25)
35-44 years	63	31 (49)	48	15 (31)	111	46 (41)
45+ years	87	49 (56)	47	15 (32)	134	64 (48)
p value		0.006		0.368		0.001
2019						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	21	7 (33)	23	4 (17)	44	11 (25)
35-44 years	57	20 (35)	45	15 (33)	102	35 (34)
45+ years	91	54 (59)	55	23 (42)	147	77 (52)
p value		0.008		0.195		0.002
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	4	0 (0)	2	0 (0)	6	0 (0)
45+ years	8	2 (25)	5	2 (40)	13	4 (31)
p value		0.590		1.000		0.404
2021						
<25 years	3	1 (33)	0	0 (0)	3	1 (33)
25-34 years	15	2 (13)	9	2 (22)	24	4 (17)
35-44 years	37	16 (43)	28	9 (32)	67	25 (37)
45+ years	61	17 (28)	30	9 (30)	94	27 (29)
p value		0.142		0.936		0.232

Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
<3 years	6	1 (17)	4	1 (25)	10	2 (20)
3 to 10 years	21	1 (5)	23	6 (26)	47	8 (17)
11+ years	90	51 (57)	93	46 (49)	185	97 (52)
p value		<0.001		0.101		<0.001
2018						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	24	3 (13)	19	2 (11)	43	5 (12)
11+ years	154	82 (53)	96	32 (33)	250	114 (46)
p value		<0.001		0.053		<0.001
2019						
<3 years	3	0 (0)	4	0 (0)	7	0 (0)
3 to 10 years	16	2 (13)	20	7 (35)	36	9 (25)
11+ years	145	74 (51)	92	33 (36)	238	107 (45)
p value		0.002		0.466		0.005
2020						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	10	2 (20)	7	2 (29)	17	4 (24)
p value		1.000		--		1.000
2021						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	10	3 (30)	9	0 (0)	19	3 (16)
11+ years	98	28 (29)	54	19 (35)	157	48 (31)
p value		0.405		0.064		0.256

Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No receptive sharing	6	2 (33)	173	75 (43)	185	79 (43)
Receptive sharing	4	0 (0)	29	15 (52)	36	17 (47)
p value		0.467		0.401		0.617
2018						
No receptive sharing	4	0 (0)	240	94 (39)	249	97 (39)
Receptive sharing	3	0 (0)	32	18 (56)	37	19 (51)
p value		--		0.065		0.152
2019						
No receptive sharing	5	0 (0)	193	83 (43)	209	90 (43)
Receptive sharing	0	0 (0)	35	12 (34)	38	13 (34)
p value		--		0.336		0.309
2020						
No receptive sharing	2	0 (0)	17	4 (24)	19	4 (21)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	2	1 (50)	118	40 (34)	127	44 (35)
Receptive sharing	0	0 (0)	17	4 (24)	19	5 (26)
p value		--		0.581		0.473

Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

South Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	1	1 (100)	80	49 (61)	83	51 (61)
Methamphetamine	7	1 (14)	113	36 (32)	126	40 (32)
Other opioids	0	0 (0)	26	15 (58)	30	17 (57)
Other drugs	2	0 (0)	10	4 (40)	13	4 (31)
p value		0.098		<0.001		<0.001
2018						
Heroin	1	0 (0)	92	48 (52)	95	50 (53)
Methamphetamine	7	0 (0)	163	53 (33)	174	54 (31)
Other opioids	0	0 (0)	21	11 (52)	21	11 (52)
Other drugs	0	0 (0)	12	4 (33)	13	5 (38)
p value		--		0.012		0.004
2019						
Heroin	0	0 (0)	69	43 (62)	72	46 (64)
Methamphetamine	6	0 (0)	141	40 (28)	157	44 (28)
Other opioids	0	0 (0)	40	19 (48)	41	20 (49)
Other drugs	1	0 (0)	17	10 (59)	20	10 (50)
p value		--		<0.001		<0.001
2020						
Heroin	0	0 (0)	5	2 (40)	5	2 (40)
Methamphetamine	2	0 (0)	10	2 (20)	12	2 (17)
Other opioids	0	0 (0)	2	0 (0)	2	0 (0)
Other drugs	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.615		0.555
2021						
Heroin	0	0 (0)	47	20 (43)	51	22 (43)
Methamphetamine	2	1 (50)	92	20 (22)	99	23 (23)
Other opioids	0	0 (0)	13	4 (31)	14	5 (36)
Other drugs	0	0 (0)	19	5 (26)	19	5 (26)
p value		--		0.083		0.083

Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Less than daily	6	1 (17)	94	42 (45)	105	44 (42)
Daily or more	4	1 (25)	110	49 (45)	119	54 (45)
Not last month	0	0 (0)	25	13 (52)	28	14 (50)
p value		1.000		0.782		0.717
2018						
Less than daily	2	0 (0)	141	56 (40)	147	58 (39)
Daily or more	5	0 (0)	135	58 (43)	143	60 (42)
Not last month	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.392		0.335
2019						
Less than daily	3	0 (0)	116	44 (38)	124	47 (38)
Daily or more	3	0 (0)	118	52 (44)	130	57 (44)
Not last month	1	0 (0)	33	16 (48)	38	16 (42)
p value		--		0.457		0.624
2020						
Less than daily	2	0 (0)	7	2 (29)	9	2 (22)
Daily or more	0	0 (0)	10	2 (20)	10	2 (20)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2021						
Less than daily	1	0 (0)	72	17 (24)	75	18 (24)
Daily or more	1	1 (100)	66	29 (44)	74	33 (45)
Not last month	0	0 (0)	33	3 (9)	34	4 (12)
p value		1.000		0.001		0.001

Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

South Australia	<3 years		3+ years		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No imprisonment	8	2 (25)	197	90 (46)	217	98 (45)
Imprisonment	2	0 (0)	25	9 (36)	28	10 (36)
p value		1.000		0.359		0.343
2018						
No imprisonment	6	0 (0)	241	93 (39)	251	96 (38)
Imprisonment	2	0 (0)	29	16 (55)	31	16 (52)
p value		--		0.086		0.151
2019						
No imprisonment	5	0 (0)	222	92 (41)	246	101 (41)
Imprisonment	1	0 (0)	30	15 (50)	32	15 (47)
p value		--		0.373		0.530
2020						
No imprisonment	2	0 (0)	17	4 (24)	19	4 (21)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2021						
No imprisonment	1	0 (0)	149	43 (29)	156	47 (30)
Imprisonment	0	0 (0)	16	1 (6)	19	1 (5)
p value		--		0.072		0.027

Table 6.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	103	48 (47)	96	43 (45)	203	91 (45)
Indigenous	21	10 (48)	22	9 (41)	44	20 (45)
p value		0.932		0.741		0.940
2018						
Non Indigenous	154	65 (42)	102	31 (30)	256	96 (38)
Indigenous	30	22 (73)	17	3 (18)	47	25 (53)
p value		0.002		0.389		0.043
2019						
Non Indigenous	133	65 (49)	98	33 (34)	231	98 (42)
Indigenous	39	14 (36)	24	9 (38)	64	23 (36)
p value		0.153		0.724		0.351
2020						
Non Indigenous	10	2 (20)	7	2 (29)	17	4 (24)
Indigenous	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		--		1.000
2021						
Non Indigenous	78	20 (26)	43	12 (28)	124	32 (26)
Indigenous	28	12 (43)	18	6 (33)	48	19 (40)
p value		0.089		0.672		0.076

Table 6.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	118	55 (47)	122	54 (44)	243	110 (45)
Non-English speaking	9	4 (44)	3	0 (0)	14	4 (29)
p value		0.900		0.258		0.276
2018						
English speaking	167	81 (49)	119	34 (29)	286	115 (40)
Non-English speaking	17	8 (47)	3	0 (0)	20	8 (40)
p value		0.910		0.559		0.985
2019						
English speaking	165	79 (48)	124	42 (34)	290	121 (42)
Non-English speaking	9	3 (33)	2	1 (50)	11	4 (36)
p value		0.503		1.000		1.000
2020						
English speaking	13	2 (15)	7	2 (29)	20	4 (20)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	110	35 (32)	63	19 (30)	178	55 (31)
Non-English speaking	3	1 (33)	4	1 (25)	7	2 (29)
p value		1.000		1.000		1.000

Table 6.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017							
Australia	113	54 (48)	112	47 (42)	228	102 (45)	
Other Oceania	1	1 (100)	2	1 (50)	3	2 (67)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	2	1 (50)	8	4 (50)	10	5 (50)	
Other	9	2 (22)	1	0 (0)	12	2 (17)	
p value		0.312		0.846		0.273	
2018							
Australia	159	75 (47)	110	30 (27)	269	105 (39)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	6	4 (67)	0	0 (0)	6	4 (67)	
UK & Ireland	12	7 (58)	8	3 (38)	20	10 (50)	
Other	7	3 (43)	2	0 (0)	9	3 (33)	
p value		0.592		0.660		0.547	
2019							
Australia	152	69 (45)	113	38 (34)	266	107 (40)	
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)	
Asia	5	1 (20)	1	1 (100)	6	2 (33)	
UK & Ireland	10	7 (70)	8	3 (38)	18	10 (56)	
Other	4	2 (50)	2	1 (50)	6	3 (50)	
p value		0.426		0.600		0.656	
2020							
Australia	12	2 (17)	5	1 (20)	17	3 (18)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	2	1 (50)	3	1 (33)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		0.509	
2021							
Australia	99	29 (29)	58	14 (24)	162	44 (27)	
Other Oceania	1	1 (100)	2	2 (100)	3	3 (100)	
Asia	2	1 (50)	1	1 (100)	3	2 (67)	
UK & Ireland	7	2 (29)	3	2 (67)	10	4 (40)	
Other	3	0 (0)	2	1 (50)	5	1 (20)	
p value		0.419		0.013		0.029	

HCV RNA prevalence

Table 6.4.1 HCV RNA prevalence by gender and survey year

South Australia	Male		Female		Total	
Survey year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*	104	30 (29)	94	21 (22)	201	51 (26)
2018*	87	21 (24)	56	8 (14)	143	29 (20)
2019*	117	18 (15)	85	5 (6)	203	23 (11)
2020	9	1 (11)	5	0 (0)	14	1 (7)
2021	87	16 (18)	54	5 (9)	146	22 (15)
X ² p trend		0.040		0.006		0.003

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 6.4.2 HCV RNA prevalence by sexual identity, gender and survey year

South Australia	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017*						
Heterosexual	84	26 (31)	59	14 (24)	143	40 (28)
Bisexual	7	1 (14)	19	4 (21)	29	5 (17)
Homosexual	5	1 (20)	14	3 (21)	19	4 (21)
p value		0.778		0.918		0.521
2018*						
Heterosexual	66	17 (26)	35	6 (17)	100	23 (23)
Bisexual	4	0 (0)	12	1 (8)	16	1 (6)
Homosexual	8	0 (0)	5	0 (0)	14	0 (0)
p value		0.178		0.369		0.037
2019*						
Heterosexual	96	15 (16)	58	4 (7)	155	19 (12)
Bisexual	5	1 (20)	12	0 (0)	18	1 (6)
Homosexual	8	0 (0)	9	0 (0)	17	0 (0)
p value		0.492		0.444		0.221
2020						
Heterosexual	7	1 (14)	4	0 (0)	11	1 (9)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		0.753
2021						
Heterosexual	76	14 (18)	38	3 (8)	114	17 (15)
Bisexual	4	2 (50)	13	1 (8)	18	3 (17)
Homosexual	5	0 (0)	0	0 (0)	6	0 (0)
p value		0.156		0.981		0.576

Table 6.4.3 HCV RNA prevalence by age group, gender and survey year

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	6	1 (17)	5	1 (20)	13	2 (15)
25-34 years	12	1 (8)	20	2 (10)	32	3 (9)
35-44 years	40	15 (38)	28	10 (36)	70	25 (36)
45+ years	45	13 (29)	41	8 (20)	86	21 (24)
p value		0.273		0.247		0.560
2018*						
<25 years	1	0 (0)	4	0 (0)	6	0 (0)
25-34 years	23	5 (22)	14	3 (21)	37	8 (22)
35-44 years	30	7 (23)	23	5 (22)	53	12 (23)
45+ years	33	9 (27)	14	0 (0)	47	9 (19)
p value		0.903		0.155		0.630
2019*						
<25 years	2	0 (0)	3	0 (0)	5	0 (0)
25-34 years	17	2 (12)	16	2 (13)	33	4 (12)
35-44 years	37	3 (8)	27	1 (4)	63	4 (6)
45+ years	60	13 (22)	39	2 (5)	100	15 (15)
p value		0.307		0.680		0.322
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	0	0 (0)	0	0 (0)
35-44 years	3	0 (0)	1	0 (0)	4	0 (0)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.501		--		0.525
2021						
<25 years	3	1 (33)	0	0 (0)	3	1 (33)
25-34 years	11	2 (18)	9	1 (11)	20	3 (15)
35-44 years	28	5 (18)	20	1 (5)	50	6 (12)
45+ years	45	8 (18)	25	3 (12)	73	12 (16)
p value		0.927		0.707		0.739

Table 6.4.4 HCV RNA prevalence by years since first injection, gender and survey year

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	4	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	16	2 (13)	13	2 (15)	30	4 (13)
11+ years	74	23 (31)	74	18 (24)	150	41 (27)
p value		0.162		0.547		0.092
2018*						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	10	0 (0)	12	1 (8)	22	1 (5)
11+ years	72	19 (26)	42	7 (17)	114	26 (23)
p value		0.196		0.565		0.074
2019*						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	10	0 (0)	15	3 (20)	25	3 (12)
11+ years	97	18 (19)	62	1 (2)	160	19 (12)
p value		0.291		0.016		0.719
2020						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	8	1 (13)	5	0 (0)	13	1 (8)
p value		0.708		--		0.773
2021						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	8	3 (38)	8	1 (13)	16	4 (25)
11+ years	73	11 (15)	42	4 (10)	120	16 (13)
p value		0.031		0.915		0.183

Table 6.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

South Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	75	23 (31)	68	13 (19)	146	36 (25)
Receptive sharing	16	4 (25)	13	1 (8)	30	5 (17)
p value		0.619		0.443		0.394
2018*						
No receptive sharing	70	16 (23)	42	6 (14)	112	22 (20)
Receptive sharing	8	4 (50)	11	1 (9)	20	5 (25)
p value		0.127		0.519		0.611
2019*						
No receptive sharing	88	15 (17)	58	4 (7)	147	19 (13)
Receptive sharing	12	2 (17)	12	0 (0)	23	2 (9)
p value		0.983		0.347		0.552
2020						
No receptive sharing	8	1 (13)	5	0 (0)	13	1 (8)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	62	16 (26)	33	4 (12)	98	20 (20)
Receptive sharing	7	0 (0)	4	0 (0)	13	1 (8)
p value		0.125		0.461		0.271

Table 6.4.6 HCV RNA prevalence by last drug injected, gender and survey year

South Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	33	11 (33)	38	13 (34)	72	24 (33)
Methamphetamine	41	11 (27)	44	6 (14)	87	17 (20)
Other opioids	18	5 (28)	8	1 (13)	26	6 (23)
Other drugs	8	3 (38)	2	0 (0)	12	3 (25)
p value		0.946		0.155		0.308
2018*						
Heroin	28	5 (18)	16	2 (13)	44	7 (16)
Methamphetamine	44	11 (25)	35	4 (11)	79	15 (19)
Other opioids	8	3 (38)	3	2 (67)	11	5 (45)
Other drugs	4	1 (25)	2	0 (0)	6	1 (17)
p value		0.810		0.065		0.254
2019*						
Heroin	24	5 (21)	23	2 (9)	48	7 (15)
Methamphetamine	65	8 (12)	43	2 (5)	109	10 (9)
Other opioids	18	3 (17)	10	1 (10)	29	4 (14)
Other drugs	6	2 (33)	5	0 (0)	11	2 (18)
p value		0.529		0.826		0.671
2020						
Heroin	3	0 (0)	1	0 (0)	4	0 (0)
Methamphetamine	4	1 (25)	3	0 (0)	7	1 (14)
Other opioids	1	0 (0)	1	0 (0)	2	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.704		--		0.783
2021						
Heroin	21	5 (24)	14	2 (14)	37	7 (19)
Methamphetamine	51	9 (18)	29	1 (3)	82	10 (12)
Other opioids	8	1 (13)	3	0 (0)	12	2 (17)
Other drugs	7	1 (14)	4	1 (25)	11	2 (18)
p value		0.875		0.334		0.784

Table 6.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

South Australia	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Less than daily	33	8 (24)	43	8 (19)	78	16 (21)
Daily or more	60	19 (32)	38	7 (18)	99	26 (26)
Not last month	8	1 (13)	11	6 (55)	19	8 (42)
p value		0.599		0.025		0.267
2018*						
Less than daily	40	6 (15)	30	3 (10)	70	9 (13)
Daily or more	42	14 (33)	23	4 (17)	66	19 (29)
Not last month	3	1 (33)	2	0 (0)	5	1 (20)
p value		0.165		0.618		0.104
2019*						
Less than daily	51	5 (10)	43	1 (2)	95	6 (6)
Daily or more	51	12 (24)	29	3 (10)	80	15 (19)
Not last month	12	1 (8)	10	1 (10)	23	2 (9)
p value		0.128		0.330		0.033
2020						
Less than daily	3	0 (0)	2	0 (0)	5	0 (0)
Daily or more	5	1 (20)	3	0 (0)	8	1 (13)
Not last month	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.638		--		0.668
2021						
Less than daily	37	6 (16)	25	2 (8)	65	8 (12)
Daily or more	32	10 (31)	14	2 (14)	48	13 (27)
Not last month	18	0 (0)	11	0 (0)	29	0 (0)
p value		0.021		0.426		0.004

Table 6.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

South Australia	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No imprisonment	82	21 (26)	84	20 (24)	169	41 (24)
Imprisonment	12	5 (42)	6	0 (0)	18	5 (28)
p value		0.258		0.135		0.792
2018*						
No imprisonment	70	14 (20)	49	7 (14)	119	21 (18)
Imprisonment	8	5 (63)	3	0 (0)	12	5 (42)
p value		0.010		0.413		0.035
2019*						
No imprisonment	86	13 (15)	71	5 (7)	158	18 (11)
Imprisonment	17	2 (12)	8	0 (0)	24	2 (8)
p value		0.750		0.440		0.639
2020						
No imprisonment	9	1 (11)	5	0 (0)	14	1 (7)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No imprisonment	71	11 (15)	46	2 (4)	122	14 (11)
Imprisonment	9	0 (0)	5	0 (0)	14	0 (0)
p value		0.204		0.634		0.181

Table 6.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

South Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
Non Indigenous	80	24 (30)	75	20 (27)	159	44 (28)	
Indigenous	21	5 (24)	13	1 (8)	34	6 (18)	
p value		0.682		0.238		0.336	
2018*							
Non Indigenous	72	15 (21)	47	8 (17)	119	23 (19)	
Indigenous	14	5 (36)	7	0 (0)	21	5 (24)	
p value		0.204		0.205		0.554	
2019*							
Non Indigenous	89	14 (16)	67	4 (6)	157	18 (11)	
Indigenous	26	4 (15)	15	1 (7)	42	5 (12)	
p value		0.956		0.981		0.962	
2020							
Non Indigenous	7	1 (14)	5	0 (0)	12	1 (8)	
Indigenous	2	0 (0)	0	0 (0)	2	0 (0)	
p value		0.571		--		0.672	
2021							
Non Indigenous	55	9 (16)	34	4 (12)	92	13 (14)	
Indigenous	25	5 (20)	17	0 (0)	44	6 (14)	
p value		0.692		0.141		0.938	

Table 6.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

South Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
English speaking	96	26 (27)	92	21 (23)	189	47 (25)	
Non-English speaking	7	3 (43)	2	0 (0)	11	3 (27)	
p value		0.202		0.355		0.635	
2018*							
English speaking	74	18 (24)	54	8 (15)	129	26 (20)	
Non-English speaking	11	3 (27)	2	0 (0)	13	3 (23)	
p value		0.903		0.564		0.824	
2019*							
English speaking	112	18 (16)	84	5 (6)	197	23 (12)	
Non-English speaking	4	0 (0)	1	0 (0)	5	0 (0)	
p value		0.383		0.803		0.416	
2020							
English speaking	9	1 (11)	5	0 (0)	14	1 (7)	
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
2021							
English speaking	84	15 (18)	51	4 (8)	140	20 (14)	
Non-English speaking	2	1 (50)	3	1 (33)	5	2 (40)	
p value		0.248		0.139		0.115	

Table 6.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
Australia	90	26 (29)	84	20 (24)	176	46 (26)	
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	3	0 (0)	7	0 (0)	10	0 (0)	
Other	7	1 (14)	1	0 (0)	9	1 (11)	
p value		0.393		0.404		0.231	
2018*							
Australia	73	18 (25)	52	8 (15)	125	26 (21)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	3	1 (33)	0	0 (0)	3	1 (33)	
UK & Ireland	5	0 (0)	2	0 (0)	7	0 (0)	
Other	3	2 (67)	1	0 (0)	4	2 (50)	
p value		0.415		0.831		0.332	
2019*							
Australia	104	16 (15)	74	4 (5)	179	20 (11)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	1	0 (0)	1	0 (0)	2	0 (0)	
UK & Ireland	8	2 (25)	7	1 (14)	15	3 (20)	
Other	2	0 (0)	2	0 (0)	4	0 (0)	
p value		0.868		0.846		0.688	
2020							
Australia	8	1 (13)	4	0 (0)	12	1 (8)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.708		--		0.672	
2021							
Australia	76	13 (17)	45	2 (4)	126	16 (13)	
Other Oceania	0	0 (0)	2	1 (50)	2	1 (50)	
Asia	1	1 (100)	1	1 (100)	2	2 (100)	
UK & Ireland	5	2 (40)	3	1 (33)	8	3 (38)	
Other	1	0 (0)	2	0 (0)	3	0 (0)	
p value		0.110		0.002		0.002	

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Tasmania	2017	2018	2019	2020*	2021*
Number of sites	4	4	4	4	4
N° surveyed	N=63	N=62	N=40	N=35	N=95
Response rate (%)	30%	23%	17%	17%	62%
Gender (%)					
Male	33 (52)	40 (65)	21 (53)	21 (60)	51 (54)
Female	30 (48)	21 (34)	19 (48)	14 (40)	44 (46)
Other	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	51 (81)	52 (84)	35 (88)	32 (91)	81 (85)
Bisexual	6 (10)	5 (8)	4 (10)	1 (3)	9 (9)
Gay/Lesbian	3 (5)	0 (0)	0 (0)	2 (6)	1 (1)
Other	-- --	-- --	-- --	0 (0)	2 (2)
Not reported	3 (5)	5 (8)	1 (3)	0 (0)	2 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	55 (87)	49 (79)	36 (90)	31 (89)	72 (76)
Yes	7 (11)	11 (18)	4 (10)	4 (11)	20 (21)
Not reported	1 (2)	2 (3)	0 (0)	0 (0)	3 (3)
Region/country of birth (%)					
Australia	59 (94)	58 (94)	39 (98)	33 (94)	86 (91)
Other Oceania	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Asia	2 (3)	0 (0)	0 (0)	0 (0)	1 (1)
UK & Ireland	1 (2)	2 (3)	1 (3)	2 (6)	0 (0)
Other	1 (2)	1 (2)	0 (0)	0 (0)	6 (6)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Main language spoken at home by parents (%)					
English	63 (100)	61 (98)	40 (100)	35 (100)	90 (95)
Non-English	0 (0)	1 (2)	0 (0)	0 (0)	4 (4)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Age and time since first injection (years)					
<i>Median age</i>	42	41.5	42	43	45
<i>Age range</i>	21-60	21-59	24-59	28-66	20-67
Age group (%)					
<25 years	2 (3)	2 (3)	1 (3)	0 (0)	2 (2)
25+ years	61 (97)	60 (97)	39 (98)	35 (100)	91 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
<i>Median age first injection</i>	20.5	19	20	20	20
<i>Age range</i>	14-57	13-48	13-38	13-36	12-55
N° not reported	3	2	0	0	2
<i>Median yrs since first injection</i>	19	20	22	23	21.5
<i>Range</i>	2-46	1-40	5-45	1-46	1-48
Years since first injection					
<3 years	1 (2)	1 (2)	0 (0)	1 (3)	5 (5)
3+ years	59 (94)	59 (95)	40 (100)	34 (97)	87 (92)
Not reported	3 (5)	2 (3)	0 (0)	0 (0)	3 (3)
Imprisonment last year (%)					
No	57 (90)	56 (90)	36 (90)	30 (86)	82 (86)
Yes	4 (6)	3 (5)	4 (10)	5 (14)	8 (8)
Not reported	2 (3)	3 (5)	0 (0)	0 (0)	5 (5)
N° in prison					
Injected in prison	0 (0)	2 (67)	0 (0)	0 (0)	2 (25)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 7.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Tasmania	2017	2018	2019	2020	2021
N° surveyed	N=63	N=62	N=40	N=35	N=95
Drug last injected (%)					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	21 (33)	22 (35)	18 (45)	15 (43)	49 (52)
Heroin	2 (3)	2 (3)	2 (5)	1 (3)	7 (7)
Pharm. opioids	15 (24)	19 (31)	3 (8)	9 (26)	14 (15)
Methadone	15 (24)	12 (19)	11 (28)	7 (20)	9 (9)
Buprenorphine	2 (3)	2 (3)	2 (5)	0 (0)	4 (4)
Buprenorphine/naloxone	1 (2)	2 (3)	1 (3)	0 (0)	4 (4)
PIEDs	1 (2)	0 (0)	1 (3)	1 (3)	2 (2)
More than one	3 (5)	1 (2)	0 (0)	1 (3)	3 (3)
Other	0 (0)	2 (3)	2 (5)	0 (0)	2 (2)
Not reported	3 (5)	0 (0)	0 (0)	1 (3)	1 (1)
Ever injected opioids					
No	5 (8)	3 (5)	3 (8)	2 (6)	32 (34)
Yes	57 (90)	59 (95)	37 (93)	33 (94)	63 (66)
Not reported	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Frequency of injection last month (%)					
Not last month	5 (8)	2 (3)	3 (8)	5 (14)	10 (11)
Less than weekly	9 (14)	7 (11)	8 (20)	7 (20)	32 (34)
Weekly not daily	17 (27)	27 (44)	17 (43)	12 (34)	20 (21)
Daily or more	32 (51)	26 (42)	11 (28)	11 (31)	31 (33)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	2 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	55 (87)	57 (92)	38 (95)	34 (97)	78 (82)
Yes	8 (13)	4 (6)	2 (5)	1 (3)	14 (15)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	3 (3)
Overdosed in last 12 months					
No	58 (92)	55 (89)	31 (78)	30 (86)	85 (89)
Yes	5 (8)	4 (6)	9 (23)	5 (14)	5 (5)
Not reported	0 (0)	3 (5)	0 (0)	0 (0)	5 (5)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Tasmania	2017	2018	2019	2020	2021
N° injected last month	N=58	N=60	N=36	N=30	N=83
Places injected last month (%)					
All private	36 (62)	35 (58)	24 (67)	24 (80)	62 (75)
Any public	22 (38)	25 (42)	12 (33)	6 (20)	21 (25)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	50 (86)	47 (78)	30 (83)	26 (87)	71 (86)
Most of the time	8 (14)	9 (15)	3 (8)	4 (13)	8 (10)
Half of the time	0 (0)	1 (2)	1 (3)	0 (0)	0 (0)
Some of the time	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	2 (3)	2 (6)	0 (0)	2 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Re-used someone else's used needle & syringe last month (%)					
None	55 (95)	56 (93)	34 (94)	30 (100)	76 (92)
Once	1 (2)	0 (0)	1 (3)	0 (0)	2 (2)
Twice	1 (2)	1 (2)	0 (0)	0 (0)	4 (5)
3-5 times	0 (0)	1 (2)	1 (3)	0 (0)	0 (0)
>5 times	1 (2)	2 (3)	0 (0)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	55 (95)	56 (93)	34 (94)	30 (100)	76 (92)
One	2 (3)	1 (2)	0 (0)	0 (0)	2 (2)
Two	0 (0)	1 (2)	0 (0)	0 (0)	1 (1)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Don't know	1 (2)	0 (0)	0 (0)	0 (0)	3 (4)
Not reported	0 (0)	1 (2)	2 (6)	0 (0)	1 (1)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	2 (3)	1 (2)	0 (0)	0 (0)	2 (2)
Casual sex partner	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Close friend	0 (0)	2 (3)	0 (0)	0 (0)	2 (2)
Acquaintance	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	8 (14)	5 (8)	3 (8)	0 (0)	11 (13)
Water	6 (10)	5 (8)	3 (8)	1 (3)	19 (23)
Filter	9 (16)	2 (3)	4 (11)	0 (0)	9 (11)
Drug mix	4 (7)	4 (7)	1 (3)	0 (0)	5 (6)
None	40 (69)	52 (87)	26 (72)	28 (93)	58 (70)
Injected by someone after that person injected themselves or others last month (%)					
No	48 (83)	53 (88)	35 (97)	28 (93)	73 (88)
Yes	7 (12)	7 (12)	1 (3)	2 (7)	9 (11)
Not reported	3 (5)	0 (0)	0 (0)	0 (0)	1 (1)
Source of needle acquisition					
Needle Syringe Program	57 (98)	57 (95)	36 (100)	29 (97)	72 (87)
Chemist/Pharmacy	10 (17)	8 (13)	6 (17)	8 (27)	19 (23)
Personal sources	5 (9)	2 (3)	2 (6)	0 (0)	5 (6)
Dispensing/Vending Machine	16 (28)	9 (15)	8 (22)	7 (23)	7 (8)
Other sources	0 (0)	2 (3)	0 (0)	0 (0)	1 (1)

Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Tasmania	2017	2018	2019	2020	2021
N° surveyed	N=47	N=62	N=40	N=35	N=95
Ever any treatment/therapy for drug use (%)					
No	16 (25)	12 (19)	10 (25)	11 (31)	33 (35)
Yes	47 (75)	50 (81)	30 (75)	24 (69)	62 (65)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	24 (38)	16 (26)	10 (25)	7 (20)	10 (11)
Previously	16 (25)	24 (39)	11 (28)	5 (14)	18 (19)
Never	22 (35)	20 (32)	19 (48)	23 (66)	62 (65)
Not reported	1 (2)	2 (3)	0 (0)	0 (0)	5 (5)
History of buprenorphine (Subutex®) treatment (%)					
Currently	7 (11)	6 (10)	5 (13)	2 (6)	12 (13)
Previously	11 (17)	19 (31)	6 (15)	9 (26)	16 (17)
Never	44 (70)	35 (56)	29 (73)	24 (69)	64 (67)
Not reported	1 (2)	2 (3)	0 (0)	0 (0)	3 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	2 (3)	4 (6)	2 (5)	1 (3)	6 (6)
Previously	11 (17)	19 (31)	6 (15)	9 (26)	16 (17)
Never	49 (78)	37 (60)	32 (80)	24 (69)	71 (75)
Not reported	1 (2)	2 (3)	0 (0)	1 (3)	2 (2)

Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Tasmania	2017	2018	2019	2020	2021
N° surveyed	N=63	N=62	N=40	N=35	N=95
Previous HIV test (%)					
Yes, ever	54 (86)	49 (79)	33 (83)	29 (83)	71 (75)
Yes, last year	24 (38)	21 (34)	14 (35)	15 (43)	40 (42)
>1 year ago	30 (48)	28 (45)	19 (48)	14 (40)	31 (33)
Never tested	9 (14)	9 (15)	6 (15)	6 (17)	19 (20)
Not reported	0 (0)	4 (6)	1 (3)	0 (0)	5 (5)
Previous HCV test (%)					
Yes, ever	52 (83)	53 (85)	36 (90)	29 (83)	79 (83)
Yes, last year	31 (49)	35 (56)	22 (55)	18 (51)	52 (55)
>1 year ago	21 (33)	18 (29)	14 (35)	11 (31)	27 (28)
Never tested	8 (13)	5 (8)	1 (3)	3 (9)	7 (7)
Not reported	3 (5)	4 (6)	3 (8)	3 (9)	9 (9)
Lifetime treatment for HCV (%)[#]					
N° self-reported HCV diagnosis	N=20	N=21	N=11	N=4	N=19
Antiviral treatment	11 (55)	15 (71)	6 (55)	3 (75)	11 (42)
No antiviral treatment	9 (45)	6 (29)	5 (45)	1 (25)	8 (58)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Treatment for HCV in past 12 months (%)^{**}					
N° self-reported HCV diagnosis	N=18	N=17	N=8	N=3	N=9
Antiviral treatment	7 (39)	9 (53)	2 (25)	1 (33)	1 (11)
No antiviral treatment	11 (61)	8 (47)	6 (75)	2 (67)	8 (89)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

[#] among people who tested HCV antibody positive and did not report spontaneous clearance

^{*} excludes people who reported treatment induced clearance more than 12 months previously

Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Tasmania	2017	2018	2019	2020	2021
N° surveyed	N=63	N=62	N=40	N=35	N=95
Sex with a regular partner last month (%)					
No	29 (46)	32 (52)	15 (38)	10 (29)	34 (36)
Yes	34 (54)	26 (42)	11 (28)	11 (31)	30 (32)
Not reported	0 (0)	4 (6)	14 (35)	14 (40)	31 (33)
Condom used with regular partner last month (%)					
N° surveyed	N=34	N=26	N=11	N=11	N=30
Never	31 (91)	21 (81)	9 (82)	9 (82)	23 (77)
Sometimes	0 (0)	4 (15)	1 (9)	1 (9)	3 (10)
Every time	3 (9)	0 (0)	1 (9)	1 (9)	1 (3)
Not reported	0 (0)	1 (4)	0 (0)	0 (0)	3 (10)
Sex with other partner(s) last month (%)					
No	62 (98)	51 (82)	24 (60)	21 (60)	57 (60)
Yes	1 (2)	6 (10)	2 (5)	1 (3)	5 (5)
Not reported	0 (0)	5 (8)	14 (35)	13 (37)	33 (35)
Condom used with other partner(s) last month (%)					
N° surveyed	N=1	N=6	N=2	N=1	N=5
Never	0 (0)	4 (67)	2 (100)	1 (100)	3 (60)
Sometimes	1 (100)	2 (33)	0 (0)	0 (0)	1 (20)
Every time	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (20)
Sex work last month (%)					
No	59 (94)	55 (89)	26 (65)	22 (63)	57 (60)
Yes	2 (3)	1 (2)	0 (0)	0 (0)	6 (6)
Not reported	2 (3)	6 (10)	14 (35)	13 (37)	32 (34)
Condom used at last sex work (%)					
Yes	1 (50)	0 (0)	0 (0)	0 (0)	3 (50)

Table 7.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

Tasmania	2020	2021
N° surveyed	N=35	N=95
More difficult to access sterile needles and syringes		
Yes	1 (3)	5 (5)
No	32 (91)	69 (73)
Not applicable	0 (0)	7 (7)
Not reported	2 (6)	14 (15)
Start depot buprenorphine		
Yes	1 (3)	2 (2)
No	17 (49)	48 (51)
Not applicable	14 (40)	30 (32)
Not reported	3 (9)	15 (16)
Access take home naloxone		
Yes	13 (37)	23 (24)
No	12 (34)	35 (37)
Not applicable	6 (17)	22 (23)
Not reported	4 (11)	15 (16)
Change illicit drug use		
Yes, increased	4 (11)	5 (5)
Yes, decreased	9 (26)	33 (35)
No change	19 (54)	37 (39)
Not reported	3 (9)	20 (21)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	0 (0)	3 (3)
No	17 (49)	47 (49)
Not applicable	15 (43)	31 (33)
Not reported	3 (9)	14 (15)
Inject own methadone/bupe/suboxone		
Yes	3 (9)	9 (9)
No	14 (40)	45 (47)
Not applicable	16 (46)	27 (28)
Not reported	2 (6)	14 (15)
COVID-19 vaccine uptake		
≥1 dose	-- --	47 (49)
COVID-19 vaccine doses		
One dose	-- --	16 (17)
Two doses	-- --	31 (33)
No doses	-- --	34 (36)
Not reported	-- --	14 (15)
Vaccine type		
Astra Zeneca	-- --	5 (5)
Pfizer	-- --	22 (23)
Don't know	-- --	5 (5)
Not reported	-- --	63 (66)
COVID-19 test		
Yes	5 (14)	22 (23)
No	25 (71)	54 (57)
Don't know	2 (6)	2 (2)
Not reported	3 (9)	17 (18)
Self-reported positive COVID-19 test result		
Yes	0 (0)	0 (0)

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017	32	0 (0.0)	30	0 (0.0)	62	0 (0.0)
2018	40	0 (0.0)	21	0 (0.0)	62	0 (0.0)
2019	20	1 (5.0)	18	0 (0.0)	38	1 (2.6)
2020	20	0 (0.0)	14	0 (0.0)	34	0 (0.0)
2021	49	0 (0.0)	42	0 (0.0)	91	0 (0.0)
X ² p trend		0.955		--		0.947

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	32	14 (44)	29	15 (52)	61	29 (48)
2018	40	21 (53)	21	12 (57)	62	34 (55)
2019	19	7 (37)	18	6 (33)	37	13 (35)
2020	20	6 (30)	14	3 (21)	34	9 (26)
2021	49	18 (37)	42	9 (21)	91	27 (30)
X ² p trend		0.185		0.001		0.001

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	28	13 (46)	23	11 (48)	51	24 (47)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.492		1.000		1.000
2018						
Heterosexual	34	18 (53)	18	9 (50)	52	27 (52)
Bisexual	2	0 (0)	2	2 (100)	5	3 (60)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.486		0.479		1.000
2019						
Heterosexual	18	7 (39)	14	6 (43)	32	13 (41)
Bisexual	1	0 (0)	3	0 (0)	4	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.515		0.274
2020						
Heterosexual	19	6 (32)	12	3 (25)	31	9 (29)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		1.000
2021						
Heterosexual	44	16 (36)	33	6 (18)	77	22 (29)
Bisexual	3	0 (0)	6	2 (33)	9	2 (22)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.219		0.260		0.147

Table 7.3.3 HCV antibody prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	2	0 (0)	0	0 (0)	2	0 (0)
25-34 years	3	1 (33)	6	5 (83)	9	6 (67)
35-44 years	12	6 (50)	12	6 (50)	24	12 (50)
45+ years	15	7 (47)	11	4 (36)	26	11 (42)
p value		0.745		0.223		0.385
2018						
<25 years	1	1 (100)	0	0 (0)	2	2 (100)
25-34 years	6	3 (50)	3	2 (67)	9	5 (56)
35-44 years	19	8 (42)	12	8 (67)	31	16 (52)
45+ years	14	9 (64)	6	2 (33)	20	11 (55)
p value		0.490		0.475		0.798
2019						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	4	2 (50)	5	2 (40)
35-44 years	12	3 (25)	7	1 (14)	19	4 (21)
45+ years	6	4 (67)	7	3 (43)	13	7 (54)
p value		0.129		0.541		0.178
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	5	1 (20)	9	1 (11)
35-44 years	5	2 (40)	3	1 (33)	8	3 (38)
45+ years	11	4 (36)	6	1 (17)	17	5 (29)
p value		0.532		1.000		0.475
2021						
<25 years	0	0 (0)	2	0 (0)	2	0 (0)
25-34 years	7	2 (29)	7	1 (14)	14	3 (21)
35-44 years	15	5 (33)	12	1 (8)	27	6 (22)
45+ years	27	11 (41)	19	6 (32)	46	17 (37)
p value		0.847		0.489		0.437

Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	4	0 (0)	1	1 (100)	5	1 (20)
11+ years	25	14 (56)	27	14 (52)	52	28 (54)
p value		0.067		1.000		0.194
2018						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	5	2 (40)	3	1 (33)	9	4 (44)
11+ years	33	17 (52)	17	11 (65)	50	28 (56)
p value		1.000		0.537		0.845
2019						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	17	7 (41)	14	5 (36)	31	12 (39)
p value		0.509		1.000		0.394
2020						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	17	6 (35)	10	2 (20)	27	8 (30)
p value		1.000		1.000		1.000
2021						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	2	0 (0)	5	0 (0)	7	0 (0)
11+ years	45	18 (40)	31	8 (26)	76	26 (34)
p value		0.394		0.607		0.067

Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No receptive sharing	1	1 (100)	49	25 (51)	53	25 (47)
Receptive sharing	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		1.000		0.605
2018						
No receptive sharing	1	1 (100)	53	30 (57)	56	32 (57)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.322		0.318
2019						
No receptive sharing	0	0 (0)	32	13 (41)	32	13 (41)
Receptive sharing	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2020						
No receptive sharing	1	0 (0)	28	9 (32)	29	9 (31)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	5	0 (0)	68	22 (32)	75	22 (29)
Receptive sharing	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		1.000		0.633

Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Tasmania Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Methamphetamine	1	1 (100)	19	6 (32)	20	6 (30)
Pharmaceutical opioids	0	0 (0)	12	7 (58)	15	7 (47)
OAT*	0	0 (0)	18	12 (67)	18	12 (67)
Other drugs	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.180		0.162
2018						
Methamphetamine	0	0 (0)	21	10 (48)	22	10 (45)
Pharmaceutical opioids	1	1 (100)	17	10 (59)	19	12 (63)
OAT*	0	0 (0)	16	9 (56)	16	9 (56)
Other drugs	0	0 (0)	5	3 (60)	5	3 (60)
p value		--		0.895		0.710
2019						
Methamphetamine	0	0 (0)	16	6 (38)	16	6 (38)
Pharmaceutical opioids	0	0 (0)	3	0 (0)	3	0 (0)
OAT*	0	0 (0)	14	6 (43)	14	6 (43)
Other drugs	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.573		0.573
2020						
Methamphetamine	1	0 (0)	13	2 (15)	14	2 (14)
Pharmaceutical opioids	0	0 (0)	9	3 (33)	9	3 (33)
OAT*	0	0 (0)	7	3 (43)	7	3 (43)
Other drugs	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.581		0.521
2021						
Methamphetamine	4	0 (0)	40	8 (20)	44	8 (18)
Pharmaceutical opioids	1	0 (0)	13	5 (38)	14	5 (36)
OAT*	0	0 (0)	15	6 (40)	16	6 (38)
Other drugs	0	0 (0)	13	6 (46)	14	6 (43)
p value		--		0.206		0.194

*OAT = methadone, buprenorphine or buprenorphine/naloxone

Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Tasmania Frequency of injection last month	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
Less than daily	0	0 (0)	25	11 (44)	25	11 (44)
Daily or more	1	1 (100)	27	16 (59)	31	16 (52)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.569		0.802
2018						
Less than daily	0	0 (0)	33	19 (58)	34	19 (56)
Daily or more	1	1 (100)	24	12 (50)	26	14 (54)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.798		1.000
2019						
Less than daily	0	0 (0)	24	7 (29)	24	7 (29)
Daily or more	0	0 (0)	9	6 (67)	9	6 (67)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.081		0.081
2020						
Less than daily	1	0 (0)	18	6 (33)	19	6 (32)
Daily or more	0	0 (0)	10	3 (30)	10	3 (30)
Not last month	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.480		0.485
2021						
Less than daily	3	0 (0)	47	11 (23)	51	11 (22)
Daily or more	2	0 (0)	26	13 (50)	29	13 (45)
Not last month	0	0 (0)	9	1 (11)	9	1 (11)
p value		--		0.032		0.048

Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Tasmania Imprisonment last year	<3 years		3+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2017						
No imprisonment	1	1 (100)	51	27 (53)	55	27 (49)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000
2018						
No imprisonment	0	0 (0)	55	29 (53)	56	29 (52)
Imprisonment	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.245		0.243
2019						
No imprisonment	0	0 (0)	33	10 (30)	33	10 (30)
Imprisonment	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.115		0.115
2020						
No imprisonment	1	0 (0)	28	8 (29)	29	8 (28)
Imprisonment	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.582		1.000
2021						
No imprisonment	3	0 (0)	73	23 (32)	79	24 (30)
Imprisonment	1	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.389		0.673

Table 7.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	28	11 (39)	26	13 (50)	54	24 (44)
Indigenous	4	3 (75)	2	1 (50)	6	4 (67)
p value		0.295		1.000		0.404
2018						
Non Indigenous	32	14 (44)	17	10 (59)	49	24 (49)
Indigenous	7	6 (86)	3	1 (33)	11	8 (73)
p value		0.091		0.566		0.193
2019						
Non Indigenous	16	5 (31)	17	6 (35)	33	11 (33)
Indigenous	3	2 (67)	1	0 (0)	4	2 (50)
p value		0.523		1.000		0.602
2020						
Non Indigenous	16	5 (31)	14	3 (21)	30	8 (27)
Indigenous	4	1 (25)	0	0 (0)	4	1 (25)
p value		1.000		--		1.000
2021						
Non Indigenous	39	13 (33)	31	7 (23)	70	20 (29)
Indigenous	10	5 (50)	8	2 (25)	18	7 (39)
p value		0.329		1.000		0.397

Table 7.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Tasmania Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	32	14 (44)	29	15 (52)	61	29 (48)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018						
English speaking	40	21 (53)	21	12 (57)	61	33 (54)
Non-English speaking	0	0 (0)	0	0 (0)	1	1 (100)
p value		--		--		1.000
2019						
English speaking	19	7 (37)	18	6 (33)	37	13 (35)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2020						
English speaking	20	6 (30)	14	3 (21)	34	9 (26)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	45	16 (36)	41	9 (22)	86	25 (29)
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.618		--		0.580

Table 7.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017							
Australia	29	13 (45)	28	14 (50)	57	27 (47)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.835		1.000		0.862	
2018							
Australia	38	21 (55)	20	12 (60)	58	33 (57)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	1	1 (100)	
p value		0.219		0.429		0.137	
2019							
Australia	19	7 (37)	17	6 (35)	36	13 (36)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		1.000		1.000	
2020							
Australia	19	6 (32)	13	3 (23)	32	9 (28)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		1.000	
2021							
Australia	42	15 (36)	40	8 (20)	82	23 (28)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	1	1 (100)	1	1 (100)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	5	2 (40)	1	0 (0)	6	2 (33)	
p value		1.000		0.387		0.415	

HCV RNA prevalence

Table 7.4.1 HCV RNA prevalence by gender and survey year

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*	27	8 (30)	26	9 (35)	53	17 (32)
2018*	32	6 (19)	17	5 (29)	49	11 (22)
2019*	16	3 (19)	16	3 (19)	32	5 (16)
2020	19	2 (11)	12	2 (17)	31	4 (13)
2021	42	6 (14)	35	3 (9)	77	9 (12)
X ² p trend		0.111		0.008		0.003

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 7.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heterosexual	25	8 (32)	20	9 (45)	45	17 (38)
Bisexual	0	0 (0)	5	0 (0)	5	0 (0)
Homosexual	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.346		0.150		0.111
2018*						
Heterosexual	28	4 (14)	13	4 (31)	41	8 (20)
Bisexual	0	0 (0)	2	1 (50)	3	1 (33)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.544		0.445
2019*						
Heterosexual	15	3 (20)	12	2 (17)	27	4 (15)
Bisexual	1	0 (0)	3	1 (33)	4	1 (25)
Homosexual	0	3 (0)	0	0 (0)	0	0 (0)
p value		0.637		0.457		0.789
2020						
Heterosexual	18	2 (11)	10	2 (20)	28	4 (14)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.725		0.787		0.782
2021						
Heterosexual	38	5 (13)	27	2 (7)	65	7 (11)
Bisexual	2	0 (0)	6	0 (0)	8	0 (0)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.583		0.759		0.586

Table 7.4.3 HCV RNA prevalence by age group, gender and survey year

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	0 (0)	5	3 (60)	8	3 (38)
35-44 years	11	4 (36)	12	2 (17)	23	6 (26)
45+ years	12	4 (33)	9	4 (44)	21	8 (38)
p value		0.567		0.175		0.821
2018*						
<25 years	0	0 (0)	0	0 (0)	1	0 (0)
25-34 years	5	1 (20)	2	1 (50)	7	2 (29)
35-44 years	15	1 (7)	10	2 (20)	25	3 (12)
45+ years	12	4 (33)	4	1 (25)	16	5 (31)
p value		0.227		0.634		0.430
2019*						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	10	1 (10)	6	1 (17)	16	2 (13)
45+ years	6	2 (33)	6	1 (17)	12	3 (25)
p value		0.340		0.886		0.669
2020						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	5	1 (20)	9	1 (11)
35-44 years	5	1 (20)	2	0 (0)	7	1 (14)
45+ years	10	1 (10)	5	1 (20)	15	2 (13)
p value		0.622		0.787		0.980
2021						
<25 years	0	0 (0)	2	0 (0)	2	0 (0)
25-34 years	6	0 (0)	6	0 (0)	12	0 (0)
35-44 years	13	0 (0)	9	0 (0)	22	0 (0)
45+ years	23	6 (26)	16	2 (13)	39	8 (21)
p value		0.056		0.520		0.041

Table 7.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	3	0 (0)	1	1 (100)	4	1 (25)
11+ years	22	8 (36)	24	8 (33)	46	16 (35)
p value		0.357		0.179		0.734
2018*						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	4	1 (25)	3	1 (33)	8	2 (25)
11+ years	26	3 (12)	13	4 (31)	39	7 (18)
p value		0.064		0.710		0.127
2019*						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	3	2 (67)	3	2 (67)
11+ years	16	3 (19)	12	1 (8)	29	3 (10)
p value		--		0.065		0.066
2020						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	16	2 (13)	8	1 (13)	24	3 (13)
p value		0.811		0.584		0.893
2021						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	2	0 (0)	3	0 (0)	5	0 (0)
11+ years	39	6 (15)	27	2 (7)	66	8 (12)
p value		0.764		0.821		0.581

Table 7.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Tasmania Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	24	6 (25)	23	8 (35)	47	14 (30)
Receptive sharing	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.123		0.585		0.094
2018*						
No receptive sharing	28	5 (18)	16	5 (31)	44	10 (23)
Receptive sharing	2	0 (0)	0	0 (0)	3	0 (0)
p value		0.525		--		0.375
2019*						
No receptive sharing	16	3 (19)	13	3 (23)	29	5 (17)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2020						
No receptive sharing	18	2 (11)	8	2 (25)	26	4 (15)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
No receptive sharing	37	5 (14)	25	1 (4)	62	6 (10)
Receptive sharing	2	0 (0)	3	1 (33)	5	1 (20)
p value		0.578		0.062		0.468

Table 7.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Tasmania Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Methamphetamine	6	0 (0)	10	2 (20)	16	2 (13)
Pharm. Opioids	11	4 (36)	4	2 (50)	15	6 (40)
OAT	7	2 (29)	7	5 (71)	15	7 (47)
Other drugs	2	1 (50)	5	0 (0)	7	1 (14)
p value		0.308		0.070		0.172
2018*						
Methamphetamine	7	0 (0)	7	2 (29)	14	2 (14)
Pharm. Opioids	14	3 (21)	3	1 (33)	17	4 (24)
OAT	9	3 (33)	5	1 (20)	14	4 (29)
Other drugs	2	0 (0)	1	0 (0)	4	0 (0)
p value		0.344		0.902		0.650
2019*						
Methamphetamine	8	2 (25)	6	2 (33)	14	3 (21)
Pharm. Opioids	1	0 (0)	2	0 (0)	3	0 (0)
OAT	6	0 (0)	8	1 (13)	14	1 (7)
Other drugs	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.161		0.534		0.067
2020						
Methamphetamine	8	1 (13)	6	1 (17)	14	2 (14)
Pharm. Opioids	6	1 (17)	1	0 (0)	7	1 (14)
OAT	3	0 (0)	3	1 (33)	6	1 (17)
Other drugs	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.835		0.753		0.872
2021						
Methamphetamine	12	0 (0)	21	2 (10)	33	2 (6)
Pharm. Opioids	11	3 (27)	3	0 (0)	14	3 (21)
OAT	11	1 (9)	3	0 (0)	14	1 (7)
Other drugs	7	2 (29)	6	0 (0)	13	2 (15)
p value		0.185		0.749		0.409

OAT: methadone, buprenorphine or buprenorphine/naloxone

Table 7.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Tasmania Frequency of injection last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Less than daily	7	0 (0)	13	3 (23)	20	3 (15)
Daily or more	18	7 (39)	12	6 (50)	30	13 (43)
Not last month	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.139		0.270		0.093
2018*						
Less than daily	16	1 (6)	12	4 (33)	28	5 (18)
Daily or more	15	4 (27)	4	1 (25)	19	5 (26)
Not last month	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.045		0.837		0.433
2019*						
Less than daily	12	2 (17)	9	2 (22)	21	3 (14)
Daily or more	4	1 (25)	4	1 (25)	8	2 (25)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
p value		0.735		0.705		0.714
2020						
Less than daily	12	1 (8)	6	2 (33)	18	3 (17)
Daily or more	6	1 (17)	2	0 (0)	8	1 (13)
Not last month	1	0 (0)	4	0 (0)	5	0 (0)
p value		0.811		0.301		0.616
2021						
Less than daily	20	1 (5)	21	2 (10)	41	3 (7)
Daily or more	19	4 (21)	7	0 (0)	26	4 (15)
Not last month	3	1 (33)	5	0 (0)	8	1 (13)
p value		0.222		0.544		0.572

Table 7.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Tasmania Imprisonment last year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No imprisonment	26	8 (31)	22	8 (36)	48	16 (33)
Imprisonment	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.508		0.988		0.767
2018*						
No imprisonment	28	4 (14)	17	5 (29)	45	9 (20)
Imprisonment	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.691		--		0.500
2019*						
No imprisonment	14	1 (7)	15	3 (20)	29	3 (10)
Imprisonment	3	2 (67)	1	0 (0)	3	2 (67)
p value		0.026		0.654		0.066
2020						
No imprisonment	15	1 (7)	11	2 (18)	26	3 (12)
Imprisonment	4	1 (25)	1	0 (0)	5	1 (20)
p value		0.288		0.640		0.605
2021						
No imprisonment	36	6 (17)	32	3 (9)	68	9 (13)
Imprisonment	4	0 (0)	2	0 (0)	6	0 (0)
p value		0.376		0.650		0.342

Table 7.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Tasmania	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Non Indigenous	25	8 (32)	22	8 (36)	47	16 (34)
Indigenous	2	0 (0)	3	0 (0)	5	0 (0)
p value		0.333		0.219		0.118
2018*						
Non Indigenous	25	4 (16)	12	5 (42)	37	9 (24)
Indigenous	6	1 (17)	3	0 (0)	10	1 (10)
p value		0.962		0.221		0.376
2019*						
Non Indigenous	15	2 (13)	15	3 (20)	29	4 (14)
Indigenous	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.203		0.654		0.417
2020						
Non Indigenous	15	2 (13)	12	2 (17)	27	4 (15)
Indigenous	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.440		--		0.409
2021						
Non Indigenous	35	6 (17)	24	3 (13)	59	9 (15)
Indigenous	7	0 (0)	8	0 (0)	15	0 (0)
p value		0.237		0.294		0.107

Table 7.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Tasmania	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
English speaking	27	8 (30)	26	9 (35)	53	17 (32)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2018*						
English speaking	31	6 (19)	17	5 (29)	48	11 (23)
Non-English speaking	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		0.605
2019*						
English speaking	16	3 (19)	16	3 (19)	32	5 (16)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2020						
English speaking	19	2 (11)	12	2 (17)	31	4 (13)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
2021						
English speaking	39	6 (15)	35	3 (9)	74	9 (12)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.463		--		0.520

Table 7.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Tasmania Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Australia	24	7 (29)	25	8 (32)	49	15 (31)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.294		0.168		0.308
2018*						
Australia	29	6 (21)	16	5 (31)	45	11 (24)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.786		0.540		0.756
2019*						
Australia	14	3 (21)	15	3 (20)	31	5 (16)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.654		0.664
2020						
Australia	18	2 (11)	11	2 (18)	29	4 (14)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.725		0.640		0.574
2021						
Australia	35	6 (17)	34	3 (9)	69	9 (13)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	1	0 (0)	1	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	5	0 (0)	0	0 (0)	5	0 (0)
p value		0.315		0.756		0.641

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2017	2018	2019	2020*	2021*
Number of sites	6	6	6	--	3
N° surveyed	N=380	N=437	N=375	--	N=40
Response rate (%)	56%	51%	52%	--	44%
Gender (%)					
Male	247 (65)	290 (66)	240 (64)	-- --	28 (70)
Female	127 (33)	145 (33)	130 (35)	-- --	11 (28)
Other	3 (1)	2 (<1)	3 (1)	-- --	1 (3)
Not reported	3 (1)	0 (0)	2 (1)	-- --	0 (0)
Sexual identity (%)					
Heterosexual	293 (77)	342 (78)	277 (74)	-- --	30 (75)
Bisexual	35 (9)	33 (8)	39 (10)	-- --	7 (18)
Gay/Lesbian	16 (4)	18 (4)	17 (5)	-- --	1 (3)
Other	-- --	-- --	-- --	-- --	2 (5)
Not reported	36 (9)	44 (10)	42 (11)	-- --	0 (0)
Aboriginal and Torres Strait Islander origin (%)					
No	320 (84)	359 (82)	296 (79)	-- --	31 (78)
Yes	55 (14)	71 (16)	66 (18)	-- --	9 (23)
Not reported	5 (1)	7 (2)	13 (3)	-- --	0 (0)
Region/country of birth (%)					
Australia	333 (88)	373 (85)	333 (89)	-- --	33 (83)
Other Oceania	9 (2)	12 (3)	7 (2)	-- --	2 (5)
Asia	5 (1)	6 (1)	3 (1)	-- --	0 (0)
UK & Ireland	13 (3)	20 (5)	7 (2)	-- --	2 (5)
Other	19 (5)	24 (5)	20 (5)	-- --	3 (8)
Not reported	1 (<1)	2 (<1)	5 (1)	-- --	0 (0)
Main language spoken at home by parents (%)					
English	336 (88)	393 (90)	345 (92)	-- --	36 (90)
Non-English	44 (12)	43 (10)	27 (7)	-- --	4 (10)
Not reported	0 (0)	1 (<1)	3 (1)	-- --	0 (0)
Age and time since first injection (years)					
<i>Median age</i>	42	42	42	-- --	46
<i>Age range</i>	19-67	17-69	20-70	-- --	29-62
Age group (%)					
<25 years	7 (2)	8 (2)	6 (2)	-- --	0 (0)
25+ years	370 (97)	424 (97)	363 (97)	-- --	40 (100)
Not reported	3 (1)	5 (1)	6 (2)	-- --	0 (0)
<i>Median age first injection</i>	18	18	18	-- --	18
<i>Age range</i>	10-58	11-52	10-51	-- --	13-50
<i>N° not reported</i>	12	23	27	-- --	0
<i>Median yrs since first injection</i>	23	22	22	-- --	27.5
<i>Range</i>	<1-47	<1-46	<1-52	-- --	<1-41
Years since first injection					
<3 years	8 (2)	18 (4)	13 (3)	-- --	2 (5)
3+ years	360 (95)	396 (91)	333 (89)	-- --	38 (95)
Not reported	12 (3)	23 (5)	29 (8)	-- --	0 (0)
Imprisonment last year (%)					
No	303 (80)	335 (77)	268 (71)	-- --	34 (85)
Yes	50 (13)	75 (17)	83 (22)	-- --	2 (5)
Not reported	27 (7)	27 (6)	24 (6)	-- --	4 (10)
N° in prison	N=50	N=75	N=83	-- --	N=2
Injected in prison	15 (30)	19 (25)	20 (24)	-- --	0 (0)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Victoria	2017	2018	2019	2020	2021
N° surveyed	N=380	N=437	N=375	--	N=40
Drug last injected (%)					
Cocaine	2 (1)	3 (1)	4 (1)	-- --	0 (0)
Methamphetamine	92 (24)	158 (36)	126 (34)	-- --	18 (45)
Heroin	234 (62)	223 (51)	198 (53)	-- --	16 (40)
Pharm. opioids	11 (3)	4 (1)	8 (2)	-- --	1 (3)
Methadone	4 (1)	3 (1)	3 (1)	-- --	0 (0)
Buprenorphine	7 (2)	7 (2)	1 (<1)	-- --	1 (3)
Buprenorphine/naloxone	4 (1)	8 (2)	2 (1)	-- --	0 (0)
PIEDs	1 (<1)	2 (<1)	0 (0)	-- --	0 (0)
More than one	19 (5)	22 (5)	25 (7)	-- --	3 (8)
Other	1 (<1)	5 (1)	5 (1)	-- --	1 (3)
Not reported	5 (1)	2 (<1)	3 (1)	-- --	0 (0)
Ever injected opioids					
No	24 (6)	40 (9)	31 (8)	-- --	6 (15)
Yes	353 (93)	393 (90)	343 (91)	-- --	34 (85)
Not reported	3 (1)	4 (1)	1 (<1)	-- --	0 (0)
Frequency of injection last month (%)					
Not last month	25 (7)	36 (8)	23 (6)	-- --	2 (5)
Less than weekly	70 (18)	66 (15)	47 (13)	-- --	10 (25)
Weekly not daily	79 (21)	104 (24)	62 (17)	-- --	6 (15)
Daily or more	202 (53)	224 (51)	240 (64)	-- --	22 (55)
Not reported	4 (1)	7 (2)	3 (1)	-- --	0 (0)
Present when someone injected for the first time in the last 12 months (%)					
No	309 (81)	356 (81)	299 (80)	-- --	28 (70)
Yes	56 (15)	67 (15)	65 (17)	-- --	7 (18)
Not reported	15 (4)	14 (3)	11 (3)	-- --	5 (13)
Overdosed in last 12 months					
No	272 (72)	297 (68)	255 (68)	-- --	30 (75)
Yes	91 (24)	125 (29)	103 (27)	-- --	4 (10)
Not reported	17 (4)	15 (3)	17 (5)	-- --	6 (15)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Victoria	2017	2018	2019	2020	2021
N° injected last month	N=351	N=394	N=349	--	N=38
Places injected last month (%)					
All private	128 (36)	152 (39)	125 (36)	-- --	18 (47)
Any public	219 (62)	239 (61)	222 (64)	-- --	20 (53)
Not reported	4 (1)	3 (1)	2 (1)	-- --	0 (0)
Use of new and sterile needles and syringes last month (%)					
All injections	267 (76)	301 (76)	252 (72)	-- --	34 (89)
Most of the time	70 (20)	69 (18)	78 (22)	-- --	2 (5)
Half of the time	3 (1)	6 (2)	3 (1)	-- --	0 (0)
Some of the time	1 (<1)	6 (2)	3 (1)	-- --	0 (0)
Not last month	0 (0)	5 (1)	2 (1)	-- --	2 (5)
Not reported	10 (3)	7 (2)	11 (3)	-- --	0 (0)
Re-used someone else's used needle & syringe last month (%)					
None	288 (82)	321 (81)	291 (83)	-- --	35 (92)
Once	18 (5)	22 (6)	20 (6)	-- --	0 (0)
Twice	18 (5)	14 (4)	13 (4)	-- --	2 (5)
3-5 times	11 (3)	16 (4)	15 (4)	-- --	0 (0)
>5 times	8 (2)	18 (5)	6 (2)	-- --	1 (3)
Not reported	8 (2)	3 (1)	4 (1)	-- --	0 (0)
Number of people needle & syringe was re-used after last month (%)					
None	288 (82)	321 (81)	291 (83)	-- --	34 (89)
One	22 (6)	26 (7)	27 (8)	-- --	1 (3)
Two	7 (2)	5 (1)	4 (1)	-- --	0 (0)
Three to five	1 (<1)	6 (2)	3 (1)	-- --	0 (0)
More than five	2 (1)	6 (2)	0 (0)	-- --	0 (0)
Don't know	15 (4)	17 (4)	15 (4)	-- --	2 (5)
Not reported	16 (5)	13 (3)	9 (3)	-- --	1 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	11 (3)	26 (7)	21 (6)	-- --	0 (0)
Casual sex partner	6 (2)	6 (2)	3 (1)	-- --	0 (0)
Close friend	14 (4)	18 (5)	10 (3)	-- --	1 (3)
Acquaintance	10 (3)	4 (1)	11 (3)	-- --	0 (0)
Other	11 (3)	6 (2)	11 (3)	-- --	0 (0)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	104 (30)	132 (34)	96 (28)	-- --	9 (24)
Water	69 (20)	77 (20)	73 (21)	-- --	4 (11)
Filter	43 (12)	42 (11)	51 (15)	-- --	5 (13)
Drug mix	34 (10)	46 (12)	37 (11)	-- --	3 (8)
None	220 (63)	233 (59)	222 (64)	-- --	28 (74)
Injected by someone after that person injected themselves or others last month (%)					
No	292 (83)	303 (77)	291 (83)	-- --	35 (92)
Yes	54 (15)	84 (21)	54 (15)	-- --	3 (8)
Not reported	5 (1)	7 (2)	4 (1)	-- --	0 (0)
Source of needle acquisition					
Needle Syringe Program	323 (92)	358 (91)	314 (90)	-- --	31 (82)
Chemist/Pharmacy	63 (18)	61 (15)	63 (18)	-- --	4 (11)
Personal sources	51 (15)	50 (13)	53 (15)	-- --	5 (13)
Dispensing/Vending Machine	53 (15)	90 (23)	68 (19)	-- --	16 (42)
Other sources	11 (3)	21 (5)	13 (4)	-- --	0 (0)

Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Victoria	2017	2018	2019	2020	2021
N° surveyed	N=380	N=437	N=375	--	N=40
Ever any treatment/therapy for drug use (%)					
No	44 (12)	51 (12)	53 (14)	-- --	6 (15)
Yes	335 (88)	385 (88)	320 (85)	-- --	34 (85)
Not reported	1 (<1)	1 (<1)	2 (1)	-- --	0 (0)
History of methadone maintenance treatment (%)					
Currently	123 (32)	139 (32)	143 (38)	-- --	16 (40)
Previously	156 (41)	155 (35)	114 (30)	-- --	12 (30)
Never	97 (26)	134 (31)	109 (29)	-- --	11 (28)
Not reported	4 (1)	9 (2)	9 (2)	-- --	1 (3)
History of buprenorphine (Subutex®) treatment (%)					
Currently	31 (8)	33 (8)	25 (7)	-- --	4 (10)
Previously	161 (42)	170 (39)	146 (39)	-- --	14 (35)
Never	181 (48)	229 (52)	194 (52)	-- --	21 (53)
Not reported	7 (2)	5 (1)	10 (3)	-- --	1 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	51 (13)	57 (13)	27 (7)	-- --	3 (8)
Previously	150 (39)	159 (36)	149 (40)	-- --	14 (35)
Never	175 (46)	216 (49)	193 (51)	-- --	23 (58)
Not reported	4 (1)	5 (1)	6 (2)	-- --	0 (0)

Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Victoria	2017	2018	2019	2020	2021
N° surveyed	N=380	N=437	N=375	--	N=40
Previous HIV test (%)					
Yes, ever	331 (87)	364 (83)	306 (82)	-- --	35 (88)
Yes, last year	223 (59)	226 (52)	206 (55)	-- --	12 (30)
>1 year ago	108 (28)	138 (32)	100 (27)	-- --	23 (58)
Never tested	33 (9)	57 (13)	54 (14)	-- --	1 (3)
Not reported	16 (4)	16 (4)	15 (4)	-- --	4 (10)
Previous HCV test (%)					
Yes, ever	317 (83)	363 (83)	309 (82)	-- --	33 (83)
Yes, last year	234 (62)	243 (56)	218 (58)	-- --	17 (43)
>1 year ago	83 (22)	120 (27)	91 (24)	-- --	17 (43)
Never tested	19 (5)	30 (7)	23 (6)	-- --	1 (3)
Not reported	44 (12)	44 (10)	43 (11)	-- --	5 (13)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=149	N=150	N=131	--	N=11
Antiviral treatment	70 (50)	86 (57)	87 (66)	-- --	5 (45)
No antiviral treatment	78 (52)	63 (42)	44 (34)	-- --	6 (55)
Not reported	1 (1)	1 (1)	0 (0)	-- --	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=140	N=121	N=100	--	N=10
Antiviral treatment	56 (40)	53 (44)	48 (48)	-- --	2 (20)
No antiviral treatment	83 (59)	67 (55)	52 (52)	-- --	8 (80)
Not reported	1 (1)	1 (1)	0 (0)	-- --	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Victoria	2017	2018	2019	2020	2021
N° surveyed	N=380	N=437	N=375	--	N=40
Sex with a regular partner last month (%)					
No	217 (57)	253 (58)	212 (57)	-- --	31 (78)
Yes	146 (38)	173 (40)	147 (39)	-- --	6 (15)
Not reported	17 (4)	11 (3)	16 (4)	-- --	3 (8)
Condom used with regular partner last month (%)					
N° surveyed	N=146	N=173	N=147	--	N=6
Never	109 (75)	126 (73)	102 (69)	-- --	5 (83)
Sometimes	17 (12)	23 (13)	20 (14)	-- --	0 (0)
Every time	15 (10)	10 (6)	13 (9)	-- --	1 (17)
Not reported	5 (3)	14 (8)	12 (8)	-- --	0 (0)
Sex with other partner(s) last month (%)					
No	301 (79)	355 (81)	297 (79)	-- --	25 (63)
Yes	52 (14)	58 (13)	54 (14)	-- --	8 (20)
Not reported	27 (7)	24 (5)	24 (6)	-- --	7 (18)
Condom used with other partner(s) last month (%)					
N° surveyed	N=52	N=58	N=54	--	N=8
Never	15 (29)	22 (38)	25 (46)	-- --	2 (25)
Sometimes	23 (44)	18 (31)	14 (26)	-- --	1 (13)
Every time	10 (19)	15 (26)	11 (20)	-- --	4 (50)
Not reported	4 (8)	3 (5)	4 (7)	-- --	1 (13)
Sex work last month (%)					
No	335 (88)	378 (87)	325 (87)	-- --	30 (75)
Yes	18 (5)	29 (7)	30 (8)	-- --	5 (13)
Not reported	27 (7)	30 (7)	20 (5)	-- --	5 (13)
Condom used at last sex work (%)					
Yes	14 (78)	22 (76)	17 (57)	-- --	4 (80)

Table 8.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

Victoria	2020	2021
N° surveyed	Not applicable	N=40
More difficult to access sterile needles and syringes		
Yes	-- --	10 (25)
No	-- --	27 (68)
Not applicable	-- --	1 (3)
Not reported	-- --	2 (5)
Start depot buprenorphine		
Yes	-- --	3 (8)
No	-- --	22 (55)
Not applicable	-- --	13 (33)
Not reported	-- --	2 (5)
Access take home naloxone		
Yes	-- --	10 (25)
No	-- --	16 (40)
Not applicable	-- --	12 (30)
Not reported	-- --	2 (5)
Change illicit drug use		
Yes, increased	-- --	9 (23)
Yes, decreased	-- --	8 (20)
No change	-- --	20 (50)
Not reported	-- --	3 (8)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	-- --	6 (15)
No	-- --	19 (48)
Not applicable	-- --	13 (33)
Not reported	-- --	2 (5)
Inject own methadone/bupe/suboxone		
Yes	-- --	1 (3)
No	-- --	26 (65)
Not applicable	-- --	10 (25)
Not reported	-- --	3 (8)
COVID-19 vaccine uptake		
≥1 dose	-- --	31 (78)
COVID-19 vaccine doses		
One dose	-- --	9 (23)
Two doses	-- --	22 (55)
No doses	-- --	7 (18)
Not reported	-- --	2 (5)
Vaccine type		
Astra Zeneca	-- --	6 (15)
Pfizer	-- --	19 (48)
Don't know	-- --	4 (10)
Not reported	-- --	11 (28)
COVID-19 test		
Yes	-- --	27 (68)
No	-- --	9 (23)
Don't know	-- --	0 (0)
Not reported	-- --	4 (10)
Self-reported positive COVID-19 test result		
Yes	-- --	2 (5)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and survey year

Victoria Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017	243	6 (2.5)	127	1 (0.8)	376	7 (1.9)
2018	289	8 (2.8)	145	1 (0.7)	436	9 (2.1)
2019	234	8 (3.4)	128	1 (0.8)	367	9 (2.5)
2020	--	-- --	--	-- --	--	-- --
2021	25	1 (4.0)	11	0 (0.0)	37	2 (5.4)
X ² p trend		0.487		0.876		0.234

Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Victoria Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heterosexual	206	3 (1.5)	84	0 (0.0)	290	3 (1.0)
Bisexual	9	0 (0.0)	23	0 (0.0)	34	0 (0.0)
Homosexual	4	2 (50.0)	9	0 (0.0)	16	2 (12.5)
p value		0.004		--		0.037
2018						
Heterosexual	240	5 (2.1)	101	1 (1.0)	341	6 (1.8)
Bisexual	11	1 (9.1)	22	0 (0.0)	33	1 (3.0)
Homosexual	11	2 (18.2)	6	0 (0.0)	18	2 (11.1)
p value		0.022		1.000		0.042
2019						
Heterosexual	194	7 (3.6)	78	1 (1.3)	272	8 (2.9)
Bisexual	11	0 (0.0)	22	0 (0.0)	37	0 (0.0)
Homosexual	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.258		1.000		0.299
2020						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heterosexual	22	0 (0.0)	4	0 (0.0)	27	1 (3.7)
Bisexual	1	0 (0.0)	6	0 (0.0)	7	0 (0.0)
Homosexual	1	1 (100.0)	1	0 (0.0)	1	1 (100.0)
p value		0.120		--		0.108

Table 8.2.3 HIV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<25 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
25-34 years	39	4 (10.3)	22	0 (0.0)	65	4 (6.2)
35-44 years	107	2 (1.9)	51	0 (0.0)	158	2 (1.3)
45+ years	91	0 (0.0)	50	1 (2.0)	143	1 (0.7)
p value		0.014		0.598		0.081
2018						
<25 years	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
25-34 years	43	4 (9.3)	30	0 (0.0)	73	4 (5.5)
35-44 years	117	0 (0.0)	57	0 (0.0)	175	0 (0.0)
45+ years	123	4 (3.3)	51	1 (2.0)	175	5 (2.9)
p value		0.013		0.604		0.024
2019						
<25 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
25-34 years	32	3 (9.4)	25	0 (0.0)	59	3 (5.1)
35-44 years	97	3 (3.1)	54	0 (0.0)	152	3 (2.0)
45+ years	99	1 (1.0)	45	1 (2.2)	145	2 (1.4)
p value		0.139		0.575		0.387
2020						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	0	0 (0.0)	1	0 (0.0)	2	1 (50.0)
35-44 years	6	1 (16.7)	4	0 (0.0)	10	1 (10.0)
45+ years	19	0 (0.0)	6	0 (0.0)	25	0 (0.0)
p value		0.240		--		0.032

Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Victoria	Male		Female		Total	
Last drug injected	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heroin	151	3 (2.0)	79	0 (0.0)	232	3 (1.3)
Methamphetamine	57	3 (5.3)	33	0 (0.0)	92	3 (3.3)
Other opioids	15	0 (0.0)	7	0 (0.0)	24	0 (0.0)
Other drugs	20	0 (0.0)	8	1 (12.5)	28	1 (3.6)
p value		0.525		0.118		0.426
2018						
Heroin	145	5 (3.5)	77	1 (1.3)	222	6 (2.7)
Methamphetamine	109	3 (2.8)	48	0 (0.0)	158	3 (1.9)
Other opioids	12	0 (0.0)	9	0 (0.0)	22	0 (0.0)
Other drugs	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		0.922
2019						
Heroin	120	5 (4.2)	72	1 (1.4)	194	6 (3.1)
Methamphetamine	78	2 (2.6)	44	0 (0.0)	124	2 (1.6)
Other opioids	11	1 (9.1)	2	0 (0.0)	13	1 (7.7)
Other drugs	22	0 (0.0)	10	0 (0.0)	33	0 (0.0)
p value		0.555		1.000		0.318
2020						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heroin	10	0 (0.0)	4	0 (0.0)	15	1 (6.7)
Methamphetamine	10	1 (10.0)	6	0 (0.0)	16	1 (6.3)
Other opioids	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
Other drugs	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
p value		1.000		--		1.000

Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
<3 years	3	0 (0.0)	3	0 (0.0)	8	0 (0.0)
3 to 10 years	22	1 (4.6)	17	0 (0.0)	39	1 (2.6)
11+ years	218	5 (2.3)	107	1 (0.9)	329	6 (1.8)
p value		0.482		1.000		0.610
2018						
<3 years	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
3 to 10 years	24	2 (8.3)	24	0 (0.0)	48	2 (4.2)
11+ years	253	6 (2.4)	115	1 (0.9)	370	7 (1.9)
p value		0.171		1.000		0.507
2019						
<3 years	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)
3 to 10 years	23	2 (8.7)	20	0 (0.0)	45	2 (4.4)
11+ years	188	5 (2.7)	93	1 (1.1)	282	6 (2.1)
p value		0.320		1.000		0.492
2020						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<3 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
3 to 10 years	4	1 (25.0)	1	0 (0.0)	6	2 (33.3)
11+ years	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
p value		0.200		--		0.042

Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
No receptive sharing	181	3 (1.7)	97	0 (0.0)	284	3 (1.1)
Receptive sharing	41	2 (4.9)	14	1 (7.1)	55	3 (5.5)
p value		0.230		0.126		0.056
2018						
No receptive sharing	210	7 (3.3)	110	1 (0.9)	320	8 (2.5)
Receptive sharing	48	1 (2.1)	21	0 (0.0)	70	1 (1.4)
p value		1.000		1.000		1.000
2019						
No receptive sharing	185	6 (3.2)	98	1 (1.0)	286	7 (2.5)
Receptive sharing	29	1 (3.5)	21	0 (0.0)	52	1 (1.9)
p value		1.000		1.000		1.000
2020						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No receptive sharing	22	1 (4.6)	9	0 (0.0)	32	2 (6.3)
Receptive sharing	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
p value		1.000		--		1.000

Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Victoria	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Less than daily	95	1 (1.1)	51	0 (0.0)	148	1 (0.7)
Daily or more	132	5 (3.8)	63	1 (1.6)	199	6 (3.0)
Not last month	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
p value		0.596		1.000		0.353
2018						
Less than daily	117	3 (2.6)	51	0 (0.0)	169	3 (1.8)
Daily or more	143	5 (3.5)	81	1 (1.2)	224	6 (2.7)
Not last month	24	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		0.870		1.000		0.882
2019						
Less than daily	70	1 (1.4)	36	0 (0.0)	107	1 (0.9)
Daily or more	145	6 (4.1)	86	1 (1.2)	235	7 (3.0)
Not last month	17	1 (5.9)	5	0 (0.0)	22	1 (4.6)
p value		0.324		1.000		0.328
2020						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Less than daily	12	1 (8.3)	3	0 (0.0)	15	1 (6.7)
Daily or more	12	0 (0.0)	7	0 (0.0)	20	1 (5.0)
Not last month	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
p value		1.000		--		1.000

Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No imprisonment	189	5 (2.7)	105	1 (1.0)	300	6 (2.0)
Imprisonment	40	0 (0.0)	10	0 (0.0)	50	0 (0.0)
p value		0.590		1.000		0.600
2018						
No imprisonment	218	7 (3.2)	115	1 (0.9)	334	8 (2.4)
Imprisonment	52	1 (1.9)	23	0 (0.0)	75	1 (1.3)
p value		1.000		1.000		1.000
2019						
No imprisonment	162	5 (3.1)	95	1 (1.1)	261	6 (2.3)
Imprisonment	55	2 (3.6)	26	0 (0.0)	82	2 (2.4)
p value		1.000		1.000		1.000
2020						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No imprisonment	24	1 (4.2)	7	0 (0.0)	32	2 (6.3)
Imprisonment	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
p value		1.000		--		1.000

Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Victoria	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No condom use	62	1 (1.6)	45	0 (0.0)	109	1 (0.9)
Condom use	22	1 (4.6)	9	1 (11.1)	32	2 (6.3)
p value		0.458		0.167		0.129
2018						
No condom use	73	2 (2.7)	53	0 (0.0)	126	2 (1.6)
Condom use	25	1 (4.0)	8	0 (0.0)	33	1 (3.0)
p value		1.000		--		0.505
2019						
No condom use	57	1 (1.8)	42	0 (0.0)	100	1 (1.0)
Condom use	18	0 (0.0)	12	0 (0.0)	32	0 (0.0)
p value		1.000		--		1.000
2020						
No condom use	--	-- --	--	-- --	--	-- --
Condom use	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No condom use	2	0 (0.0)	3	0 (0.0)	5	0 (0.0)
Condom use	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
p value		--		--		--

Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Victoria	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
No sex work	223	5 (2.2)	103	1 (1.0)	332	6 (1.8)
Sex work	4	0 (0.0)	14	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
2018						
No sex work	257	8 (3.1)	118	1 (0.9)	377	9 (2.4)
Sex work	13	0 (0.0)	16	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
2019						
No sex work	210	8 (3.8)	107	1 (0.9)	321	9 (2.8)
Sex work	14	0 (0.0)	14	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
2020						
No sex work	--	-- --	--	-- --	--	-- --
Sex work	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No sex work	23	1 (4.4)	4	0 (0.0)	27	1 (3.7)
Sex work	0	0 (0.0)	4	0 (0.0)	5	1 (20.0)
p value		--		--		0.292

Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Non Indigenous	207	4 (1.9)	104	0 (0.0)	316	4 (1.3)
Indigenous	34	2 (5.9)	20	1 (5.0)	55	3 (5.5)
p value		0.201		0.161		0.070
2018						
Non Indigenous	240	4 (1.7)	117	0 (0.0)	358	4 (1.1)
Indigenous	43	4 (9.3)	27	1 (3.7)	71	5 (7.0)
p value		0.021		0.187		0.008
2019						
Non Indigenous	183	4 (2.2)	102	0 (0.0)	289	4 (1.4)
Indigenous	42	4 (9.5)	23	1 (4.4)	65	5 (7.7)
p value		0.042		0.184		0.012
2020						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Non Indigenous	19	1 (5.3)	10	0 (0.0)	30	2 (6.7)
Indigenous	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
p value		1.000		--		1.000

Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
English speaking	203	5 (2.5)	124	1 (0.8)	333	6 (1.8)
Non-English speaking	40	1 (2.5)	3	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		0.576
2018						
English speaking	254	8 (3.2)	136	1 (0.7)	392	9 (2.3)
Non-English speaking	34	0 (0.0)	9	0 (0.0)	43	0 (0.0)
p value		0.602		1.000		0.609
2019						
English speaking	209	7 (3.4)	125	1 (0.8)	338	8 (2.4)
Non-English speaking	23	1 (4.4)	2	0 (0.0)	26	1 (3.9)
p value		0.572		1.000		0.491
2020						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
English speaking	21	1 (4.8)	11	0 (0.0)	33	2 (6.1)
Non-English speaking	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
p value		1.000		--		1.000

Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Australia	209	5 (2.4)	116	1 (0.9)	329	6 (1.8)
Other Oceania	5	0 (0.0)	3	0 (0.0)	9	0 (0.0)
Asia	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)
UK & Ireland	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)
Other	17	0 (0.0)	1	0 (0.0)	19	0 (0.0)
p value		0.246		1.000		0.250
2018						
Australia	243	8 (3.3)	127	1 (0.8)	372	9 (2.4)
Other Oceania	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
Asia	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)
UK & Ireland	8	0 (0.0)	12	0 (0.0)	20	0 (0.0)
Other	21	0 (0.0)	3	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		1.000
2019						
Australia	206	6 (2.9)	119	1 (0.8)	328	7 (2.1)
Other Oceania	2	0 (0.0)	4	0 (0.0)	7	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
Other	16	2 (12.5)	3	0 (0.0)	19	2 (10.5)
p value		0.283		1.000		0.234
2020						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Australia	20	1 (0.0)	10	0 (0.0)	30	1 (3.3)
Other Oceania	0	0 (0.0)	1	0 (0.0)	2	1 (50.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
Other	3	0 (0.0)	0	0 (0.0)	3	0 (0.0)
p value		1.000		--		0.212

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and survey year

Victoria Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	230	160 (70)	118	85 (72)	353	246 (70)
2018	284	161 (57)	145	81 (56)	431	243 (56)
2019	236	153 (65)	126	76 (60)	367	232 (63)
2020	--	-- --	--	-- --	--	-- --
2021	25	8 (32.0)	11	8 (72.7)	37	16 (43.2)
X ² p trend		0.008		0.233		0.005

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Victoria Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	193	135 (70)	76	52 (68)	269	187 (70)
Bisexual	9	6 (67)	23	19 (83)	34	25 (74)
Homosexual	4	1 (25)	9	6 (67)	16	8 (50)
p value		0.185		0.392		0.217
2018						
Heterosexual	236	136 (58)	101	58 (57)	337	194 (58)
Bisexual	10	4 (40)	22	12 (55)	32	16 (50)
Homosexual	11	7 (64)	6	4 (67)	18	11 (61)
p value		0.471		0.889		0.668
2019						
Heterosexual	196	129 (66)	77	46 (60)	273	175 (64)
Bisexual	11	6 (55)	22	12 (55)	37	20 (54)
Homosexual	6	1 (17)	10	7 (70)	16	8 (50)
p value		0.041		0.737		0.290
2020						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heterosexual	22	8 (36.4)	4	4 (100.0)	27	12 (44.4)
Bisexual	1	0 (0.0)	6	3 (50.0)	7	3 (42.9)
Homosexual	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
p value		1.000		0.273		1.000

Table 8.3.3 HCV antibody prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	3	0 (0)	4	3 (75)	7	3 (43)
25-34 years	36	22 (61)	20	13 (65)	59	35 (59)
35-44 years	101	70 (69)	47	34 (72)	148	104 (70)
45+ years	87	67 (77)	47	35 (74)	136	103 (76)
p value		0.019		0.899		0.046
2018						
<25 years	2	0 (0)	6	2 (33)	8	2 (25)
25-34 years	43	22 (51)	30	17 (57)	73	39 (53)
35-44 years	115	69 (60)	57	31 (54)	173	101 (58)
45+ years	120	68 (57)	51	31 (61)	172	99 (58)
p value		0.300		0.647		0.294
2019						
<25 years	3	2 (67)	3	0 (0)	6	2 (33)
25-34 years	32	13 (41)	25	17 (68)	59	30 (51)
35-44 years	98	56 (57)	54	30 (56)	153	87 (57)
45+ years	100	79 (79)	43	29 (67)	144	109 (76)
p value		<0.001		0.090		<0.001
2020						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)
35-44 years	6	2 (33.3)	4	2 (50.0)	10	4 (40.0)
45+ years	19	6 (31.6)	6	6 (100.0)	25	12 (48.0)
p value		1.000		0.061		0.542

Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<3 years	3	0 (0)	3	1 (33)	8	1 (13)
3 to 10 years	20	9 (45)	17	12 (71)	37	21 (57)
11+ years	201	147 (73)	93	69 (74)	297	217 (73)
p value		0.001		0.264		<0.001
2018						
<3 years	12	2 (17)	6	0 (0)	18	2 (11)
3 to 10 years	24	13 (54)	24	13 (54)	48	26 (54)
11+ years	233	137 (59)	107	64 (60)	342	202 (59)
p value		0.014		0.013		<0.001
2019						
<3 years	6	1 (17)	7	0 (0)	13	1 (8)
3 to 10 years	23	10 (43)	20	8 (40)	45	19 (42)
11+ years	189	129 (68)	91	62 (68)	281	191 (68)
p value		0.003		<0.001		<0.001
2020						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<3 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
3 to 10 years	4	1 (25.0)	1	1 (100.0)	6	2 (33.3)
11+ years	20	7 (35.0)	9	7 (77.8)	29	14 (48.3)
p value		1.000		0.491		0.575

Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No receptive sharing	6	0 (0)	256	177 (69)	265	180 (68)
Receptive sharing	1	0 (0)	50	39 (78)	53	40 (75)
p value		--		0.209		0.277
2018						
No receptive sharing	14	1 (7)	291	174 (60)	315	180 (57)
Receptive sharing	3	1 (33)	60	39 (65)	70	46 (66)
p value		0.331		0.452		0.188
2019						
No receptive sharing	11	1 (9)	259	169 (65)	285	184 (65)
Receptive sharing	0	0 (0)	44	30 (68)	52	35 (67)
p value		--		0.705		0.703
2020						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No receptive sharing	2	0 (0.0)	30	14 (46.7)	32	14 (43.8)
Receptive sharing	0	0 (0.0)	3	2 (66.7)	3	2 (66.7)
p value		--		0.601		0.582

Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	3	1 (33)	206	158 (77)	217	165 (76)
Methamphetamine	4	0 (0)	83	49 (59)	88	50 (57)
Other opioids	0	0 (0)	21	15 (71)	21	15 (71)
Other drugs	1	0 (0)	23	15 (65)	24	15 (63)
p value		0.386		0.024		0.008
2018						
Heroin	6	1 (17)	200	134 (67)	216	141 (65)
Methamphetamine	8	1 (13)	142	68 (48)	156	72 (46)
Other opioids	0	0 (0)	19	8 (42)	20	8 (40)
Other drugs	4	0 (0)	22	15 (68)	30	17 (57)
p value		0.704		0.001		0.001
2019						
Heroin	4	1 (25)	177	126 (71)	194	138 (71)
Methamphetamine	9	0 (0)	104	63 (61)	121	69 (57)
Other opioids	0	0 (0)	12	6 (50)	13	7 (54)
Other drugs	0	0 (0)	29	13 (45)	33	16 (48)
p value		0.118		0.017		0.013
2020						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heroin	0	0 (0.0)	15	6 (40.0)	15	6 (40.0)
Methamphetamine	2	0 (0.0)	14	7 (50.0)	16	7 (43.8)
Other opioids	0	0 (0.0)	2	1 (50.0)	2	1 (50.0)
Other drugs	0	0 (0.0)	4	2 (50.0)	4	2 (50.0)
p value		--		0.951		0.981

Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Less than daily	5	0 (0)	132	95 (72)	139	96 (69)
Daily or more	2	0 (0)	180	127 (71)	186	131 (70)
Not last month	1	1 (100)	21	15 (71)	25	18 (72)
p value		0.125		0.963		0.966
2018						
Less than daily	11	0 (0)	153	89 (58)	168	91 (54)
Daily or more	6	2 (33)	201	125 (62)	220	136 (62)
Not last month	1	0 (0)	31	12 (39)	36	12 (33)
p value		0.209		0.046		0.005
2019						
Less than daily	3	0 (0)	98	58 (59)	107	62 (58)
Daily or more	9	1 (11)	208	142 (68)	234	158 (68)
Not last month	1	0 (0)	17	9 (53)	23	11 (48)
p value		1.000		0.174		0.064
2020						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Less than daily	0	0 (0.0)	15	7 (46.7)	15	7 (46.7)
Daily or more	2	0 (0.0)	18	9 (50.0)	20	9 (45.0)
Not last month	0	0 (0.0)	2	0 (0.0)	2	0 (0.0)
p value		--		0.641		0.657

Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No imprisonment	6	1 (17)	268	183 (68)	283	189 (67)
Imprisonment	2	0 (0)	44	37 (84)	46	37 (80)
p value		1.000		0.033		0.064
2018						
No imprisonment	16	2 (13)	304	165 (54)	332	173 (52)
Imprisonment	2	0 (0)	64	50 (78)	72	53 (74)
p value		1.000		<0.001		0.001
2019						
No imprisonment	11	1 (9)	236	140 (59)	263	152 (58)
Imprisonment	1	0 (0)	69	52 (75)	81	61 (75)
p value		1.000		0.015		0.005
2020						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No imprisonment	2	0 (0.0)	30	12 (40.0)	32	12 (37.5)
Imprisonment	0	0 (0.0)	2	1 (50.0)	2	1 (50.0)
p value		--		1.000		1.000

Table 8.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	195	133 (68)	97	67 (69)	297	201 (68)
Indigenous	33	25 (76)	18	15 (83)	51	40 (78)
p value		0.384		0.269		0.124
2018						
Non Indigenous	237	131 (55)	117	64 (55)	355	195 (55)
Indigenous	42	27 (64)	27	17 (63)	70	45 (64)
p value		0.277		0.435		0.149
2019						
Non Indigenous	185	113 (61)	100	62 (62)	289	177 (61)
Indigenous	42	34 (81)	23	12 (52)	65	46 (71)
p value		0.015		0.385		0.151
2020						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Non Indigenous	19	7 (36.8)	10	7 (70.0)	30	14 (46.7)
Indigenous	6	1 (16.7)	1	1 (100.0)	7	2 (28.6)
p value		0.624		1.000		0.674

Table 8.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	192	130 (68)	115	83 (72)	312	214 (69)
Non-English speaking	38	30 (79)	3	2 (67)	41	32 (78)
p value		0.169		1.000		0.215
2018						
English speaking	249	137 (55)	136	75 (55)	387	213 (55)
Non-English speaking	34	24 (71)	9	6 (67)	43	30 (70)
p value		0.086		0.731		0.065
2019						
English speaking	210	134 (64)	123	73 (59)	337	209 (62)
Non-English speaking	24	19 (79)	2	2 (100)	27	22 (81)
p value		0.134		0.516		0.043
2020						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
English speaking	21	6 (28.6)	11	8 (72.7)	33	14 (42.4)
Non-English speaking	4	2 (50.0)	0	0 (0.0)	4	2 (50.0)
p value		0.570		--		1.000

Table 8.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Australia	196	133 (68)	107	79 (74)	306	212 (69)
Other Oceania	5	3 (60)	3	2 (67)	9	6 (67)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	8	7 (88)	5	3 (60)	13	10 (77)
Other	17	14 (82)	1	0 (0)	19	14 (74)
p value		0.587		0.180		0.936
2018						
Australia	238	132 (55)	127	72 (57)	367	205 (56)
Other Oceania	9	4 (44)	3	1 (33)	12	5 (42)
Asia	6	5 (83)	0	0 (0)	6	5 (83)
UK & Ireland	8	3 (38)	12	6 (50)	20	9 (45)
Other	21	16 (76)	3	2 (67)	24	18 (75)
p value		0.140		0.826		0.121
2019						
Australia	207	133 (64)	117	71 (61)	327	205 (63)
Other Oceania	2	2 (100)	4	1 (25)	7	4 (57)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	6	5 (83)	1	1 (100)	7	6 (86)
Other	16	11 (69)	3	2 (67)	19	13 (68)
p value		0.855		0.485		0.802
2020						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Australia	20	7 (35.0)	10	8 (80.0)	30	15 (50.0)
Other Oceania	0	0 (0.0)	1	0 (0.0)	2	0 (0.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
Other	3	1 (33.3)	0	0 (0.0)	3	1 (33.3)
p value		1.000		0.273		0.435

HCV RNA prevalence

Table 8.4.1 HCV RNA prevalence by gender and survey year

Victoria	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*	137	51 (37)	70	22 (31)	210	74 (35)
2018*	198	46 (23)	99	20 (20)	299	66 (22)
2019*	219	49 (22)	117	23 (20)	341	73 (21)
2020	--	-- --	--	-- --	--	-- --
2021	19	0 (0)	8	4 (50)	28	5 (18)
X ² p trend (4 year)		<0.001		0.578		<0.001

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 8.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Victoria	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heterosexual	115	43 (37)	43	15 (35)	158	58 (37)
Bisexual	6	3 (50)	12	3 (25)	19	7 (37)
Homosexual	1	1 (100)	4	0 (0)	6	1 (17)
p value		0.313		0.366		0.627
2018*						
Heterosexual	163	41 (25)	71	16 (23)	234	57 (24)
Bisexual	8	0 (0)	15	3 (20)	23	3 (13)
Homosexual	6	2 (33)	4	0 (0)	10	2 (20)
p value		0.222		0.548		0.325
2019*						
Heterosexual	183	42 (23)	71	15 (21)	254	57 (22)
Bisexual	9	2 (22)	20	2 (10)	33	6 (18)
Homosexual	6	0 (0)	10	5 (50)	16	5 (31)
p value		0.394		0.045		0.604
2020						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heterosexual	16	0 (0)	3	1 (33)	20	2 (10)
Bisexual	1	0 (0)	4	2 (50)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		0.659		0.228

Table 8.4.3 HCV RNA prevalence by age group, gender and survey year

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	2	0 (0)	3	1 (33)	5	1 (20)
25-34 years	24	8 (33)	10	3 (30)	36	11 (31)
35-44 years	68	25 (37)	32	11 (34)	100	36 (36)
45+ years	43	18 (42)	25	7 (28)	68	25 (37)
p value		0.668		0.988		0.866
2018*						
<25 years	2	0 (0)	5	3 (60)	8	3 (38)
25-34 years	23	5 (22)	23	5 (22)	47	10 (21)
35-44 years	86	25 (29)	34	7 (21)	121	32 (26)
45+ years	84	15 (18)	35	4 (11)	120	20 (17)
p value		0.295		0.077		0.131
2019*						
<25 years	2	0 (0)	3	0 (0)	5	0 (0)
25-34 years	30	6 (20)	22	3 (14)	53	9 (17)
35-44 years	92	20 (22)	51	12 (24)	144	31 (22)
45+ years	92	22 (24)	40	8 (20)	134	31 (23)
p value		0.814		0.656		0.493
2020						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	1	0 (0)	2	1 (50)
35-44 years	4	0 (0)	2	1 (50)	6	1 (17)
45+ years	15	0 (0)	5	3 (60)	20	3 (15)
p value		--		0.549		0.466

Table 8.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	2	0 (0)	2	0 (0)	5	0 (0)
3 to 10 years	15	3 (20)	9	3 (33)	24	6 (25)
11+ years	115	47 (41)	56	19 (34)	173	66 (38)
p value		0.167		0.622		0.139
2018*						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 10 years	11	3 (27)	13	6 (46)	24	9 (38)
11+ years	170	39 (23)	77	12 (16)	248	51 (21)
p value		0.442		0.092		0.243
2019*						
<3 years	6	1 (17)	7	0 (0)	13	1 (8)
3 to 10 years	20	6 (30)	19	3 (16)	40	10 (25)
11+ years	175	37 (21)	85	20 (24)	261	57 (22)
p value		0.639		0.290		0.398
2020						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	3	0 (0)	1	1 (100)	5	2 (40)
11+ years	15	0 (0)	7	3 (43)	22	3 (14)
p value		--		0.285		0.340

Table 8.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	99	36 (36)	58	19 (33)	160	55 (34)
Receptive sharing	32	14 (44)	5	1 (20)	37	15 (41)
p value		0.407		0.604		0.430
2018*						
No receptive sharing	141	33 (23)	71	12 (17)	212	45 (21)
Receptive sharing	36	9 (25)	18	8 (44)	55	18 (33)
p value		0.761		0.005		0.065
2019*						
No receptive sharing	174	38 (22)	91	16 (18)	269	55 (20)
Receptive sharing	25	7 (28)	19	5 (26)	45	13 (29)
p value		0.549		0.358		0.225
2020						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No receptive sharing	18	0 (0)	6	3 (50)	25	4 (16)
Receptive sharing	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.350		0.234

Table 8.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Victoria	Male		Female		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	93	37 (40)	44	16 (36)	139	53 (38)
Methamphetamine	27	11 (41)	17	5 (29)	46	16 (35)
Other opioids	3	1 (33)	4	1 (25)	8	2 (25)
Other drugs	12	2 (17)	3	0 (0)	15	2 (13)
p value		0.606		0.615		0.369
2018*						
Heroin	111	25 (23)	55	9 (16)	167	34 (20)
Methamphetamine	65	16 (25)	27	8 (30)	93	24 (26)
Other opioids	7	1 (14)	6	0 (0)	14	1 (7)
Other drugs	12	4 (33)	7	3 (43)	19	7 (37)
p value		0.800		0.187		0.199
2019*						
Heroin	115	19 (17)	67	12 (18)	183	30 (16)
Methamphetamine	69	19 (28)	38	9 (24)	109	29 (27)
Other opioids	11	11 (100)	2	0 (0)	13	5 (38)
Other drugs	19	5 (26)	10	2 (20)	31	7 (23)
p value		0.088		0.814		0.092
2020						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Heroin	9	0 (0)	3	0 (0)	13	1 (8)
Methamphetamine	8	0 (0)	4	3 (75)	12	3 (25)
Other opioids	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.082		0.398

Table 8.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Victoria Frequency of injection last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Less than daily	47	16 (34)	29	8 (28)	77	24 (31)
Daily or more	84	34 (40)	36	13 (36)	121	47 (39)
Not last month	5	1 (20)	4	1 (25)	9	2 (22)
p value		0.596		0.856		0.475
2018*						
Less than daily	70	14 (20)	33	6 (18)	104	20 (19)
Daily or more	107	28 (26)	57	14 (25)	164	42 (26)
Not last month	19	4 (21)	8	0 (0)	27	4 (15)
p value		0.538		0.219		0.186
2019*						
Less than daily	65	13 (20)	32	6 (19)	96	19 (20)
Daily or more	135	33 (24)	91	15 (16)	220	50 (23)
Not last month	17	2 (12)	5	2 (40)	22	4 (18)
p value		0.409		0.490		0.742
2020						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Less than daily	9	0 (0)	2	2 (100)	11	2 (18)
Daily or more	10	0 (0)	5	2 (40)	16	3 (19)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.202		0.893

Table 8.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Victoria Imprisonment last year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No imprisonment	109	39 (36)	57	17 (30)	168	56 (33)
Imprisonment	22	11 (50)	5	1 (20)	27	12 (44)
p value		0.203		0.687		0.239
2018*						
No imprisonment	148	34 (23)	81	15 (19)	229	49 (21)
Imprisonment	33	8 (24)	13	4 (31)	46	12 (26)
p value		0.691		0.333		0.370
2019*						
No imprisonment	156	27 (17)	90	18 (20)	250	46 (18)
Imprisonment	48	16 (33)	22	4 (18)	71	20 (28)
p value		0.030		0.865		0.058
2020						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
No imprisonment	19	0 (0)	4	3 (75)	24	4 (17)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.171		0.656

Table 8.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Non Indigenous	114	42 (37)	55	14 (25)	171	56 (33)
Indigenous	22	8 (36)	14	7 (50)	37	15 (41)
p value		0.911		0.049		0.305
2018*						
Non Indigenous	159	38 (24)	80	17 (21)	240	55 (23)
Indigenous	37	7 (19)	19	3 (16)	57	10 (18)
p value		0.417		0.840		0.411
2019*						
Non Indigenous	175	34 (19)	91	18 (20)	270	53 (20)
Indigenous	39	14 (36)	23	5 (22)	61	19 (31)
p value		0.035		0.801		0.066
2020						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Non Indigenous	14	0 (0)	7	3 (43)	22	4 (18)
Indigenous	5	0 (0)	1	1 (100)	6	1 (17)
p value		--		0.285		0.932

Table 8.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
English speaking	112	41 (37)	70	22 (31)	185	63 (34)
Non-English speaking	25	10 (40)	0	0 (0)	25	10 (40)
p value		0.715		--		0.537
2018*						
English speaking	172	36 (21)	94	18 (19)	267	54 (20)
Non-English speaking	26	10 (38)	5	2 (40)	31	12 (39)
p value		0.061		0.097		0.013
2019*						
English speaking	195	44 (23)	114	21 (18)	313	66 (21)
Non-English speaking	23	5 (22)	2	2 (100)	26	8 (31)
p value		0.891		0.004		0.274
2020						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
English speaking	16	0 (0)	8	4 (50)	25	5 (20)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		0.393

Table 8.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Australia	119	46 (39)	64	20 (31)	186	66 (35)
Other Oceania	3	1 (33)	2	1 (50)	5	2 (40)
Asia	2	1 (50)	0	0 (0)	2	1 (50)
UK & Ireland	4	1 (25)	3	1 (33)	7	2 (29)
Other	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.947		0.757		0.921
2018*						
Australia	168	34 (20)	84	14 (17)	254	48 (19)
Other Oceania	6	2 (33)	3	1 (33)	10	3 (30)
Asia	3	3 (100)	0	0 (0)	3	3 (100)
UK & Ireland	4	0 (0)	9	3 (33)	13	3 (23)
Other	15	7 (47)	3	2 (67)	18	9 (50)
p value		0.004		0.249		0.001
2019*						
Australia	192	42 (22)	109	21 (19)	304	64 (21)
Other Oceania	2	1 (50)	3	1 (33)	6	3 (50)
Asia	3	0 (0)	0	0 (0)	3	0 (0)
UK & Ireland	6	2 (33)	1	1 (100)	7	3 (43)
Other	15	4 (27)	3	0 (0)	18	4 (22)
p value		0.690		0.155		0.248
2020						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--
2021						
Australia	14	0 (0)	8	4 (50)	22	4 (18)
Other Oceania	0	0 (0)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)
Other	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		0.128

Western Australia
Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Western Australia	2017	2018	2019	2020*	2021*
Number of sites	4	4	4	4	4
N° surveyed	N=508	N=521	N=528	N=399	N=485
Response rate (%)	72%	71%	78%	57%	68%
Gender (%)					
Male	340 (67)	309 (59)	327 (62)	246 (62)	292 (60)
Female	166 (33)	211 (41)	199 (38)	152 (38)	187 (39)
Other*	1 (<1)	1 (<1)	1 (<1)	1 (<1)	4 (1)
Not reported	1 (<1)	0 (0)	1 (<1)	0 (0)	2 (0)
Sexual identity (%)					
Heterosexual	421 (83)	408 (78)	415 (79)	311 (78)	397 (82)
Bisexual	32 (6)	48 (9)	39 (7)	37 (9)	49 (10)
Gay/Lesbian	9 (2)	16 (3)	12 (2)	13 (3)	16 (3)
Other	-- --	-- --	-- --	13 (3)	18 (4)
Not reported	46 (9)	49 (9)	62 (12)	25 (6)	5 (1)
Aboriginal and Torres Strait Islander origin (%)					
No	397 (78)	367 (70)	374 (71)	258 (65)	306 (63)
Yes	106 (21)	139 (27)	146 (28)	123 (31)	150 (31)
Not reported	5 (1)	15 (3)	8 (2)	18 (5)	29 (6)
Region/country of birth (%)					
Australia	423 (83)	427 (82)	457 (87)	336 (84)	401 (83)
Other Oceania	9 (2)	21 (4)	14 (3)	14 (4)	22 (5)
Asia	7 (1)	11 (2)	4 (1)	4 (1)	4 (1)
UK & Ireland	45 (9)	33 (6)	31 (6)	24 (6)	27 (6)
Other	16 (3)	23 (4)	21 (4)	14 (4)	14 (3)
Not reported	8 (2)	6 (1)	1 (<1)	7 (2)	17 (4)
Main language spoken at home by parents (%)					
English	484 (95)	489 (94)	509 (96)	381 (95)	462 (95)
Non-English	21 (4)	26 (5)	17 (3)	15 (4)	17 (4)
Not reported	3 (1)	6 (1)	2 (<1)	3 (1)	6 (1)
Age and time since first injection (years)					
<i>Median age</i>	42	41	41	43	44
<i>Age range</i>	18-70	18-69	15-70	18-74	23-66
Age group (%)					
<25 years	19 (4)	30 (6)	22 (4)	13 (3)	7 (1)
25+ years	484 (95)	490 (94)	505 (96)	385 (96)	472 (97)
Not reported	5 (1)	1 (<1)	1 (<1)	1 (<1)	6 (1)
Median age first injection					
<i>Median age first injection</i>	18	19	19	19	19
<i>Age range</i>	10-53	11-59	10-66	10-57	10-85
<i>N° not reported</i>	33	20	31	11	17
Median yrs since first injection					
<i>Median yrs since first injection</i>	21	20	21	22	23
<i>Range</i>	<1-54	<1-51	<1-55	<1-52	<1-49
Years since first injection					
<3 years	31 (6)	35 (7)	28 (5)	16 (4)	17 (4)
3+ years	444 (87)	465 (89)	467 (88)	372 (93)	448 (92)
Not reported	33 (7)	21 (4)	33 (6)	11 (3)	20 (4)
Imprisonment last year (%)					
No	386 (76)	404 (78)	429 (81)	329 (82)	395 (81)
Yes	71 (14)	80 (15)	69 (13)	54 (14)	61 (13)
Not reported	51 (10)	37 (7)	30 (6)	16 (4)	29 (6)
N° in prison					
<i>N° in prison</i>	N=71	N=80	N=69	N=54	N=61
Injected in prison	20 (28)	25 (31)	23 (33)	12 (22)	14 (23)

* Implementation of the 2020 and 2021 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Western Australia	2017	2018	2019	2020	2021
N° surveyed	N=508	N=521	N=528	N=399	N=485
Drug last injected (%)					
Cocaine	0 (0)	1 (<1)	0 (0)	1 (<1)	1 (<1)
Methamphetamine	275 (54)	357 (69)	352 (67)	254 (64)	282 (58)
Heroin	113 (22)	80 (15)	104 (20)	73 (18)	86 (18)
Pharm. opioids	24 (5)	18 (3)	17 (3)	12 (3)	12 (2)
Methadone	28 (6)	8 (2)	7 (1)	11 (3)	21 (4)
Buprenorphine	8 (2)	9 (2)	5 (1)	10 (3)	21 (4)
Buprenorphine/naloxone	9 (2)	6 (1)	8 (2)	8 (2)	17 (4)
PIEDs	6 (1)	4 (1)	7 (1)	4 (1)	9 (2)
More than one	35 (7)	33 (6)	21 (4)	20 (5)	32 (7)
Other	6 (1)	3 (1)	6 (1)	1 (<1)	3 (1)
Not reported	4 (1)	2 (<1)	1 (<1)	5 (1)	1 (<1)
Ever injected opioids					
No	142 (28)	187 (36)	181 (34)	137 (34)	154 (32)
Yes	363 (71)	330 (63)	341 (65)	261 (65)	327 (67)
Not reported	3 (1)	4 (1)	6 (1)	1 (<1)	4 (1)
Frequency of injection last month (%)					
Not last month	40 (8)	28 (5)	26 (5)	32 (8)	40 (8)
Less than weekly	57 (11)	55 (11)	70 (13)	84 (21)	98 (20)
Weekly not daily	109 (21)	104 (20)	124 (23)	91 (23)	121 (25)
Daily or more	292 (57)	321 (62)	298 (56)	189 (47)	215 (44)
Not reported	10 (2)	13 (3)	10 (2)	3 (1)	11 (2)
Present when someone injected for the first time in the last 12 months (%)					
No	363 (71)	372 (71)	401 (76)	317 (79)	395 (81)
Yes	118 (23)	125 (24)	104 (20)	77 (19)	83 (17)
Not reported	27 (5)	24 (5)	23 (4)	5 (1)	7 (1)
Overdosed in last 12 months					
No	368 (72)	390 (75)	409 (77)	346 (87)	412 (85)
Yes	112 (22)	107 (21)	96 (18)	47 (12)	63 (13)
Not reported	28 (6)	24 (5)	23 (4)	6 (2)	10 (2)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year

Western Australia	2017	2018	2019	2020	2021
N° injected last month	N=458	N=480	N=492	N=364	N=434
Places injected last month (%)					
All private	207 (45)	193 (40)	217 (44)	169 (46)	183 (42)
Any public	247 (54)	286 (60)	274 (56)	194 (53)	247 (57)
Not reported	4 (1)	1 (<1)	1 (<1)	1 (<1)	4 (1)
Use of new and sterile needles and syringes last month (%)					
All injections	275 (60)	278 (58)	322 (65)	244 (67)	269 (62)
Most of the time	140 (31)	146 (30)	124 (25)	96 (26)	126 (29)
Half of the time	22 (5)	31 (6)	24 (5)	9 (2)	14 (3)
Some of the time	10 (2)	14 (3)	16 (3)	10 (3)	17 (4)
Not last month	4 (1)	5 (1)	1 (<1)	2 (1)	3 (1)
Not reported	7 (2)	6 (1)	5 (1)	3 (1)	5 (1)
Re-used someone else's used needle & syringe last month (%)					
None	331 (72)	330 (69)	354 (72)	276 (76)	321 (74)
Once	33 (7)	56 (12)	39 (8)	30 (8)	34 (8)
Twice	28 (6)	27 (6)	48 (10)	22 (6)	27 (6)
3-5 times	33 (7)	32 (7)	22 (4)	27 (7)	22 (5)
>5 times	23 (5)	31 (6)	21 (4)	9 (2)	26 (6)
Not reported	10 (2)	4 (1)	8 (2)	0 (0)	4 (1)
Number of people needle & syringe was re-used after last month (%)					
None	331 (72)	330 (69)	354 (72)	276 (76)	321 (74)
One	51 (11)	62 (13)	72 (15)	39 (11)	49 (11)
Two	14 (3)	14 (3)	14 (3)	8 (2)	17 (4)
Three to five	10 (2)	15 (3)	7 (1)	6 (2)	11 (3)
More than five	3 (1)	8 (2)	8 (2)	4 (1)	7 (2)
Don't know	25 (5)	18 (4)	20 (4)	21 (6)	18 (4)
Not reported	24 (5)	33 (7)	17 (3)	10 (3)	11 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]					
Regular sex partner	41 (9)	58 (12)	56 (11)	39 (11)	43 (10)
Casual sex partner	4 (1)	7 (1)	7 (1)	6 (2)	6 (1)
Close friend	40 (9)	47 (10)	25 (5)	16 (4)	33 (8)
Acquaintance	16 (3)	17 (4)	15 (3)	15 (4)	26 (6)
Other	12 (3)	14 (3)	15 (3)	11 (3)	6 (1)
Equipment used after someone else last month (%) [more than one could be selected]					
Spoon	107 (23)	91 (19)	94 (19)	56 (15)	94 (22)
Water	113 (25)	132 (28)	115 (23)	86 (24)	130 (30)
Filter	56 (12)	59 (12)	32 (7)	21 (6)	46 (11)
Drug mix	52 (11)	63 (13)	47 (10)	36 (10)	56 (13)
None	273 (60)	284 (59)	304 (62)	230 (63)	255 (59)
Injected by someone after that person injected themselves or others last month (%)					
No	345 (75)	361 (75)	379 (77)	304 (84)	327 (75)
Yes	104 (23)	110 (23)	105 (21)	60 (16)	103 (24)
Not reported	9 (2)	9 (2)	8 (2)	0 (0)	4 (1)
Source of needle acquisition					
Needle Syringe Program	363 (79)	374 (78)	398 (81)	293 (80)	350 (81)
Chemist/Pharmacy	157 (34)	185 (39)	177 (36)	138 (38)	153 (35)
Personal sources	60 (13)	72 (15)	72 (15)	49 (13)	57 (13)
Dispensing/Vending Machine	12 (3)	11 (2)	15 (3)	3 (1)	4 (1)
Other sources	24 (5)	21 (4)	23 (5)	10 (3)	8 (2)

Table 9.1.4 Number (percentage) of respondents by treatment for drug use and survey year

Western Australia	2017	2018	2019	2020	N=485
N° surveyed	N=508	N=521	N=528	N=399	
Ever any treatment/therapy for drug use (%)					
No	189 (37)	239 (49)	225 (43)	177 (44)	206 (42)
Yes	316 (62)	277 (53)	303 (57)	222 (56)	279 (58)
Not reported	3 (1)	5 (1)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)					
Currently	71 (14)	56 (11)	68 (13)	42 (11)	59 (12)
Previously	96 (19)	72 (14)	83 (16)	55 (14)	70 (14)
Never	324 (64)	373 (72)	365 (69)	295 (74)	345 (71)
Not reported	17 (3)	20 (4)	12 (2)	7 (2)	11 (2)
History of buprenorphine (Subutex®) treatment (%)					
Currently	35 (7)	28 (5)	34 (6)	19 (5)	33 (7)
Previously	83 (16)	88 (17)	93 (18)	51 (13)	81 (17)
Never	379 (75)	388 (74)	399 (76)	323 (81)	358 (74)
Not reported	11 (2)	17 (3)	2 (<1)	6 (2)	13 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)					
Currently	24 (5)	30 (6)	41 (8)	17 (4)	30 (6)
Previously	71 (14)	80 (15)	87 (16)	52 (13)	76 (16)
Never	397 (78)	393 (75)	394 (75)	327 (82)	372 (77)
Not reported	16 (3)	18 (3)	6 (1)	3 (1)	7 (1)

Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia	2017	2018	2019	2020	2021
N° surveyed	N=508	N=521	N=528	N=399	N=485
Previous HIV test (%)					
Yes, ever	384 (76)	389 (75)	391 (74)	303 (76)	370 (76)
Yes, last year	226 (44)	252 (48)	253 (48)	179 (45)	216 (45)
>1 year ago	158 (31)	137 (26)	138 (26)	124 (31)	154 (32)
Never tested	84 (17)	99 (19)	106 (20)	83 (21)	92 (19)
Not reported	40 (8)	33 (6)	31 (6)	13 (3)	23 (5)
Previous HCV test (%)					
Yes, ever	397 (78)	397 (76)	396 (75)	315 (79)	377 (78)
Yes, last year	252 (50)	273 (52)	264 (50)	188 (47)	258 (53)
>1 year ago	145 (29)	124 (24)	132 (25)	127 (32)	119 (25)
Never tested	51 (10)	64 (12)	73 (14)	52 (13)	63 (13)
Not reported	60 (12)	60 (12)	59 (11)	32 (8)	45 (9)
Lifetime treatment for HCV (%)#					
N° self-reported HCV diagnosis	N=97	N=99	N=103	N=87	N=110
Antiviral treatment	34 (35)	42 (42)	60 (58)	45 (52)	58 (53)
No antiviral treatment	62 (64)	55 (56)	42 (41)	41 (47)	52 (47)
Not reported	1 (1)	2 (2)	1 (1)	1 (1)	0 (0)
Treatment for HCV in past 12 months (%)**					
N° self-reported HCV diagnosis	N=90	N=93	N=76	N=64	N=86
Antiviral treatment	20 (22)	28 (30)	25 (33)	12 (19)	22 (26)
No antiviral treatment	69 (77)	63 (68)	50 (66)	51 (80)	64 (74)
Not reported	1 (1)	2 (2)	1 (1)	1 (2)	0 (0)

among people who tested HCV antibody positive and did not report spontaneous clearance

* excludes people who reported treatment induced clearance more than 12 months previously

Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year

Western Australia	2017	2018	2019	2020	2021
N° surveyed	N=508	N=521	N=528	N=399	N=485
Sex with a regular partner last month (%)					
No	240 (47)	235 (45)	252 (48)	209 (52)	226 (47)
Yes	228 (45)	256 (49)	249 (47)	181 (45)	242 (50)
Not reported	40 (8)	30 (6)	27 (5)	9 (2)	17 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=228	N=256	N=249	N=181	N=242
Never	157 (69)	195 (76)	174 (70)	141 (78)	192 (79)
Sometimes	35 (15)	37 (14)	42 (17)	16 (9)	16 (7)
Every time	25 (11)	15 (6)	23 (9)	13 (7)	20 (8)
Not reported	11 (5)	9 (4)	10 (4)	11 (6)	14 (6)
Sex with other partner(s) last month (%)					
No	385 (76)	390 (75)	414 (78)	329 (82)	389 (80)
Yes	78 (15)	99 (19)	82 (16)	59 (15)	72 (15)
Not reported	45 (9)	32 (6)	32 (6)	11 (3)	24 (5)
Condom used with other partner(s) last month (%)					
N° surveyed	N=78	N=99	N=82	N=59	N=72
Never	37 (47)	50 (51)	44 (54)	33 (56)	41 (57)
Sometimes	27 (35)	25 (25)	24 (29)	16 (27)	14 (19)
Every time	13 (17)	20 (20)	9 (11)	8 (14)	13 (18)
Not reported	1 (1)	4 (4)	5 (6)	2 (3)	4 (6)
Sex work last month (%)					
No	435 (86)	446 (86)	460 (87)	364 (91)	432 (89)
Yes	24 (5)	35 (7)	27 (5)	20 (5)	26 (5)
Not reported	49 (10)	40 (8)	41 (8)	15 (4)	27 (6)
Condom used at last sex work (%)					
Yes	15 (63)	23 (66)	11 (41)	5 (25)	11 (42)

Table 9.1.7 Number (percentage) of respondents by COVID-19 related impacts, 2020-2021

Western Australia	2020	2021
N° surveyed	N=399	N=485
More difficult to access sterile needles and syringes		
Yes	52 (13)	59 (12)
No	289 (72)	341 (70)
Not applicable	30 (8)	37 (8)
Not reported	28 (7)	48 (10)
Start depot buprenorphine		
Yes	11 (3)	17 (4)
No	238 (60)	258 (53)
Not applicable	114 (29)	146 (30)
Not reported	36 (9)	64 (13)
Access take home naloxone		
Yes	56 (14)	75 (15)
No	202 (51)	229 (47)
Not applicable	106 (27)	127 (26)
Not reported	35 (9)	54 (11)
Change illicit drug use		
Yes, increased	21 (5)	48 (10)
Yes, decreased	181 (45)	191 (39)
No change	161 (40)	182 (38)
Not reported	36 (9)	64 (13)
Start or increase takeaway dose of methadone/bupe/suboxone		
Yes	22 (6)	29 (6)
No	209 (52)	236 (49)
Not applicable	132 (33)	159 (33)
Not reported	36 (9)	61 (13)
Inject own methadone/bupe/suboxone		
Yes	40 (10)	59 (12)
No	195 (49)	226 (47)
Not applicable	130 (33)	143 (29)
Not reported	34 (9)	57 (12)
COVID-19 vaccine uptake		
≥1 dose	-- --	182 (38)
COVID-19 vaccine doses		
One dose	-- --	86 (18)
Two doses	-- --	96 (20)
No doses	-- --	236 (49)
Not reported	-- --	67 (14)
Vaccine type		
Astra Zeneca	-- --	33 (7)
Pfizer	-- --	106 (22)
Don't know	-- --	43 (9)
Not reported	-- --	303 (62)
COVID-19 test		
Yes	77 (19)	119 (25)
No	265 (66)	267 (55)
Don't know	26 (7)	28 (6)
Not reported	31 (8)	71 (15)
Self-reported positive COVID-19 test result		
Yes	2 (3)	3 (1)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017	310	3 (1.0)	154	2 (1.3)	466	5 (1.1)
2018	299	6 (2.0)	207	4 (1.9)	507	10 (2.0)
2019	320	4 (1.3)	198	3 (1.5)	520	7 (1.4)
2020	239	3 (1.3)	152	2 (1.3)	392	5 (1.3)
2021	289	5 (1.7)	187	1 (0.5)	482	6 (1.2)
X ² p trend		0.702		0.384		0.818

Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
Heterosexual	265	2 (0.8)	116	2 (1.7)	382	4 (1.1)
Bisexual	10	1 (10.0)	22	0 (0.0)	32	1 (3.1)
Homosexual	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		0.162		1.000		0.401
2018						
Heterosexual	249	4 (1.6)	148	2 (1.4)	397	6 (1.5)
Bisexual	16	1 (6.3)	31	2 (6.5)	47	3 (6.4)
Homosexual	10	1 (10.0)	5	0 (0.0)	16	1 (6.3)
p value		0.102		0.230		0.037
2019						
Heterosexual	264	2 (0.8)	145	2 (1.4)	409	4 (1.0)
Bisexual	15	2 (13.3)	23	0 (0.0)	39	2 (5.1)
Homosexual	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
p value		0.019		1.000		0.135
2020						
Heterosexual	195	1 (0.5)	111	2 (1.8)	306	3 (1.0)
Bisexual	16	1 (6.3)	18	0 (0.0)	35	1 (2.9)
Homosexual	10	1 (10.0)	3	0 (0.0)	13	1 (7.7)
p value		0.058		1.000		0.142
2021						
Heterosexual	258	3 (1.2)	136	1 (0.7)	395	4 (1.0)
Bisexual	12	0 (0.0)	36	0 (0.0)	49	0 (0.0)
Homosexual	9	2 (22.2)	5	0 (0.0)	15	2 (13.3)
p value		0.038		1.000		0.067

Table 9.2.3 HIV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
<25 years	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
25-34 years	53	0 (0.0)	38	0 (0.0)	92	0 (0.0)
35-44 years	114	0 (0.0)	59	0 (0.0)	174	0 (0.0)
45+ years	127	3 (2.4)	49	2 (4.1)	176	5 (2.8)
p value		0.323		0.231		0.064
2018						
<25 years	15	0 (0.0)	13	0 (0.0)	28	0 (0.0)
25-34 years	54	1 (1.9)	58	0 (0.0)	112	1 (0.9)
35-44 years	99	1 (1.0)	78	0 (0.0)	178	1 (0.6)
45+ years	131	4 (3.1)	57	4 (7.0)	188	8 (4.3)
p value		0.822		0.031		0.081
2019						
<25 years	10	0 (0.0)	11	0 (0.0)	22	0 (0.0)
25-34 years	54	1 (1.9)	49	0 (0.0)	103	1 (1.0)
35-44 years	124	1 (0.8)	79	1 (1.3)	203	2 (1.0)
45+ years	131	2 (1.5)	59	2 (3.4)	191	4 (2.1)
p value		0.847		0.560		0.718
2020						
<25 years	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
25-34 years	37	0 (0.0)	32	1 (3.1)	70	1 (1.4)
35-44 years	80	1 (1.3)	60	0 (0.0)	140	1 (0.7)
45+ years	118	2 (1.7)	51	1 (2.0)	169	3 (1.8)
p value		1.000		0.412		0.870
2021						
<25 years	4	1 (25.0)	3	0 (0.0)	7	1 (14.3)
25-34 years	31	1 (3.2)	28	0 (0.0)	61	1 (1.6)
35-44 years	103	0 (0.0)	83	0 (0.0)	189	0 (0.0)
45+ years	147	3 (2.0)	71	1 (1.4)	219	4 (1.8)
p value		0.018		0.551		0.016

Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2017						
Heroin	72	0 (0.0)	32	1 (3.1)	105	1 (1.0)
Methamphetamine	166	2 (1.2)	83	1 (1.2)	249	3 (1.2)
Other opioids	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
Other drugs	31	0 (0.0)	17	0 (0.0)	49	0 (0.0)
p value		0.647		0.711		1.000
2018						
Heroin	48	0 (0.0)	31	1 (3.2)	79	1 (1.3)
Methamphetamine	204	5 (2.5)	144	3 (2.1)	348	8 (2.3)
Other opioids	23	0 (0.0)	17	0 (0.0)	40	0 (0.0)
Other drugs	24	1 (4.2)	15	0 (0.0)	40	1 (2.5)
p value		0.508		0.769		1.000
2019						
Heroin	66	1 (1.5)	38	1 (2.6)	104	2 (1.9)
Methamphetamine	201	2 (1.0)	142	2 (1.4)	344	4 (1.2)
Other opioids	29	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other drugs	24	1 (4.2)	10	0 (0.0)	34	1 (2.9)
p value		0.286		0.633		0.511
2020						
Heroin	44	1 (2.3)	27	1 (3.7)	71	2 (2.8)
Methamphetamine	150	1 (0.7)	100	1 (1.0)	250	2 (0.8)
Other opioids	26	0 (0.0)	14	0 (0.0)	41	0 (0.0)
Other drugs	17	1 (5.9)	10	0 (0.0)	27	1 (3.7)
p value		0.161		0.563		0.180
2021						
Heroin	48	2 (4.2)	36	1 (2.8)	86	3 (3.5)
Methamphetamine	168	3 (1.8)	112	0 (0.0)	281	3 (1.1)
Other opioids	44	0 (0.0)	24	0 (0.0)	69	0 (0.0)
Other drugs	29	0 (0.0)	15	0 (0.0)	45	0 (0.0)
p value		0.468		0.401		0.259

Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
<3 years	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 10 years	38	0 (0.0)	24	0 (0.0)	62	0 (0.0)
11 + years	252	3 (1.2)	120	2 (1.7)	374	5 (1.3)
p value		1.000		1.000		1.000
2018						
<3 years	15	1 (6.7)	17	0 (0.0)	32	1 (3.1)
3 to 10 years	46	0 (0.0)	46	0 (0.0)	92	0 (0.0)
11 + years	238	5 (2.1)	144	4 (2.8)	383	9 (2.4)
p value		0.309		0.698		0.259
2019						
<3 years	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
3 to 10 years	36	0 (0.0)	50	1 (2.0)	87	1 (1.2)
11 + years	248	4 (1.6)	124	2 (1.6)	372	6 (1.6)
p value		1.000		1.000		1.000
2020						
<3 years	7	0 (0.0)	9	0 (0.0)	16	0 (0.0)
3 to 10 years	39	0 (0.0)	30	1 (3.3)	70	1 (1.4)
11 + years	187	3 (1.6)	108	1 (0.9)	295	4 (1.4)
p value		1.000		0.462		1.000
2021						
<3 years	13	0 (0.0)	3	0 (0.0)	17	0 (0.0)
3 to 10 years	38	3 (7.9)	35	0 (0.0)	73	3 (4.1)
11 + years	224	2 (0.9)	144	1 (0.7)	372	3 (0.8)
p value		0.039		1.000		0.099

Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2017						
No receptive sharing	197	2 (1.0)	105	2 (1.9)	304	4 (1.3)
Receptive sharing	73	1 (1.4)	32	0 (0.0)	105	1 (1.0)
p value		1.000		1.000		1.000
2018						
No receptive sharing	193	4 (2.1)	130	3 (2.3)	323	7 (2.2)
Receptive sharing	85	0 (0.0)	58	0 (0.0)	143	0 (0.0)
p value		0.317		0.554		0.106
2019						
No receptive sharing	208	3 (1.4)	139	2 (1.4)	348	5 (1.4)
Receptive sharing	85	1 (1.2)	43	0 (0.0)	128	1 (0.8)
p value		1.000		1.000		1.000
2020						
No receptive sharing	175	2 (1.1)	94	2 (2.1)	270	4 (1.5)
Receptive sharing	46	1 (2.2)	42	0 (0.0)	88	1 (1.1)
p value		0.505		1.000		1.000
2021						
No receptive sharing	184	5 (2.7)	133	1 (0.8)	318	6 (1.9)
Receptive sharing	68	0 (0.0)	38	0 (0.0)	109	0 (0.0)
p value		0.328		1.000		0.345

Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year

Western Australia		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
Less than daily	103	2 (1.9)	48	1 (2.1)	152	3 (2.0)	
Daily or more	172	1 (0.6)	92	1 (1.1)	265	2 (0.8)	
Not last month	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)	
p value		0.663		1.000		0.591	
2018							
Less than daily	101	2 (2.0)	56	2 (3.6)	157	4 (2.6)	
Daily or more	179	2 (1.1)	134	2 (1.5)	313	4 (1.3)	
Not last month	12	2 (16.7)	15	0 (0.0)	27	2 (7.4)	
p value		0.016		0.693		0.093	
2019							
Less than daily	130	2 (1.5)	61	2 (3.3)	192	4 (2.1)	
Daily or more	169	2 (1.2)	123	1 (0.8)	292	3 (1.0)	
Not last month	15	0 (0.0)	11	0 (0.0)	26	0 (0.0)	
p value		1.000		0.375		0.615	
2020							
Less than daily	111	1 (0.9)	61	1 (1.6)	173	2 (1.2)	
Daily or more	110	2 (1.8)	75	1 (1.3)	185	3 (1.6)	
Not last month	17	0 (0.0)	14	0 (0.0)	31	0 (0.0)	
p value		0.697		1.000		1.000	
2021							
Less than daily	130	4 (3.1)	84	0 (0.0)	216	4 (1.9)	
Daily or more	124	1 (0.8)	89	1 (1.1)	215	2 (0.9)	
Not last month	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)	
p value		0.504		1.000		0.816	

Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year

Western Australia		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No imprisonment	232	2 (0.9)	123	2 (1.6)	356	4 (1.1)	
Imprisonment	48	0 (0.0)	16	0 (0.0)	65	0 (0.0)	
p value		1.000		1.000		1.000	
2018							
No imprisonment	227	3 (1.3)	168	3 (1.8)	396	6 (1.5)	
Imprisonment	51	3 (5.9)	28	0 (0.0)	79	3 (3.8)	
p value		0.077		1.000		0.176	
2019							
No imprisonment	252	1 (0.4)	168	3 (1.8)	421	4 (1.0)	
Imprisonment	50	1 (2.0)	19	0 (0.0)	69	1 (1.5)	
p value		0.304		1.000		0.533	
2020							
No imprisonment	191	2 (1.1)	131	2 (1.5)	323	4 (1.2)	
Imprisonment	40	1 (2.5)	13	0 (0.0)	53	1 (1.9)	
p value		0.436		1.000		0.534	
2021							
No imprisonment	222	3 (1.4)	166	1 (0.6)	392	4 (1.0)	
Imprisonment	47	1 (2.1)	13	0 (0.0)	61	1 (1.6)	
p value		0.538		1.000		0.516	

Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year

Western Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No condom use	88	0 (0.0)	54	0 (0.0)	142	0 (0.0)	
Condom use	35	0 (0.0)	21	0 (0.0)	56	0 (0.0)	
p value		--		--		--	
2018							
No condom use	103	2 (1.9)	91	1 (1.1)	194	3 (1.6)	
Condom use	28	0 (0.0)	21	0 (0.0)	49	0 (0.0)	
p value		1.000		1.000		1.000	
2019							
No condom use	86	1 (1.2)	86	0 (0.0)	172	1 (0.6)	
Condom use	40	0 (0.0)	24	1 (4.2)	64	1 (1.6)	
p value		1.000		0.218		0.470	
2020							
No condom use	75	1 (1.3)	63	1 (1.6)	138	2 (1.5)	
Condom use	20	1 (5.0)	8	0 (0.0)	28	1 (3.6)	
p value		0.378		1.000		0.428	
2021							
No condom use	99	3 (3.0)	90	0 (0.0)	192	3 (1.6)	
Condom use	19	0 (0.0)	16	0 (0.0)	36	0 (0.0)	
p value		1.000		--		1.000	

Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year

Western Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
No sex work	265	3 (1.1)	131	2 (1.5)	398	5 (1.3)	
Sex work	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	
2018							
No sex work	262	5 (1.9)	174	2 (1.2)	436	7 (1.6)	
Sex work	15	0 (0.0)	18	0 (0.0)	33	0 (0.0)	
p value		1.000		1.000		1.000	
2019							
No sex work	279	4 (1.4)	174	3 (1.7)	454	7 (1.5)	
Sex work	14	0 (0.0)	12	0 (0.0)	26	0 (0.0)	
p value		1.000		1.000		1.000	
2020							
No sex work	223	3 (1.4)	133	1 (0.8)	357	4 (1.1)	
Sex work	10	0 (0.0)	10	1 (10.0)	20	1 (5.0)	
p value		1.000		0.135		0.240	
2021							
No sex work	263	3 (1.1)	162	1 (0.6)	430	4 (0.9)	
Sex work	11	1 (9.1)	15	0 (0.0)	26	1 (3.9)	
p value		0.152		1.000		0.255	

Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
Non Indigenous	248	0 (0.0)	116	1 (0.9)	364	1 (0.3)	
Indigenous	59	3 (5.1)	36	1 (2.8)	97	4 (4.1)	
p value		0.007		0.419		0.008	
2018							
Non Indigenous	225	3 (1.3)	137	1 (0.7)	362	4 (1.1)	
Indigenous	67	2 (3.0)	65	2 (3.1)	132	4 (3.0)	
p value		0.324		0.243		0.219	
2019							
Non Indigenous	238	2 (0.8)	131	1 (0.8)	369	3 (0.8)	
Indigenous	76	2 (2.6)	66	2 (3.0)	144	4 (2.8)	
p value		0.248		0.260		0.101	
2020							
Non Indigenous	165	1 (0.6)	87	1 (1.2)	252	2 (0.8)	
Indigenous	65	2 (3.1)	57	1 (1.8)	122	3 (2.5)	
p value		0.193		1.000		0.335	
2021							
Non Indigenous	185	4 (2.2)	115	1 (0.9)	303	5 (1.7)	
Indigenous	80	1 (1.3)	68	0 (0.0)	150	1 (0.7)	
p value		1.000		1.000		0.669	

Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
English speaking	294	3 (1.0)	147	2 (1.4)	443	5 (1.1)	
Non-English speaking	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
p value		1.000		1.000		1.000	
2018							
English speaking	282	6 (2.1)	196	3 (1.5)	478	9 (1.9)	
Non-English speaking	15	0 (0.0)	9	0 (0.0)	25	0 (0.0)	
p value		1.000		1.000		1.000	
2019							
English speaking	306	4 (1.3)	194	3 (1.6)	502	7 (1.4)	
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		1.000	
2020							
English speaking	227	3 (1.3)	147	2 (1.4)	375	5 (1.3)	
Non-English speaking	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
p value		1.000		1.000		1.000	
2021							
English speaking	274	4 (1.5)	179	1 (0.6)	459	5 (1.1)	
Non-English speaking	11	1 (9.1)	6	0 (0.0)	17	1 (5.9)	
p value		0.180		1.000		0.197	

Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
2017							
Australia	251	3 (1.2)	135	2 (1.5)	388	5 (1.3)	
Other Oceania	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)	
Asia	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)	
UK & Ireland	33	0 (0.0)	10	0 (0.0)	43	0 (0.0)	
Other	13	0 (0.0)	1	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	
2018							
Australia	238	6 (2.5)	180	3 (1.7)	418	9 (2.2)	
Other Oceania	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)	
Asia	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
UK & Ireland	26	0 (0.0)	6	0 (0.0)	32	0 (0.0)	
Other	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)	
p value		1.000		1.000		1.000	
2019							
Australia	273	4 (1.5)	175	3 (1.7)	450	7 (1.6)	
Other Oceania	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	19	0 (0.0)	11	0 (0.0)	30	0 (0.0)	
Other	17	0 (0.0)	4	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	
2020							
Australia	190	3 (1.6)	139	2 (1.4)	330	5 (1.5)	
Other Oceania	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)	
Other	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	
2021							
Australia	235	3 (1.3)	158	1 (0.6)	399	4 (1.0)	
Other Oceania	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)	
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)	
Other	9	2 (22.2)	5	0 (0.0)	14	2 (14.3)	
p value		0.037		1.000		0.058	

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017	296	140 (47)	153	57 (37)	451	198 (44)
2018	297	115 (39)	204	72 (35)	502	188 (37)
2019	320	149 (47)	197	76 (39)	519	225 (43)
2020	239	114 (48)	151	63 (42)	391	177 (45)
2021	289	120 (42)	187	68 (36)	482	192 (40)
X ² p trend		0.732		0.714		0.940

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heterosexual	252	117 (46)	116	41 (35)	369	158 (43)
Bisexual	10	6 (60)	21	9 (43)	31	15 (48)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.039		0.421		0.020
2018						
Heterosexual	249	94 (38)	147	57 (39)	396	151 (38)
Bisexual	16	8 (50)	30	5 (17)	46	13 (28)
Homosexual	10	3 (30)	5	3 (60)	16	7 (44)
p value		0.552		0.024		0.366
2019						
Heterosexual	264	120 (45)	144	55 (38)	408	175 (43)
Bisexual	15	6 (40)	23	6 (26)	39	12 (31)
Homosexual	9	1 (11)	3	1 (33)	12	2 (17)
p value		0.113		0.665		0.078
2020						
Heterosexual	196	95 (48)	110	42 (38)	306	137 (45)
Bisexual	16	8 (50)	18	11 (61)	35	19 (54)
Homosexual	9	3 (33)	3	2 (67)	12	5 (42)
p value		0.193		0.227		0.283
2021						
Heterosexual	257	113 (44)	136	43 (32)	394	157 (40)
Bisexual	12	4 (33)	36	19 (53)	49	23 (47)
Homosexual	10	1 (10)	5	2 (40)	16	3 (19)
p value		0.089		0.050		0.378

Table 9.3.3 HCV antibody prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<25 years	14	3 (21)	5	0 (0)	19	3 (16)
25-34 years	52	23 (44)	37	9 (24)	90	33 (37)
35-44 years	109	46 (42)	59	21 (36)	169	67 (40)
45+ years	119	66 (55)	49	25 (51)	168	91 (54)
p value		0.041		0.022		0.001
2018						
<25 years	14	5 (36)	13	4 (31)	27	9 (33)
25-34 years	53	19 (36)	57	16 (28)	110	35 (32)
35-44 years	99	30 (30)	77	26 (34)	177	57 (32)
45+ years	131	61 (47)	56	25 (45)	187	86 (46)
p value		0.086		0.311		0.022
2019						
<25 years	10	2 (20)	11	2 (18)	22	4 (18)
25-34 years	54	13 (24)	49	18 (37)	103	31 (30)
35-44 years	124	55 (44)	78	28 (36)	202	83 (41)
45+ years	131	79 (60)	59	28 (47)	191	107 (56)
p value		<0.001		0.258		<0.001
2020						
<25 years	3	0 (0)	9	4 (44)	12	4 (33)
25-34 years	37	15 (41)	32	9 (28)	70	24 (34)
35-44 years	80	43 (54)	59	29 (49)	139	72 (52)
45+ years	118	55 (47)	51	21 (41)	169	76 (45)
p value		0.220		0.281		0.089
2021						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	31	7 (23)	28	9 (32)	61	17 (28)
35-44 years	103	41 (40)	83	25 (30)	189	68 (36)
45+ years	147	71 (48)	71	32 (45)	219	104 (47)
p value		0.039		0.236		0.013

Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
<3 years	19	0 (0)	10	0 (0)	29	0 (0)
3 to 10 years	38	11 (29)	24	5 (21)	62	16 (26)
11+ years	225	119 (53)	104	44 (42)	330	163 (49)
p value		<0.001		0.005		<0.001
2018						
<3 years	15	2 (13)	17	1 (6)	32	3 (9)
3 to 10 years	45	11 (24)	45	15 (33)	90	26 (29)
11+ years	227	96 (42)	135	52 (39)	363	149 (41)
p value		0.009		0.019		<0.001
2019						
<3 years	18	2 (11)	10	0 (0)	28	2 (7)
3 to 10 years	36	8 (22)	50	17 (34)	87	25 (29)
11+ years	248	132 (53)	123	51 (41)	371	183 (49)
p value		<0.001		0.021		<0.001
2020						
<3 years	7	0 (0)	9	0 (0)	16	0 (0)
3 to 10 years	39	11 (28)	30	11 (37)	70	22 (31)
11+ years	187	97 (52)	107	49 (46)	294	146 (50)
p value		0.001		0.014		<0.001
2021						
<3 years	13	0 (0)	3	1 (33)	17	1 (6)
3 to 10 years	38	9 (24)	35	10 (29)	73	19 (26)
11+ years	224	107 (48)	144	54 (38)	372	164 (44)
p value		<0.001		0.746		<0.001

Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No receptive sharing	25	0 (0)	251	110 (44)	292	123 (42)
Receptive sharing	2	0 (0)	92	54 (59)	102	59 (58)
p value		--		0.015		0.006
2018						
No receptive sharing	17	2 (12)	296	100 (34)	320	105 (33)
Receptive sharing	9	1 (11)	125	63 (50)	141	69 (49)
p value		1.000		0.001		0.001
2019						
No receptive sharing	19	1 (5)	309	140 (45)	348	151 (43)
Receptive sharing	8	0 (0)	111	51 (46)	128	54 (42)
p value		1.000		0.908		0.814
2020						
No receptive sharing	14	0 (0)	247	113 (46)	268	118 (44)
Receptive sharing	1	0 (0)	85	43 (51)	88	45 (51)
p value		--		0.441		0.246
2021						
No receptive sharing	9	0 (0)	298	116 (39)	319	119 (37)
Receptive sharing	2	1 (50)	102	54 (53)	108	58 (54)
p value		0.182		0.013		0.003

Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Heroin	3	0 (0)	86	57 (66)	96	64 (67)
Methamphetamine	20	0 (0)	209	69 (33)	241	76 (32)
Other opioids	1	0 (0)	55	33 (60)	62	35 (56)
Other drugs	5	0 (0)	33	16 (48)	42	19 (45)
p value		<0.001		<0.001		<0.001
2018						
Heroin	0	0 (0)	76	40 (53)	78	41 (53)
Methamphetamine	29	3 (10)	294	93 (32)	337	105 (31)
Other opioids	0	0 (0)	40	20 (50)	40	20 (50)
Other drugs	3	0 (0)	33	17 (52)	37	17 (46)
p value		0.558		0.001		0.001
2019						
Heroin	1	1 (100)	95	67 (71)	100	71 (71)
Methamphetamine	23	1 (4)	293	99 (34)	339	109 (32)
Other opioids	1	0 (0)	34	20 (59)	37	21 (57)
Other drugs	3	0 (0)	29	19 (66)	34	20 (59)
p value		0.004		<0.001		<0.001
2020						
Heroin	1	0 (0)	69	51 (74)	71	52 (73)
Methamphetamine	15	0 (0)	226	76 (34)	247	80 (32)
Other opioids	0	0 (0)	40	27 (68)	41	28 (68)
Other drugs	0	0 (0)	24	12 (50)	26	14 (54)
p value		--		<0.001		<0.001
2021						
Heroin	2	1 (50)	82	45 (55)	85	47 (55)
Methamphetamine	8	0 (0)	257	82 (32)	274	85 (31)
Other opioids	3	0 (0)	62	33 (53)	68	35 (51)
Other drugs	3	0 (0)	36	19 (53)	44	20 (45)
p value		0.058		<0.000		<0.000

Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Less than daily	10	0 (0)	130	56 (43)	148	62 (42)
Daily or more	18	0 (0)	219	111 (51)	254	123 (48)
Not last month	1	0 (0)	34	8 (24)	39	9 (23)
p value		--		0.010		0.010
2018						
Less than daily	11	2 (18)	143	53 (37)	157	57 (36)
Daily or more	16	1 (6)	280	112 (40)	308	120 (39)
Not last month	5	0 (0)	20	5 (25)	27	6 (22)
p value		0.734		0.381		0.217
2019						
Less than daily	13	2 (15)	170	81 (48)	192	88 (46)
Daily or more	15	0 (0)	255	113 (44)	292	122 (42)
Not last month	0	0 (0)	26	11 (42)	26	11 (42)
p value		0.206		0.753		0.675
2020						
Less than daily	7	0 (0)	161	70 (43)	173	74 (43)
Daily or more	8	0 (0)	171	86 (50)	183	89 (49)
Not last month	1	0 (0)	30	11 (37)	32	12 (38)
p value		--		0.256		0.359
2021						
Less than daily	9	0 (0)	201	74 (37)	217	77 (35)
Daily or more	3	1 (33)	201	96 (48)	214	101 (47)
Not last month	4	0 (0)	35	9 (26)	40	9 (23)
p value		0.187		0.013		0.003

Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
No imprisonment	25	0 (0)	298	129 (43)	345	142 (41)
Imprisonment	1	0 (0)	56	30 (54)	62	35 (56)
p value		--		0.156		0.025
2018						
No imprisonment	26	3 (12)	357	137 (38)	392	146 (37)
Imprisonment	4	0 (0)	69	28 (41)	79	31 (39)
p value		1.000		0.731		0.738
2019						
No imprisonment	24	1 (4)	373	163 (44)	420	175 (42)
Imprisonment	3	0 (0)	58	30 (52)	69	34 (49)
p value		1.000		0.253		0.236
2020						
No imprisonment	14	0 (0)	299	134 (45)	321	140 (44)
Imprisonment	2	0 (0)	49	26 (53)	54	29 (54)
p value		--		0.283		0.168
2021						
No imprisonment	15	1 (7)	364	147 (40)	392	151 (39)
Imprisonment	2	0 (0)	55	27 (49)	61	30 (49)
p value		1.000		0.242		0.114

Table 9.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
Non Indigenous	235	99 (42)	115	44 (38)	350	143 (41)
Indigenous	58	38 (66)	36	12 (33)	96	51 (53)
p value		0.001		0.593		0.032
2018						
Non Indigenous	224	76 (34)	136	42 (31)	360	118 (33)
Indigenous	66	36 (55)	64	28 (44)	130	64 (49)
p value		0.002		0.075		0.001
2019						
Non Indigenous	238	107 (45)	131	49 (37)	369	156 (42)
Indigenous	76	40 (53)	65	27 (42)	143	67 (47)
p value		0.243		0.576		0.349
2020						
Non Indigenous	165	66 (40)	86	32 (37)	251	98 (39)
Indigenous	65	40 (62)	57	26 (46)	122	66 (54)
p value		0.003		0.316		0.006
2021						
Non Indigenous	185	63 (34)	115	37 (32)	303	101 (33)
Indigenous	80	43 (54)	68	30 (44)	150	75 (50)
p value		0.003		0.105		0.001

Table 9.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year

Western Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017						
English speaking	281	132 (47)	146	54 (37)	429	187 (44)
Non-English speaking	13	7 (54)	6	3 (50)	19	10 (53)
p value		0.628		0.672		0.437
2018						
English speaking	280	107 (38)	194	68 (35)	474	175 (37)
Non-English speaking	15	7 (47)	9	4 (44)	25	12 (48)
p value		0.512		0.723		0.265
2019						
English speaking	306	140 (46)	193	75 (39)	501	215 (43)
Non-English speaking	13	9 (69)	3	1 (33)	16	10 (63)
p value		0.154		1.000		0.120
2020						
English speaking	227	110 (48)	146	60 (41)	374	170 (45)
Non-English speaking	11	4 (36)	4	3 (75)	15	7 (47)
p value		0.543		0.310		0.926
2021						
English speaking	274	113 (41)	179	64 (36)	459	181 (39)
Non-English speaking	11	4 (36)	6	3 (50)	17	7 (41)
p value		1.000		0.669		0.885

Table 9.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017							
Australia	240	110 (46)	134	49 (37)	376	160 (43)	
Other Oceania	4	0 (0)	3	2 (67)	7	2 (29)	
Asia	3	2 (67)	2	2 (100)	5	4 (80)	
UK & Ireland	32	17 (53)	10	2 (20)	42	19 (45)	
Other	12	7 (58)	1	0 (0)	13	7 (54)	
p value		0.275		0.166		0.414	
2018							
Australia	236	84 (36)	178	64 (36)	414	148 (36)	
Other Oceania	12	5 (42)	8	0 (0)	20	5 (25)	
Asia	7	4 (57)	4	4 (100)	11	8 (73)	
UK & Ireland	26	12 (46)	6	1 (17)	32	13 (41)	
Other	14	9 (64)	7	3 (43)	22	13 (59)	
p value		0.158		0.008		0.018	
2019							
Australia	273	126 (46)	174	66 (38)	449	192 (43)	
Other Oceania	7	2 (29)	7	4 (57)	14	6 (43)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	19	10 (53)	11	5 (45)	30	15 (50)	
Other	17	10 (59)	4	0 (0)	21	10 (48)	
p value		0.587		0.318		0.878	
2020							
Australia	190	93 (49)	139	60 (43)	330	153 (46)	
Other Oceania	10	4 (40)	4	1 (25)	14	5 (36)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	18	8 (44)	5	1 (20)	23	9 (39)	
Other	12	6 (50)	2	1 (50)	14	7 (50)	
p value		0.909		0.711		0.809	
2021							
Australia	235	98 (42)	158	61 (39)	399	163 (41)	
Other Oceania	11	6 (55)	11	3 (27)	22	9 (41)	
Asia	2	0 (0)	2	0 (0)	4	0 (0)	
UK & Ireland	19	6 (32)	7	0 (0)	26	6 (23)	
Other	9	4 (44)	5	2 (40)	14	6 (43)	
p value		0.654		0.194		0.219	

HCV RNA prevalence

Table 9.4.1 HCV RNA prevalence by gender and survey year

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*	171	52 (30)	77	16 (21)	249	68 (27)
2018*	67	17 (25)	48	10 (21)	115	27 (23)
2019*	313	63 (20)	138	23 (17)	453	86 (19)
2020	219	59 (27)	132	31 (23)	351	90 (26)
2021	286	75 (26)	177	27 (15)	469	103 (22)
X ² p trend		0.670		0.424		0.356

* 2017, 2018, 2019: Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 9.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heterosexual	147	41 (28)	62	12 (19)	210	53 (25)
Bisexual	6	5 (83)	11	4 (36)	17	9 (53)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.010		0.535		0.039
2018*						
Heterosexual	56	15 (27)	35	8 (23)	91	24 (26)
Bisexual	2	1 (50)	6	0 (0)	8	1 (13)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.311		0.355		0.362
2019*						
Heterosexual	261	50 (19)	102	16 (16)	363	65 (18)
Bisexual	15	2 (13)	18	3 (17)	34	4 (12)
Homosexual	11	1 (9)	1	0 (0)	12	1 (8)
p value		0.479		0.909		0.443
2020						
Heterosexual	177	49 (28)	95	27 (28)	272	76 (28)
Bisexual	16	5 (31)	15	1 (7)	31	6 (19)
Homosexual	9	2 (22)	3	0 (0)	12	2 (17)
p value		0.889		0.116		0.430
2021						
Heterosexual	255	70 (27)	128	18 (14)	384	88 (23)
Bisexual	12	2 (17)	35	5 (14)	48	7 (15)
Homosexual	9	1 (11)	5	2 (40)	15	3 (20)
p value		0.404		0.277		0.414

Table 9.4.3 HCV RNA prevalence by age group, gender and survey year

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<25 years	10	2 (20)	1	0 (0)	11	2 (18)
25-34 years	32	11 (34)	22	5 (23)	54	16 (30)
35-44 years	56	19 (34)	30	5 (17)	87	24 (28)
45+ years	71	19 (27)	24	6 (25)	95	26 (27)
p value		0.685		0.783		0.877
2018*						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	7	0 (0)	15	5 (33)	22	5 (23)
35-44 years	27	5 (19)	21	2 (10)	48	7 (15)
45+ years	32	12 (38)	10	2 (20)	42	14 (33)
p value		0.134		0.461		0.294
2019*						
<25 years	13	1 (8)	10	2 (20)	24	3 (13)
25-34 years	65	8 (12)	35	5 (14)	99	13 (13)
35-44 years	117	21 (18)	51	7 (14)	168	27 (16)
45+ years	117	33 (28)	42	10 (24)	160	43 (27)
p value		0.017		0.617		0.009
2020						
<25 years	3	0 (0)	9	3 (33)	12	3 (25)
25-34 years	32	7 (22)	25	3 (12)	57	10 (18)
35-44 years	74	27 (36)	53	15 (28)	127	42 (33)
45+ years	109	25 (23)	45	10 (22)	154	35 (23)
p value		0.121		0.385		0.097
2021						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	30	5 (17)	26	5 (19)	58	11 (19)
35-44 years	101	27 (27)	76	8 (11)	180	35 (19)
45+ years	147	42 (29)	70	13 (19)	218	55 (25)
p value		0.612		0.399		0.482

Table 9.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
<3 years	11	0 (0)	6	0 (0)	17	0 (0)
3 to 10 years	23	6 (26)	12	5 (42)	35	11 (31)
11+ years	133	43 (32)	52	7 (13)	186	50 (27)
p value		0.067		0.072		0.040
2018*						
<3 years	2	0 (0)	4	2 (50)	6	2 (33)
3 to 10 years	9	1 (11)	10	3 (30)	19	4 (21)
11+ years	55	14 (25)	34	5 (15)	89	20 (22)
p value		0.519		0.291		0.795
2019*						
<3 years	24	1 (4)	6	0 (0)	30	2 (7)
3 to 10 years	42	7 (17)	36	9 (25)	80	16 (20)
11+ years	229	50 (22)	86	11 (13)	315	61 (19)
p value		0.219		0.140		0.156
2020						
<3 years	6	0 (0)	6	0 (0)	12	0 (0)
3 to 10 years	36	8 (22)	26	5 (19)	62	13 (21)
11+ years	172	48 (28)	95	25 (26)	267	73 (27)
p value		0.261		0.284		0.071
2021						
<3 years	13	0 (0)	3	0 (0)	17	0 (0)
3 to 10 years	36	11 (31)	31	6 (19)	67	17 (25)
11+ years	223	62 (28)	138	18 (13)	365	80 (22)
p value		0.077		0.513		0.072

Table 9.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
No receptive sharing	121	31 (26)	55	15 (27)	176	46 (26)
Receptive sharing	32	16 (50)	14	1 (7)	46	18 (39)
p value		0.008		0.221		0.109
2018*						
No receptive sharing	44	7 (16)	36	7 (19)	80	14 (18)
Receptive sharing	17	8 (47)	4	2 (50)	21	10 (48)
p value		0.018		0.178		0.005
2019*						
No receptive sharing	199	48 (24)	94	14 (15)	294	62 (21)
Receptive sharing	89	12 (13)	33	8 (24)	122	20 (16)
p value		0.040		0.207		0.261
2020						
No receptive sharing	161	40 (25)	77	19 (25)	238	59 (25)
Receptive sharing	39	16 (41)	40	9 (23)	79	25 (32)
p value		0.043		0.794		0.232
2021						
No receptive sharing	182	46 (25)	125	16 (13)	308	62 (20)
Receptive sharing	67	23 (34)	36	9 (25)	106	32 (30)
p value		0.157		0.075		0.033

Table 9.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2017*						
Heroin	49	18 (37)	23	7 (30)	73	25 (34)
Methamphetamine	89	20 (22)	41	7 (17)	131	28 (21)
Other opioids	17	7 (41)	4	0 (0)	21	7 (33)
Other drugs	14	7 (50)	8	1 (13)	23	8 (35)
p value		0.122		0.371		0.176
2018*						
Heroin	17	3 (18)	9	2 (22)	26	5 (19)
Methamphetamine	38	11 (29)	28	4 (14)	66	15 (23)
Other opioids	7	2 (29)	4	1 (25)	11	3 (27)
Other drugs	3	0 (0)	5	3 (60)	8	3 (38)
p value		0.657		0.251		0.849
2019*						
Heroin	50	19 (38)	22	8 (36)	71	27 (38)
Methamphetamine	209	37 (18)	100	13 (13)	311	50 (16)
Other opioids	27	6 (22)	7	1 (14)	34	7 (21)
Other drugs	23	1 (4)	8	2 (25)	30	3 (10)
p value		0.002		0.048		<0.001
2020						
Heroin	41	13 (32)	26	10 (38)	67	23 (34)
Methamphetamine	137	27 (20)	81	14 (17)	218	41 (19)
Other opioids	23	12 (52)	14	3 (21)	37	15 (41)
Other drugs	15	5 (33)	9	4 (44)	24	9 (38)
p value		0.007		0.068		0.003
2021						
Heroin	48	14 (29)	33	7 (21)	83	21 (25)
Methamphetamine	159	44 (28)	104	13 (13)	264	57 (22)
Other opioids	43	13 (30)	23	3 (13)	67	16 (24)
Other drugs	29	1 (3)	15	4 (27)	44	5 (11)
p value		0.035		0.379		0.308

Table 9.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Western Australia		Male		Female		Total	
Frequency of injection last month	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2017*							
Less than daily	62	15 (24)	21	6 (29)	83	22 (27)	
Daily or more	93	34 (37)	49	10 (20)	143	44 (31)	
Not last month	15	2 (13)	7	0 (0)	22	2 (9)	
p value		0.092		0.269		0.105	
2018*							
Less than daily	15	5 (33)	16	4 (25)	31	9 (29)	
Daily or more	46	11 (24)	24	3 (13)	70	14 (20)	
Not last month	5	1 (20)	6	2 (33)	11	3 (27)	
p value		0.820		0.554		0.579	
2019*							
Less than daily	130	25 (19)	44	11 (25)	175	36 (21)	
Daily or more	164	36 (22)	85	11 (13)	249	47 (19)	
Not last month	14	2 (14)	8	1 (13)	22	3 (14)	
p value		0.591		0.155		0.571	
2020							
Less than daily	105	25 (24)	54	13 (24)	159	38 (24)	
Daily or more	95	31 (33)	63	15 (24)	158	46 (29)	
Not last month	18	2 (11)	13	3 (23)	31	5 (16)	
p value		0.111		0.997		0.256	
2021							
Less than daily	131	36 (27)	82	11 (13)	215	47 (22)	
Daily or more	120	33 (28)	81	15 (19)	203	48 (24)	
Not last month	28	3 (11)	12	1 (8)	40	4 (10)	
p value		0.157		0.519		0.158	

Table 9.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Western Australia		Male		Female		Total	
Imprisonment last year	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	
2017*							
No imprisonment	131	37 (28)	64	12 (19)	195	49 (25)	
Imprisonment	27	11 (41)	8	2 (25)	35	13 (37)	
p value		0.245		0.447		0.129	
2018*							
No imprisonment	52	13 (25)	41	8 (20)	93	21 (23)	
Imprisonment	11	4 (36)	4	2 (50)	15	6 (40)	
p value		0.696		0.181		0.289	
2019*							
No imprisonment	236	47 (20)	114	19 (17)	351	66 (19)	
Imprisonment	55	12 (22)	16	3 (19)	71	14 (20)	
p value		0.816		1.000		0.765	
2020							
No imprisonment	174	46 (26)	113	26 (23)	287	72 (25)	
Imprisonment	38	10 (26)	12	4 (33)	50	14 (28)	
p value		0.988		0.426		0.663	
2021							
No imprisonment	220	58 (26)	156	21 (13)	380	80 (21)	
Imprisonment	47	12 (26)	13	4 (31)	61	16 (26)	
p value		0.906		0.091		0.363	

Table 9.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Western Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
Non Indigenous	142	38 (27)	58	10 (17)	200	48 (24)	
Indigenous	27	11 (41)	18	6 (33)	45	17 (38)	
p value		0.104		0.163		0.049	
2018*							
Non Indigenous	53	11 (21)	30	6 (20)	83	17 (20)	
Indigenous	13	6 (46)	16	3 (19)	29	9 (31)	
p value		0.097		0.760		0.334	
2019*							
Non Indigenous	234	46 (20)	86	16 (19)	319	62 (19)	
Indigenous	73	16 (22)	51	7 (14)	126	23 (18)	
p value		0.610		0.366		0.794	
2020							
Non Indigenous	148	35 (24)	71	18 (25)	219	53 (24)	
Indigenous	62	20 (32)	53	11 (21)	115	31 (27)	
p value		0.196		0.550		0.581	
2021							
Non Indigenous	182	39 (21)	108	12 (11)	293	51 (17)	
Indigenous	80	26 (33)	65	15 (23)	147	42 (29)	
p value		0.056		0.036		0.007	

Table 9.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
English speaking	162	49 (30)	73	15 (21)	235	64 (27)	
Non-English speaking	8	2 (25)	3	1 (33)	11	3 (27)	
p value		0.770		0.474		0.896	
2018*							
English speaking	64	15 (23)	46	10 (22)	110	26 (24)	
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)	
p value		0.567		0.597		0.798	
2019*							
English speaking	299	58 (19)	134	22 (16)	434	81 (19)	
Non-English speaking	14	4 (29)	3	1 (33)	16	5 (31)	
p value		0.280		0.453		0.178	
2020							
English speaking	208	57 (27)	128	29 (23)	336	86 (26)	
Non-English speaking	10	2 (20)	4	2 (50)	14	4 (29)	
p value		0.607		0.204		0.803	
2021							
English speaking	271	70 (26)	170	24 (14)	447	95 (21)	
Non-English speaking	11	4 (36)	6	2 (33)	17	6 (35)	
p value		0.436		0.192		0.169	

Table 9.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
2017*							
Australia	136	38 (28)	67	14 (21)	204	52 (25)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	3	2 (67)	1	0 (0)	4	2 (50)	
UK & Ireland	19	6 (32)	5	1 (20)	24	7 (29)	
Other	9	4 (44)	0	0 (0)	9	4 (44)	
p value		0.431		0.644		0.714	
2018*							
Australia	54	12 (22)	41	9 (22)	95	21 (22)	
Other Oceania	1	0 (0)	2	0 (0)	3	0 (0)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	9	2 (22)	1	1 (100)	10	3 (30)	
Other	3	2 (67)	2	0 (0)	5	2 (40)	
p value		0.227		0.306		0.565	
2019*							
Australia	266	53 (20)	119	20 (17)	388	73 (19)	
Other Oceania	8	2 (25)	5	1 (20)	13	3 (23)	
Asia	5	1 (20)	0	0 (0)	5	1 (20)	
UK & Ireland	19	3 (16)	9	2 (22)	27	5 (19)	
Other	15	3 (20)	3	0 (0)	18	3 (17)	
p value		0.995		0.829		1.000	
2020							
Australia	174	44 (25)	123	29 (24)	297	73 (25)	
Other Oceania	10	2 (20)	4	1 (25)	14	3 (21)	
Asia	4	0 (0)	0	0 (0)	4	0 (0)	
UK & Ireland	15	6 (40)	4	1 (25)	19	7 (37)	
Other	12	5 (42)	1	0 (0)	13	5 (38)	
p value		0.340		0.957		0.380	
2021							
Australia	234	61 (26)	152	23 (15)	392	85 (22)	
Other Oceania	11	6 (55)	9	2 (22)	20	8 (40)	
Asia	2	0 (0)	2	1 (50)	4	1 (25)	
UK & Ireland	18	3 (17)	6	0 (0)	24	3 (13)	
Other	8	2 (25)	5	0 (0)	13	2 (15)	
p value		0.196		0.374		0.250	

Appendix A: Participating NSP services

Year	'17	'18	'19	'20	'21
Number of NSP sites	52	53	54	38	37
Australian Capital Territory	1	1	1	1	1
Directions Health, Canberra	✓	✓	✓	✓	✓
New South Wales	18	19	18	12	3
ACON Hunter	✓	✓	✓	✓	
Ballina Harm Reduction Services	✓	✓	✓		
Blacktown HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	
Byron/Tweed Harm Reduction Services	✓	✓	✓		
Canterbury Harm Minimisation Program	✓	✓	✓	✓	
Clinic 180 (formerly K2), Kings Cross	✓	✓	✓		
Coffs Harbour/Grafton Harm Reduction Services	✓	✓	✓		
First Step Program, Port Kembla	✓	✓	✓		
Health ConneXions, Liverpool		✓		✓	
Hunter Harm Reduction Services	✓	✓	✓	✓	
Kelly Close Needle Syringe Program, Mt Druit	✓	✓	✓	✓	
Kirketon Road Centre	✓	✓	✓	✓	✓
KRC South, Sutherland	✓	✓	✓	✓	✓
Nimbin/Lismore Harm Reduction Services	✓	✓	✓		
NSW Users and AIDS Association (NUAA)	✓	✓	✓	✓	✓
Parramatta HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	
Redfern Harm Minimisation Program	✓	✓	✓	✓	
Royal Prince Alfred Hospital, Camperdown	✓	✓	✓		
South Court Primary Care NSP	✓	✓	✓	✓	
Northern Territory	3	3	3	3	3
Northern Territory AIDS & Hepatitis Council, Alice Springs	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Darwin	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Palmerston	✓	✓	✓	✓	✓
Queensland	9	9	10	7	11
Biala Community Alcohol and Drug Services, Brisbane	✓	✓	✓	✓	✓
Cairns ATODS NSP	✓	✓	✓		✓
Inala Alcohol and Drugs Service					✓
Kobi House, Toowoomba	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Brisbane	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Gold Coast	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Sunshine Coast	✓	✓	✓	✓	✓
Rockhampton AODS NSP			✓		✓
Townsville ATODS NSP	✓	✓	✓	✓	✓
West Moreton Sexual Health Service	✓	✓	✓		✓
Youth Link, Cairns	✓	✓	✓	✓	✓

Year	'17	'18	'19	'20	'21
Number of NSP sites	52	53	54	38	37
South Australia	7	7	8	7	8
Anglicare Salisbury (formerly SAVIVE – Shopfront)	✓	✓			
Community Access & Services SA (CASSA)		✓	✓	✓	✓
Drug Arm Australasia	✓	✓	✓		
Hindmarsh Centre	✓				
Kurlana Tampawardli, Hendon			✓	✓	✓
Noarlunga Primary Health (formerly SAVIVE Noarlunga)	✓	✓	✓	✓	✓
Northern DASSA Elizabeth					✓
Nunkuwarnin Yunti Community Health Centre	✓	✓	✓	✓	✓
Streetlink Youth Services	✓	✓	✓	✓	✓
Watto Purrinna, Port Adelaide (formerly SAVIVE Port Adelaide)	✓	✓	✓	✓	✓
West Coast Youth, Port Lincoln			✓	✓	✓
Tasmania	4	4	4	4	4
Clarence Integrated Care Centre	✓	✓	✓	✓	✓
Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart NSP Service	✓	✓	✓	✓	✓
Salvation Army Launceston	✓	✓	✓	✓	✓
Victoria	6	6	6	0	3
Barwon Health Drug and Alcohol Services	✓	✓	✓		✓
Innerspace, Collingwood	✓	✓	✓		
Health Works, Footscray	✓	✓	✓		✓
SHARPS, Frankston	✓	✓	✓		
North Richmond NSP Services	✓	✓	✓		
Health Information Exchange, St Kilda	✓	✓	✓		✓
Western Australia	4	4	4	4	4
HepatitisWA	✓	✓	✓	✓	✓
Peer Based Harm Reduction WA (formerly WASUA) - Perth	✓	✓	✓	✓	✓
Peer Based Harm Reduction WA (formerly WASUA) - Bunbury	✓	✓	✓	✓	✓
WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Appendix B: Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 3 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Between 2017 and 2021, HCV RNA was detected and quantified on the Hologic Panther™ using the Aptima™ HCV Quant Dx assay (Hologic, Inc. San Diego, Calif) which has a limit of quantitation (LOQ) 10 IU/mL and an upper limit of quantitation of 10^8 IU/mL in plasma. An offboard DBS elution protocol was applied prior to sampling. To correct for haematocrit, all post run DBS VL results on the Aptima assay were multiplied by a plasma conversion factor of 36.36. This calculation was based on the following assumptions: 45% haematocrit average per DBS, 50uL DBS volume and 1000ul Aptima transport media volume. A qualitative result of <10IU/mL detected (trace/equivocal) was applied to samples <400IU/mL (plasma equivalency).

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Temporal changes in HIV/HCV antibody and HCV RNA prevalence were assessed using the χ^2 test for linear trend. Associations between demographic and behavioural variables and HIV/HCV antibody and HCV RNA prevalence were assessed using the χ^2 test or Fisher's exact test where frequencies were less than five. It should be noted that in 2017, 2018 and 2019 the sub-sample of respondents with sufficient DBS sample for HCV RNA testing was <90% and HCV RNA tables were weighted to account for potential sample bias with respect to HCV antibody status and gender. Weights were applied to national data and to each individual jurisdiction, such that jurisdictional HCV RNA results will not necessarily add to data presented at the national level. Results with small sample size, particularly at the jurisdictional level, should be interpreted with caution.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as other. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection. Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years.

Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

Appendix C: List of tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year
Table 1.1.7	Number (percentage) of respondents by COVID-19 related behaviours in 2021

2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.10	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.11	HCV antibody prevalence by region/country of birth, gender and survey year

4. HCV RNA prevalence

Table 1.4.1 HCV RNA prevalence by gender and survey year

Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Table 1.4.3 HCV RNA prevalence by age group, gender and survey year

Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

